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Abstract 
Acute lymphoblastic leukaemia (ALL) is the commonest childhood malignancy. Once a 
universally fatal disease, modern therapy has achieved excellent outcome and the majority 
of children achieve long term cure. Yet relapse remains a challenge. One of the major 
hurdles in achieving complete cure is the relapse of ALL at extramedullary sites such as 
the central nervous system (CNS). Despite significant advances in understanding 
leukaemia biology, most predictors of leukaemic behaviour are accurate for the bone 
marrow disease only. The precise timing, frequency and properties of CNS infiltrating 
leukaemic cells are not elucidated. Therefore, the broad aim of this thesis is to develop a 
better understanding of the mechanisms of leukaemic entry and infiltration patterns of 
leukaemic cells in the CNS. In order to address the frequency and pattern of CNS 
infiltration, a xenograft model using primary leukaemic cells from children with B-cell 
precursor (BCP) ALL in NOD/Scid IL2Rγ null (NSG) mice was established. The majority 
of samples from children with and without overt CNS disease were able to infiltrate the 
CNS in NSG mice. CNS infiltration was seen in mice engrafted with small numbers of 
cells and distinct immunophenotypic subpopulations. The leukaemic samples followed a 
distinct and reproducible pattern of CNS infiltration with leukaemic infiltrates in the 
meninges while sparing the CNS parenchyma.  
To investigate whether a distinct set of leukocyte trafficking molecules provided tissue 
specificity for entering the CNS, leukaemic cells retrieved from the bone marrow and the 
CNS were assessed for expression levels of selected chemokine receptors and P-selectin 
glycoprotein ligand-1 (PSGL1). Additionally, chemotaxis assays were utilized to 
investigate the function of the chemokine receptor CXCR4. Despite surface expression of 
chemokine receptors on leukaemic cells and presence of chemokines in the CNS, no 
evidence for positive selection of a high-expressing subpopulation was seen. Overall, it 
appears that, unlike the bone marrow, chemokine receptors do not direct leukaemic cell 
trafficking to the CNS. 
To investigate the published observation that interleukin-15 (IL-15) expression in 
leukaemic samples correlates with the risk of CNS disease, the effects of IL-15 stimulation 
on BCP-ALL cells were assessed. IL-15 and IL-15 receptor subunits were noted to be 
expressed at mRNA level in samples from BCP-ALL patient and cell lines. Exogenous IL-
15 stimulated leukaemic cell proliferation and upregulated genes associated with migration 
and invasion in SD1 cells. A higher proliferative advantage was observed at low-serum 
conditions which mimics conditions found in the CNS. Therefore a plausible mechanistic 
2 
 
link was established for the association of CNS disease with high IL-15 expression levels. 
In cerebrospinal fluid (CSF) samples from patients, quantitative PCR (qPCR) was utilized 
to detect submicroscopic levels of CNS disease. In approximately 40% patients, qPCR 
using patient specific primers tested positive for the presence of leukaemic DNA. 
Therefore this test is much more sensitive than conventional diagnostic techniques which 
only detect CNS disease in 2-5% of patients. CSF supernatants were also tested to assess 
whether the levels of chemokines could be used to diagnose patients with qPCR positive 
disease. Although differences in the levels of chemokines between qPCR positive and 
negative patients were noted, the values are not sufficiently discriminatory to be clinically 
useful.  
In conclusion, CNS entry appears to be a much more frequent property of leukaemic cell 
than previously appreciated.  Leukocyte trafficking molecules do not appear to play an 
instructive role in the CNS entry and therefore, it is unlikely that expression levels of 
leukocyte trafficking molecules or the levels of chemokines in the CSF will be useful 
biomarkers of CNS disease. In addition, CNS disease appears to be present at diagnosis in 
at least 40% of patients. Therefore, attempts at blocking leukaemic entry into the CNS are 
unlikely to be therapeutically useful. Instead, analysing and targeting factors that allow 
long-term survival of leukaemic cells in the CNS may be a better strategy to eradicate CNS 
disease and prevent leukaemic relapse. 
  
3 
 
Abstract ................................................................................................................................. 1 
List of Tables ........................................................................................................................ 9 
List of Figures ..................................................................................................................... 10 
Publication arising from this work ................................................................................... 12 
Acknowledgments .............................................................................................................. 13 
Author’s declaration .......................................................................................................... 14 
Definitions/Abbreviations .................................................................................................. 15 
Chapter1: Introduction ..................................................................................................... 18 
1.1 Epidemiology and aetiology .................................................................................. 19 
1.2 Pathogenesis .......................................................................................................... 20 
1.2.1 Chromosomal translocations in ALL ............................................................. 20 
1.2.2 Leukaemia as an evolutionary process ........................................................... 23 
1.2.3 Clonal evolution in ALL ................................................................................ 24 
1.3 Prognostic factors in ALL ..................................................................................... 25 
1.3.1 Patient characteristics ..................................................................................... 25 
1.3.2 Immunophenotype.......................................................................................... 26 
1.3.3 Cytogenetic characteristics............................................................................. 27 
1.3.4 Risk assignment ............................................................................................. 31 
1.3.5 Response to treatment .................................................................................... 32 
1.3.6 Extramedullary disease (excluding CNS) ...................................................... 36 
1.3.7 CNS disease ................................................................................................... 37 
1.4 ALL treatment ....................................................................................................... 42 
1.5 Current clinical challenges .................................................................................... 46 
1.6 Extramedullary dissemination in ALL – cell entry ............................................... 47 
1.6.1 Physiological leukocyte trafficking................................................................ 48 
1.6.2 Leukocyte trafficking molecules in site-specific trafficking ......................... 57 
1.6.3 Leukocyte trafficking into the CNS ............................................................... 58 
1.6.4 Malignant cell trafficking ............................................................................... 61 
1.6.5 Chemokine receptors and extramedullary dissemination in ALL.................. 63 
1.6.6 CXCR4 in ALL .............................................................................................. 63 
1.6.7 CXCR7 in ALL .............................................................................................. 65 
1.6.8 BCR/ABL1 and leukaemic trafficking in ALL .............................................. 65 
1.6.9 Chemokine receptors and CNS entry ............................................................. 67 
1.6.10 CNS entry - alternative mechanisms .............................................................. 68 
1.7 Extramedullary dissemination in ALL – microenvironmental niche .................... 69 
1.7.1 CNS stromal support ...................................................................................... 69 
1.7.2 Chemotherapy penetration in the CNS .......................................................... 70 
1.7.3 Immune surveillance ...................................................................................... 71 
1.7.4 Host factors – IL-15 and IL-15 receptor ........................................................ 72 
4 
 
1.8 Study aims ............................................................................................................. 74 
Chapter 2: Materials and methods ................................................................................... 76 
2.1 General equipment and reagents ........................................................................... 76 
2.1.1 Plastics ........................................................................................................... 76 
2.1.2 General reagents ............................................................................................. 76 
2.2 Cell culture methods .............................................................................................. 77 
2.2.1 Cell lines ........................................................................................................ 78 
2.2.2 Thawing of cells from frozen stocks .............................................................. 78 
2.2.3 Cell counting .................................................................................................. 78 
2.2.4 Maintenance of cell lines in culture ............................................................... 79 
2.2.5 Passage of cell lines ....................................................................................... 79 
2.2.6 Cryopreservation of cells ............................................................................... 79 
2.3 Patient Methods ..................................................................................................... 80 
2.3.1 Ethics approval ............................................................................................... 80 
2.3.2 Collection of human CSF ............................................................................... 80 
2.3.3 Processing of CSF .......................................................................................... 80 
2.3.4 Blood collection ............................................................................................. 80 
2.4 Animal methods .................................................................................................... 81 
2.4.1 Mice................................................................................................................ 81 
2.4.2 Intra-femoral injections of primary cells........................................................ 81 
2.4.3 Intravenous injections of cell lines ................................................................. 81 
2.4.4 Monitoring of engraftment ............................................................................. 82 
2.4.5 Tail vein blood sampling of xenograft mice .................................................. 82 
2.4.6 Culling and dissection .................................................................................... 82 
2.4.7 In vitro imaging of xenografts injected with REHGFP-Luciferase cells ................ 83 
2.5 Cell based assays ................................................................................................... 83 
2.5.1 Flow cytometry .............................................................................................. 83 
2.5.2 General equipment, materials and solutions .................................................. 84 
2.5.3 Analysis of surface receptor expression ......................................................... 86 
2.5.4 Chemotaxis assay ........................................................................................... 86 
2.5.5 Chemokine receptor internalization and recycling assay ............................... 87 
2.5.6 Chemokine competition assay ....................................................................... 87 
2.5.7 Analysis of cellular proliferation using cytoplasmic dye Celltrace Violet .... 88 
2.6 Molecular biology methods: DNA ........................................................................ 89 
2.6.1 DNA extraction using Trizol .......................................................................... 89 
2.6.2 DNA extraction from CSF using QIAmp DNA micro kit ............................. 89 
2.6.3 DNA extraction from blood, cultured cells and bone marrow samples using 
Qiagen blood DNA mini kit ........................................................................................... 90 
2.6.4 DNA concentration and cleanup .................................................................... 90 
5 
 
2.6.5 DNA quantification by spectrophotometric method ...................................... 90 
2.7 Molecular biology: RNA ....................................................................................... 91 
2.7.1 RNA extraction from cells ............................................................................. 91 
2.7.2 cDNA synthesis .............................................................................................. 91 
2.8 Molecular biology: SYBR Green qPCR ............................................................... 92 
2.8.1 Primer design ................................................................................................. 92 
2.8.2 Generation of standards.................................................................................. 95 
2.8.3 TOPO cloning of vectors ............................................................................... 96 
2.8.4 SYBR Green qPCR ........................................................................................ 97 
2.8.5 Analysis of SYBR Green qPCR assay ........................................................... 98 
2.8.6 Normalization of qPCR data .......................................................................... 98 
2.9 Molecular biology: TaqMan qPCR ....................................................................... 99 
2.9.1 TaqMan qPCR for relative gene expression .................................................. 99 
2.9.2 TaqMan qPCR for Albumin gene .................................................................. 99 
2.10 Cytology methods ................................................................................................ 100 
2.10.1 Cytospin preparation .................................................................................... 100 
2.10.2 Blood smear preparation .............................................................................. 101 
2.10.3 Giemsa staining ............................................................................................ 101 
2.10.4 Immunofluorescence staining ...................................................................... 101 
2.11 Histology methods ............................................................................................... 102 
2.11.1 Tissue fixation, embedding and cutting ....................................................... 102 
2.11.2 Haemotoxylin and Eosin staining ................................................................ 102 
2.11.3 Immunohistochemistry ................................................................................. 102 
2.12 Molecular biology: Protein .................................................................................. 104 
2.12.1 Western blotting ........................................................................................... 104 
2.12.2 ELISA .......................................................................................................... 106 
2.12.3 Luminex multiplex protein detection assay ................................................. 107 
2.13 Statistical analysis ............................................................................................... 108 
Chapter 3: Investigating frequency and patterns of central nervous system 
infiltration in xenograft models of acute lymphoblastic leukaemia ............................ 109 
3.1 Introduction and aims .......................................................................................... 109 
3.1.1 Selecting an appropriate model .................................................................... 110 
3.1.2 Selecting leukaemic samples for xenograft experiments ............................. 112 
3.1.3 Other factors influencing xenograft models ................................................. 113 
3.2 Development of a xenograft model of extramedullary disease ........................... 115 
3.2.1 Primary leukaemic cells ............................................................................... 115 
3.2.2 Mice.............................................................................................................. 115 
3.2.3 Flow cytometry for identification of leukaemic cells .................................. 116 
3.2.4 Determining engraftment at early and late time points ................................ 117 
6 
 
3.2.5 Monitoring for engraftment.......................................................................... 117 
3.2.6 Analysis of bone marrow engraftment upon cull ......................................... 118 
3.2.7 Analysis of extramedullary infiltration (excluding the CNS) ...................... 121 
3.3 Analysis of CNS infiltration ................................................................................ 127 
3.3.1 Comparison of IV vs IF route of transplant ................................................. 127 
3.3.2 Frequency of infiltration in the CNS ............................................................ 128 
3.3.3 Pattern of leukaemic infiltration in the CNS ................................................ 130 
3.3.4 Validation using independent cohort of primary xenografts........................ 132 
3.3.5 Analysis of CNS leukaemia in mice engrafted with limiting numbers of 
leukaemic cells ............................................................................................................. 134 
3.3.6 Analysis of CNS leukaemia in mice engrafted with immunophenotypically 
sorted cells .................................................................................................................... 135 
3.3.7 Analysing CNS-specific tropism with serial transplants ............................. 137 
3.4 Discussion ........................................................................................................... 140 
Chapter 4: Investigating leukocyte trafficking molecules in association with central 
nervous system disease in acute lymphoblastic leukaemia ........................................... 144 
4.1 Introduction and aims .......................................................................................... 144 
4.2 Differential CNS homing and chemokine receptor expression in BCP-ALL cell 
lines 147 
4.2.1 Validation of surface expression using flow cytometry ............................... 150 
4.2.2 Functional analysis using chemotaxis assays ............................................... 152 
4.2.3 CXCL12 mediated chemotaxis in primagraft cells ...................................... 154 
4.3 Analysing expression levels of selected leukocyte trafficking molecules in cells 
from the CNS and the bone marrow ................................................................................ 156 
4.3.1 Retrieval of cells from the CNS compartment ............................................. 156 
4.3.2 Expression of selected leukocyte trafficking molecules on primagraft samples 
retrieved from the bone marrow ................................................................................... 157 
4.3.3 Comparing bone marrow- and CNS- retrieved leukaemic cells for expression 
of selected leukocyte trafficking molecules ................................................................. 157 
4.4 Investigating the dysfunctional CXCR4-CXCL12 axis in SD1 cells .................. 161 
4.4.1 Functional assays of CXCR4 ....................................................................... 162 
4.4.2 Analysing the effect of CXCR7 on CXCL12 mediated chemotaxis............ 166 
4.4.3 Analysing the effect of CXCR7 blockade on CXCL12 mediated chemotaxis
 170 
4.4.4 Does inhibiting BCR/ABL tyrosine kinase restore CXCL12 mediated 
chemotaxis? .................................................................................................................. 172 
4.4.5 Investigating key CXCL12-activated signalling pathways .......................... 177 
4.5 Discussion ........................................................................................................... 180 
Chapter 5: Investigating interleukin-15 mediated proliferative advantage in B- cell 
precursor acute lymphoblastic leukaemia cells ............................................................. 185 
5.1 Introduction and aims .......................................................................................... 185 
5.2 Expression patterns of IL-15 and IL-15 receptors in BCP-ALL ......................... 187 
7 
 
5.2.1 ALL cells express differential levels of IL-15 mRNA................................. 188 
5.2.2 ALL cells differentially express IL-15 receptor sub-units ........................... 190 
5.2.3 Association of IL-15/IL-15 receptor expression with CNS disease in 
xenograft models .......................................................................................................... 192 
5.2.4 Detecting IL-15 in CSF samples from BCP-ALL patients .......................... 194 
5.3 Investigating mechanisms of the association of IL-15 with the CNS disease ..... 195 
5.3.1 Analysing effect of exogenous IL-15 on growth of BCP-ALL cells ........... 195 
5.3.2 Determining the role of endogenous IL-15 on growth by IL-15Rα blockade
 197 
5.3.3 Determining IL-15 mediated growth advantage under serum depletion ..... 198 
5.3.4 IL-15 mediated growth is a result of increased proliferation ....................... 199 
5.3.5 Investigating the effects of IL-15 - induced signalling on the growth of SD1 
cells 201 
5.3.6 Regulation of genes associated with leukaemic dissemination following 
exposure to IL-15 ......................................................................................................... 202 
5.4 Discussion ........................................................................................................... 205 
Chapter 6: Investigating novel biomarkers to improve diagnostic accuracy of central 
nervous system disease in childhood acute lymphoblastic leukaemia ......................... 208 
6.1 Introduction and aims .......................................................................................... 208 
6.2 Study design ........................................................................................................ 210 
6.2.1 Ethics ............................................................................................................ 210 
6.2.2 Study population .......................................................................................... 210 
6.2.3 Inclusion criteria........................................................................................... 210 
6.2.4 Exclusion criteria ......................................................................................... 210 
6.2.5 Patient selection and enrolment ................................................................... 210 
6.2.6 Treatment protocols ..................................................................................... 211 
6.2.7 Data collection ............................................................................................. 211 
6.2.8 Initial sample processing .............................................................................. 211 
6.2.9 Detection of leukaemic DNA ....................................................................... 212 
6.3 Method optimization ........................................................................................... 213 
6.3.1 Optimization of DNA quantification ........................................................... 213 
6.3.2 Optimization of DNA extraction .................................................................. 215 
6.3.3 Effect of storage and shipment on DNA yield ............................................. 217 
6.3.4 Optimization of patient specific (ASO) primers and probes ........................ 218 
6.4 Detection of CNS disease by PCR ...................................................................... 219 
6.4.1 Clinical and demographic features of recruited patients .............................. 220 
6.4.2 Frequency of CSF qPCR positivity at diagnosis .......................................... 220 
6.4.3 Frequency of qPCR positivity during treatment .......................................... 223 
6.4.4 Analysing chemokines as novel biomarkers for CNS disease ..................... 224 
6.5 Discussion ........................................................................................................... 230 
8 
 
Chapter 7: General discussion and conclusions ............................................................ 234 
7.1 Summary of findings ........................................................................................... 234 
7.2 How do these finding extend current knowledge on CNS involvement in 
leukaemia? ....................................................................................................................... 235 
7.2.2 Clinical implications of the findings ............................................................ 242 
7.3 Future directions .................................................................................................. 244 
7.3.1 Leukaemia-host microenvironment factors may play a dominant role in 
determining the risk of CNS relapse disease ................................................................ 244 
7.3.2 Investigating the biomarkers for CNS disease ............................................. 245 
7.3.3 Clonal origins of CNS infiltrating cells ....................................................... 246 
7.4 Overall conclusions ............................................................................................. 246 
Appendix: Interleukin-15 enhances cellular proliferation and upregulates CNS 
homing molecules in pre-B acute lymphoblastic leukaemia ........................................ 247 
List of References ............................................................................................................. 248 
  
9 
 
List of Tables 
Table 1-1 Diagnostic criteria for CNS disease ..................................................................... 38 
Table 1-2 Chemokine receptor nomenclature ...................................................................... 53 
Table 2-1 Plastic lab-ware used in this thesis ...................................................................... 76 
Table 2-2 Composition of solutions ..................................................................................... 77 
Table 2-3 Clinical and immunophenotypic characteristics of the cell lines ........................ 78 
Table 2-4 Antibodies, fluorescent conjugated and native chemokines and reagents for FCM
 .............................................................................................................................................. 85 
Table 2-5 Criteria for optimal primer design ....................................................................... 92 
Table 2-6 Primer details for PCR, SYBR Green qPCR and TaqMan qPCR. ...................... 94 
Table 2-7 PCR cycling conditions for generating standards ................................................ 95 
Table 2-8 Calculation for SYBR Green qPCR mastermix .................................................. 97 
Table 2-9 Temperature conditions for SYBRGreen qPCR assay ........................................ 97 
Table 2-10 Calculation of TaqMan qPCR mastermix for Albumin gene .......................... 100 
Table 2-11 Temperature conditions for TaqMan qPCR assay for Albumin gene ............. 100 
Table 2-12 Antibodies and reagents for western blotting .................................................. 104 
Table 3-1 Analysis of engraftment at early and late time point ......................................... 117 
Table 3-2 Clinical and laboratory features of patients ....................................................... 119 
Table 3-3 Association of successful engraftment with clinical feature ............................. 120 
Table 3-4 Details of individual xenograft experiments...................................................... 121 
Table 3-5 Comparison of IV vs IF route of transplant. ...................................................... 128 
Table 3-6 Analysis of CNS infiltration in primary xenografts .......................................... 129 
Table 3-7 Clinical characteristics and CNS engraftment ................................................... 133 
Table 4-1: Clinical and cytogenetic features of BCP-ALL cell lines ................................ 147 
Table 4-2 FCM analysis of primagraft cells for selected trafficking molecules ................ 157 
Table 4-3: Correlation of chemotaxis with signalling molecules ...................................... 179 
Table 5-1: Clinical features of patients .............................................................................. 187 
Table 5-2: Individual results of IL-15 and IL-15 receptor expression data in 4 cell lines, 13 
primary samples and 5 primagraft samples. ....................................................................... 191 
Table 6-1 Demographic and clinical features of recruited patients in comparison with 
SJCRH and BFM trial cohorts ........................................................................................... 220 
Table 6-2 Comparison between CSF qPCR+ve and qPCR –ve patients ........................... 221 
Table 6-3 Raw data of individual patients ......................................................................... 225 
  
10 
 
List of Figures 
Figure 1-1 Common genetic rearrangements with chromosomal translocation .................. 20 
Figure 1-2 Clonal evolution and heterogeneity in ALL ....................................................... 24 
Figure 1-3 Philadelphia chromosome and BCR-ABL1 variants.......................................... 30 
Figure 1-4 Principle of MRD monitoring ............................................................................ 33 
Figure 1-5 Simplified model of (a) B- cell development stages and corresponding BCP-
ALL types and (b) V(D)J and VJ rearrangement ................................................................. 34 
Figure 1-6 Possible mechanisms of leukaemic entry into extramedullary tissues. .............. 48 
Figure 1-7 Leukocyte migration across the endothelium into the tissue ............................. 50 
Figure 1-8: Illustration of a typical and an atypical chemokine receptor ............................ 56 
Figure 1-9: Routes of leukocyte entry into the CNS ............................................................ 61 
Figure 1-10 Possible modes of IL-15/IL-15 receptor signalling .......................................... 73 
Figure 3-1 Scheme of transplantation experiments ............................................................ 115 
Figure 3-2 Monitoring for engraftment .............................................................................. 116 
Figure 3-3 Kinetics of engraftment .................................................................................... 118 
Figure 3-4 Pattern of leukaemic infiltration in the liver .................................................... 122 
Figure 3-5 Correlation of BM engraftment with splenic infiltration ................................. 123 
Figure 3-6 Pattern of leukaemic infiltration in the kidneys ............................................... 124 
Figure 3-7 Histological sections of gonads showing patterns of leukaemic infiltration .... 125 
Figure 3-8 Histological sections of nodules showing patterns of leukaemic infiltration in 
skeletal muscle and uterus .................................................................................................. 126 
Figure 3-9 Pattern of CNS infiltration in NSG mice in the independent cohort of samples
 ............................................................................................................................................ 132 
Figure 3-10 Frequency of CNS infiltrating leukaemic cells using limiting dilution 
experiments ........................................................................................................................ 135 
Figure 3-11 Frequency of CNS infiltrating leukaemic cells in various immunophenotypic 
subpopulations ................................................................................................................... 136 
Figure 3-12 Experimental scheme for analysing CNS-specific tropism of REHLuc-GFP cells
 ............................................................................................................................................ 138 
Figure 3-13 Analysis of CNS tropism of CNS- and BM-isolated cells using in vivo 
bioluminescence ................................................................................................................. 139 
Figure 4-1: The potential utility for identifying mechanism of CNS entry of leukaemic 
cells. ................................................................................................................................... 145 
Figure 4-2: Time to hind-limb paralysis and expression of leukocyte trafficking molecules.
 ............................................................................................................................................ 149 
Figure 4-3: Chemokine receptor and PSGL1 expression in BCP-ALL cell lines ............. 151 
Figure 4-4: CXCL12-mediated chemotaxis in BCP-ALL cell lines .................................. 153 
Figure 4-5 CXCL12 mediated chemotaxis in primagraft cells .......................................... 155 
Figure 4-6 Comparison of expression of chemokine receptors and PSGL1 in primagraft 
cells retrieved from the BM and the CNS compartments. ................................................. 158 
Figure 4-7 Effect of AMD3100 on REH engraftment in NSG mice. ................................ 160 
Figure 4-8: Effect of CXCR4 blockade on CXCL12 mediated chemotaxis ...................... 162 
Figure 4-9: Dose-dependent binding of CXCL12AF647 in SD1 and Sup B15 .................... 163 
Figure 4-10 CXCR4 internalisation in response to CXCL12 stimulation: ........................ 164 
Figure 4-11: Time-dependent restoration of surface CXCR4 following CXCL12-mediated 
internalization ..................................................................................................................... 165 
Figure 4-12: Comparison between CXCR7 mRNA in SD1 and Sup B15 ......................... 166 
Figure 4-13: CXCR7 protein expression in SD1 & Sup B15 ............................................ 167 
Figure 4-14: CXCR7/CXCR4 co-expression in SD1 and Sup B15 ................................... 169 
Figure 4-15: CXCL12-CXCL11 competition assay .......................................................... 170 
Figure 4-16: Effect of CXCR7 blockade on CXCL12-mediated chemotaxis in SD1. ...... 171 
Figure 4-17: BCR-ABL1 expression in SD1 and Sup B15 ............................................... 173 
11 
 
Figure 4-18 Effect of BCR-ABL inhibition on CXCR4 expression and function. ............ 175 
Figure 4-19: Downstream signalling pathways activated by CXCL12 in cell lines .......... 178 
Figure 5-1: IL-15 mRNA expression in BCP-ALL cells ................................................... 189 
Figure 5-2 IL-15 receptor subunit mRNA expression in BCP-ALL cells ......................... 191 
Figure 5-3: Relative expression levels of IL-15 receptor subunits in BCP-ALL cell lines.
 ............................................................................................................................................ 193 
Figure 5-4: ELISA detection of IL-15 levels in CSF supernatants from patients with CNS 
disease. ............................................................................................................................... 194 
Figure 5-5 Effect of exogenous IL-15 on growth of BCP-ALL cell lines ......................... 196 
Figure 5-6: Growth of BCP-ALL cell lines following blockade of IL-15 Rα. .................. 197 
Figure 5-7: Growth of IL-15 treated SD1 cells under low serum conditions: ................... 198 
Figure 5-8: Effect of IL-15 treatment on apoptosis and cell proliferation: ........................ 200 
Figure 5-9: Effect of inhibition of downstream signalling pathways on IL-15 mediated 
growth. ............................................................................................................................... 201 
Figure 5-10: qPCR analysis of metastasis-associated genes identified by RT2 profiler array
 ............................................................................................................................................ 203 
Figure 5-11: qPCR and FCM analysis of IL-15 treated SD1 cells. ................................... 204 
Figure 6-1: Envisaged potential for using more sensitive methods for the diagnosis of CNS 
disease in ALL. .................................................................................................................. 209 
Figure 6-2 Scheme for patient recruitment and sample analysis ....................................... 212 
Figure 6-3: Optimization of DNA quantification............................................................... 214 
Figure 6-4: Optimization of DNA extraction methods ...................................................... 216 
Figure 6-5: Effect of storage and shipping on CSF DNA yield ......................................... 218 
Figure 6-6: Flow chart for patient recruitment and analysis .............................................. 219 
Figure 6-7 CSF qPCR detection by PCR ........................................................................... 222 
Figure 6-8 CSF qPCR positivity during induction chemotherapy ..................................... 223 
Figure 6-9 Levels of chemokines in CSF qPCR +ve and CSF qPCR –ve patients ........... 227 
Figure 6-10 ROC analysis for diagnostic accuracy of chemokine levels to predict CSF 
qPCR positivity .................................................................................................................. 229 
Figure 7-1 IL-15 stimulation may provide survival advantage to leukaemic cells in the 
CNS but less so in the bone marrow .................................................................................. 241 
  
12 
 
Publication arising from this work 
Williams, M. T., Yousafzai, Y., Cox, C., Blair, A., Carmody, R., Sai, S., Chapman, K. E., 
McAndrew, R., Thomas, A., Spence, A., Gibson, B., Graham, G. J. & Halsey, C. 2014. 
Interleukin-15 enhances cellular proliferation and upregulates CNS homing molecules in 
pre-B acute lymphoblastic leukemia. Blood, 123, 3116-27. 
 
  
13 
 
Acknowledgments 
I am grateful to the Khyber Medical University and Yorkhill Children’s Charity for the 
generous funding of this research project. I would like to thank my supervisors Dr Chris 
Halsey and Professor Gerard Graham for their close supervision, mentorship and guidance 
during this PhD project. Chris has always been there for discussions on research projects, 
providing useful feedback on the thesis, and keeping me on track. Thanks to my assessors 
Professor Rob Nibbs and Professor Hugh Willison for assessing my progress during the 
PhD. Many thanks to all the members of the chemokine research group, especially to Dr 
Mark Williams for teaching most of the laboratory techniques, Dr Clive McKimmie for his 
guidance on qPCR, Dr Alasdair Fraser for his help in flow cytometry and Dr Ruaidhri 
Carmody for his guidance in western blotting experiments. 
In connection to the work presented in this thesis, I gratefully acknowledge the 
contribution of our collaborators who shared their valuable resources such as cell lines, 
primary samples and mouse brains. Research staff Alison, Wendy and Saeeda provided 
invaluable help in obtaining clinical information and patient recruitment. Members of the 
UK MRD laboratory including Sandra, Linda and Amanda provided patient specific 
reagents. I am grateful to all the patients and their parents who agreed to participate in the 
research presented in this thesis.  
14 
 
Author’s declaration 
I declare that, except where explicit reference is made to the contribution of others, that 
this thesis is the result of my own work and has not been submitted for any other degree at 
the University of Glasgow or any other institution. 
Signature:…………………………………………. 
Printed name: Yasar Mehmood Yousafzai  
15 
 
Definitions/Abbreviations 
 
ACKR Atypical chemokine receptor 
ALL Acute lymphoblastic leukaemia 
AML Acute myeloid leukaemia 
APC Allophycocyanin 
BBB Blood-brain barrier 
BCP B-cell precursor 
BCR B-cell receptor 
BCSFB Blood-CSF barrier 
BM Bone marrow 
BP Base pair 
BSA Bovine serum albumin 
CALLA Common ALL antigen 
CAN Copy number alteration 
CCG Children's Cancer group 
CD Cluster of differentiation 
cDNA complementary DNA 
CML Chronic myeloid leukaemia 
CNS Central nervous system 
CPE Choroid plexus epithelium 
cRNA Carrier RNA 
CSC  Cancer stem cell 
CTV CellTrace violet 
Ct Cycle threshold 
DAB 3. 3'-diaminobenzidine 
DARC Duffy antigen /receptor for chemokines 
DAPI 4' , 6-diamidino-2-phenylindole 
ddH2O distilled, deionized water 
DMSO Dimethylsulfozide 
DNA deoxyribonucleic acid 
EAE Experimental autoimmune encephalitis 
EDTA Ethylenediaminetetraacetic acid 
ETP Early T-cell precursor 
EFS Event free survival 
ELISA Enzyme linked immunosorbent assay 
ERK Extracellular signal-regulated kinase 
EtOH Ethanol 
FACS Fluorescence activated cell sorting 
FBC Full blood count 
FCM flow cytometry 
FCS Foetal calf serum 
FISH Fluorescence in site hybridisation 
FITC Fluorescein isothiocyanate 
FSC  Forward Scatter 
GAPDH Glyceraldehyde 3-phosphate 
GAG Glycosaminoglycan 
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GFP Green fluorescent protein 
GPCR G-protein coupled receptor 
HH High hyperdiploid 
HSC Haematopoietic stem cells 
HSCT Haematopoietic stem cell transplant 
HSPC Haematopoietic stem and progenitor cell 
I.P Intraperitoneal 
ICAM Intracellular adhesion molecule 
id Identity 
IF Intrafemoral 
Ig Immunoglobulin 
IgH Immunoglobulin heavy 
IL-15 Interleukin-15 
IL-15R IL-15 receptor 
IV Intravenous 
JAK Janus activated kinase 
kDa KiloDalton 
KO knock-out 
LPS Lipopolysacchride 
Luc Luciferase 
LSC Leukaemia stem cell 
mAB monoclonal antibody 
MAPK Mitogen-activated protein kinase 
m-BCR Minor-breakpoint cluster region 
MFI Mean fluorescence intensity 
MMP Matrix metalloproteinase 
MNC mononuclear cell 
MRD Minimal residual disease 
MRI Magnetic resonance imaging 
mRNA Messenger RNA 
MS multiple sclerosis 
NBF Neutral buffered saline 
NCI National Cancer Institute 
NK Natural killer (cell) 
NOD Non-obese diabetic 
NOG NOD/Shi-scid IL-2Rγ-/- 
NSG NOD/LtSz-Scis IL-2Rγ-/- 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PE-Cy7 PE with cyanine 7 conjugate 
PFA Paraformaldehyde 
Ph Philadelphia chromosome 
g gravitational force 
qPCR quantitative Polymerase chain reaction 
RBC Red blood cell 
RBC Red blood cell 
RFS Relapse free survival 
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RPM Revolutions per minute 
RPMI Roswell park memorial institute media 
RQ Relative quantitative 
S.c. Subcutaneous 
SCF Stem cell factor 
SD  Standard deviation 
SDS PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SSC Side scatter 
STAT Signal Trunsducer and Activator of Transcription 
TCM Central memory T cell 
TBP TATA binding protein 
TdT Terminal deoxynucleotidyl transferase 
TBS-Tween Tris-buffered sodium Tween 
TE Tris-EDTA 
TLDA TaqMan low density array 
TPMT Thiopurine S-methyltransferase  
TRITC Tetramethyl rhodamine isothiocyante 
UV Ultra violet 
V Volts 
VCAM Vascular-associated adhesion molecule 
WCC White cell count 
WHIM Warts, Hypogammaglobulinemia, Infections, and Myelokathexis 
WT Wild type 
µg microgram 
µl microliter 
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1 Introduction 
The first descriptions of signs that can be retrospectively interpreted as cancer date as far 
back as 3000 BC. Ancient Egyptian writings say about the disease, ‘There is no treatment’ 
(Cancer.gov). For several centuries after recognising solid cancers, physicians remained 
unaware of a similar pathology of the blood. Even long after the discovery of the 
microscope and identification of the white blood cells, haematological pathologies were 
considered mostly as pus and inflammation. It was only in the early 19th century, when 
European physicians identified patients with uncommon alteration of the blood - findings 
then interpreted as inflammation. David Craigie, a physician at the Royal Infirmary of 
Edinburgh began to question interpretation of such peculiar findings on a patient admitted 
and later died in his ward in 1841. Three years later, when he admitted another such 
patient, he had no doubt that the patient would meet a similar fate. A young Pathologist 
John Hughes Bennet who performed autopsy on this patients and published the findings, 
concluded that the alteration of blood was independent of inflammation and that the 
pathology involved the whole blood system. Shortly after, Rudolf Wirchow described the 
case of a woman with distended abdomen and increased circulating white blood cells – 
findings that can be interpreted in retrospect as chronic leukaemia. Wirchow called it 
‘Weisses Blut (White blood) and later used the term ‘Leukhemia’ (Piller, 2001). 
Currently, leukaemia comprises a diverse and heterogenous group of malignant 
proliferations of blood cells. Leukaemia can arise from lymphoid or myeloid 
haematopoietic precursors and can present in an acute or chronic form. Over the past few 
decades, the world has seen great improvements in the diagnosis and success of treatment 
in leukaemic patients. Not only has the treatment of certain leukaemias been a success 
story, this group of disorders has been on the frontier of scientific discovery and 
therapeutic advancements in the field of cancer. The current classification of leukaemias 
incorporates immunology, cytogenetics and molecular genetics for the diagnosis and 
management (Swerdlow et al., 2008). 
This thesis focuses on childhood Acute Lymphoblastic Leukaemia (ALL) that arises within 
the haematopoietic precursors of B- and T- cell origin. In this PhD project, I have 
investigated aspects of leukaemic cell dissemination to extramedullary sites with a 
particular emphasis on the CNS. Therefore, this chapter begins with an overview of 
relevant biological and clinical aspects of ALL followed by a discussion on possible 
mechanisms of extramedullary dissemination of ALL and how this is relevant to the 
current clinical problems, followed by aims of the study. 
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1.1 Epidemiology and aetiology 
Despite being a rare disease, ALL is the commonest childhood malignancy accounting for 
75-80% cases of leukaemia and 25% of all malignancies of children 
(NationalCancerInstitute, 2014). The incidence of ALL in under-developed countries, and 
poor socioeconomic groups is lower than developed countries. Small differences in 
prognosis are observed between different races, although the reasons for such differences 
are poorly understood. In the United Kingdom (UK), approximately 300 children are 
diagnosed with ALL each year. The peak incidence of ALL is seen at 2-3 years of age and 
decreases sharply afterwards. This disease is slightly more common in boys than in girls 
with a ratio of 1.3:1 (CancerResearchUK, 2014). Fortunately, recent decades have seen a 
decrease in mortality from ALL – with a 5 year overall survival now above 90% (Hunger 
et al., 2012). However, prognosis in relapsed cases is still poor and the majority of children 
with relapse die due to treatment failure or therapy related complications (Roy et al., 
2005).  Overall, leukaemia account for 30% of cancer related deaths in children 
(CancerResearchUK, 2014). 
What exactly causes leukaemia is not known. There are, however, a few predisposing 
inherited conditions, and acquired risk factors associated with a higher incidence of ALL. 
Disorders associated with chromosomal aneuploidy or instability such as Down syndrome, 
ataxia telengectasia and Bloom syndrome are more commonly associated with ALL. 
Similarly, exposure to mutagens such as ionizing radiation, Benzene or chemotherapy has 
been implicated. However, the majority of cases occur sporadically (Pui et al., 2008). 
Epidemiologic data point to infections as causal exposure for the development of ALL 
(Kinlen, 1995, Kinlen, 1988, Greaves, 2006).  Germline single nucleotide polymorphisms 
(SNPs) in patients with ALL and control populations have implicated ARID5B and IKZF1 
(Trevino et al., 2009) and IL-15 genes (Lin et al., 2010) in leukaemia. The mechanistic link 
between these SNPs and ALL is still unclear. 
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1.2 Pathogenesis 
1.2.1 Chromosomal translocations in ALL 
The majority of leukaemias contain a variety of genetic changes such as deletions and 
point mutations. However, chromosomal numerical or structural abnormalities such as 
translocations are characteristic of ALL. Chromosomal translocations result from breakage 
of double-stranded DNA followed by their recombination resulting in a fusion gene, loss of 
function or an altered functioning gene. For example, translocation between chromosome 9 
and 22 (t(9;22)) where the fusion gene ‘BCR-ABL1’ encodes for a novel chimeric 
oncoprotein. This aberrant protein is associated with constitutively active tyrosine kinase. 
Translocations may also result in an intact gene being placed next regulatory elements of 
another gene on the partner chromosome resulting in dysregulated expression of normal 
proteins. Such translocations result in an aberrant function of a normal protein. For 
instance, t(1;14)(p34;q11) involves coding regions of the transcription factor TAL1/SCL 
being placed adjacent to constitutively active T-cell receptor α/β region (Figure 1-1). In a 
similar manner, chromosomal inversion can place a transcription factor besides a 
regulatory gene and result in aberrant gene expression. However, chromosomal 
translocations may not always be enough to initiate overt leukaemia and the fact that many 
ALL cases lack recurring chromosomal alterations, required high resolution screening of 
the leukaemic genomic and genetic make-up. 
 
Figure 1-1 Common genetic rearrangements with chromosomal translocation 
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1.2.1.1 The multi-step pathogenesis of leukaemia 
The incidence of leukaemia in monozygotic twins has long been observed. It was also 
realized that the concordance of leukaemia is identical twins varied with age. For instance, 
the concordance of neonatal leukaemia in identical twins in nearly 100% while in 
childhood age group this drops down to nearly 10%. Molecular genetic analyses have 
identified that the leukaemic cells in the twins share clonal origins. This implies that the 
mutation arise in a progenitor cell in one twin and its daughter cells spread to the other 
twin through trans-placental circulation (Greaves et al., 2003). Further evidence came from 
the retrospective studies analysing archival material from children with leukaemia. 
Strikingly, many children with ALL were found to have the characteristic translocation 
present in their post-natal Guthrie card blood samples. The latency period between birth 
and leukaemia implied that further post-natal events are necessary for transformation from 
a mutant progenitor cell to the heterogeneous population of leukaemic cells numbering in 
order of 1012. This latent period is generally translocation-specific. For instance, MLL-
rearrangements have a very short latency period to overt clinical disease whereas TEL-
AML1 have longer latency and lower transformation rate (Greaves and Wiemels, 2003). 
These findings suggest that some leukaemic subtypes need accumulation of more 
secondary hits than others. The evidence for this multi-step model further cemented with 
the identification of leukaemia-associated translocation (TEL-AML1) in a high frequency 
of samples from normal children (approximately 1%). This implies that TEL-AML1 
translocation is not sufficient to cause overt leukaemia and further mutations are necessary 
for frank disease (Mori et al., 2002). 
Studies on genetically engineered mice have not only validated the multiple-hit hypothesis, 
but also shed light on the behaviour of pre-leukaemic clones – at least in TEL-AML1 
subtype. Transplantation of TEL-AML1 transfected bone marrow cells into 
immunodeficient mice resulted in increased self-renewal capacity and relative 
accumulation of early B cell progenitors compromising the differentiated populations 
(Tsuzuki et al., 2004). However, this translocation was not sufficient to cause leukaemia in 
mice even till the age of 1 year (Fischer et al., 2005). When additional mutations are 
accrued, the mice quickly develop acute leukaemia (Bernardin et al., 2002). 
It is not exactly known as to how the haematopoietic precursors acquire the first and 
second hit. It is hypothesised that the prenatal immune system is prone to chromosomal 
translocations due to rapid expansion and genetic rearrangements needed for normal B- 
and T- cell development. Once generated, the mutant clone will undergo limited 
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expansion. During the post natal life, this clone will normally be cleared from the body, 
unless a second mutation is acquired. Epidemiologic data points to an increased incidence 
of leukaemia in children unexposed to normal infectious agents during early life and it is 
suggested that immune system may need such exposures for normal development. 
Exposure to infection at a later-than-usual stage results in abnormal immune responses 
which may lead to acquisition of further hits (Greaves, 2006). This ‘delayed-infection’ 
hypothesis presents plausible explanations to the observed peak incidence seen in 
leukaemia (2-5 years of age), the latency period after the first hit (months to years), and the 
rare transformation of pre-leukaemic clones to overt leukaemia (1%). However, in utero 
acquisition of pre-leukaemic clone has been identified in only a subset of childhood ALL. 
It is not known if other subtypes of leukaemia, especially those at a later age acquire the 
pre-leukaemic clone in utero, or are a result of sporadic post-natal incidence. It is likely 
that other mechanisms of leukaemogenesis co-exist.  
1.2.1.2 Additional genomic abnormalities in ALL 
Cytogenetic abnormalities such as rearrangements and aneuploidy are insufficient to 
explain the myriad of cellular abnormalities found in leukaemia. Genome-wide association 
studies to determine copy number alterations (CNAs) and loss of heterozygosity (LOH) 
performed using single nucleotide polymorphism (SNP) arrays in ALL have opened up 
new avenues for new classification and therapeutic strategies. In 2007, Mullighan et al. 
analysed 242 children with ALL using SNP arrays and reported several novel genetic 
alterations in different leukaemic subsets. Notably, patients with MLL-rearrangements had 
approximately one abnormality while TEL-AML1 leukaemia had an average of 6 
abnormalities. This could explain for the high concordance and short latency in MLL-
rearranged ALL while a low concordance and long latency in TEL-AML1 leukaemia. 
Furthermore, the researchers identified more than 50 recurrent genetic abnormalities that 
involved genes with potential role in lymphoid development and leukaemogenesis. For 
instance, EBF1, PAX5 and IKZF1 play important roles in B- cell development and 
differentiation (Mullighan et al., 2007). The same group later identified IKZF1 deletion in 
76.2% paediatric BCR-ABL1 cases (Mullighan et al., 2008a). 
These observations were followed by in vivo studies to explore their role in 
leukaemogenesis. In once such study, transgenic mice carrying BCR-ABL1 mutation were 
crossed with mice carrying mutant IKZF1 allele with impaired functions. These mice 
experienced leukaemia with a significantly shorter latency compared to mice carrying 
BCR-ABL1 alone. Furthermore, comparative genomic hybridization analysis (CGH) of 
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leukaemic cells from these mice exhibited fewer additional chromosomal abnormalities. 
This implies that impaired IKAROS, a transcription factor encoded by IKZF1, shortens 
leukaemia latency by bypassing the requirement for additional pro-oncogenic hits in BCR-
ABL1 positive leukaemias (Virely et al., 2010). In fact, IKZF1 deletions have been 
described in other subtypes of ALL and are reported to have poor prognostic outcome 
(Mullighan et al., 2009b). 
Not only these novel genetic mutations expanded our understanding of the pathogenesis of 
ALL, but also led to therapeutic decision making. SNP analysis of a large cohort of 
childhood ALL cases identified mutations in CRLF2 in high proportion in a cohort of 
childhood ALL and Down syndrome associated ALL. These mutations are associated with 
activating mutations in the Janus-kinase (JAK) family genes or JAK/STAT signalling 
pathways (Mullighan et al., 2009a). Such patients are likely candidates for the newly 
developed inhibitor Ruxolinib. Phase I studies are underway studying the patients with 
relapsed or refractory disease (ClinicalTrials, 2014). Recently, whole exome sequencing, 
lesions involving tyrosine kinases and key signalling pathways were identified in near 
haploid ALL (Holmfeldt et al., 2013). These pathways can certainly be attractive targets 
for the use of tyrosine kinase inhibitors. 
1.2.2  Leukaemia as an evolutionary process 
In 1976, Peter Nowell published a landmark perspective on the development of cancer. He 
suggested that the development of cancer as a process of somatic evolution – much like 
Darwinian principle of natural selection – with cancer cells acting as organisms and the 
body as an ecosystem (Nowell, 1976). Beginning in embryonic life, cells are under 
continuous internal and external factors which may introduce mutations such as DNA 
damage or chromosomal breaks within the rapidly dividing cells. Postnatally, mutations 
continue to accumulate in low frequency within the dividing and ageing cells. Fortunately, 
the majority of these mutations are within the non-coding parts of the genome and 
therefore are inconsequential (passenger mutations). When these mutations are incurred 
upon parts of the genome vital for cell survival the cell may die. Rarely, the mutations will 
involve areas of genomes associated with regulation of cell growth or apoptosis and will 
result in a phenotype with enhanced proliferative ability or resistance to programmed cell 
death. 
This mutant clone expands along with the normally proliferating cells. However, in a 
Darwinian manner, selective pressure results in preferential expansion of the biologically 
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fittest daughter cells of this clone. Subsequent mutations arising in the progeny of such 
cells allow expansion of subclones with accumulated mutations resulting in further 
dysregulated cellular processes. Many regulators of cell cycle which are responsible for 
programmed cell death are inactivated. Such clones have an increased capability to survive 
further DNA damage and are naturally more suited to survive (Figure 1-2).  
 
 
Figure 1-2 Clonal evolution and heterogeneity in ALL 
Mutation involving normal haematopoeietic stem/progenitor cells results in limited expansion of the mutant 
cell. Additional mutations form subclones. Selective pressures allow some mutant subclones to expand while 
others become extinct or remain dormant. Ecosystems represent the different tissue niches. Relapse may be 
caused by expansion of (a) a resistant subclone or (b) additional mutations in the ancestral clone. Each 
differently coloured circle represents a genetically distinct subclone. (adapted from (Greaves and Maley, 
2012) 
1.2.3 Clonal evolution in ALL 
Historically, chromosomal analysis has been the main tool for analysing genetic changes in 
leukaemic cells. Due to the low resolution power of karyotyping, and reliance upon in vitro 
culture of leukaemic cells, the genetic heterogeneity in ALL was missed. It is certainly true 
that fewer additional genetic mutations may be required to initiate leukaemia, however, at 
the time of presentation, leukaemic cells are a heterogeneous population carrying several 
additional mutations. 
The initial convincing evidence for sub-clonal heterogeneity in ALL came from 
comparison of matched leukaemic samples at the time of diagnosis and relapse. For 
instance, Raimondi et al. (1993) reported completely unique karyotypes at relapse in 
approximately 10% children. Like the general consensus at that time, these cases could 
represent secondary malignancies. However, the authors raised the possibility of a pre-
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leukaemic or ancestral clone which might be present in minor proportion at the time of 
diagnosis. Using multicolour fluorescence in situ hybridisation (FISH) analysis, Anderson 
et al. (2011) identified multiple subclones in cases of TEL-AML1 positive ALL cases in 30 
cases with diverse and complex sub-clonal architecture. Selective pressure on the 
leukaemic cell population could have resulted in elimination of the dominant clone, which 
could result in expansion of a minor subclone. The convincing evidence of such an 
ancestral clone was only possible after back-tracking of relapse-specific mutation. Analysis 
of paired diagnostic and relapse samples by analysis of antigen receptor gene 
rearrangement identified crucial differences between the dominant clones at diagnosis and 
relapse (Konrad et al., 2003). Moreover, single nucleotide polymorphisms (SNPs) in 
samples revealed that the majority of mutations found in the dominant clone at relapse 
could be traced back to a rare clone present at diagnosis. Importantly, more than half of the 
relapse-associated clones shared some but not all copy number alterations (CNAs) 
identified in the diagnostic clone. This suggested that the relapsed clones most likely 
evolved from an ancestral clone (Mullighan et al., 2008b).  
While these genetic abnormalities certainly influence leukaemic behaviour and clinical 
outcome, a number of other factors are taken into account when making clinical decisions. 
1.3 Prognostic factors in ALL 
Several factors determine the outcome of patients in ALL. These include demographic 
factors (e.g age and gender), disease factors (e.g. presenting white cell count (WCC) or 
cytogenetics) and treatment factors (e.g. drug regimen, treatment duration and intensity). 
These various factors have been utilized for risk assessment of patients. More recently, 
therapy response based stratification has emerged as a single most significant prognostic 
factor in ALL.  
1.3.1 Patient characteristics 
Age has been a major determinant in the outcome of leukaemic patients. Infants (van der 
Linden et al., 2009) and adolescents (Ramanujachar et al., 2006) have a much worse 
outcome than young children. This difference is mainly due to the characteristic MLL- 
rearrangements seen in infants (van der Linden et al., 2009), and due to the higher 
frequency of high risk cytogenetics (e.g. BCR-ABL1) and the poor drug tolerability in the 
older patients. Indeed in young adults the outcome is much superior when treated on 
paediatric protocols (Ramanujachar et al., 2006, de Bont et al., 2004, Stock et al., 2008). 
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Boys have historically had a worse outcome than girls. One reason for this poor prognosis 
is perhaps the increased incidence of T-ALL in boys. Traditionally, testicular relapses have 
been considered poor risk factors. Even the more recent studies continue to show the slight 
inferior outcome in boys compared to girls (Escherich et al., 2010). 
The diagnostic WCC is considered to be a crucial variable for the outcome of the patient. 
Whether it represents a high tumour burden or a more aggressive disease is not known. 
Conventionally, a WCC higher than 50 x 109/L is used as a cut-off between better and 
worse risk. Patients with BCP-ALL and a high WCC at diagnosis are at an increased risk 
of treatment failure. The relationship of WCC with prognosis in T-ALL is much less clear. 
This is perhaps because of the low presenting WCC seen with Early T-cell precursor (ETP) 
ALL – an aggressive subtype (Vaitkeviciene et al., 2011). Signs of extramedullary 
infiltration such as hepatosplenomegaly, lymphadenopathy and mediastinal involvement 
are also considered as measures of tumour burden. Overt testicular involvement most 
commonly seen with T-ALL does not appear to be of prognostic significance when treated 
with the more intense protocols (Sirvent et al., 2007). The presence of CNS leukaemia at 
diagnosis is associated with worse outcome. Not only do these patients require additional 
treatment, but this also significantly increases the risk of CNS-relapses. A more extensive 
discussion on CNS leukaemia is presented in section 1.3.7. 
1.3.2 Immunophenotype 
ALL arises from haematopoietic precursors of the B- or T lymphoid origin. The leukaemic 
cells tend to recapitulate stages of normal B- or T cell development. Expression of lineage 
specific immunological markers on leukaemic cells is used for the classification of ALL. 
The initial diagnostic method utilized sheep rosette formation to identify T- lineage blasts 
and a polyclonal antiserum with affinity to the common acute lymphoblastic leukaemia 
antigen (CALLA) to identify B-lineage ALL. Emergence of polyclonal antibodies against 
the lineage-associated markers (cluster of differentiation or CD markers) allowed 
identification of specific maturation stage of leukaemic cells. As a consequence, ALL was 
classified into several B- and T- lineage categories by various study groups (Bene et al., 
1995). In 2008, the World Health Organization (WHO) classified B- lineage leukaemias as 
precursor- B lymphoblastic leukaemia (B-cell precursor ALL or BCP-ALL) and Burkitt 
leukaemia. BCP-ALL identified by expression of B-lineage markers such as cytoplasmic 
CD79a, CD19, HLA-DR and CD10 whereas Burkitt leukaemia is identified by surface 
Immunoglobulin (Ig) expression (Swerdlow et al., 2008). T-ALL is characterized by the 
expression of T- lineage associated markers such as cytoplasmic CD3, CD7 and CD2 or 
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CD5.  
T-ALL is frequently associated with male gender, older age, high WCC and mediastinal 
mass and is treated as high-risk disease. ETP-ALL is characterized by a very early lineage 
phenotype (Coustan-Smith et al., 2009) and shows a unique gene expression signature that 
overlaps with stem-cell and AML (Zhang et al., 2012). Approximately 80-85% cases of 
paediatric ALL comprise of BCP-ALL and are characterized by good prognosis whereas 
T-ALL form about 10-15% cases of childhood ALL and carry inferior prognosis. 
However, the independent prognostic value of T-cell phenotype is disputed. Differences in 
outcome previously attributed to immunophenotypes can now be classified based upon 
cytogenetic and molecular genetic abnormalities. Treatment intensification of T-ALL has 
resulted in an overall improved outcome with a treatment success approaching that of 
BCP-ALL (Mitchell et al., 2010, Escherich et al., 2010). 
1.3.3 Cytogenetic characteristics 
As discussed earlier, chromosomal abnormalities play a crucial role in the development of 
leukaemia, have distinct clinical and phenotypic properties and have a strong impact on the 
prognosis of disease, especially in BCP-ALL. Chromosomal analysis has been in use for 
the past several decades and is used for diagnostic classification, risk stratification and 
monitoring of disease progression. Cytogenetic/FISH analysis can identify chromosomal 
abnormalities with a high success rate. In the Medical Research Council (MRC) UK ALL 
trials, chromosomal abnormalities were performed using cytogenetics/FISH analysis in up 
to 91% patients out of which 89% had identifiable cytogenetic abnormalities (Harrison et 
al., 2005). The WHO classification has included BCP-ALL with the following cytogenetic 
abnormalities as distinct disease entities (Swerdlow et al., 2008): 
- Numerical chromosomal abnormalities 
- Hyperdiploidy 
- Hypodiploidy  
- Structural chromosomal abnormalities 
- t(9;22)(q34;q11.2); BCR-ABL1 
- t(v;11q23); MLL- rearranged 
- t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 
- t(5;14)(q31;q32);IL3-IGH 
- t(1;19)(q23;p13.3);E2A-PBX1 (TCF3-PBX1) 
The most common cytogenetic abnormalities relevant to this thesis are briefly discussed 
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below. One specific chromosomal translocation t(9;22)(q34;q11.2) (BCR-ABL1) is of 
particular interest to this thesis and is there discussed in more detail in this section (also in 
section 1.6.8).  
1.3.3.1 High hyperdiploid 
High hyperdiploid (chromosome number of 51-68) is the commonest cytogenetic subtype 
and represent approximately 25-30% of all ALL cases. High Hyperdiploidy is found 
mostly in BCP-ALL and rarely in T-ALL. The hyperdiploid leukaemic cells have a 
propensity to undergo apoptosis, and accumulate methotrexate and its active metabolites 
(Synold et al., 1994); thus explaining the independent favourable outcome in this category. 
Patients with chromosome numbers 58-66 offer the best prognosis in this category. Near 
triploid (69-81) or near tetraploid are rare but distinct types of ALL and are associated with 
ETV6-RUNX1 BCP-ALL, T-ALL and a favourable outcome (Raimondi et al., 2006). 
1.3.3.2 TEL-AML1 (ETV6-RUNX1) 
The t(12;21)(p12;q21) translocation results in fusion of ETV6 gene on chromosome 12 to 
the RUNX1 gene on chromosome 21. ETV6 gene is a regulator of haematopoiesis while 
RUNX1 encodes a transcription factor necessary for haematopoiesis. The fusion gene 
encodes a protein that binds to Smad3, a transforming growth factor-β (TGF-β) signalling 
target and alters its ability to inhibit proliferation (Ford et al., 2009). ETV6-RUNX1 
translocation is the most common specific genetic rearrangement and is seen in 20-25% of 
BCP-ALL but rarely seen in T-ALL (Attarbaschi et al., 2004) This rearrangement is 
associated with good prognosis characteristics and a favourable outcome (Loh et al., 2006). 
However, the prognostic value is modified by coincidence of other prognostic variables 
such as age, presenting white cell count (WCC) and response to treatment (Enshaei et al., 
2013, Borowitz et al., 2008). Furthermore, some of the patients with TEL-AML1 tend to 
suffer from late relapses despite initial clearance of disease. The late relapses usually have 
a better outcome than other categories. Interestingly, some of the relapses represent an 
independent second hit in a persistent ancestral TEL-AML1 rearranged clone (Ford et al., 
2001). 
1.3.3.3 Philadelphia chromosome (BCR/ ABL1) 
The Philadelphia (Ph) chromosome was the first specific chromosomal abnormality 
identified in human cancers (Nowell and hungerford, 1960) as well as ALL (Propp and 
Lizzi, 1970). Philadelphia chromosome is formed as a result of reciprocal translocation 
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between the long arms of chromosome 9 and 22. Fusion of ABL1 gene with the breakpoint 
cluster region (BCR) on chromosome 22 generates the BCR-ABL1 fusion gene. The 
breakpoints on the chromosome 9 are located within the first intron whereas on the 
chromosome 22 are scattered in three main regions. As a consequence three different sized 
mRNA and translated products are formed i.e p190BCR-ABL1 (190 kDa), p210BCR-ABL1 
(210kDa) and p230BCR-ABL1(230 kDa) (Figure 1-3). p190BCR-ABL1is most commonly 
associated with Paediatric BCR-ABL1 ALL whereas p230 BCR-ABL1 is a characteristic 
feature of chronic myeloid leukaemia (CML). It is not clear whether the intrinsic 
differences in the three variants of BCR-ABL1 protein account for the clinical phenotypes 
or whether the differences in clinical disease are merely due to the distinct lineage of the 
transformed cells – there is evidence for both. Adult BCR-ABL1 positive ALL cases with 
either p190 or p210 fusion gene present with similar clinical characteristics and prognosis 
(Kantarjian et al., 1991). On the other hand, p190BCR-ABL1 is suggested to be more efficient 
in promoting secondary mutations necessary for transformation into acute leukemic 
phenotype (Lugo et al., 1990). 
BCR-ABL1 translocation is not sufficient to induce leukaemia and additional genetic 
aberrations are thought to be necessary for progression to overt ALL. For instance, 
deletions of IKZF1 with loss of the transcription factor IKAROS are commonly seen in 
BCR-ABL1 ALL and are thought to play a critical role in leukaemic progression. Other 
less common mutations such as deletions of CDKN2A and PAX5 are also seen (Mullighan 
et al., 2008a). 
BCR-ABL1 ALL comprises 3-5% of childhood ALL cases and is associated with a poor 
prognostic outcome and generally treated as high risk patient (Jeha et al., 2014). BCR-
ABL1 ALL is associated with older age, higher WCC and CNS disease at diagnosis. 
Before the introduction of tyrosine kinase inhibitors, BCR-ABL1 ALL presented the worst 
prognostic type of ALL with a very high likelihood of treatment failure (Ribeiro et al., 
1987). However, with the use of tyrosine kinase inhibitors, there has been a dramatic 
decrease in leukaemia burden and end-of-induction minimal residual disease (MRD) levels 
similar to non-Ph+ ALLs (Jeha et al., 2014, Conter et al., 2010). With the use of tyrosine 
kinase inhibitors and accurate measurement of response by MRD monitoring, it has been 
possible that some of high risk patients can be re-classified as standard risk. BCR-ABL1 
ALL with other favourable clinical features such as low WCC count, age <10 years and 
good response to remission induction can be expected to have better overall prognosis 
(Bhojwani et al., 2009). 
Recent microarray data have identified a subset of paediatric ALL with poor outcome 
demonstrating genetic signatures that clusters with BCR-ABL1 ALL (e.g. IKZF1 deletion) 
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(Mullighan et al., 2009b) without the BCR-ABL1 translocation. These patients are 
classified as BCR-ABL1-like ALL (van der Veer et al., 2013, Den Boer et al., 2009). 
 
 
(a) 
 
(b) 
(c) 
Figure 1-3 Philadelphia chromosome and BCR-ABL1 variants 
(a) Chromosomal translocation between 9 and 22 (b) BCR and ABL1 genes with common breakpoints (c) 
translocated, transcribed and spliced mRNA. *abnormal chromosome 9. Adapted from (Chasseriau et al., 
2004) 
1.3.3.4 11q23; MLL- rearranged 
This translocation represents approximately 2% of childhood ALL. The translocation 
occurs between MLL- gene on chromosome 11 and any one of a large number of 
translocation partners. The most common MLL rearrangements are MLL-AF4 found in 
approximately 50% of MLL-rearranged BCP-ALL. MLL gene is responsible for regulation 
of haematopoiesis and the translocation leads to abnormal expression of several 
transcription factors and regulatory genes (eg. FLT3) resulting in a ‘stem-cell like’ state of 
maturation (Mullighan, 2012). MLL-rearranged ALL patients have a poor prognosis, 
especially when diagnosed shortly after birth.  
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1.3.4  Risk assignment  
While acknowledging ALL as a heterogeneous group of disorders, efforts have been made 
to define guidelines for uniform risk criteria, treatment regimen and analysis of the 
effectiveness of therapy. Treatment for ALL children is based on the theoretical risk of 
treatment failure and relapse defined by clinical and laboratory features. The aim of risk 
assignment is to achieve balanced therapeutic regimen where patients with favourable 
features receive less intensive drug therapy while patients with less favourable features 
who are likely to have poor outcome receive more intensive therapy. 
Several features contribute to the risk assessment of ALL patients. These include:  
- Demographic features such as age and sex. 
- Presenting clinical and laboratory features such as WCC, presence of 
extramedullary disease, immunological subtype and cytogenetic characteristics 
- Response to therapy. 
At the time of diagnosis, the usual clinical decision is to stratify patients according to age, 
sex, WCC and immunophenotype. The allocated treatment regimens are usually redefined 
based on subsequent information on cytogenetic subtypes and the response to induction 
therapy. The National Cancer Institute (NCI) risk group stratifies patients according to the 
following criteria (Smith et al., 1996): 
- NCI standard risk  - WCC <50 x 109/L and age 1-<10 years 
- NCI high risk – WCC >50 x 109/L and age <1 / >10 years 
Patients with T-ALL are generally stratified as NCI- high risk irrespective of the other 
variables. Other patient characteristics affecting the prognosis include extramedullary 
disease such as CNS or testicular involvement at diagnosis. If patients initially stratified in 
the standard risk category are subsequently found to have high risk cytogenetics (e.g. 
hypodiploidy, MLL- rearrangement), they are allocated into the high risk category.  
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1.3.5  Response to treatment 
In addition to the recognised clinical and biological factors associated with prognosis, there 
are several additional features that define individual patient’s outcome. The 
pharmacogenomic and pharmacokinetics factors, the treatment intensity, scheduling and 
compliance and other yet unrecognised factors may play a complex interactive role in 
individual patients – thus limiting the sensitivity of predicting the outcome of the 
individual patient. As a result, response to leukaemic therapy has emerged as an 
independent prognostic factor which includes all of the above characteristics. 
Modern treatment achieves clinical and morphological remission in most patients. 
However, with complete clinical remission (CCR) (<5% blasts in BM), the disease burden 
may not be completely eradicated and as many as 1010 cells may theoretically persist in the 
marrow (Pui and Campana, 2000). The morphological examination of the bone marrow is 
not sensitive for monitoring residual disease, as only 1-5 blasts/100 cells can be identified. 
Furthermore, morphological examination of the bone marrow is difficult to interpret and 
presence of increased numbers of blasts may merely represent the regenerating bone 
marrow – therefore, this method is not specific. In addition, the morphologic examination 
is subjective to the observer’s interpretation; therefore standardization within a laboratory 
and between laboratories is difficult. Historically, all patients in CCR received the same 
consolidation treatment irrespective of the extent of submicroscopic disease burden. Some 
patients in CCR may not have required any treatment at all while others should have 
received enhanced treatment because of the burden of submicroscopic disease (Figure 1-4). 
The international Berlin-Frankfurt-Munster (BFM) group has long used 1-week single 
agent steroid response as a measure for monitoring treatment response (Schrappe et al., 
2000). However, more recently, focus has shifted to using more sensitive, specific and 
reproducible methods for the detection of minimal residual disease (MRD). 
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Figure 1-4 Principle of MRD monitoring 
Prognosis of individual leukaemia is affected by the host characteristics (e.g. age, pharmacogenomics), 
leukaemia characteristics (e.g. WCC, cytogenetics) and treatment factors (dose intensity, duration). 
Submicroscopic residual leukaemic burden can exist wtih morphological remission which is responsible for 
treatment failure or relapse. (Adapted from Campana (2003)). 
1.3.5.1 MRD determination by flow cytometry 
Lymphocyte development begins in the bone marrow with pluripotent haematopoietic stem 
cells (HSC). Upon appropriate stimuli, the HSCs differentiate into lymphoid and 
subsequently B- and T- lymphoid lineage. A number of surface and intracellular proteins 
(e.g. cluster of differentiation or CD markers) are expressed during specific stages of 
development. As discussed in section 1.3.2, leukaemic cells tend to mimic the normal 
stages of B- and T cell differentiation (Figure 1-5). In addition, leukaemic cells express 
proteins not seen in any of the normal lymphocytes in the same stage of development and 
may lack some antigens expressed by their normal counterparts. As a result, individual 
patient’s leukaemic cells can be discriminated from normal developing lymphocytes based 
on aberrant expression of such markers. This immunophenotypic signature, called 
Leukaemia associated immunophenotype (LAIP) can be used to monitor residual 
leukaemic cells over time.  
Flow cytometry based MRD detection (flow-MRD) has the ability to detect 1 leukemic cell 
in a background of 10,000 normal haematopoietic cells (0.01%) (Coustan-Smith et al., 
1998, Weir et al., 1999) and can be applied in more than 95% cases of childhood ALL 
(Weir et al., 1999, Dworzak et al., 2002). However, flow cytometry requires fresh material 
for analysis and expertise in interpretation of results. In addition, leukaemic relapse may be 
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accompanied by emergence of a different LAIP thus making accurate monitoring difficult. 
The Children’s oncology group (COG) routinely uses flow cytometry for MRD monitoring 
(Chen et al., 2012). In one study on 2143 of BCP-ALL patients, MRD at day 29 (end of 
induction) was able to effectively predict outcome. Importantly, in multivariate anaylsis, 
MRD at day 29 was the strongest risk factor for event free survival (EFS) while a 
conventional risk factor ETV6:RUNX1 translocation was not associated with a significant 
difference in outcome (Borowitz et al., 2008). Efforts at standardization of flow-MRD in 
the UK in multicentre setting have shown promising results (Irving et al., 2009). 
 
Figure 1-5 Simplified model of (a) B- cell development stages and corresponding BCP-ALL 
types and (b) V(D)J and VJ rearrangement 
Schematic representation of (a) B- cell differentiation stages and expression of relevant CD markers with 
leukaemic counterparts above. (b)(i) V(D)J rearrangement process with D-J rearrangement followed by a V- 
DJ rearrangement I (Ig heavy chain (IGH), TCR beta (TCRB), & TCR delta (TCRD) genes (ii) direct V-J 
rearrangements in case of Ig kappa (IGK), Ig lambda (IGL), TCR alpha (TCRA), and TCR gamma (TCRG) 
genes. Rearrangement is initiated following expression of recombination activation gene (RAG1 and 2). HSC 
(Haematopoietic stem cell), LSC (Lymphoid stem cell, CD (Cluster of differentiation) Adapted from 
(Cobaleda and Sanchez-Garcia, 2009, Bene and Kaeda, 2009). 
1.3.5.2 MRD determination by polymerase chain reaction 
The main function of normal B- and T cells is to maintain the immune defences by 
identifying and neutralizing foreign antigens. The ability of lymphocytes to identify 
potentially unlimited number of antigens is based on the repertoire of antigen receptor 
molecules expressed by the lymphocytes. This diversity to identify millions of antigens is 
created by Ig and T-cell receptor (TCR) gene rearrangements. This involves random 
recombination of variable (V), diversity (D) and junctional (J) region genes (Tonegawa, 
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1983). In addition, insertion of non-templated (N-) nucleotides provides additional 
diversity to the Ig and TCR molecules. Consequently, each lymphoid precursor and its 
progeny differ from the others. This unique identity – a DNA finger-print – forms the basis 
for monitoring leukaemic cells in the background on normal regenerating bone marrow. 
The principle underlying real-time quantitative PCR (qPCR) monitoring of MRD is the 
specific amplification of leukaemic DNA sequences in the background of predominantly 
normal DNA from the bone marrow. Using DNA from diagnostic bone marrow specimen 
as a control to generate standard curve, accurate quantification of minimal levels of 
residual leukaemia is possible. Since the leukaemic cell population carry identical Ig/TCR 
gene rearrangement, diagnostic bone marrow DNA is used to identify and sequence the 
junctional regions of the rearranged genes. These sequences are used to design allele 
specific oligonucleotide (ASO) primers. A laborious standardization phase involves testing 
for sensitivity. Comprehensive guidelines for optimum DNA extraction, testing for 
sensitivity and specificity, and data interpretation have been published (van der Velden et 
al., 2007, Flohr et al., 2008, van der Velden et al., 2003) . In principal, qPCR is capable of 
detecting a single copy of leukemic DNA. However, practically, a sensitivity of 1 x 10 -5 (1 
leukaemic cell/ 100,000 cells) can be achieved in nearly 95% patients with this method. 
Currently, this method is widely used in many paediatric ALL protocols (van der Velden et 
al., 2003, Vora et al., 2013, Zhou et al., 2007). 
Levels of qPCR MRD after induction therapy are associated with relapse and poor 
prognosis. In an earlier study, patients with 10-3 residual leukaemic cells at any time point 
(after induction, consolidation or delayed intensification) were at a very high risk of 
relapse. MRD levels were the most important prognostic factors followed by 
immunophenotype and WCC (Cave et al., 1998). Since then, molecular monitoring of 
MRD is applied in several major treatment protocols with strong association of MRD 
positivity and relapse, treatment failure and other poor outcome variables (Zhou et al., 
2007, van Dongen et al., 1998, Flohr et al., 2008, van der Velden et al., 2003, Vora et al., 
2013). Based on MRD results, treatment reduction for some low risk ALL types has shown 
promise. Treatment reduction of MRD negative low risk children and young adults in the 
MRC UKALL 2003 trial showed that there was no significant difference in EFS in any of 
the randomized groups (Vora et al., 2013). 
In addition to MRD monitoring for rearranged Ig/TCR genes, qPCR can also be used to 
identify the fusion genes transcript levels in ALL with recurrent cytogenetic abnormalities 
(e.g. BCR-ABL1). This method carries the advantage of detection of the genetic mutation 
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associated with the leukaemia and the potential detection of pre-leukemic clone, 
irrespective of the clonal evolution and clonal heterogeneity. In addition, this method 
carries the advantage of a fixed set of standardized primers for the fusion gene transcripts 
(Gabert et al., 2003). Global use of this technique has been limited due to: a small 
proportion of suitable patients with fusion genes (40%), issues with RNA stability, the 
levels of fusion gene transcripts produced /cell may vary even for the same fusion gene 
type and finally, due to the potential variation in the levels of the house-keeping gene to 
control for sample quantities (van Dongen et al., 1999). Therefore, currently, this method is 
in use only for BCR-ABL1 ALL (Jeha et al., 2014). 
Despite being a strong indicator of treatment response and prognosis, a negative MRD 
does not always predict outcome and approximately 5-12% patients with a negative MRD 
at the end of induction still relapse (van Dongen et al., 1998, Cave et al., 1998, Zhou et al., 
2007, Flohr et al., 2008). In addition, MRD monitoring only reliably demonstrates the 
levels of leukaemia in the bone marrow. Theoretically, leukaemic cells in the so-called 
sanctuary sites (such as the testes and the CNS) can be the cause of relapses in patients 
who clear bone marrow MRD. In addition, there is not enough evidence to show whether 
MRD levels can be used as a surrogate marker while testing new therapies. For instance, in 
the recent UK ALLR3 trial, significantly improved EFS was observed in children treated 
with Mitoxantrone compared to Idarubicin despite similar levels of post-induction MRD in 
the two groups (Parker et al., 2010). 
1.3.6  Extramedullary disease (excluding CNS) 
The clonal concept of leukaemia implies that leukaemic cells originate from the sites of 
lymphoid development (i.e. bone marrow or thymus), yet at the time of diagnosis, 
leukaemic infiltration of several extramedullary organs such as the liver, spleen, (Steinherz 
et al., 1998) testes and the CNS is common (Reiter et al., 1994, Burger et al., 
2003).Traditionally, extramedullary involvement at diagnosis has been considered a 
measure of tumour burden and has been associated with poor outcome (Steinherz et al., 
1998). Presence of extramedullary disease at diagnosis can be important therapeutically. 
Occult leukaemia at the so-called sanctuary sites can seed the bone marrow and result in 
relapse or treatment failure. Therefore, current treatment protocols include assessment of 
testicular and nervous system disease.  
Overt testicular involvement is seen in 2% children with ALL at diagnosis and is 
associated with a significantly higher rate of relapse. Isolated testicular relapse is the 
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second most common site of extramedullary relapse in children. Testicular disease at 
diagnosis is associated with other high risk prognostic features. As a result, the majority of 
boys with bulky testicular disease at diagnosis are treated as high risk (Hijiya et al., 2005, 
Sirvent et al., 2007). The reason for testicular involvement in ALL is not understood 
completely. A poorly defined blood-testis barrier may protect leukaemic cells from tumour 
immune surveillance. Alternatively, the external location of the testes may provide survival 
advantage to leukaemic cells. 
Ovaries are the embryological counterparts of testes. A series of autopsies revealed similar 
incidence of ovarian (58%) and testicular (48.5%) infiltration by leukaemia (Kamiyama 
and Funata, 1976). However due to their position in the abdominal cavity, clinical signs of 
leukaemic infiltration appear less often. Current protocols do not actively look for ovarian 
infiltration at diagnosis and relapse. It is possible that because of same embryological 
origin, the ovarian environment is also protective to leukaemic cells. Moreover, in girls 
with leukaemia, cryopreservation and re-implantation of ovarian tissue is a potential 
method of preservation of fertility. In a recent article, cryopreserved ovarian tissue from 9 
girls with ALL showed presence of leukaemia by PCR (5/9 patients) and engraftment of 
leukaemia in immunodeficient SCID mice transplanted with the ovarian tissue (4/9 
patients) (Dolmans et al., 2010). 
1.3.7  CNS disease 
With improving success rates in control of leukaemia, central nervous system involvement 
in ALL emerged as a new phenomenon. The longer the patients lived, the greater the 
chances of them developing CNS disease. Between 1948-1960, the incidence of CNS 
leukaemia increased from 3% to 40% as the median survival of patients increased from 4 
to 12 months (Evans and Craig, 1964). In a series of 126 autopsies on children who died of 
leukaemia, almost 60% of the autopsies showed evidence of leukaemia in the CNS, 
predominantly the meninges (Price and Johnson, 1973). In patients surviving for 4 years or 
longer, up to 75% had CNS disease (Evans et al., 1970). The increasing incidence of CNS 
disease was attributed to poor penetration of anti-leukaemic agents into the CNS. With the 
realization that any improvement in survival rates could only be possible with effective 
clearance of CNS disease, prophylactic CNS therapy quickly reduced the frequency of 
CNS infiltration and improved survival (Hustu et al., 1973). Over the past few decades, 
survival from ALL has improved dramatically. Yet, CNS disease continues to pose 
challenges. 
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CNS disease is diagnosed and monitored by microscopic analysis of CSF. 1-2 ml of CSF is 
obtained through lumbar puncture. CSF cells counts are determined using automated cell 
counters while morphologic examination of CSF cytospin slides is performed to identify 
and count leukaemic cells. Based on this, CNS disease is classified into CNS disease 
categories (Table 1-1). At diagnosis, approximately 3% patients have CNS-3, 15-20% 
present with CNS-2 status (Gilchrist et al., 1994, Mahmoud et al., 1993, Burger et al., 
2003) while approximately 10% have traumatic lumbar puncture (TLP) with blood 
contamination of the CSF at the time of diagnosis (Gajjar et al., 2000). The majority of 
children with CNS-3 disease are asymptomatic. However, some may present with clinical 
or radiological signs without leukaemic cells in the CSF. 
Category Definition 
CNS-1  Non-traumatic lumbar puncture without leukaemic blasts a 
CNS-2 Non-traumatic puncture, ≤ 5 WBC/µL CSF with identifiable blasts 
CNS-3 Non-traumatic puncture, ≥ 5 WBC/µL CSF with identifiable blasts or  
cranial nerve palsies or cerebral mass 
TLP positive Traumatic lumbar puncture with obvious blasts 
TLP negative Traumatic lumbar puncture without blasts 
Table 1-1 Diagnostic criteria for CNS disease 
 
Acknowledging that the current methods of diagnosing CNS disease may not be sensitive 
enough, a number of researchers have tested novel methods to improve the diagnostic 
accuracy of CNS disease.  
 
1.3.7.1 Experimental methods for detection of CNS disease 
Following the improved survival with prophylactic CNS therapy, it was proposed that sub-
clinical level of leukaemia in the CNS were present at diagnosis (Hustu et al., 1973). There 
was a need to improve the diagnostic accuracy of CNS involvement. Several alternative 
methods to detect sub-clinical levels of leukaemia in the CSF have been tried. Three main 
approaches have been reported: increasing sensitivity of detecting blasts in the 
cerebrospinal fluid samples, and indirect estimation of CNS leukaemia by detecting soluble 
biomarkers of leukaemia in the CSF, and using radiological diagnostic methods. These are 
briefly described here. 
1.3.7.2 Detection of CNS leukaemia by immunological markers 
Leukaemic blasts are difficult to be discriminated from normal leukocytes on cytospin. Use 
of immunological markers can identify leukaemic cells with accuracy. The initial studies 
used Terminal deoxynucleotidyl transferase (TdT) (Hooijkaas et al., 1989) and TdT/CD10 
39 
 
 
(Homans et al., 1990) staining of CSF cytospin preparation. TdT staining from patients 
with TdT-expressing leukaemias identified approximately 25% patients to be positive for 
CNS disease. Moreover, TdT staining at diagnosis was predictive of a CNS relapse during 
the follow up period (Hooijkaas et al., 1989). More recently, multi-colour flow cytometry 
has added to the accuracy of diagnosing CNS disease (Sayed et al., 2009, Del Principe et 
al., 2014, Martinez-Laperche et al., 2013, Bromberg et al., 2007, Cancela et al., 2013). For 
example, in a study on 219 patients with different haematological malignancies, 
flowcytometry detected CNS leukaemia in 44 (20%) patients compared to 19 (8%) by 
cytology. Four flow cytometry +ve/cytology-ve patients subsequently relapsed in the CNS 
(Bromberg et al., 2007). Similarly, in a recent study on 113 paediatric ALL patients, CNS 
leukaemia was found in 27.8% patients by flow cytometry compared to 2.8% by cytology. 
Moreover, appearance of leukaemic phenotype during treatment period was predictive of 
CNS relapse (Martinez-Laperche et al., 2013). 
1.3.7.3 Detections of CNS disease by PCR 
PCR for clonal Ig/TCR gene rearrangements can be used to determine the clonality of 
leukaemic cells in the CNS (Scrideli et al., 2004, Scrideli et al., 2003, Pine et al., 2005, 
Biojone et al., 2012, de Haas et al., 2002, Galoin et al., 1997). DNA is stable and can be 
recovered from cells with poor viability. Studies utilizing PCR have demonstrated not only 
a higher incidence of CNS disease, but also poor prognosis in CSF PCR positive patients. 
For example, using PCR, in a series of 37 paediatric ALL patients, 46% were positive for 
CNS disease while morphology could only determine 5.4% CNS-3 cases. Moreover, the 4 
year EFS in qPCR positive patients was significantly worse than qPCR negative patients 
(Scrideli et al., 2004). qPCR studies can also be useful in cases suspected of CNS 
leukaemia. For instance, Scrideli et al. describe a small series of cases with and without 
CNS disease. In one such patient where CSF cytology was considered positive, 
heteroduplex analysis of the PCR product identified oligoclonal bands, suggesting reactive 
lymphocytosis instead of CNS disease (Scrideli et al., 2003). However, presence of 
clonally evolved leukaemic cells in the CNS may lead to false negative results when tested 
by qPCR for Ig/TCR rearrangements.  It is currently not known whether leukaemic cells in 
the CNS represent the same dominant clones in the bone marrow. 
The worse prognosis associated with sub-clinical levels of CNS disease tends to reduce in 
more recent trials. In a study using qPCR for clonal Ig/TCR rearrangement 29/62 patients 
were positive for CNS leukaemia at diagnosis. Patients treated with a low intensity 
regimen had a significantly poor 5 year EFS and Relapse Free survival (RFS) compared to 
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CSF negative patient, while there was no difference in the outcome of CSF qPCR positive 
and negative patients allocated to intensive treatment group. Three CNS relapses were seen 
in the duration of follow up, all were CSF qPCR positive at diagnosis (Biojone et al., 
2012). Similarly, CSF positivity by flow cytometry in adult ALL is associated with worse 
overall survival (Del Principe et al., 2014). A similar effect of treatment was seen with 
flowcytometry positive CSF leukaemia where enhanced intrathecal methotrexate was used 
(Liang et al., 2013). 
It is clear that when flow cytometry or PCR is used, CNS disease can be detected at a 
higher rate than by microscopy. This added information has shown to be useful in 
predicting relapse, and improving the outcome in some cases with therapy escalation. 
However, the published literature lacks comparability due to different panels of antibodies 
used or different PCR techniques employed. Flow cytometric analysis of CNS leukaemia is 
limited so far by limited number of cells, poor viability of cells after lumbar puncture, 
different combinations of antibodies used in literature. LAIP may change and result in a 
false negative result. Low yield of amplifiable DNA for PCR excludes patients who may 
be true negatives but follow up data from these patients is missing. In addition, analysis by 
PCR may not detect CNS homing clones if different from the dominant clone. The above 
described studies are mostly clinical and fail to provide any explanation for discordance 
between cytology and Flow cytometry /PCR results. More of leukaemic burden is present 
on the surface of meninges and leukaemic cells may not necessarily be always present in 
CSF circulation. This prompts for indirect determination of leukaemia in the CNS through 
soluble biomarkers of CNS leukaemia.   
1.3.7.4 Soluble biomarkers of CNS disease 
Leukaemia-associated soluble factors may be released by the malignant cells into the 
extracellular compartment and their levels in the CSF could be an indirect measure of 
disease burden in the CNS. Early attempts to identify leukaemia specific soluble 
biomarkers focused on assessing markers of inflammation, cellular activity and the blood-
brain barrier integrity such as levels of lactate dehydrogenase (Reeves et al., 1978), and 
CSF protein levels (Harms, 1974). Few candidate lymphoid cell proteins associated with 
adhesion, chemotaxis and immune response have shown promise. Not only do the soluble 
biomarkers associated with CNS disease be useful clinically, but also they can provide 
clues on disease biology – soluble L-selectin (sL-selectin) is one of such biomarkers. 
Stucki et al. categorised a group of adult leukaemia patients into plasma sL-seletinhigh and 
sL-selectinlow groups. The authors observed that patients with confirmed CNS disease had 
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significantly higher levels of CSF sL-selectin compared to patients without CNS disease or 
controls (Stucki et al., 1995). The levels of CSF sL-selectin have shown to rise before 
clinical CNS-relapse, peaking at overt CNS relapse and declining post- treatment 
(Dagdemir et al., 1998). sL-selectin has been shown to inhibit blast cell adhesion to the 
endothelium and thus may have been responsible for excessive mobilization of leukaemic 
cells in the CNS compartment (Spertini et al., 1994). 
Soluble Interleukin-2 Receptor alpha (sIL2-Rα) was tested in 19 patients with CNS disease 
and 134 controls patients. sIL2-Rα level >10U/ml was suggestive of CNS leukaemia with a 
high sensitivity (89.5%) and specificity (89.6%). However, these values could only be used 
in conjunction with CSF cytology (Lee et al., 2005). Soluble CD27 (sCD27) was analysed 
in 70 children with various haematological malignancies. sCD27 levels possessed high 
sensitivity and specificity, however in many cases there was a considerable overlap in 
sCD27 levels between CNS cytology positive and cytology negative cases (Kersten et al., 
1996). The chemokine CXCL13 has also been investigated in various CNS malignancies 
expressed on the tumour (Smith et al., 2003), host tissue (Brunn et al., 2007), or secreted in 
the CSF (Rubenstein et al., 2013). CXCL13 and IL-10 combined had a diagnostic 
specificity of >99% in primary CNS lymphoma (Rubenstein et al., 2013). Several groups 
have also tested CCL2 (Eisenkraft et al., 2006), β2 microglobulin (Mavlight et al., 1980), 
Fibronectin (Rajantie et al., 1989) and Vascular endothelial growth factor 1 & 2 
(VEGF1&2) (Tang et al., 2013) in the CSF from leukaemia and lymphoma patients with 
inconclusive results. In a recent study conducted on B-cell lymphoma patients several 
candidate biomarkers were tested. In patients with primary CNS lymphoma, higher levels 
of soluble CD19 (sCD19) were found in the CSF in 88% patients. sCD19 positivity was 
associated with a poor EFS however, no CNS relapse was seen on follow up (Muniz et al., 
2014). Recently, significantly higher CSF osteopontin levels were found in a cohort of 
paediatric patients with CNS relapse compared to CNS negative controls. However, the 
findings were limited by a small number of control group and low specificity of the test 
(İncesoy-Özdemir et al., 2013). 
Soluble biomarkers of disease in the CNS are limited by high false negative and false 
positive results. A possible explanation to this could be the insensitive comparator (CSF 
cytology) used in these studies. As we have already discussed, CSF cytology lacks 
sensitivity and many CSF cytology negative cases may harbour disease in the CNS. Such 
cases are wrongly put in the CNS negative category, thus making adequate comparisons 
difficult. CSF cytology only identifies 3-5% cases at diagnosis while data from PCR and 
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flow cytometry suggest that up to 60% cases of paediatric ALL may be positive for CNS 
disease at diagnosis. A study of CSF biomarkers in flow cytometry/ PCR defined CNS 
disease has never been performed.  
1.4 ALL treatment 
Acute lymphoblastic leukaemia was invariably fatal disease until the 1960s. Patients 
treated with single agents rarely achieved remission and the disease would take over again. 
It was soon realized that when vincristine, prednisolone and L-asparaginase were 
combined, the remissions lasted longer. The realization that systemic therapies could not 
effectively eradicate the subclinical CNS disease was a major breakthrough. The 
prophylactic cranial and craniospinal irradiation dramatically improved prognosis and 
within a decade, nearly half of the patients could be expected to achieve long-term 
survival. Formation of large cooperative study groups meant more uniform approaches for 
treatment could be employed and smaller differences in survival could be exploited. 
Understanding of prognostic risk factors and adaptation of risk-adapted therapeutic 
regimen along with improved management of toxicities resulted in an excellent survival of 
paediatric ALL patients. 
The current treatment of ALL typically involves chemotherapy given for 2-3 years and is 
intended to achieve cure in patients. Therefore children at a higher risk of treatment failure 
receive more intense and prolonged chemotherapy. The majority of patients are treated at 
specialized centres with risk-stratified treatment protocols. The core chemotherapeutic 
drugs have principally remained unchanged over the last decades. The main classes of 
drugs used in paediatric ALL include corticosteroids (prednisolone, dexamethasone), 
anthracyclines (Daunorubicin) and purine analogues (6-Mercaptopurine). The treatment is 
distributed into different phases spanning over 2 years for girls and 3 years for boys. 
1.4.1.1 Remission induction 
Remission induction includes intensive chemotherapy for a short period (typically 4 
weeks) and is intended to eradicate the bulk of disease along with restoration of normal 
haematopoiesis. Commonly used drugs include a glucocorticoid (prednisolone or 
dexamethasone), vincristine and asparaginase. This drug combination allows targeting 
multiple key pathways in leukaemic cells. High risk patients may receive additional 
daunorubicin. BCR-ABL1 ALL patients may also receive a tyrosine kinase inhibitor 
(Imatinib or Dasatinib) (Schultz et al., 2009). Following induction chemotherapy, the 
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majority of patients achieve clinical and morphological remission (<5% BM blasts, no 
circulating and CSF blasts, no cerebral mass). MRD studies performed at the end of 
induction period are used to assess patient response to treatment and re-assign risk.  
1.4.1.2 Intensification (consolidation) 
The aim of consolidation therapy is to eradicate any residual disease using a combination 
of chemotherapeutic agents. The combination and intensity is dependent upon clinical risk-
status and MRD results. The drug combinations vary in different protocols but include 
methotrexate, mercaptopurine, asparaginase along with frequent pulses of vincristine and 
corticosteroids. Intensification is typically administered for 10-12 weeks. (Vora et al., 
2013) CNS directed therapy is given to eliminate CNS disease. Many protocols include a 
delayed intensification phase consisting of a 3 week re-induction and re-consolidation 
towards the end of intensification phase (Moricke et al., 2008, Schrappe et al., 2011). 
1.4.1.3 Maintenance 
Maintenance therapy is typically given over a period of 2-3 years of continuous remission -
three years for boys while two years for girls (Vora et al., 2013, Gaynon et al., 2010). The 
maintenance therapy generally includes oral 6-mercaptopurine and weekly or parenteral 
methotrexate and targets residual slow-cycling leukaemic cells. Therefore, careful 
monitoring of drug toxicities and compliance to drugs is essential for the whole duration of 
maintenance therapy. Non-compliance to 6-mercaptopurine is shown to be associated with 
significant increase in relapse risk (Bhatia et al., 2012) whereas toxicities may arise in 
patients with deficiency of S-methyltransferase – an enzyme that inactivates 
mercaptopurine (Relling et al., 1999). CNS prophylaxis continues during maintenance 
(Mitchell et al., 2010). 
1.4.1.4 CNS-directed therapy 
At diagnosis, only 3-5% children present with morphological or clinical evidence of CNS 
disease (CNS-3). However, unless CNS-directed therapy is administered, the majority of 
children will eventually present with CNS disease. Therefore, CNS- directed treatment is 
given to all patients irrespective of the evidence of CNS involvement at diagnosis. The 
initial CNS prophylaxis consisted of cranial or cranio-spinal irradiation (Hustu et al., 
1973). However, due to toxicities associated with radiation, the use of radiation in most 
modern protocols is reserved for patients at high risk for CNS relapse (Richards et al., 
2013). CNS- directed therapy comprises of high intensity systemic chemotherapy with 
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CNS bioavailability, intra-thecal chemotherapy and cranial radiation in some cases. The 
choice of drugs and intensity is calculated on the NCI-risk, MRD risk and CNS disease 
status at presentation (Gaynon et al., 2010, Mitchell et al., 2010, Schmiegelow et al., 2010, 
Salzer et al., 2010). 
1.4.1.5 ALL relapse 
Approximately 20-25% children with ALL will eventually relapse, mostly in the bone 
marrow and or CNS (Nguyen et al., 2008, Mitchell et al., 2010). Despite intensive therapy, 
the prognosis of relapsed ALL has not improved in the past few decades (Nguyen et al., 
2008, Roy et al., 2005). Features associated with poor prognosis include NCI- high risk 
category, early relapse, age >10 years, CNS disease at diagnosis, male gender, T-cell 
immunophenotype, high risk cytogenetics (Nguyen et al., 2008, Chessells et al., 2003) and 
MRD at the end of induction (Raetz, 2008). More recently, acquired genetic mutations 
such as TP53 gene mutations and IKZF1 deletions are found to be associated with a higher 
frequency of relapse and carry risk of second relapse (Krentz et al., 2013). However, the 
defining characteristics for risk stratification are the duration of first remission, site of 
relapse and immunophenotype (Einsiedel et al., 2005, Masurekar et al., 2014, Nguyen et 
al., 2008). 
The duration of first remission is an important determinant of outcome – with late relapses 
having a much better prognosis than early relapses. For instance, in the UK, 5 year EFS 
following bone marrow relapse occurring within 18 months from diagnosis was 20% while 
prognosis after relapses occurring more than 18 months but within 6 months after 
completion of therapy was 49% (Roy et al., 2005). For patients with CNS relapse, the 
overall survival in late relapses was 69% compared to 41.9% for very early relapses 
(Masurekar et al., 2014). This probably could be due to incidence of late relapses in TEL-
AML1 ALL cases. On the other hand, T-ALL cases tend to relapse early – both these 
characteristics are independent poor prognostic features (Einsiedel et al., 2005). 
Site of the relapse is an independent prognostic factor. CNS involvement at the time of 
relapse (isolated or combined with bone marrow relapse) can be seen in 20-40% of patients 
(Krishnan et al., 2010, Masurekar et al., 2014). CNS relapses are frequently associated 
with high risk features such as T-cell ALL, WBC > 100,000/ul, BCR-ABL1 and MLL-
rearrangement and CNS disease at diagnosis (Pui, 2006) The role of CNS-2 status and 
traumatic lumbar puncture is debated (te Loo et al., 2006, Mahmoud et al., 1993, Gilchrist 
et al., 1994, Burger et al., 2003). Despite this risk stratification, CNS relapses are 
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frequently seen in patients stratified as low risk for CNS disease. The earlier CCG 
(childhood cancer group) trial data (1983-1989) from 2712 ALL children nearly 1/3rd 
relapsed with highest number of relapses in the bone marrow, followed by isolated CNS 
relapse (Gaynon et al., 1998). Moreover, the median time to CNS relapse was shorter (19 
months) and 6 year survival of only 48% (Gaynon et al., 1998).  In a Dutch Childhood 
Leukemia study group (DCLSG) study, out of 526 paediatric ALL cases, only 22 cases of 
isolated CNS relapse were seen; however the majority of CNS relapse patients were from 
CNS1 category (te Loo et al., 2006). Similarly more CNS relapses were seen in standard 
risk (SR) patients compared to high risk (HR) in 491 children treated at Dana Farber 
Cancer Institute (DFCI) (Moghrabi et al., 2007). In the BFM group study, more isolated 
CNS relapses were seen in medium risk patients compared to high risk group (Moricke et 
al., 2008). 
Isolated CNS relapses tend to respond better to treatment than patients with combined 
(bone marrow>5% blasts + CNS>5 blasts/µl) relapses (Krishnan et al., 2010) which in turn 
have a better outcome than isolated bone marrow relapses (>25% blasts). This improved 
outcome in isolated CNS relapse is attributed to high dose CNS directed systemic and 
intrathecal chemotherapy followed by cranial radiation (Ritchey et al., 1999). Moreover, it 
can also be argued that since bone marrow and CNS relapses are competing events, 
isolated CNS relapses would represent efficient clearance of bone marrow blasts and 
therefore a less aggressive disease. This hypothesis is supported by identification of a new 
group of patients with overt CNS relapse with bone marrow disease detectable only by 
qPCR. Such patients tend to have a worse outcome in comparison with truly isolated CNS 
relapses (Hagedorn et al., 2007). Therefore, the prognosis of patients with CNS relapse 
worsens with increasing levels of disease in the bone marrow. Weather the sub-
microscopic bone marrow disease is a result of secondary seeding from the CNS blasts or 
alternately CNS relapse is the result of an early dissemination from sub-microscopic bone 
marrow disease remains to be clarified. This may have important biologic and therapeutic 
implications. Leukaemic cells in the bone marrow at relapse can represent expansion from 
an ancestral clone (Mullighan et al., 2008b) and are frequently found to have additional 
genomic mutations (Krentz et al., 2013). If the leukaemic cells in the CNS are different 
from the bone marrow clone at relapse, different therapeutic approaches may be required.  
1.4.1.6 Toxicity of ALL therapy 
Intensive chemotherapeutic regimen along with the use of CNS prophylaxis has increased 
chances of survival even in relapsed ALL. This success has not been without the cost of 
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significant treatment related toxic effects.  Therapeutic agents may affect the growth of the 
developing bodies of the children, may cause acute toxicities or may result in late effects 
such as secondary neoplasms. The use of multiple chemotherapeutic agents during 
induction and consolidation can result in neutropenia. Bacterial and fungal infections 
during this period are an important cause of treatment related mortality. In addition, 
individual therapeutic agents have specific side effects with may cause complications and 
limit the use of these drugs. CNS complications of cranial and craniospinal irradiation have 
reduced in the past few decades due to the reduction in the use of radiation. However, 
current CNS directed therapies are not without complications either. Children on 
methotrexate suffer signs of meningeal irritation such as seizures and irritability which 
have a debilitating effect on the quality of life. CNS infections due to myelosuppression 
require aggressive treatment and prophylaxis.  
The long treatment duration in ALL has resulted in appearance of many delayed adverse 
events. Long term survivors of ALL continue to present with secondary tumours (Pui et al., 
2003). While the majority of these were treated with irradiation, the long-term effects of 
systemic and intra-thecal chemotherapy are not known yet. The combined effects of 
chemotherapy and radiation can affect the developing brain – young children especially 
girls are particularly susceptible to these. While most children treated on contemporary 
protocols have IQ scores within the normal range (Halsey et al., 2011) some children show 
significant reduction in the IQ scores (15 points or more) irrespective of the treatment 
modality (Mulhern et al., 1991). 
1.5 Current clinical challenges 
Much of the recent improvement in the outcome of childhood ALL has been a result of 
more intensive therapeutic protocols.  Several challenges remain: our understanding of the 
etiological factors that cause leukaemia are limited. How gene polymorphisms affect the 
development of leukaemia and response to therapy remains to be investigated. Treatment 
related toxicities remain a major cause of mortality in ALL patients (Hunger et al., 2012). 
Risk based treatment assignment has resulted in higher survival; however considerable 
overlap exists. For instance, standard risk patients and those with a good initial MRD 
response may ultimately relapse. Earlier trials with low intensity chemotherapeutic 
protocols resulted in nearly 50% cure rates (Eden et al., 1991). Subsequent trials have 
progressively escalated dose intensities to cure another 35-40% patients while theoretically 
over treating patients who would have been cured with much less intense treatment. Recent 
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trends towards use of less intensive regimen for good risk patients have shown promise 
(Vora et al., 2013), however, these measures will only be successful after careful 
assessment of the risk factors. Patients at a high risk of drug toxicity (e.g. thiopurine S-
methyltransferase (TPMT) deficiency) can benefit from such dose reduction approaches. 
Finally, the role of the pre-leukaemic stem cells is not well understood. Whether such 
cancer stem cells exist in all subtypes of ALL, they must be targeted to achieve complete 
cure.  
With the declining rate of relapse cases over the past few decades, it is becoming difficult 
to test new treatment modalities. These would require patients in large numbers and long 
follow up times to prove the superiority of one treatment over the other. In order to test 
experimental treatments, it has been suggested to use MRD to quantify the differences in 
the treatment efficacy. However, bone marrow MRD levels do not predict the risk of 
extramedullary relapse as accurately as bone marrow relapse. Not only are end-induction 
MRD levels of patients with and without CNS disease (CNS-3 and CNS-1) are similar 
(Levinsen et al., 2014) but also that CNS relapses are seen in both MRD-low and MRD-
high categories with similar frequencies (Bowman et al., 2011). 
Effective clearance of CNS disease is another major challenge to be addressed if universal 
cure of ALL is to be aimed. Currently, all the patients receive some form of CNS-directed 
chemotherapy. In addition, high risk and relapsed patients receive radiation therapy. 
Nonetheless, significant numbers of patients in CNS-low risk group suffer from relapse in 
the CNS. Little is known regarding the biological mechanisms underlying the CNS relapse. 
Whether blasts in the CNS at the time of relapse are remnants of the initial seeding from 
the diagnosis or represent secondary involvement following bone marrow relapse is not 
known. If CNS relapse is a result of secondary infiltration of leukaemic cells, then 
investigating the mechanisms underlying the dissemination of leukaemic cells from the site 
of origin to extramedullary organs will aid in developing therapeutic modalities to prevent 
this spread. If CNS relapse is a result of expansion of CNS-residual blasts, then it would be 
important to investigate the factors that allow leukaemic cells escape the initial therapy.  
1.6 Extramedullary dissemination in ALL – cell entry 
It is conceivable that the first leukaemic population reside in a distinct bone marrow site 
and subsequently disseminate to other medullary and extramedullary sites through blood 
circulation. This is a crucial step in leukaemic progression, although little is known 
regarding the biology of leukaemic cells that enable them to enter such sites. Entry of 
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circulating leukaemic cells into extramedullary organs may result from a number of 
biological processes. Leukaemic cells may enter the extravascular tissue using an invasive 
mechanism as seen in many solid tumours. Alternately, leukaemic dissemination may be a 
result of a more specific trafficking process mimicking normal leukocyte transport. And 
finally this may be a random event dependent on the total leukaemic burden and/or number 
of blasts in circulation. It is also possible that these processes may co-exist. These 
hypotheses are presented in Figure 1-6. This thesis focusses more on the role of normal 
leukocyte trafficking mechanisms and how these may go wrong in leukaemic 
dissemination. 
 
 
Figure 1-6 Possible mechanisms of leukaemic entry into extramedullary tissues. 
Leukaemic entry into extramedullary tissue (i) utilizing normal physiological trafficking mechanism. This 
property may reside in (ia) all the cells or (ib) within a smaller subclonal population, (ii) random entry due to 
high tumour burden/over spill, (iii) leukaemic entry as an invasive process. 
1.6.1 Physiological leukocyte trafficking 
The immune system has the capability to rapidly act against an injury. This capability 
relies upon trafficking specific subsets of leukocytes to specific tissue sites in a precisely 
controlled manner. This precision is orchestrated by expression of a combination of 
leukocyte trafficking molecules (selectins, adhesion molecules and chemokine receptors) 
expressed in leukocytes. This combination or a molecular ‘post-code’ ensures that the right 
population of leukocytes home to the tissues exactly where intended, both during 
homeostasis and inflammation (Ley et al., 2007, Luster et al., 2005). The processes 
involved in entry of circulating leukocytes into a tissue site have been well described and 
Bone marrow
(ii)(i)a (iii)
Circulation
EM tissue
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consist of various distinct steps. These are briefly described below. The leukocyte 
trafficking molecules will be discussed in more details in the subsequent sections. 
The first step in leukocyte homing to the target tissues is extravasation through the blood 
vessels. Several stages have been identified and each requires specific sets of trafficking 
molecules. These steps are described as leukocyte rolling, activation and arrest, adhesion 
strengthening, intravascular crawling, paracellular and trancellular transmigration, and 
migration through the basement membrane (Figure 1-7) (Ley et al., 2007). 
The first step in leukocyte extravasation is Leukocyte rolling. This involves transient 
contact of leukocytes with the vascular endothelium resulting in slowing down of 
leukocytes. Leukocyte rolling is mediated by interaction of selectin molecules (L-selection, 
E-selectin and P-selectin) on the vascular endothelium with their ligand P- selectin 
glycoprotein ligand-1 (PSGL1) on the leukocytes. Leukocytes can also interact with each 
other through these molecules during rolling (McEver and Cummings, 1997, Ley et al., 
2007). In addition to the role of selectin molecules, others such as integrins may play an 
assistive role (Alon et al., 1995). For instance, the integrin (very late antigen-4 (VLA4)) is 
shown to support lymphocyte rolling on venules of the CNS in conjunction with P-selectin 
or alone (Kerfoot and Kubes, 2002). 
The next steps in this cascade are leukocyte activation and arrest. Slow rolling leukocytes 
come in contact with chemokines on the vascular endothelial surface. Components of 
extracellular matrix such as glycosaminoglycans (GAGs) immobilize the chemokines on 
endothelial surface, thus preventing dilution by blood flow. Chemokine receptor-ligand 
pairing initiates a cascade of intracellular signalling pathways, and results in ‘activation’ of 
leukocytes. As a consequence, integrins on leukocyte surface change from low- to high 
affinity conformation, exposing their ligand binding sites. These high affinity integrins 
readily bind endothelial adhesion molecules such as ICAM1 (intracellular adhesion 
molecule 1) and VCAM1 (vascular cell adhesion molecule 1) forming firm adhesions. 
Consequently, the leukocytes come to a state of ‘arrest’(Shulman et al., 2009). This 
signalling cascade is called ‘inside-out’ signalling where G-protein coupled receptor 
(GPCR)-mediated signalling leads to activation of surface integrins, modifying integrins 
from a low affinity to high affinity conformations (Ley et al., 2007) (Also see section 
1.6.1.3). Following leukocyte arrest, adhesion is further strengthened by ‘outside-in’ 
signalling initiated by integrin activation. The necessary specificity required for leukocyte 
entry to specific tissues is regulated by the chemokine receptor-ligand pairing. If the 
leukocytes lack chemokine receptors specific for the endothelial chemokines, activation 
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and extravasation will not take place and the temporary interactions during rolling will 
break and the leukocyte would resume circulation. 
Just prior to crossing the endothelium, the activated leukocytes seek a preferred 
transmigration point in a ‘crawling’ movement. This crawling is made possible by 
cytoskeletal rearrangement. Leukocyte transmigration or diapedesis begins with the 
extension of membrane protrusions into the endothelial cells. The endothelial cells trigger 
cytoplasmic signalling leading to formation of channels through which leukocytes can 
migrate (Greenwood et al., 1995). After passing through the endothelial lining, the 
emigrating leukocytes encounter the basement membrane and in most venules, the 
pericytes. Transmigrating leukocytes utilize matrix metalloproteinase enzymes to degrade 
and pass through the basement membrane (Leppert et al., 1995). 
Following transmigration, leukocytes migrate towards the target tissue. It is hypothesised 
that matrix-fixed chemokines form a physiological gradient which guides the leukocytes 
towards the target tissues (Ley et al., 2007, Ebert et al., 2005). Thus, the coordinated 
cascade of events, tightly controlled by chemokines, results in directed migration of 
leukocytes from the circulation to the target tissues.  
The individual types of these trafficking molecules are discussed in subsequent sections. 
 
Figure 1-7 Leukocyte migration across the endothelium into the tissue 
Circulating leukocytes come in contact with selectins and roll along the vascular endothelium. The leukocyte 
surface-expressed chemokine receptors interact with immobilized chemokines on endothelial surface. The 
chemokine receptor-ligand interactions lead to ‘activation’ manifested by conformational change in integrin 
molecules. The now-high affinity integrins bond with cognate molecules on endothelium, leading to firm 
adhesion and leukocyte arrest. At this stage the cytoskeletal machinery is active for cellular locomotion. 
Subsequently, leukocytes crawl with the aim to identify an optimal exit-point and extravasate across the 
endothelial barrier. Leukocytes then cross the basement membrane and migrate towards a gradient formed by 
immobilized chemokines. Drawn with information from  Ley et al. (2007). 
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1.6.1.1 Selectins 
Selectins are a family of closely related calcium-dependent glycoprotein cell adhesion 
molecules which bind to carbohydrate moieties on target cells. The selectin family 
comprises of S- selectin, E- selectin and P-selectin. Selectins are anchored in the 
membrane by a transmembrane domain and contain a cytoplasmic tail (Patel et al., 2002). 
P-selectin, the most widely expressed member of the family is present in platelets and 
endothelial cells in intracellular vesicles. Upon stimulation by appropriate factors, the 
vesicles quickly fuse with the plasma membrane expressing the P-selectin on the surface. 
For this reason, P-selectin is the first to respond during leukocyte recruitment for an 
inflammatory response. E-selectin, is present on the endothelium and its expression can be 
induced upon inflammatory stimuli. L-selectin is constitutively expressed on the surface of 
most leukocytes and their precursors in the bone marrow (Patel et al., 2002). Generally, 
selectins bind to various classes of molecules (e.g mucins, GAGs) but P-selectin 
glycoprotein ligand (PSGL1) is the most extensively characterized selectin ligand for its 
role in leukocyte recruitment (Ley, 2003). This is a mucin-like ligand for selectins and is 
expressed on myeloid, lymphoid and dendritic cells (Laszik et al., 1996). 
As mentioned, selectins play an important role in leukocyte recruitment during 
homeostasis and inflammation. For instance, L-selectin deficient mice display deficient 
leukocyte-endothelium adhesion and poor recruitment to the lymph nodes (LNs). In 
addition, these knockouts demonstrate impaired leukocyte recruitment during 
inflammation (Tedder et al., 1995, Arbones et al., 1994). In addition to their role in 
physiological processes, selectins and their ligands have also been implicated in 
pathological states such as cancer metastasis. L-selectin may be cleaved from the cell 
surface of normal and leukemic cells and levels can be detected in plasma (Spertini et al., 
1991). Levels of secreted L-selectin (sL-selectin) reflects leukocyte turnover (Zetterberg 
and Richter, 1993), and is a candidate biomarker of leukaemic burden and aggressiveness. 
For example, high sL-selectin levels are associated with poor prognostic subtypes of AML 
(Extermann et al., 1998) and ALL (Herold et al., 2002, Spertini et al., 1994). This 
association with poor prognosis can be a reflection of higher tumour burden (Zetterberg 
and Richter, 1993), or an independent risk factor for it is shown to inhibit ALL cell 
adhesion in vitro (Spertini et al., 1994) thus suggesting it may promote extramedullary 
dissemination. 
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1.6.1.2 Chemokines and chemokine receptors 
The chemokine family comprises of more than 50 small (6-10 KDa) structurally related 
proteins. Based on the structural criteria, chemokines are classified into 4 sub-categories, 
i.e CC, CXC, XC and CX3C chemokines (Charo and Ransohoff, 2006). CC chemokines 
are the largest subfamily of chemokines with 28 members (CCL1-CCL28), while CXC 
sub-family comprises of 17 members. XC and CX3C sub-families have one member each 
(Table 1-2). Chemokines play a variety of functions; however their most established role is 
in the directed migration of leukocytes during homeostasis and inflammation. Chemokines 
involved in basal leukocyte trafficking are constitutively expressed and are classified as 
homeostatic chemokines while chemokines which are induced upon inflammatory stimuli 
are referred to as inflammatory cytokines (Zlotnik and Yoshie, 2000). 
Chemokines exert their biological function by binding to chemokine receptors. 
Chemokines receptors form a family of 7-transmembrane spanning G-protein couple 
receptors (GPCRs). CC chemokine receptors form the biggest sub-family of chemokine 
receptors comprising of 10 members (CCR1-CCR10), while CXC family comprises of 6 
members (CXCR1-6). XCR1 is the only receptor for XCL1 and CX3CR1 for CX3CL1 
(Table 1-2). Chemokine receptor-ligand interaction leads to activation of G-proteins which 
modulate the second messenger systems and further downstream signalling cascades. The 
downstream signalling pathways differ depending on the chemokine, the receptors and the 
cell type. The receptor-ligand pairing rapidly activates receptor internalization/endocytosis 
machinery whereby the receptor-ligand complex is ‘pinched-off’ from the surface and 
processed into an endosomal vesicle terminating the downstream signals. The internalized 
chemokine receptor may be transported for lysosomal degradation or recycled back to the 
surface (Neel et al., 2005). 
In addition to the classical chemokine receptors, a recent addition to the chemokine 
receptor family is the ‘Atypical chemokine receptor (ACKR) sub-family. These receptors 
are characterized by alteration in their conserved motif (Figure 1-8), lack of GPCR 
mediated downstream signalling and a resultant lack of chemokine driven chemotactic 
response. (Bachelerie et al., 2014b). ACKRs are generally considered to be ‘decoy’ or 
‘scavenger’ receptors with the ability to bind and internalize the chemokines without 
inducing chemokine driven motility (Graham et al., 2012). The chemokine receptors and 
ligands more relevant to this thesis (CXCL12 and its receptors CXCR4 and CXCR7) are 
briefly described below. 
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Receptor Ligands 
CXC receptors 
CXCR1 CXCL5, 6, 8 
CXCR2 CXCL1, 2, 3, 5, 6, 7, 8 
CXCR3A CXCL9, 10, 11 
CXCR3B CXCL9, 10, 11, 4 
CXCR4 CXCL12 
CXCR5 CXCL13 
CXCR6 CXCL13 
CC receptors 
CCR1 CCL3,4, 5, 7, 13, 14, 15, 16, 23 
CCR2 CCL2, 5, 7, 8, 13, 16 
CCR3 CCL4, 5, 7, 11, 13, 15, 24, 26, 28 
CCR4 CCL17, 22 
CCR5 CCL3, 4, 5, 7, 14, 16 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCL1, 18 
CCR9 CCL25 
CCR10 CCL27, 28 
XC receptor 
XCR1 XCL1, XCL2 
CX3C receptor 
CX3CR1 CX3CL1 
ACK receptors 
ACKR1 CXCL5, 6, 8, 11, 2, 5, 7, 11, 13, 14, 17 
ACKR2 CCL8, 2, 3, 4, 5, 7,  8, 11, 13, 14, 17, 22 
ACKR3/CXCR7 CXCL11, 12 
ACKR4 CCL19, 21, 25 
CCRL2/ACKR5 CCL19 
Table 1-2 Chemokine receptor nomenclature 
Members of the chemokine receptor sub-families including ACKRs and their respective ligands. Drawn with 
information from Bachelerie et al. (2014a). 
1.6.1.2.1 CXCR4-CXCL12 axis 
CXCL12 and its receptor CXCR4 are perhaps the most widely characterized chemokine 
receptor-ligand pair. CXCL12 is a constitutively expressed homeostatic chemokine and is 
expressed in various tissues of the body during foetal and post-natal life such as the bone 
marrow, liver, spleen, lymph nodes, lungs and brain. CXCL12 binds to endothelial- and 
interstitial GAGs to form functional gradients. CXCR4, a typical 7-transmembrane GPCR 
binds to its only chemokine ligand CXCL12. Ligand binding initiates a downstream 
signalling cascade which results in a multitude of effects. CXCR4/CXCL12 deficiency in 
mice results in perinatal death along with severely deranged haematopoiesis and 
organogenesis (Nagasawa et al., 1996, Zou et al., 1998). In humans, WHIM (Warts, 
Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a genetic disorder 
caused by a mutated CXCR4, results in enhanced response to CXCL12 and retention of 
mature leukocytes in the bone marrow and other immune organs. As a result, patients with 
WHIM syndrome are immunodeficient and susceptible to infections (McDermott et al., 
2014). CXCR4 is also a co-receptor for HIV-1 protein gp120 (Feng et al., 1996). Not only 
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is CXCL12 important in homing and retention of HSPCs but it is also suggested to play a 
role in proliferation and survival of these cells. For example, CXCR4-CXCL12 axis was 
shown to directly enhance the survival of myeloid progenitors in vitro (Broxmeyer et al., 
2003). These critical functions of CXCR4-CXCL12 have led to the development of 
CXCR4 inhibitor AMD3100 (Plerixafor). AMD3100 irreversibly blocks CXCR4 and 
inhibits HIV entry, promotes stem cell mobilization for bone marrow transplant and is 
being tested in WHIM syndrome (Bachelerie et al., 2014a, McDermott et al., 2014). 
Clinical deficiency of CXCR4 has not been reported in humans. 
1.6.1.2.2  CXCR7 
Until recently, CXCR4 was the only known receptor for CXCL12. In 2005, Balabanian et 
al. demonstrated that the orphan receptor RDC-1 had an affinity for CXCL12 (Balabanian 
et al., 2005). A year later RDC1 was recognised as a member of CXC chemokine receptor 
family, and named CXCR7. CXCR7 binds to CXCL11 and CXCL12, but unlike typical 
chemokine receptors, CXCR7 activation does not cause classic chemokine receptor 
responses such as calcium flux or chemotaxis, but offered some growth and survival 
advantage and increased adhesion properties (Burns et al., 2006). Since then, CXCR7 has 
been extensively studied for its expression patterns and role in homeostasis, inflammation 
and malignancy. CXCR7 has an altered composition in the cysteine motif and therefore 
classified as an atypical chemokine receptor. In the recent nomenclature CXCR7 has been 
renamed as ACKR3 (Bachelerie et al., 2014a). However, in this thesis, the alias CXCR7 
will be used. CXCR7 is shown to be present on embryonic, juvenile and adult tissue 
including the haematopoietic cells, endothelial cells and cancerous tissue (Maksym et al., 
2009, Sanchez-Martin et al., 2013, Berahovich et al., 2010, Humpert et al., 2012, Wang et 
al., 2012, Infantino et al., 2006). The discovery of CXCR7 has important implications: (i) 
CXCR7 binds CXCL12 with a 10 fold higher affinity than CXCR4 (Sanchez-Martin et al., 
2013), (ii) the widely used CXCR4 inhibitor AMD3100 is a partial agonist for the CXCR7 
receptor (Kalatskaya et al., 2009), (iii) published literature on CXCR4-CXCL12 interaction 
before 2005 does not take into account CXCR7.  
The exact mechanism of CXCR7 function is still under debate. The generally accepted role 
of CXCR7 is of a CXCL12-scavenging receptor. CXCL12 binding leads to receptor 
internalization mediated by β-arrestin. The internalized CXCL12 is degraded and the 
CXCR7 recycled back to the surface. Evidence from Zebra fish embryos demonstrate that 
CXCL12 scavenging by CXCR7 helps form a CXCL12 gradient for the migration of 
lateral primordial line (Boldajipour et al., 2008). Inhibition of CXCR7 using a small 
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molecule inhibitor results in an increase in abluminal CXCL12 (Sanchez-Martin et al., 
2013, Cruz-Orengo et al., 2011). In addition, other roles of CXCR7 have been reported by 
some. CXCR7 has been shown to dimerize with CXCR4 (Hartmann et al., 2008), and alter 
CXCR4-CXCL12 mediated responses (Levoye et al., 2009). CXCR7 is also reported to 
function as a G-protein independent signalling receptor activating alternate signalling 
pathways such as MAP kinases (Rajagopal et al., 2010) and Akt (Zhang et al., 2014). 
Another report suggests CXCR7 signals through its ligand CXCL11 (Tarnowski et al., 
2010). 
A number of phenomena make the field of chemokine biology complex and difficult to 
study. For instance, the majority of chemokines bind to several receptors, while many 
chemokine receptors can bind to multiple ligands (promiscuity) (Table 1-2). A single 
receptor type can identify various ligands and activate distinct signalling pathways 
(Murphy et al., 2000, Zweemer et al., 2014). Moreover, chemokine receptors may form 
homo- or heterodimers, altering receptor response to ligand binding (Levoye et al., 2009). 
And thirdly, atypical chemokine receptors may scavenge chemokine ligands affecting the 
levels of available chemokine (Naumann et al., 2010). These phenomena allow the 
chemokine system to finely regulate leukocyte migratory responses and provide 
redundancy in the immune system. 
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Figure 1-8: Illustration of a typical and an atypical chemokine receptor 
(a) CXCR4 has a 7-transmembrane spanning receptor structure which, upon ligand binding,activates the 
trimeric G-proteins in the vicinity. The GDP associated with the G-protein is replaced by GTP. The sub-units 
of G-proteins split and initiate signalling. The receptor-ligand complex is internalized and either degraded or 
the receptor is recycled back to surface. (b) CXCR7 on the other hand has an altered amino acid sequence in 
the conserved motif (indicated in red). Ligand binding to the receptor does not initiate G-protein response. 
Ligand binding to CXCR7 initiates internalization. Drawn with information from Bachelerie et al. (2014b), 
Bachelerie et al. (2014a), Graham et al. (2012), and Comerford and McColl (2011). 
1.6.1.3 Integrins 
Integrins are members of a family of transmembrane cell-cell and cell-matrix adhesion 
proteins. Each integrin molecule comprises of heterodimers of different α- and β subunits 
and this combination forms the basis for their nomenclature (Hynes, 2002). Each subunit 
of integrin heterodimer contains an extracellular domain, a single spanning transmembrane 
domain and a cytoplasmic tail. The extracellular domain binds to extracellular matrix 
proteins (collagens, fibronectin and laminin etc.) or cell surface adhesion proteins (e.g. 
Intracellular adhesion molecule-1 (ICAM-1)) whereas the intracellular tail binds to 
intracellular anchor proteins (Hynes, 2002). 
In circulating leukocytes, integrin molecules are in a basally inactive state. Chemokine 
receptor mediated activation signals from within the cell induce activation leading to 
conformational change in integrin molecules exposing their ligand binding sites. This type 
of activation signalling is called ‘inside-out signalling’. These high affinity integrin 
molecules bind to their ligands resulting in signal transduction in the classical ‘outside-in’ 
fashion. The outside-in signalling is involved in cytoskeletal changes resulting in a 
multitude of effects ranging from cellular movement to cell division and apoptosis (Srichai 
and Zent, 2010). 
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1.6.2 Leukocyte trafficking molecules in site-specific trafficking 
Tissue specific homing is determined by specific expression of trafficking molecules 
during different stages of development in haematopoietic cells. During early foetal life, 
liver is the primary site for haematopoiesis, and the haematopoietic stem and progenitor 
cells (HSPCs) are primarily present in liver tissue. However, in later stages, the bone 
marrow takes the central role – a phenomenon called the ‘haematopoietic switch’. It is now 
well understood that the HSPCs utilize CXCR4 for homing to the bone marrow. CXCR4 or 
CXCL12 knockout mice present with severe defects in haematopoiesis in the bone marrow 
(Nagasawa et al., 1996, Zou et al., 1998).This receptor-ligand pair continually mediates 
haematopoiesis after birth by retaining HSPCs in the bone marrow. In the bone marrow 
microenvironment, factors such as adhesion molecules strengthen the retention of these 
cells in the bone marrow supportive niche. For instance, blocking of adhesion molecule 
VLA-4 leads to prolonged mobilization of haematopoietic progenitors (Craddock et al., 
1997). 
During differentiation and maturation, haematopoietic subset of cells migrate from the 
bone marrow and home to appropriate tissue sites such as the thymus and lymph nodes. To 
make this happen, cells bring about changes in their ‘molecular postcode’ by altering the 
expression of leukocyte trafficking molecules, especially chemokine receptors. One classic 
example of this ‘chemokine receptor switch’ is observed in migration of T- cell progenitors 
to the thymus. This is orchestrated in a chemokine dependent manner with up-regulation of 
CCR7 and CCR9. Engraftment studies using CCR7+CCR9+ and CCR7-/CCR9- chimeric 
bone marrow samples in CCR7/CCR9 double-knockout (KO) mice demonstrate the CCR7-
/CCR9- progenitors completely fail to engraft into thymus despite adequate engraftment in 
bone marrow and mobilization into the blood. This illustrates the importance of chemokine 
receptors as entry signals into thymus (Zlotoff et al., 2010). The role of PSGL1 is 
evidenced from homing studies performed in mice. PSGL1-knockout cells have a 
competitive disadvantage in homing to the thymus compared to wild-type cells. 
Differential chemokine gradients may further refine the positioning of maturing subsets in 
specific regions in thymus (Kwan and Killeen, 2004). In a similar manner, mature 
lymphocytes utilize the leukocyte trafficking molecules to home to peripheral organs and 
perform their routine functions. For instance, homing of T- lymphocyte subpopulations to 
the skin is mediated by E-selectin dependent rolling and CCR4, CCR10 dependent 
positioning in the skin (Reiss et al., 2001).  
In summary, leukocyte trafficking molecules drive the process of tissue specific homing 
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during homeostasis and inflammatory conditions. The organising principles that determine 
the expression pattern of these molecules is not clearly understood. However, there is clear 
evidence to suggest that these molecules are the prime factors for entry and retention of 
leukocytes in tissues.  
1.6.3  Leukocyte trafficking into the CNS 
The CNS comprises of the brain and the spinal cord (SC), present within the cranial cavity 
and vertebral column, respectively. The CNS is protected by layers of fibro-collagenous 
tissue collectively called the meninges. Dura mater is the thicker outer most layer that lines 
the inside of the skull bones and consists of fibro-collagenous connective tissue and large 
blood vessels. The arachnoid and pia mater are thinner finer layers and are collectively 
called the leptomeninges. The pia mater is the innermost layer and lines the brain. The 
irregular space between the dura and pia is the cerebrospinal space. This CSF filled space 
is criss-crossed by a dense stroma and contains cerebral and spinal arteries (Ransohoff and 
Engelhardt, 2012). 
Under normal homeostasis, the CNS is protected from a variety of cell populations and 
molecules that can potentially harm the brain. This property, for which the CNS is 
considered as immune-specialized site, is characterized by physiological and physical 
barriers such as: absence of lymphatics, lack of classical antigen-presenting cells (APCs), 
low expression of antigenic molecules (MHC-I and MHC-II) and the physical barriers 
between the circulation and the brain parenchyma. Under physiological circumstances, 
circulating cells do not enter the brain parenchyma, while only a small population of 
leukocytes is seen in the CSF. Nonetheless, leukocytes are capable of crossing the barriers 
and entering the CNS in cases of acute injury (e.g meningitis) or chronic insult (multiple 
sclerosis (MS)) (Ransohoff and Engelhardt, 2012, Romo-Gonzalez et al., 2012). Leukocyte 
are shown to enter the CNS across a number of routes described below and summarized in 
Figure 1-9. 
1.6.3.1 Blood-brain barrier 
The BBB is primarily formed by the brain microvascular endothelial cells (BMVECs) 
surrounded by basement membrane, pericytes and astrocytic foot processes. The BMVECs 
maintain the barrier function by the following features: Lack of fenestrations, relatively 
poor pinocytic ability, and presence of tight junctions. The barrier function is further 
reinforced by the surrounding basement membrane (Takeshita and Ransohoff, 2012). 
Moreover, the capillaries are guarded by the astrocytic foot processes, preventing the free 
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entry of leukocytes and macromolecules into the CNS. Astrocytes almost completely 
ensheath the brain vessels, separated only by the basement membrane (Hawkins and Davis, 
2005). The pericytes cover a minor proportion of the capillaries and post capillary venules. 
These features almost completely seal the brain from large molecules, and immune cells. 
In this pathway, the cells are required for transition across the capillary endothelium, the 
basement membranes on the inner and outer siders of BMVECs to enter the parenchymal 
perivascular space. To reach the brain parenchyma, leukocytes are further required to cross 
the Glia Limitans (basement membrane and astrocytic foot processes) (Wilson et al., 
2010). During infection, the inflamed endothelium upregulates selectins and adhesion 
molecules which, in turn, facilitates leukocyte rolling and adhesion (Wilson et al., 2010). 
In overt brain infections, leukocytes utilize matrix metalloproteinases (MMPs) to disrupt 
the glia limitans and enter the brain parenchyma (Rosenberg, 2002). 
1.6.3.2 Blood-CSF barrier 
As the name indicates, the BCSFB is the barrier between peripheral circulation and the 
CSF compartment. The BCFSB is located in the cerebral ventricles, and is composed of 
networks of capillaries embedded within a stroma underlying a monolayer of choroid 
plexus epithelial (CPE) cells. The capillaries of the BCSFB are fenestrated and contain gap 
junctions. Barrier function is maintained by tight junctions of the choroid plexus 
epithelium (CPE) cells (Man et al., 2007). The CPE cells generate CSF from the capillaries 
through diffusion and active transport. The CSF circulates in the CSF space and is re-
absorbed through arachnoid villi in the cerebral venous sinuses. Cells migrating through 
this pathway are required to cross the fenestrated endothelium into the choroid plexus 
stroma and then cross the CPE to enter the CSF (Ransohoff and Engelhardt, 2012).  
1.6.3.3 Virchow-Robin perivascular space 
The vessels penetrating the CNS parenchyma are ensheathed by the leptomeninges for 
some distance giving rise to the Virchow-Robin perivascular space (Figure 1-9). 
Leukocytes may enter the cerebrospinal space while passing through the post capillary 
venules at the pial surface into Virchow-Robin perivascular surface (Man et al., 2007). It 
has been shown that the antigen presenting cells in this region are derived from circulation 
suggesting Virchow-Robin spaces are involved in cellular exchange between the 
circulation and the CNS (Hickey and Kimura, 1988). 
Leukocyte populations in the CSF compartment are predominantly T lymphocyte subsets 
involved in routine immune surveillance. The median CSF leukocyte count in neonates and 
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young infants is 2-3/µl, however upto 20/µl can be normal (Kestenbaum et al., 2010) while 
in adults, the normal CSF leukocyte count is 1-3/µl. The majority (90%) of these cells are 
lymphocytes, mostly CD4+ memory T cells, 5% B-cells and monocytes each while 
infrequent dendritic cells (DCs) and polymorphonuclear cells are also seen (Kivisakk et al., 
2003, Svenningsson et al., 1995, Seehusen et al., 2003). CCR7-CCL19 pair has been 
implicated in the entry of CCR7 expressing CD4+ central memory T (TCM) cells, (Kivisakk 
et al., 2003) while CCL19 is constitutively present in the CSF (Krumbholz et al., 2007), 
Thus implying that constitutively present CCL19 at the BCSFB facilitates CCR7 
expressing cells’ entry to the CSF compartment. 
Leukocyte entry into the CNS has been studied extensively in experimental autoimmune 
encephalomyelitis (EAE) - a murine model of multiple sclerosis (MS). In this model, 
inflammation is initiated by myelin-specific T- lymphocytes routinely entering the CNS 
across the BCSFB where they are activated upon stimulation with myelin antigens. As a 
consequence, inflammatory signals from these ‘pioneer’ lymphocytes result in active 
recruitment of inflammatory cells into the brain parenchyma.  The initial T-lymphocyte 
entry across the BCSFB rolling on the vascular surface is mediated by selectins 
(Sathiyanadan et al., 2014, Carrithers et al., 2000) following which the CCR6-CCL20 
dependent interactions is important for leukocyte activation. In one such study, the T 
lymphocytes entered through the choroid plexus which expressed CCR6 ligand CCL20. 
Additionally, CCR6 KO mice were refractory to development of EAE (Reboldi et al., 
2009). The activated lymphocytes utilize integrins such as α4β1 (Yednock et al., 1992) and 
VLA-4 (Carrithers et al., 2000) for adhesion and transmigration. CXCR3-CXCL10 
interactions have also been reported in EAE with some conflicting results. For instance, 
using antibodies against CXCL10 were found to have a protective role of EAE (Fife et al., 
2001). In contrast, another study showed that CXCR3 knockout mice were equally 
susceptible to EAE in comparison with CXCR3 wild-type mice (Liu et al., 2006). It can be 
conceived that the role for CXCR3 may be redundant if at all. 
In summary, leukocyte subtypes transit across different compartments of the CNS during 
homeostasis and inflammation in an immune-privileged manner. There is some evidence to 
suggest that chemokine receptors may be important in controlling leukocyte migration to 
the CNS. The complexity of the CNS circulation and the redundancy leukocyte trafficking 
molecules present challenges in dissecting out the mechanisms of CNS entry of leukocytes. 
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Figure 1-9: Routes of leukocyte entry into the CNS 
(a) A human head in the midline sagittal section showing relevant anatomical structures in schematic form. 
(b) arachnoid granulations in relation to the subarachnoid space and brain parenchyma. (c) Subpial space and 
Virchow-Robin space. (d) BBB and glia limitans. (e) Choroid plexus structure. Adapted from Ransohoff and 
Engelhardt (2012), Takeshita and Ransohoff (2012). 
1.6.4 Malignant cell trafficking 
One defining property of cancers is to form distant metastasis. In fact, at the time of 
diagnosis, most aggressive cancers are already found to have metastasised to distant 
tissues. To metastasise to other tissues, cancer cells have to detach from their primary site, 
enter the circulation, and lodge into another organ suitable for their survival – A process 
principally similar to tissue specific recruitment of leukocytes. It would not be surprising if 
the mechanisms governing leukocyte migration and homing would also be involved in 
malignant cell trafficking. Furthermore, cancer cells appear to have acquired the ability to 
overexpress chemokine receptors and utilize this for metastasis – They ‘hijack’ the 
trafficking mechanisms for their advantage (Zlotnik et al., 2011). The following sections 
discuss the role of chemokine receptor ligand pairing in cancer metastasis relevant to this 
thesis.  
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1.6.4.1 CXCL12-CXCR4/CXCR7 axis and site-specific cancer metastasis 
CXCL12-CXCR4 interactions are the most widely characterized and perhaps the most 
important receptor-ligand interactions in cancer metastasis. Overexpression of CXCR4 has 
been reported in more than 23 cancers (Kakinuma and Hwang, 2006) while its ligand 
CXCL12 is constitutively present in several tissues including the bone marrow, lymphoid 
organs and the CNS (Kucia et al., 2004). The initial evidence for CXL12-CXCR4 
involvement in cancer metastasis came from studies by Muller and coworkers (2001). The 
authors screened 7 human breast cancer cell lines for expression of 17 chemokine 
receptors. Using flow cytometry, CXCR4 was found to be consistently overexpressed in all 
the cell lines and human breast cancer samples. Furthermore, PCR analysis of the most 
common sites for breast cancer metastasis (lymph nodes, liver, lung, bone marrow) 
revealed high mRNA expression of CXCL12. The breast cancer cell lines exhibited avid 
migration to protein extracts from these tissues in a CXCR4/CXCL12 dependent manner in 
vitro. In addition to this, using a CXCR4 neutralizing antibody showed significant 
reduction in lung metastasis in xenograft models using breast cancer cell lines in scid mice 
(Muller et al., 2001). 
Tumour cells are shown to manipulate the expression of CXCR4 to their advantage. For 
example, hypoxic stress induces over-expression of CXCR4 via hypoxia-induced factor 
(HIF) (Schioppa et al., 2003), or human epithelial growth receptor-2 (HER2) in breast 
cancer (Li et al., 2004). This overexpression of CXCR4 may act in a multitude of ways to 
promote cancer survival and metastasis. CXCR4-CXCL12 axis may indirectly promote 
survival by providing cellular attachment to the supportive stromal niches as documented 
by reduced over-all tumour burden with the use of AMD3100 in xenograft models 
(Murakami et al., 2002, Muller et al., 2001). Alternately, it may directly promote cell 
survival (Marchesi et al., 2004). VEGF, a key factor in tumour angiogenesis, is induced by 
CXCR4 expression in breast cancer cell lines in vitro, and reducing vessel formation in 
xenograft mice treated with CXCR4 antagonist (Liang et al., 2007). CXCR4 is shown to 
stimulate MMP production which is associated with invasion and metastasis (Singh et al., 
2004). 
There is growing evidence for the role of CXCR7 in cancer. Not only is CXCR7 expressed 
in many primary cancer cells and cell lines, it is implicated in multiple cancer types and 
shown to enhance proliferation and angiogenesis (Wang et al., 2008, Miao et al., 2007), 
tumour invasion (Burns et al., 2006) and transendothelial migration (Zabel et al., 2011). 
Despite a lack of typical GPCR signalling response, CXCL12 stimulation results in 
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activation of alternate signalling pathways such as Akt and β-arrestin (Zhang et al., 2014). 
Generally, CXCR7 activation has not been shown to be directly chemotactic. However, 
CXCR7 may indirectly affect tumour metastasis. When co-expressed with CXCR4, 
CXCR7 enhanced chemotaxis in vitro but reduced CXCL12 mediated invasion in vitro and 
in vivo. Recently, CXCR7 was shown to be involved in CXCL12 mediated transendothelial 
migration of Burkitt’s lymphoma cell lines. The cell lines exhibited migration in response 
to CXCL12 which was blocked after using CXCR7 inhibitor CCX771 or CXCL11. The 
role of CXCR7 in site-specific metastasis is not clear. However, this may be cell-type and 
context specific. 
1.6.5 Chemokine receptors and extramedullary dissemination in 
ALL 
Several lines of investigations suggest that chemokine receptors may be important in 
dissemination to extramedullary organs. Firstly, chemokine receptor-ligand interaction 
drives the site specific trafficking of HSPCs, leukaemic cells’ presumed normal 
counterparts. Secondly, there is increasing evidence of chemokine receptor driven site 
specific metastasis in solid tumours. Thirdly, chemokine receptors are frequently 
upregulated in acute lymphoblastic leukaemia. And finally, chemokine receptors have 
shown to interact with aberrant oncogenic pathways in leukaemia (eg. BCR/ABL1). In the 
following sections, I have presented a review of the current understanding of CXC4 and 
CXCR7 mediated chemotaxis and their possible roles in ALL dissemination. In addition, 
the role of BCR-ABL1 signalling in alteration of chemotactic responses is discussed. 
1.6.6  CXCR4 in ALL 
At the time of ALL diagnosis, most patients present with signs of extramedullary 
dissemination such as lymph node enlargement or organomegaly. The mechanisms 
associated with this extramedullary dissemination are poorly understood. It is hypothesised 
that ALL cells utilize CXCR4-CXCL12 axis to disseminate to extramedullary organs. ALL 
cells not only also overexpress CXCR4 but also exhibit chemotaxis to CXCL12. Several 
clinical studies have demonstrated that ALL blasts express CXCR4 (Corcione et al., 2006, 
Wong and Fulcher, 2004, Wu et al., 2006, Crazzolara et al., 2001, Schneider et al., 2002, 
van den Berk et al., 2014), and show efficient chemotaxis towards its ligand CXCL12 
(Bendall et al., 2005, Corcione et al., 2006). Moreover, higher expression levels of CXCR4 
are associated with extramedullary disease and poor prognosis (Schneider et al., 2002, 
Crazzolara et al., 2001).  
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Crazzolara et al. (2001) demonstrated that paediatric ALL samples with high levels of 
CXCR4 expression were associated with extramedullary disease and inferior outcome. 
Leukaemic cells retrieved from extramedullary organs (thymus, testes and CNS) of ALL 
patients also exhibited strong expression of CXCR4. Moreover, the leukaemic blasts 
showed avid transendothelial migration towards CXCL12 in vitro. Another study observed 
that high CXCR4 expression was associated with organ infiltration at diagnosis and a 
shorter disease free survival. However, an association of CXCR4 with extramedullary 
relapse could not be confirmed (Schneider et al., 2002). These studies used a relatively 
small number of patients and insensitive methods to determine extramedullary infiltration. 
Nevertheless, based on these observations, it is conceivable that circulating blasts may 
interact with endothelium-presented CXCL12 and extravasate to tissues with high 
CXCL12 (such as liver, spleen, lymph nodes). Recently, using a murine model of 
paediatric ALL, it was shown that leukaemic cells engrafted in liver were enriched for 
CXCR4 expression. The liver retrieved leukaemic cells migrated to CXCL12 in vitro and 
this migration was inhibited with use of AMD3100. Treatment of transplanted mice with 
AMD3100 resulted in prolonged survival of mice demonstrating the important of CXCR4 
in engraftment and survival in vivo (Kato et al., 2011). Blocking CXCR4 on ALL cells 
with antagonists blocks interaction of ALL cells with the bone marrow stromal cells, 
disturbing the stromal protection of ALL cells from the chemotherapeutic agents making 
them susceptible to the chemotherapy (Juarez et al., 2003). In addition, CXCR4 expressing 
ALL can modulate CXCL12 levels in the bone marrow microenvironment and utilize this 
for extramedullary spread (van den Berk et al., 2014). Taken together, the above data 
suggest that leukaemic cells expressing functional CXCR4 may migrate and home to sites 
where CXCL12 is constitutively present.  
Cancer cells often acquire aberrant cellular mechanisms for their survival and 
dissemination. It is plausible that aberrant leukocyte trafficking mechanisms may be seen 
in leukaemia. These may result from abnormal signalling pathways. For example, in a 
series using primary ALL samples, Bendall el at. (2005) documented that CXCL12 
mediated chemotactic response was mediated through p38-MAPK signalling pathway. 
Some CXCR4-expressing ALL samples did not exhibit CXCL12 mediated migration. 
Samples showing CXCL12 mediated chemotaxis exhibited activation of p38-MAPK with 
CXCL12 stimulation while in samples with poor CXCL12 mediated chemotaxis, this 
signalling pathway was constitutively activated. Later findings from the same group 
suggested that the bone marrow homing of leukaemic cells required p38-MAPK signalling 
pathway (Juarez et al., 2009). It is possible that leukaemic cells acquire aberrant receptor 
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function at the time of malignant transformation of cells. Compared to normal CD34+ 
progenitors, CXCL12 stimulation may activate a different set of integrins compared in 
ALL cells (Spiegel et al., 2004). Leukaemic cells with complex genetic abnormalities have 
shown aberrant or dysfunctional chemotactic responses. For instance, a subset of human 
pre-B ALL cell line Sup B15 expressing high levels of 5T4 oncofetal antigen demonstrates 
high CXCL12 mediated chemotaxis and invasion  in vitro and ovarian engraftment in vivo, 
despite lower CXCR4 expression than the parent Sup B15 cell line (Castro et al., 2012). 
1.6.7 CXCR7 in ALL 
As mentioned in the above section, it is clear that CXCR4 signalling and trafficking can be 
dysregulated in some cases of ALL, it is essential to explore any role CXCR7 may play. So 
far, few groups have investigated the expression and function of CXCR7 in ALL. A recent 
study investigated the expression patterns and functions of CXCR7 in leukaemic primary 
samples and cell lines. CXCR7 gene expression analysis demonstrated CXCR7 expression 
in myeloid and lymphoid leukaemia cell lines and primary ALL samples. Flow cytometry 
and western blot analysis for CXCR7 was performed for cell lines only. Differential 
expression of CXCR7 was observed with T-ALL cell lines (MOLT4 and Jurkat). CXCR7 
gene silencing resulted in reduced CXCL12 mediated chemotaxis in vitro while  no effect 
on cellular proliferation and apoptosis was documented (Melo et al., 2014). Preliminary 
reports presented in international meetings show contradicting results with regards to 
expression patterns and role of CXCR7 in chemotaxis, transendothelial migration and 
adhesion (Jalili et al., 2008, Sridharan, 2012, Konoplev et al., 2008).  
1.6.8  BCR/ABL1 and leukaemic trafficking in ALL 
Several studies have demonstrated an association between the extramedullary infiltration in 
blast crisis with overexpression of p210BCR-ABL1, increased activity of p210BCR-ABL1 tyrosine 
kinase and loss of chemotactic response to the chemokine ligand CXCL12. Two different 
mechanisms have been proposed. First, p210BCR-ABL1 tyrosine kinase may affect CXCL12 
mediated downstream signalling and adhesion (Ptasznik et al., 2002, Chen et al., 2008), 
and the second is the downregulaton of CXCR4 surface expression by BCR/ABL1 (Geay 
et al., 2005). These are briefly discussed here. 
Loss of chemotactic response to CXCL12 was initially observed in p210BCR/ABL1 
transfected myeloid cell lines. Despite surface expression of CXCR4, CXCL12 failed to 
initiate calcium flux and chemotaxis in transmigration assays. A paradoxical increase in 
spontaneous motility was seen in these transfected cell lines. This was paralleled by 
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reduced chemotaxis of p210BCR/ABL1 transfected Ba/F3 cell lines in vivo (Salgia et al., 
1999). There are conflicting explanations to the mechanism underlying this phenomenon. 
One of these is the cross-talk of the BCR/ABL1 tyrosine kinase and CXCR4 at a common 
downstream pathway ‘Lyn kinase’ which is a possible downstream effector for leukaemic 
cell motility. CXCL12 mediated activation of this tyrosine kinase pathway was seen in 
peripheral CD34+ precursors and BCR/ABL1 negative cell line HL-60. While BCR/ABL1 
transfected HL-60 cells and leukaemic blasts from CML patients, Lyn kinase was 
constitutively activated and unaffected by CXCL12 stimulation. BCR/ABL1 transfected 
cell line HL60 showed a 4 fold higher spontaneous motility and lack of CXCL12 directed 
chemotaxis in vitro. BCR/ABL1 inhibition by the tyrosine kinase inhibitor Imatinib (STI-
571) restored CXCL12 mediated Lyn kinase activation. However, the authors did not 
report whether p210BCR-ABL1 inhibition restored CXCL12 mediated chemotaxis (Ptasznik et 
al., 2002). The same group later demonstrated that p210BCR-ABL1 transfected human 
megakaryoblastic cell line Mo7e, exhibited higher affinity to adhesion molecules ICAM-1 
– typically associated with chemokine receptor activation. It was postulated that p210BCR-
ABL1 tyrosine kinase ‘hijacks’ the CXCL12 mediated integrin activation and resulting 
adhesiveness which may be responsible for retention of cells in the extramedullary organs 
(Chen et al., 2008). This hypothesis however does not explain the high spontaneous 
motility, or increase in circulating blasts in CML. Other groups investigating CXCR4 
function in CML have reported somewhat conflicting observations. For instance, in an 
article megakaryoblastic cell line Mo7e was transfected with BCR/ABL1. Subsequently, 
two populations of BCR/ABL1-high and BCR/ABL1-low expressing cells were sorted by 
fluorescence activated cell sorting (FACS). Mo7eBCR/ABL1-low cells demonstrated a 
signalling defect whereas Mo7eBCR/ABL-high was shown to down-regulate CXCR4 mRNA 
and surface expression. Treatment of primary CML blasts with Imatinib led to an up-
regulation of mRNA and surface expression of CXCR4 (Geay et al., 2005). Overall, these 
studies consistently show that BCR/ABL1 oncoprotein affects CXCR4 – although the 
exact underlying mechanism is debated. This raises the question whether similar cross-talk 
is seen in p190BCR-ABL1. P190 oncoprotein differs in molecular behaviour from p210 in a 
number of ways. P190 tyrosine kinase not only has a significantly higher constitutive 
activity (Lugo et al., 1990) but also has a different set of downstream effects (Li et al., 
1999). 
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1.6.9  Chemokine receptors and CNS entry 
Chemokines are expressed by many cell types in the CNS such as astrocytes, microglial 
cells, choroid plexus and the neurons (Bajetto et al., 2001). These chemokines may allow 
entry of specific leukaemic cells. Preliminary evidence regarding a single chemokine 
receptor-ligand interaction for leukaemic cell entry into the CNS was described in T-ALL. 
Buonamici et al. (2009) have reported that in a murine model of T-ALL, CCR7-CCL19 
interactions are both necessary for CNS infiltration. In this study, the authors used 
transgenic models of NOTCH-1 activating mutation which develop T-ALL with overt 
involvement of the CNS. Gene expression profiling of murine haematopoietic progenitors 
infected with NOTCH-1 carrying retrovirus resulted in up-regulation of CCR7 and 
efficient chemotaxis towards CCR7 ligands CCL19 and CCL21. Furthermore, T-ALL cell 
lines and patient samples carrying NOTCH-1 mutations overexpressed CCR7 while 
treatment with NOTCH-1 inhibitor resulted in reduction in CCR7 expression. This 
demonstrates the association of NOTCH-1 activating mutations with CCR7 expression. 
Furthermore, using human T-ALL cell lines (CEM/CCR7+, DND41/CCR7- and CCR7 
transduced DND/mCCR7+) transplanted in immunodeficient mice, the authors demonstrate 
that mice injected with CCR7 expressing cell lines developed aggressive disease with CNS 
involvement while CCR7 negative line failed to show CNS engraftment – although, the 
overall leukaemic burden in these mice was also lower. NOTCH-1 transduced in CCR7 
knockout mice developed T-ALL but without CNS infiltration, providing further evidence 
for the role of CCR7 in CNS disease. However, here again CCR7 expressing cells lead to a 
more aggressive overall disease. Furthermore, CCL19 negative mouse strain was engrafted 
with NOTCH-1 expressing haematopoietic progenitors. These mice developed aggressive 
leukaemia but the leukaemic cells failed to infiltrate to the CNS (Buonamici et al., 2009). 
These findings provide a proof of principle that a single chemokine receptor-ligand pairing 
can provide access to the leukaemic cells in the CNS compartment. However, little is 
known about the subsequent mechanisms involved in T-ALL cells after CCR7-CCL19 
mediated interactions and no such interactions have been reported in CNS engraftment of 
BCP-ALL.  
Thus, there is some evidence that leukaemic cells may utilize chemokine receptor-ligand 
interaction for motility and site-specific homing. Nonetheless, little is known regarding 
leukaemic cell entry into the CNS compartment. Aberrant receptor ligand interactions are 
frequently seen in leukaemia and to understand site-specific trafficking of leukaemia, a 
further understanding of molecules interacting with the trafficking pathways is necessary. 
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1.6.10 CNS entry - alternative mechanisms 
Chemokine receptor-ligand interactions may not be the only means by which leukaemic 
cells gain entry into the CNS compartment. Given the heterogeneity of ALL, it is 
conceivable that multiple leukaemia subtype-specific factors may be involved in CNS 
entry of cells. Other possible mechanisms have been proposed. One of these is the 
leukaemic cellular entry across the BBB or BCSFB through an invasive process. Holland 
and colleagues have suggested a collective role of invasive proteins, adhesion molecules 
and cyctoskeletal proteins in ALL cell infiltration to the CNS (Holland et al., 2011). The 
authors observed that different BCP-ALL cell lines (SD1, Sup B15 and REH) differed in 
their ability to infiltrate the CNS when transplanted in immunodeficient SCID/beige mice. 
SD1 cells showed heavy CNS infiltration while Sup B15 caused systemic ALL only 
without any evidence of CNS infiltration. Histological examination of the murine brains 
showed presence of leukaemia in the CSF compartment and brain parenchyma. SD1 cells 
demonstrated in vitro invasion which was significantly reduced with inhibition of the 
enzyme asparaginase endopeptidase (AEP). However, when REH cells were transduced 
with AEP, the cells showed only a modest increase in invasion suggesting a partial role of 
AEP in invasion. Ras-related C3 botulinum toxin substrate 2 (Rac-2), a protein related to 
cytoskeletal organization was overexpressed in SD1 cells. Inhibiting RAC-2 resulted in 
delayed overall engraftment and CNS infiltration. SD1 cells also had high expression 
levels of adhesion molecules ICAM-1 and LFA1 (Holland et al., 2011). Together, these 
findings suggest that many factors play a role in CNS infiltration of leukaemic cell in BCP-
ALL cell lines and individual factors may only contribute partially to this phenomenon. 
Circulating blasts expressing adhesion molecules such as ICAM-1 may adhere to the 
choroid plexus epithelial cells or brain microvascular endothelial cells. AEP enzyme 
activity may facilitate invasion across the BBB or BCSFB. RAC-2 may initiate the 
extravasation of these cells into the CSF space and/or brain parenchyma. However, this 
postulate fails to address whether AEP mediated invasive process is CNS specific or 
representative of an overall invasive phenotype. 
As discussed under section 1.3.7, CNS relapse may be a result of leukaemic cells gaining 
entry into the CNS or alternatively, this may be due to expansion of resident blasts once 
treatment in complete. If the latter is true, then gaining a better understanding of the CNS 
micro-environmental factors that may protect leukaemic cells from months to years of 
intensive chemotherapy.  
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1.7 Extramedullary dissemination in ALL – 
microenvironmental niche 
Leukaemic cells cannot live in isolation in any tissue in the body. The microenvironment 
of the host tissue must interact with the leukaemic cells and provide a fertile soil that 
provides shelter to the leukaemic cells and shields them from chemotherapy. This seed-
and-soil theory has been extensively studied in leukaemic cell interaction with the bone 
marrow nice (Sipkins et al., 2005, Burger and Burkle, 2007, Boyerinas et al., 2013). Not 
only the bone marrow microenvironment provides leukaemic stem cells a place to reside, it 
also provides essential factors for their growth and proliferation. Moreover, the bone 
marrow microenvironment interactions with the leukaemic cells provide protections from 
the chemotherapy (Boyerinas et al., 2013, Iwamoto et al., 2007) and essential signals for 
mobilization in blood resulting in dissemination (Fukuda et al., 2005). The CNS 
microenvironment differs from the bone marrow microenvironment in cellular, physical 
and chemical composition. Yet, the CNS has proven to be a sanctuary site for leukaemic 
cells. It is necessary to understand the components of the CNS microenvironment and how 
these interact with leukaemic cells.  
1.7.1  CNS stromal support 
The CNS differs from conventional leukaemia-host microenvironments in a number of 
ways. The physical barriers of the CNS compartment may restrict free entry of leukaemic 
cells into the CNS. In addition, the CNS stromal support network differs from the bone 
marrow microenvironment. Moreover, CSF is a unique feature which differs from the bone 
marrow interstitial fluid in physical and chemical properties. Despite these differences, 
evidence from MS patients shows that B cells can live in the CSF compartment and expand 
clonally to contribute to the pathogenesis of MS (Owens et al., 2003). However, the 
mechanisms underlying this protective effect remain poorly understood. This is partly due 
to the lack of suitable in vitro and in vivo models to study the effect of CNS niche on ALL 
(Tenenbaum et al., 2013). 
Recently, Akers et al. (2011) provided in vitro evidence of interaction of stromal cells of 
the CNS with leukaemic cells. The authors used BCP-ALL cell lines and CNS stromal 
cells, namely, normal human astrocytes (NHA), primary human choroid plexus epithelial 
cells (HCPEpiCs) and human meningeal cells (HMCs) to dissect out critical interactions 
between the leukaemia cells and the CNS niche. The authors observed that leukaemic cells 
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migrated towards conditioned media from these three stromal components. Upon using 
CXCR4 inhibitor AMD3100, there was a significant reduction in migration towards 
HCPEpic and HMC conditioned media but not with NHA conditioned media. This 
suggests that while CXCL12 plays an important role in leukaemic cell migration, alternate 
soluble chemotactic factors may be involved. In co-culture studies, leukaemic cell lines 
were cultured individually with the stromal components. Leukaemic cells were found to 
adhere to the cellular layers suggesting physical interactions between the leuakaemic cells 
and cellular components. Furthermore, ALL cell lines, and primary leukaemic cells from 
two patients were co-cultured with the stromal components with addition of 
chemotherapeutic agents. The co-culture provided variable resistance to CNS-directed 
chemotherapy (Cytosine arabinoside, Dexamethasone and methotrexate) induced death. 
Additionally, modest protection from chemotherapy-induced death was seen when the cell 
lines cultured on fixed stromal cell layer, or in conditioned media alone (Akers et al., 
2011). These preliminary findings highlight the impact of the CNS microenvironment on 
disease. However several questions remain unanswered. This study used a limited number 
of cell lines and primary samples. The factors that allow initial interaction and subsequent 
adhesion to the stromal components are not known. Further work is required to ascertain 
whether these observations are reproduced in vivo and in patients. Answer to these 
questions will be of critical importance in understanding disease kinetics and designing 
novel therapies. 
1.7.2 Chemotherapy penetration in the CNS 
Another challenge faced in preventing and treating CNS disease in ALL is the drug 
delivery to the CNS. BBB restricts the entry of chemotherapeutic agents into the brain, the 
drugs are distributed in the cellular compartments, bind to proteins or reabsorbed into the 
systemic circulation making it difficult to achieve a high concentration of drugs in CNS. 
Furthermore, drug delivery to the meninges might equally affect the susceptibility of cells 
to therapy. Use of prednisolone is associated with a higher risk of CNS relapse in 
comparison with Dexamethasone. Rapid clearance of prednisolone from the CSF may limit 
the duration of leukaemic cell exposure to cytotoxic concentrations of the drug (Balis et al., 
1987). Therefore, Dexamethasone is preferred despite the several toxicities associated with 
its use. Regardless of the type of drug used, attention should be paid to the distributions 
and clearance of the agent. Direct delivery of the chemotherapy through the intrathecal 
route or intracerebroventricular route through indwelling catheter achieves high 
concentration of drugs in the cerebrospinal space. Not only is the volume of the drug 
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injected important, but also factors such as body position plays a role in distribution of the 
drug within the cerebrospinal space. Injection of a higher volume (6 ml or more) of the 
drug achieves better distribution of the drug (Pui, 2006) while removal of equal volume of 
CSF before administration of the drug may prevent leakage from the injection site (Pui and 
Howard, 2008). Lying in a prone position after the injection is shown to achieve better 
distribution within the CSF compartment in an animal model (Blaney et al., 1995). 
1.7.3  Immune surveillance 
The ability of the host immune system to identify and destroy tumours has been a focus of 
considerable scientific debate. It is proposed that the host immune system has the ability to 
identify and destroy cancer cells on the basis of expression of aberrant tumour-specific 
antigens on cancer cells. Identification of cancer cells by cytotoxic T- and NK cells may 
allow the body to eliminate the cancer. Conversely, cancer cells can evolve to escape 
identification by immune surveillance mechanisms and cause overt tumour. This idea of 
immune surveillance is exploited in graft-leukaemia effect after transplant, donor 
lymphocyte infusion (DLI), and immune-modulation therapy. Graft versus leukaemia 
effect is now considered to be a key factor in improved prognosis after allogenic bone 
marrow transplant. The immunological mismatch between the donor and recipient cells 
leads to activation of NK- and T cells of the donor to identify and target tumour cells in the 
bone marrow and extramedullary tissue. 
Isolated CNS relapse is seen in some patients following Haematopoeitic stem cell 
transplant (HSCT) (Oshima et al., 2008). The mechanism underlying the selective 
involvement of extramedullary site remains unclear. Furthermore, the effect of immune 
surveillance in the CNS compartment is not extensively studied in ALL. Few clinical 
studies have described the risk factors for CNS relapse after HSCT. For instance, Patients 
with CNS-3 disease at diagnosis or relapse are at a higher risk of isolated CNS relapse after 
HSCT (Thompson et al., 1986, Oshima et al., 2008, Ganem et al., 1989). Consequently, 
these patients receive CNS prophylaxis (Thompson et al., 1986). Although the beneficial 
effect of CNS directed therapy after HSCT in such patients is debated (Oshima et al., 
2008). The incidence of CNS relapse after allogenic transplant is lower than autologous 
transplant suggesting a role for the immune surveillance provided by the donor immune 
system in the CNS (Ganem et al., 1989). Moreover, the risk of CNS relapse in patients 
with chronic graft-versus-host disease (cGVHD) and HLA mismatch in cord blood 
transfusion tends to be lower supporting this hypothesis (Oshima et al., 2008). 
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1.7.4 Host factors – IL-15 and IL-15 receptor 
An alternative translational approach to explore the mechanisms governing CNS disease in 
ALL is to analyse the genetic make-up of leukaemias associated with high risk for CNS 
disease. Host factors may play an important role in leukaemia development and prognosis. 
However, such studies merely show association between host genomic make-up and the 
observed disease and it is necessary to investigate the biological association between such 
observations. One such gene identified by genome-wide studies, IL-15, is relevant to this 
thesis and discussed here. 
In 1994, two groups simultaneously reported a novel cytokine that shared many 
physiological characteristics with IL-2 (Grabstein et al., 1994, Burton et al., 1994) and 
named this as IL-15 (Grabstein et al., 1994). Subsequently, cloning of the IL-15 gene 
identified two distinct isoforms, formed due to alternative splicing: the long signal peptide 
(IL-15LSP) and a short signal peptide (IL-15SSP). IL-15SSP has a shorter signal peptide 
(21 compared to 48 amino acids), but has an additional 119 BP sequence in mRNA, 
however, both the isoforms produce the same mature protein (114 amino acids). The 
signalling peptides (LSP and SSP) have a profound role in intracellular trafficking of the 
protein (Tagaya et al., 1997). IL15-SSP is directed to the cytoplasm and the nucleus 
whereas IL-15LSP is sorted to Golgi complex for presentation on the cell surface and/or 
secretion (Gaggero et al., 1999). The IL-15 transcript is abundantly expressed in a variety 
of tissues and cell types, however, due to strict regulation, protein expression is more 
restricted on the cells (Onu et al., 1997). 
IL-15 signals via a hetero-trimeric receptor complex with a specific high affinity α- subunit 
(IL-15Rα) (Giri et al., 1995), a shared IL15/IL-2 β-subunit (IL-15Rβ) and a common γ- 
subunit shared by several other cytokines (IL-15Rγc) (Giri et al., 1994). IL-15Rα confers 
the specificity to IL-15, (Giri et al., 1995) although IL-15 can also bind directly to IL-2 
Rβγc complex with lower affinity (Giri et al., 1994). Many cell types express IL-15Rα 
independently of the IL-15Rβ/γc subunits and therefore can potentially be activated by IL-
15 stimulation. Notably, IL-15Rα also exists in a soluble form (sIL-15Rα) (Budagian et al., 
2004), and together with IL-15 forms biologically active IL-15/sIL-15Rα complex. This 
complex is suggested to be the main active form of IL-15. This may also explain the 
difficulties in detection of secreted IL-15 in body fluids. The promiscuity in IL-15 biology 
allows IL-15/IL-15Rα complex to be cis- or trans- presented to IL-15Rβγc and signal in 
autocrine, paracrine, juxtacrine  and even endocrine fashion (Bulfone-Paus et al., 
2006)(Figure 1-10). IL-15 stimulation of the IL-15 receptor complex initiates multiple 
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downstream signalling pathways including JAK/STAT, PI3K/Akt and MAPK pathways 
resulting in strong proliferative and anti-apoptotic effects.  
Perhaps the most important role for IL-15 is in the development and proliferation of T- 
(Grabstein et al., 1994) and NK cells (Carson et al., 1997). Therefore, it is not surprising 
that IL-15 is suggested to potentiate a T- and NK cell mediated anti-tumour effect 
(Roychowdhury et al., 2004). Ironically, for the same pro-survival and anti-apoptotic 
effect, IL-15 has increasingly been implicated in the development and progression of many 
tumours including haematological malignancies. Uncontrolled expression in transgenic 
mice results in expansion of peripheral blood lymphocytes and ultimately develop T-cell 
leukaemia. This suggests continuous stimulation by IL-15 may overcome the regulatory 
checkpoints turning the balance in favour of leukaemogenesis (Fehniger et al., 2001). 
Malignant cells respond to IL-15 by reduced apoptosis and increased proliferation. For 
example, exogenous IL-15 results in resistance to apoptosis in primary human NK 
leukaemia cells and cell lines (Yamasaki et al., 2004), and proliferative advantage in B cell 
chronic lymphocytic leukaemia (CLL) (Trentin et al., 1996) and adult T cell 
leukaemia/lymphoma cells (Kukita et al., 2002). Additionally, IL-15 has been shown to 
mediate leukocyte motility. For example, it has been shown to induce T- cell polarization 
and distribution of integrin molecules (Nieto et al., 1996). Moreover, exogenous IL-15 is 
shown to be chemotactic for NK cells and pre-incubation of NK cells resulted in enhanced 
adhesion with endothelial cells in vitro (Allavena et al., 1997). 
 
 
 
Figure 1-10 Possible modes of IL-15/IL-15 receptor signalling 
(i) cis- presentation to the heterotrimeric receptor (ii) trans- presentation of the IL-15/sIL-15Rα complex (iii) 
trans- presentation of the IL-15/IL-15Rα complex. Drawn with information from Budagian et al. (2006) 
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Recently, Genome-wide analysis demonstrate single nucleotide polymorphisms SNPs in 
IL-15 gene associated with a higher risk of leukaemia in adult ALL (Lin et al., 2010) and 
resistance to therapy in paediatric ALL. It is also suggested that the SNPs in IL-15 gene 
may be associated with a high expression of IL-15 by leukaemic cells in paediatric ALL 
(Yang et al., 2009). Clinically, IL-15 expression by leukaemic cells is associated with 
aggressive disease and extramedullary dissemination. In a series of 87 adult ALL patients, 
IL-15 expression was found in the majority of patients with a high IL-15 expression 
associated with T-ALL, mediastinal and nodal infiltration and a poor prognosis. No 
association was seen with CNS, hepatic or splenic involvement (Wu et al., 2010). In 
paediatric ALL, using cDNA microarray technology, Cario and co-workers (2007) 
demonstrated high IL-15 expression was associated with CNS involvement. IL-15 was 
shown to be significantly overexpressed in patients with CNS-3 disease at diagnosis 
compared to CNS-1 controls. Despite a high false discovery rate (FDR) of 61% in this 
technique, this observation was validated by qPCR in an independent group of patients. In 
CNS-1 patients at diagnosis, a higher IL-15 expression level was significantly associated 
with a subsequent CNS relapse.  
Despite the increasing number of reports describing a link between IL-15 and ALL, 
questions remain. It is not known whether IL-15 SNPs have a direct role in leukaemia 
development and dissemination or an indirect role via modulation of anti-tumour immune 
responses. Further investigation into IL-15 biology may provide crucial insights into the 
observed associations with ALL in general and CNS disease in particular. 
1.8 Study aims  
Despite the clinical impact of CNS disease on the outcome of patients, little is known 
about the true incidence of CNS disease and the mechanisms underlying leukaemic cell 
migration and survival in the CNS. A number of gaps in the current knowledge regarding 
the CNS disease exist. The true incidence of CNS disease at diagnosis is a matter of 
debate. In addition, the mechanisms underlying the entry of leukaemic cells in the CNS 
compartment and that allow leukaemic cells to survive in the CNS remain to be 
investigated. It is hypothesised that leukaemic cells utilize a combination of leukocyte 
trafficking molecules to enter the CNS. If a particular combination or a molecular address 
code is identified, this information can be used to design and test novel therapies to block 
the CNS entry of leukaemic cells and prevent CNS relapse. Alternately, leukaemic cells 
may already be present in the CNS compartment at diagnosis. In this case, mechanisms 
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which allow leukaemic cells to proliferate in the CNS may be more important. 
 In order to contribute to the current body of knowledge, the purpose of this thesis is to: 
- Develop an in vivo murine xenograft model for CNS disease in ALL in order to 
address specific research questions concerning the leukaemic infiltration of the 
CNS.  
- Develop and test novel biomarkers of CNS disease to identify patients with 
submicroscopic levels of CNS disease.  
The key aims investigated in each chapter are: 
Chapter 3 Aim: To Develop and characterise a xenograft model of CNS disease using 
primary BCP-ALL cells in NSG mice and use this model to describe the frequency and 
pattern of extramedullary dissemination including an in depth analysis of the CNS 
infiltration.  
Chapter 4 Aim: To utilize in vivo techniques to investigate the role of leukocyte trafficking 
molecules in the leukaemic cell entry into the CNS compartment. Due to the observed 
CXCR4 dysfunction in a BCP-ALL cell line SD1, an additional aim of this chapter is to 
characterise the CXCR4-CXCL12 interactions in SD1 cell line. 
Chapter 5 Aim: To investigate the reported association between IL-15 and CNS disease 
using in vitro analysis of IL-15 and IL-15 receptors and their impact on cellular 
proliferation and gene expression in conditions mimicking the CSF.  
Chapter 6 Aim: To develop and utilize sensitive assays (qPCR and Luminex) as 
biomarkers of CNS disease in CSF samples from childhood ALL patients. 
The results of these investigations are presented in the following chapters. 
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2 Materials and methods 
2.1 General equipment and reagents 
2.1.1 Plastics  
All consumable plastic lab-ware were purchased from Starlabs (Milton Keynes, UK) 
except the following: 
Consumable Supplier 
Tissue culture plates and flasks Corning Inc. (Poole, UK) 
Microcentrifuge tubes Eppendorf (Hamburg, Germany) 
Falcon conical tubes 15 ml and 50 ml BD Biosciences (Le pont de Claix, France) 
BD Plastipak syringes BD Biosciences (Le pont de Claix, France) 
Polystyrene 5 ml round bottom Flow 
cytometry tubes BD Biosciences (Le pont de Claix, France) 
96 well round bottom tissue culture plates Nunc International/Thermoscientific 
Table 2-1 Plastic lab-ware used in this thesis 
 
2.1.2 General reagents 
The composition of chemical solutions, buffers and reagents that were used in 
experiments is given in table Table 2-2. Unless otherwise stated, all chemical reagents 
were purchased from Sigma-Aldrich.  
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Reagent/solution Composition 
Phosphate buffered 
saline (PBS) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 
Tris-buffered saline 
(TBS) 50 mM Tris-Cl, pH 7.5, 150 mM NaCl 
Flow cytometry 
(FCM) buffer 0.5% Foetal calf serum (FCS), 2.5mM EDTA in PBS 
chemotaxis buffer 0.5% Bovine Serum Albumin (BSA) in Rosewell Park Memorial Institute (RPMI) media 
Tris-acitate-EDTA 
(TAE) buffer 40 mM TAE, 1 mM EDTA (pH 8.2 - 8.4) 
PBS-Tween buffer 0.5% Tween20 in PBS 
TBS-Tween buffer 0.5% Tween20 in TBS 
PBS-EDTA buffer 
(PEB) 2.5mM EDTA in PBS 
Citrate buffer 10 mM Citric acid, 0.05% Tween20, pH 6 
1% acid alcohol 1% concentrated hydrochloric acid (HCl) in 70% ethanol 
Complete media 10% FCS, penicillin (100units/ml), streptomycin (100units/ml), L-Glutamine (2mM) in RPMI. 
10% Dulbecco’s 
modified Eagle 
medium (DMEM) 
10% FCS, penicillin (100units/ml), streptomycin (100units/ml), L-
Glutamine (2mM) in DMEM (Gibco) 
4% 
Paraformaldehyde 
(PFA) solution 
4% (v/w) PFA in PBS. pH 6.9 with 1N NaOH. Stored at -20C. 
Red Blood cell 
(RBC) lysis buffer 
10% (v/v) 10x RBC lysis soln (Miltenye Biotech, Bergisch 
Gladbach, Germany) in dH2O 
Cryopreservation 
media 90% FCS, 10% Dimethyl Sulphoxide (DMSO) 
Table 2-2 Composition of solutions 
 
2.2 Cell culture methods 
All procedures involved in cell culture were conducted using sterile conditions in a 
laminar flow hood with HEPA filtration. All materials such as pipettes, vortices, 
glassware and pasticware and reagents were sterile. The surfaces and equipment were 
wiped with 70% ethanol. Unless otherwise stated, all centrifugation steps were 
performed at 300 g for 5 minutes. All cultures were incubated in a standard tissue 
culture incubator at 37 ºC with 5% CO2 and 95% humidity. 
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2.2.1 Cell lines 
SD1 and REH were kind gifts of Professor Vaskar Saha (University of Newcastle). 
SEM cell line was gifted by Dr Olaf Heidenreich (University of Newcastle). Sup B15 
cell line was purchased from DSMZ (German collection of Microorganisms and Cell 
Cultures). Clinical details of the patients these cell lines and the immunophenotypic 
features of the cell lines is presented in Table 2-3. 
Cell line Patient age Sex Presentation /relapse Cytogenetics 
Immuno- 
phenotype* References 
SD1 NA F Presentation t(9;22) m-bcr**  CD34+, CD10-, CD19+, Cy79a+ 
Dhut et al. 
(1991) 
Sup B15 9 years M Second relapse t(9;22) m-bcr  CD10+, sIg - Naumovski et 
al. (1988) 
REH 15 years F Relapse t(12;21) CD34+, CD10
-
, 
CD19+, Cy79a+ 
Alkatib et al. 
(1985) 
SEM 5 years  F Relapse t(4;11) CD34-, CD19+ Greil et al. (1994) 
Table 2-3 Clinical and immunophenotypic characteristics of the cell lines 
** minor breakpoint cluster region 
2.2.2 Thawing of cells from frozen stocks 
Frozen cell lines stored in liquid nitrogen (-196 ºC) were identified and thawed in 
water bath at 37 ºC. The cells were washed in 5 ml complete culture media followed 
by centrifugation. Supernatants were removed and the cells were re-suspended in 5 ml 
complete media (pre-warmed to 37°C) and transferred to 25 cm2 flasks for subsequent 
culture. 
2.2.3 Cell counting 
Cell counts were performed using Haemocytometer (modified Neubauer chamber). 
Cells were thoroughly mixed in the suspension and 100 µl of cell suspension was 
added to 300 µl of Trypan blue. After thorough mixing, 10 µl of this suspension was 
loaded into the counting chamber. Cells negative for trypan blue were counted in the 
4x4 grid. The number of cells counted was multiplied by 1 x 104 which represented the 
counts per ml of the original cell suspension. Viability was measured by dividing 
number of live cells by total number of cells and multiplied by 100 to get the 
percentage viability.  
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2.2.4 Maintenance of cell lines in culture 
Cells were grown in complete media (Table 2-2) and passaged as recommended by 
DSMZ. SD1 cells were cultured in complete media. Cell lines were maintained in 25 
ml cell suspension in 75 cm2 vented tissue culture flasks. Cells were monitored daily 
using inverted microscope to monitor confluence and general culture conditions. SD1 
cells were maintained at a concentration of 0.25-1.2 x 106 /ml and were split every 
third day at a dilution of 1:5 with fresh complete media. Sup B15 cells were 
maintained in complete media at a concentration of 1-2 x 106 /ml and were split at a 
dilution of 1:5 every third day. REH cells were maintained in complete media at a 
concentration of 0.5 - 2 x 106 /ml and split once every 3 days at a dilution of 1:5 in 
complete media. SEM cells were maintained in complete media at a concentration of 
0.2-2 x106 /ml and split 1:4 once every 4 days. Cell lines were grown approximately at 
a concentration of 1-1.2 x 106 /ml just before using in experiments.  
2.2.5 Passage of cell lines 
SD1, Sup B15 and REH cell lines were thoroughly resuspended using 10 ml pipette 
and an aliquot of 5 ml was transferred to a 25 ml centrifuge tube. The cells were 
centrifuged and the supernatant discarded. The cells were resuspended in 25 ml fresh 
pre-warmed media and transferred to a new 75cm2 sterile tissue culture flask. For SEM 
split 1:4, 6 ml of cell suspension was expanded in 24 ml fresh media. Adherent cell 
lines were grown at a maximum confluence of 80% upon which the cell layers were 
gently detached using Trypsin or a cell scraper. 10 ml of complete media was added 
and the cells were thoroughly re-suspended by pipetting. Two ml of the cell 
suspension was transferred to a new 75cm2 flask and 13 ml complete media was added 
on top.  
2.2.6 Cryopreservation of cells 
Cells were frozen down from the growing cultures at early passage numbers. Cells 
were supplemented with fresh media one night before freezing down. The cells were 
counted using haemocytometer with trypan blue dead cell exclusion method. Different 
cell lines vary in the optimum cell density for freezing as recommended by DSMZ. 
Cells were resuspended in cryopreservation media (90% FCS, 10%DMSO or for some 
cell lines 20% FCS, 10% DMSO in 70% RPMI) at the optimum density. For primary 
cells retrieved from patients or primagraft cells (human leukaemic cells expanded and 
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retrieved from mice organs), 1 x 107 cells were frozen in 1ml of 90% FCS, 10% 
DMSO solution.  
2.3 Patient Methods 
2.3.1 Ethics approval 
All human research conducted was in accordance the ethical standards of the Helsinki 
declaration and was approval by West of Scotland research ethics committee 
(WoSREC reference: 09/SO703/77).  
2.3.2 Collection of human CSF 
Patients were diagnosed at the Royal Hospital for Sick Children (RHSC or Yorkhill), 
Glasgow. CSF samples were obtained under anaesthesia using standard lumbar 
puncture technique. About 1 ml of CSF was withdrawn from children in a sterile tube 
and sent to the diagnostic lab. About half of the sample was removed for CSF 
cytology. The remaining sample was transferred to be processed as described below. 
2.3.3 Processing of CSF 
Samples were transferred to a 1.5 ml eppendorf tube and centrifuged at 1000 g for 10 
minutes at 4 ºC. The supernatants were carefully transferred into new 1.5 ml eppendorf 
tubes in 210 µl aliquots. Tubes were labelled and stored at -80 ºC. DNA extractions 
were performed from the cell pellet described later in section 2.6.2. 
2.3.4 Blood collection 
Blood samples were collected in the Schiehallion ward, Yorkhill using heal prick 
(young children), or cuboital vein or Hickman line (adolescents) by trained 
phlebotomists using standard techniques. Blood samples were sent to the laboratory 
where automated full blood counts (FBC) were performed. Leftover blood samples 
were processed as described under section 2.6.3. 
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2.4 Animal methods 
2.4.1 Mice 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (Charles River) were maintained at 
the Central Research Facility, University of Glasgow, in strictly sterile conditions with 
filtered air and autoclaved food, water and bedding. Mice were used between 6 and 14 
weeks of age for all studies. All procedures were carried out in accordance with the 
United Kingdom Home Office regulations under the authority of the appropriate 
project licence (number: 60/4092) and personal licence (number: 60/13504). 
2.4.2 Intra-femoral injections of primary cells 
Primary cells from frozen stocks were thawed and counted. For each injection, 
between 1 x 105- 1 x 106 cells were resuspended in 30 µl PBS in 0.5 ml syringe with 
29 gauge needle. For intrafemoral injections, the mice were anaesthetised with 
Isoflurane. Knees were shaved and cleaned with 70% ethanol solution. One of the 
knees was flexed and the direction of the femur was assessed by palpation with index 
finger. A 25 gauge needle was inserted at the distal end of the femur just about the 
knee cap, first puncturing the skin, and then boring through the distal end of the bone. 
The needle was advanced in the bone marrow cavity in a boring motion. The boring 
needle was removed and the needle attached to syringe with cells was inserted. Cells 
were carefully injected and the knee extended. Sterile gauze swab was pressed to 
prevent any bleeding from skin. Intra-peritoneal carprofen (0.125 mg) was used per 
mouse as a post-operative analgesia. The mice were monitored until completely 
recovered and observed for signs of pain or fracture. 
2.4.3 Intravenous injections of cell lines 
Primary cells from frozen stocks were thawed and between 1 x 105 – 1 x 106 cells/ 
mouse were used. For cell lines grown in culture, between 1 x 106 – 1 x 107 cells were 
used. Cells were resuspended in 100 µl PBS and loaded in 0.5 ml syringe with 29 
gauge needle. Mice tails were cleaned with ethanol and injections were given through 
tail veins.  
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2.4.4 Monitoring of engraftment 
Engraftment was assessed by monitoring mice for signs of ill health, weekly weight 
measurements and quantifying circulating human CD10/CD19 positive cells via tail 
vein blood sampling (section 2.4.5). Mice were culled following any sign of 
engraftment (>10% human CD10/CD19 positive cells in tail vein blood sample, signs 
of ill health, or weight loss of >10% for 3 days or >20% on one occasion). If there 
were no detectable signs of engraftment, mice were culled 28 weeks post injection 
2.4.5 Tail vein blood sampling of xenograft mice 
Mice were moved from their cages to a laminar flow cabinet and restrained using a 
restrainer. Their tails were wiped with 70% ethanol and a small incision given using a 
blade. Approximately 3-4 drops of blood were collected in a 1.5 ml eppendorf tube 
containing 30 µl 0.5 mM EDTA to prevent blood coagulation. After collection, mice 
were transferred back to their cages and blood samples were kept on ice. Red blood 
cell lysis was performed using RBC lysis solution. Cells were then washed in FCM 
buffer and stained with human CD10/CD19 antibodies (section 0). 
2.4.6 Culling and dissection 
All mice were humanely culled with CO2 asphyxiation. Blood samples were taken 
from cardiac puncture and anticoagulated using EDTA. Liver, kidneys and gonads 
were removed, weighed and fixed in 4% paraformaldehyde (PFA) solution. Skulls 
were isolated after removing skin, facial muscles and bones and fixed in 10% Neutral 
buffer saline (NBF) (Cell store) unless otherwise specified; in which case brains were 
removed from the skulls and cells harvested from the brains by vortexing. Spleens 
were removed, weighed and passed through 40 micron cell strainer to isolate cells. 
Using a 23-21 gauge needle and a syringe, bone marrow samples were harvested from 
the femur and tibia by flushing the bones with PBS or, in some cases, by grinding the 
bones with a mortar and pestle. Spinal cords were removed from the vertebral column 
by flushing with PBS using a wide gauge needle. The spinal cords were vortexed in 
PBS in a 50 ml tube at medium speed for 5 minutes. Cells were passed through 40 
micron cell strainer. 
RBC lysis was performed on cells from blood, spleen, BM and the cells were washed 
and assessed for quantification and viability. Histology, chemotaxis assays and flow 
cytometry for chemokine receptor expression assays were performed as described  in 
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the subsequent sections. 
2.4.7 In vitro imaging of xenografts injected with REHGFP-
Luciferase cells 
1 x 107 REHGFP-Luc cells were counted and injected, intravenously, into the tail vein of 
4-8 week-old NSG mice. Mice were culled after 4 weeks, and femurs and skulls were 
removed. Bone marrow was harvested from tibiae using mortar and pestle. Cells from 
the CNS were isolated by carefully removing the brains from the skull cavity and 
vortexing the brain in PBS in 50 ml tube at moderate speed for 5 minutes. Cells from 
bone marrow and the CNS were passed through 40 micron cell strainer and quantified 
using a haemocytometer and their viability assessed using Trypan blue. Cells from 
bone marrow/CNS (5 x 105) were intravenously injected into 4-8 week-old NSG mice.  
Bioluminescent-imaging used an IVIS100 system (PerkinElmer, Seer Green, UK). 
Mice were imaged under 2% isoflurane anesthesia following subcutaneous injection of 
luciferin (100mg/kg, PerkinElmer). Image-acquisition of whole animals (dorsal and 
ventral views) used 1-60 seconds exposure at a low binning level. Data analysis used 
Living Image software v3.1 (PerkinElmer).  
2.5 Cell based assays 
2.5.1 Flow cytometry 
Flow cytometry is a powerful tool to identify a surface or intracellular markers of 
interest by measuring fluorescence signals from cells. The process involves the 
preparation of a single cell suspension, labelled with fluorescently-conjugated 
antibodies. Cells are injected into a complex tubing system that generates a stream of 
single cells. Each cell passes through an interrogation point where lasers with distinct 
wavelength shed beams of light. Light scatter and fluorescence emission from 
fluorochromes are detected by light detectors and provides information about the cell’s 
particular properties. Light scatter and fluorescence are digitally converted to generate 
Forward Scatter (FSC), Side Scatter (SSC) and fluorescence intensity. A combination 
of FSC and SSC provides information about the size and granularity of cells while 
markers of interest are assessed using fluorescence. In this thesis, flow cytometry was 
used in a number of experiments, each described under appropriate headings. 
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2.5.2 General equipment, materials and solutions 
Cells, labelled with the appropriate fluorescently-conjugated antibodies, were analysed 
using a MacsQuantTM analyser (Miltenyi). Acquisition parameters for multiparameter 
flow cytometry were established using unstained cells and cells stained with single 
fluorochromes. Data were analysed using data analysis software FlowJo (FowJo LLC). 
Monoclonal antibodies used were either directly, or indirectly, conjugated with 
fluorochromes: Fluorescein isothiocynate (FITC), R-phycoerythrin (PE), 
allophycocyanin (APC), PE conjugated to Cyanine 7 (PE-Cy7). Cell viability dyes 
used were Draq7, conjugated to APC-Cy7 (Biostatus, shepherd, UK), or Viaprobe (7-
AAD)(BD Biosciences). All the antibody concentrations were used according to 
manufacturers’ instructions and were between 1-5 µg/ml. All the dilutions were 
between 1:10-20. A detailed list of fluorescently labelled antibodies, viability dyes, 
fluorescently labelled dyes or other materials is given in Table 2-4. Due to the limited 
variety of available conjugated fluorochromes, and to avoid the overlap of 
fluorescence emission signals (spectral overlap), it was decided to use PE- and/or 
APC-conjugated antibodies for CXCR3, CXCR4, CCR6, CCR7, CX3CR1 and 
PSGL1. Consequently, analysis for each of these molecules was performed 
individually or a combination of two antibodies (1 PE and 1 APC).  
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Antibody Cat.no concentration Manufacturer 
Anti-Human CCR6-PE 12-6969-42 0.6 µg/ml eBioscience, 
Anti-Human CCR7-APC 17-1979-42 1.25 µg/ml eBioscience 
Anti-Human CD10-FITC 11-0106-42 1.25 µg/ml eBioscience 
Anti-Human CXCR4-APC 17-9999-42 2.5 µg/ml eBioscience 
Anti-Human CD19-PE-Cy7 25-0199-42 2.5 µg/ml eBioscience 
Anti-Human CD45-FITC 11-9459-42 10 µg/ml eBioscience 
Anti-Human CX3CR1-PE 12-6099-41 1.25 µg/ml eBioscience 
Anti-Human CXCR3-PE 121839 2.5 µg/ml eBioscience 
Anti-Human CD184 (CXCR4) Purified 14-9999 2.5-10 µg/ml eBioscience 
Human CXCR7/RDC-1 MAb, Mouse IgG1 MAB42273 2.5-10 µg/ml R&D systems 
Mouse anti human CXCR7/RDC-1-PE FAB42271P 2.5-10 µg/ml R&D systems 
anti-Human Annexin V-APC 88-8007-72  eBioscience 
Secondary antibodies  
Goat Anti-Mouse IgG1, Human ads-TRITC 1070-03  0.3 µg/ml Southern biotech 
Goat Anti-Mouse IgG2b, Human ads-FITC 1090-02  0.3 µg/ml Southern biotech 
Viability dyes  
BD Via-probe 555815 0.5 µg/ml BD Biosciences 
Draq7 DR71000 0.3 µM  Biostatus 
Propidium Iodide 00-6990 10 µg/ml eBioscience 
Isotype control antibodies  
CXCR7 inhibitor isotype control ccx704 Non commercial Chemocentryx 
Mouse IgG1 K Isotype Control-PE 12-4714-42 0.6-2.5 µg/ml eBioscience 
Mouse IgG2a K Isotype Control-APC 17-4724-42 0.6-2.5 µg/ml eBioscience 
Chemokines  
Recombinant Human CXCL12-AF647 CAF-11 1-300 ng/ml Almac group 
Recombinant Human CXCL11 300-4 1000 ng/ml Peprotech 
Inhibitors  
CXCR7 small molecule inhibitor CCX771 Non commercial 01-10 µg/ml Chemocentryx 
CXCR7 inhibitor isotype control ccx704 Non commercial 0.1-10 µg/ml Chemocentryx 
Other reagents used 
CellTrace violet cell proliferation kit C34557 Invitrogen 
Apoptosis activator 2 (AA2) 2098 50 µM Tocris Bioscience 
Table 2-4 Antibodies, fluorescent conjugated and native chemokines and reagents for 
flow cytometry 
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2.5.3 Analysis of surface receptor expression 
Surface expression of various leukocyte trafficking molecules was determined using 
multi-parameter flow cytometry. Cells (1 x 106) were washed twice in FCM buffer and 
resusupended in 100 µl FCM buffer. FC block was added and incubated on ice for 10 
minutes to prevent non-specific binding of antibodies to the Fc receptors. 
Specific/isotype antibody was added as per manufacturer’s recommended 
concentration. Cells were incubated on ice for 30 minutes, with periodic gentle 
flicking of the tubes. Cells were washed twice in FCM buffer and resuspended in 100 
µl FCM buffer. Suitable viability dye (7-AAD or Draq7) was added just before 
acquisition. Cells were acquired on MacsQuant with medium acquisition settings, 
keeping the event rate between 1000-10,000 events/seconds. 50,000-5,00,000 events 
were counted depending on rarity of the subpopulation of interest. Adjusted mean 
fluorescence intensities (MFIs) were calculated according to the formula: cMFI = 
MFItest
 
-MFIisotype 
2.5.4 Chemotaxis assay 
Transwell® transmigration assays were used to determine the chemotactic activity of a 
particular chemoattractant or inhibitors of chemotaxis for cells. The assay utilizes a 
microporous permeable membrane positioned between two compartments. Cell 
suspensions are placed in the top compartment and a chemokine solution was added to 
the bottom compartment. This forms a chemokine gradient and allows the cells to 
migrate towards the chemokine. Cells that migrate across the membrane are collected 
from the bottom compartment and counted using haemocytometer or by flow 
cytometry. 
Working concentrations of the chemokine +/- chemokine receptor inhibitor were 
prepared in chemotaxis buffer according to the experimental conditions. 600 µl of the 
prepared chemokine solution was added to wells of a 24 well tissue culture plate and 
5µM Transwell® inserts were placed on top. Cells were then counted, washed and 
resuspended in complete media to a concentration of 5 x 106 cell/ml. The plate was 
covered and incubated for 3 hours at 37 ºC, 5% CO2. Inserts were then carefully 
removed and the contents of the bottom well were transferred to a new eppendorf tube 
leaving no residual cell suspension behind. Cells were centrifuged, supernatants 
removed and the pellets resuspended in 100 µl sterile ice cold PBS or FCM buffer. 
Cells were counted using either a haemocytometer with or by flow cytometry. 
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Migration indices were calculated by the formulae: Cells in the chemokine well/Cells 
in the control well. Percent migration was calculate by the formula: No of cells in the 
well/ 5x105 x 100 
2.5.5 Chemokine receptor internalization and recycling assay 
Receptor internalization and recycling assay was performed to determine the extent of 
CXCR4 expression levels, reduction in surface expression following exposure to 
CXCL12 and restoration of surface expression following removal of CXCL12 from 
media. 
Cells were counted and resuspended at a concentration of 1 x 106 /ml in a 24 well plate 
in complete media. CXCL12 was added at a final concentration of 100 ng/ml to the 
appropriate wells. The plate was then incubated at 37 ºC for 30 minutes. Following the 
incubation, the cell suspension was transferred to a new eppendorf tube, centrifuged, 
resuspended in complete media and then transferred to a new 24- well plate. The plate 
was incubated at 37 ºC, 5% CO2 for up to 120 minutes. At each time point, the plate 
was removed from the incubator, and the cell suspension transferred to a new 
eppendorf tube and incubated on ice to stop metabolism. The time points used were 0, 
30, 60, 90, 120 minutes. After the last time point, cells were washed twice and 
resuspended in ice cold FCM buffer. Cells were stained with CXCR4-APC antibody as 
described in section 0 and acquired on MACSQuant.  
Formula for calculating adjusted/corrected MFI is: 
% Adjusted MFI = (MFICXCR4 - MFIisotype) / (MFIn min-CXCR4 MFIn min-isotype)x100. 
Where n= specific time point 
2.5.6 Chemokine competition assay 
To determine the relative surface expression of CXCR7, a competition assay was 
performed whereby cells were incubated with alexa-fluor labelled chemokine, 
CXCL12 (CXCL12AF647). As CXCL12 will label both CXCR7- and CXCR4 positive 
cells, cells were labelled in the presence or absence of a non-fluorescent competing 
chemokine, CXCL11.  CXCL11 binds to CXCR7 (and CXCR3), but does not bind to 
CXCR4. Consequently, any CXCL12 labelling that is attenuated in the presence of 
CXCL11, must be due to the specific interaction between CXCR7 and CXCL12.  
Cells were counted and resuspended at 1 x 107 /ml in a staining buffer (5uM HEPES, 
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10% FCS in RPMI). 100µl Cell suspension was transferred to a sterile 96 well plate 
(NUNC) and incubated on ice to stop metabolism. CXCL12AF647 was added to a final 
concentration of 100ng/ml. A tenfold excess of native CXCL11 was added to the 
appropriate wells at a final concentration of 1µg/ml. An equal volume of PBS was 
added to the negative control wells. The plate was incubated for 1 hour at 37 ºC, 5% 
CO2. Cells were then washed twice in FCM buffer to remove excess chemokine. Dead 
cell discriminator, 7-AAD, was added just before analysis. Using FlowJo, MFIs were 
calculated and the MFI of control cells was compared to that of CXCL11-treated cells. 
2.5.7 Analysis of cellular proliferation using cytoplasmic dye 
Celltrace Violet 
CellTrace Violet (CTV) is a cytoplasmic dye which is cleaved by intracellular 
esterases to yield a highly fluorescent compound which binds to intracellular amines. 
With every cell division, fluorescence is halved, giving discrete peaks of fluorescence 
when analysed using a flow cytometer. Apoptosis was measured by AnnexinV-APC 
kit (eBioscience, San Diego) and dead cells were measured using 7-AAD staining. 
Cell numbers were measured using event count on MACSQuant. 
Cells (2 x 106 /ml), resuspended in pre warmed staining buffer (2% FCS in PBS), were 
labelled with CTV (5 µM) and incubated at 37 ºC, 5% CO2 for 20 minutes. 30 ml of 
complete media was added, following which the cell suspension was incubated at 37 
ºC, 5% CO2 for 5 minutes to quench the unbound dye. Next, cells were washed and 
resuspended in staining buffer (30 ml) and incubated for two hours to allow the cells 
to recover from the toxic effects of CTV. After the incubation, cells were counted and 
treated with IL-15 (25 ng/ml) or media for the defined time points (72 - 96 hours). 
Following treatment, the cell suspensions were collected and washed in Annexin V 
staining buffer twice, and then resuspended in 100 µl of Annexin V staining buffer. 
Annexin V-APC was added and the cells were incubated for 20 minutes on ice. The 
cells were then washed twice in Annexin V staining buffer and analysed on the 
MACSQuant after adding cell viability dye 7-AAD. Cells treated with Apoptosis 
Activator 2 (AA2, Tocris Bioscience, UK) were used as a positive control for 
Apoptosis.  
 
89 
 
 
2.6 Molecular biology methods: DNA 
2.6.1 DNA extraction using Trizol 
Cells were counted, pelleted by centrifugations and lysed in 1 ml Trizol (Life 
Technologies) by thorough pipetting. For cerebrospinal fluid (CSF) samples, cells 
were pelleted and lysed without counting. Lysates were incubated for 3 minutes at 
room temperature to complete lysis. 200 µl of chloroform was added and thoroughly 
mixed by vigorously shaking by hand for 15 seconds. Lysates were incubated at room 
temperature for 3 minutes and then the tubes centrifuged at 8000 g for 10 minutes at 4 
ᴼC. This formed an upper clear ‘aqueous phase’ containing RNA, an ‘interphase’ and a 
lower ‘organic phase’ containing DNA. The aqueous phase was carefully removed and 
stored. In the organic phase from CSF samples, a co-precipitant (Glycogen (sigma, 
UK) or Pellet paint co-precipitant (EMD Millipore)) was added to the solution 
containing the DNA and the sample mixed by vortexing. Samples were incubated for 3 
minutes at room temperature and centrifuged at 2000 g for 5 minutes at 4 ºC to pellet 
the DNA. Supernatants were carefully removed leaving the DNA pellet behind. The 
DNA pellets were washed with 1 ml of sodium citrate/ethanol solution (0.1 M Sodium 
Citrate in 10% ethanol pH 8.5). Samples were incubated for 30 minutes at room 
temperature, occasionally inverting the tube to mix. Samples were then centrifuged at 
2000 g for 5 minutes at 4 ºC. This wash step was repeated once. 1.5 ml 70% ethanol 
was added and incubated for 20 minutes at room temperature, periodically inverting 
the tubes. Sample tubes were then centrifuged for five minutes at 4 ºC. Supernatants 
were completely removed and discarded. The pellets were air dried by leaving the 
tubes open for 15 minutes to evaporate the residual ethanol without over drying the 
pellets. DNA pellets were dissolved in 35 µl nuclease free water by incubating at room 
temperature for 1 hour. DNA quantification was performed as described in section 
2.6.5. 
2.6.2 DNA extraction from CSF using QIAmp DNA micro kit 
Where specified, DNA extraction was performed using QIAmp DNA micro kit 
(Qiagen). This kit utilizes spin column technology and is optimized for DNA 
extraction from small samples. Cells were lysed and passed through silica-gel 
membranes which bind to DNA and allow contaminants to pass through. 
Contaminants are further removed in two wash steps followed by high-speed 
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centrifugation. DNA was then eluted using RNAse free water or an elution buffer 
provided with the kit. Carrier RNA (cRNA) was used to the cell lysates to increase  
DNA yield. Cells were pelleted and supernatants removed. Lysis buffer, along with 
proteinase K and cRNA was added and lysates homogenised by pulse vortexing for 15 
seconds. The lysates were then incubated at 56 ᴼC for 10 minutes to increase the 
protein digestion activity. Absolute ethanol was added to precipitate the DNA and the 
whole lysates were transferred to the column and centrifuged. Wash steps were 
performed according to the manufacturer’s instructions. Residual ethanol was removed 
by centrifugation at 17000 g for 2 minutes. The bound DNA was eluted with 35 µl of 
nuclease free water in a new eppendorf tube and stored at -80 ºC until use. 
2.6.3 DNA extraction from blood, cultured cells and bone 
marrow samples using Qiagen blood DNA mini kit 
The Blood DNA mini kit (Qiagen) utilizes the column based principle of DNA 
extraction. An appropriate volume of cell suspension (50 µl of whole blood, 105 – 106 
cultured cells or purified mononuclear cells from bone marrow samples) was taken 
and lysed usinglysis buffer provided with the kit. Protein digestion was performed by 
adding proteinase K solution and incubating lysates at 56 ᴼC for 10 minutes. After 
adding 100% ethanol, the lysates were transferred to the membrane columns and 
centrifuged. Wash steps were performed according to the manufacturer’s instructions 
and the DNA eluted in 50 µl of nuclease free water. DNA was quantified as described 
in section 2.6.5 and stored at -20°C until use. 
2.6.4 DNA concentration and cleanup 
A DNA cleanup procedure was performed if better quality, or higher concentration, 
was needed. This step was performed using Qiagen DNeasy mini kit according to 
manufacturer’s instructions. For DNA extracted from very low number of cells, 
Qiagen QiAmp DNA micro kit was used according the manufacturer’s instructions.  
2.6.5 DNA quantification by spectrophotometric method 
DNA was assessed for quantity and quality using Nanodrop1000 spectrophotometer 
(Thermofisher). The samples were brought to room temperature and mixed well. The 
pedestals of the spectrophotometer were wiped clean with lint free tissue soaked in 
nuclease free water and then with a new dry tissue. Nuclease free water was used as 
blank and the OD260 was measured. Purity of DNA was assessed by measuring the 
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absorption ratio at 260:280 nm, with normal levels between 1.7-1.9 (optimum 1.9). 
Readings below 1.7, or above 1.9, indicated phenol or protein contamination.  
DNA quantification of patient CSF samples was performed using qPCR for Albumin 
gene (section 2.9.2) 
2.7 Molecular biology: RNA 
While performing assays with RNA, measures were taken to prevent RNA 
degradation. Prior to starting RNA work, all surfaces were decontaminated from 
RNases using RNAzap RNase decontaminating solution (Ambion). All equipments, 
reagents, plastics and pipette tips were RNase free. Samples were processed quickly 
and all steps of the procedures were performed while keeping the samples on ice. 
2.7.1 RNA extraction from cells 
RNA was extracted using spin-column based RNA isolation technology. Depending 
on the amount of available cells for RNA extraction, an RNAeasy Mini kit (Qiagen) 
(>5x105 cells), or RNAeasy Micro kit (Qiagen) (<5x105 cells) was used. Cells were 
lysed using RLT buffer and homogenized using QIAshredder spin column (Qiagen). 
RNA extraction was performed according to manufacturer’s instructions. In order to 
remove DNA contaminants, lysates were treated with RNase free DNase I (Qiagen) 
according to manufacturer’s instructions. RNA was eluted with RNase free water and 
quantified using Nanodrop1000.  
2.7.2 cDNA synthesis 
RNA was converted to complementary DNA (cDNA) using Precision nanoScript 
Reverse Transcription kit (Primerdesign, Southampton, UK). Depending on the 
concentration of available RNA, 200-1000 µg RNA was used in each reaction. cDNA 
synthesis was performed according to manufacturer’s instructions. cDNA synthesis 
involves two main steps: annealing and reverse transcription. RNA samples were 
mixed with random nanomer primermix and heated to 65 ºC for 5 minutes and to 
allow annealing of primers to the isolated RNA. Subsequently, reverse transcription 
was performed by adding reverse transcriptase, dNTP mix, DNAse, buffer and water 
according to the manufacturer’s instructions. For RT-ve controls, RNase free water 
was added instead of reverse transcriptase enzyme. Samples were incubated at 25 ºC 
for 5 minutes, 55 ºC for 20 minutes, and 75 ºC for 15 minutes. cDNA samples were 
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stored frozen at -20°C until use. 
2.8 Molecular biology: SYBR Green qPCR 
qPCR allows determination of relative and absolute numbers of transcripts of a gene 
present in a sample. This technique utilizes SYBR Green fluorescent dye which binds 
to double stranded DNA and emits fluorescence in bound form. With each PCR 
reaction cycle, the amount of DNA is amplified with a proportional increase in signal 
from SYBR Green, thus allowing real-time measurement of DNA amplification. 
Absolute transcript quantification, by SYBR Green qPCR, requires primers specific to 
the transcript of interest, and standard primers, which are used to generate standard 
curves for analysis of transcript copy numbers. Absolute numbers of a transcript 
encoding an appropriate housekeeping gene must also be assessed to normalise for 
different quantities of template cDNA. The following sections describe design and 
verification of both qPCR and standard primers, followed by the SYBR Green qPCR 
method that has been utilized in this thesis. 
2.8.1 Primer design 
A set of ‘inner’ and ‘outer’ primers were designed using online software ‘Primer3’ 
(available online at http://bioinfo.ut.ee/primer3-0.4.0/ ). The outer primers were 
designed to create PCR products, used to create a standard curve, while the inner 
primers were used to efficiently amplify a suitable region of the transcript of interest. 
Three sets of primers were generated for each gene transcrips and one best set of 
primers was selected based on amplification efficiency determined in qPCR reaction. 
It was preferred to design intron spanning primes. The following criteria were taken 
into consideration while designing the primers (Table 2-5): 
Factor Optimal value 
Sequence length 18-23 base-pairs (BP) 
GC content 40-65% (50% optimal) 
Melting temperature (Tm) 59-61 oC ( 60 oC optimal) 
Max. self complimentarity 2 
Max. 3’ self complimentarity 1 
Amplicon size <150bp ( 250-1000 for outer primers) 
GC bases at the end Not more than two G or C based in last 5’ or 3’ end of 
each primer. 
GC repeats <4 or G and/or C in a row 
Table 2-5 Criteria for optimal primer design 
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Outer primers were designed to amplify the region where inner primers would bind. 
The conditions for these primers were similar to the inner primers, apart from their 
length which was at least 80 BP larger. Also, as these primers were not to be used in 
the final qPCR reaction, other conditions for primer design could be slightly relaxed if 
the software did not suggest suitable primers.  
BLAST analysis was performed to confirm the specificity of the primers, and to 
exclude amplification of splice variants or genomic DNA. Specificity was further 
confirmed by performing a PCR reaction (section 2.8.2.1) and separating the amplified 
PCR products according to size, using agarose gel electrophoresis (2% agarose in Tris-
EDTA). Amplified DNA was visualized using ethidium bromide. Presence of a sharp 
clear band of the appropriate size confirmed a specific product, whilst multiple bands 
suggested non-specific amplification, the presence of primer dimers, or genomic DNA 
amplification. Unsuitable primers were not used any further.  List of primers is 
presented in Table 2-6. 
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RT-PCR 
Target Sequence Annealing 
temperature  
Product size 
IL-15 5′ AAACCCCTTGCCATAGCCAGCTCT T 
3′ CTTCTGTTTTAGGAAGCCCTGCAC T 
55  201bp LSP-IL-15 
320bp SSP-IL-15 
IL-15 Rα 5′ GCCAGCGCCACCCTCCACAGTAA 
3′ GCCAGCGGGGGAGTTTGCCTTGAC 
55 ºC 402 bp 
IL-15 Rβ 5′ CACAGATGCAACATAAGCTGG 
3′ ACT TCA GGA CCT TCT TCA GCC 
52 ºC 403 bp 
IL-15 Rγ 5′ AGC CCCAGC CTACCAACCTCACT 
3′ TTAAAGCGGCTCCGAACACGAA 
55 ºC 447 bp 
Serpine 1 
Standard 
5′ CTCTCTCTGCCCTCACCAAC 
3′ TGCCACTCTCGTTCACCTC 
60 ºC 261 bp 
MMP9 
Standard 
5’ CCTGGAGACCTGAGAACCAA 
3’ CACCAAACTGGATGACGATG 
60 ºC 366 bp 
PTEN 
standard 
5’ ATGTGGCGGGACTCTTTATG 
3’ TCAGGAGAAGCCGAGGAA 
60 ºC 241 bp 
DENR 
standard 
5’ CAGTAACAGGGGAGGATGAAA 
3’ CAGGCAACAGTGCGAGAC 
60 ºC 600 bp 
TIMP4 
standard 
5’ CAGACCCTGCTGACACTGAA 
3’ GGGAAGGAGAACTGGCTTG 
60 ºC 553 bp 
CDH11 
stanadard 
5’ CAGATGACCCCACTTATGGAA 
3’ GCTTTATCACCCCCTCCTGT 
60 ºC 1051 bp 
CXCR4 
standard 
5’ TCATCAAGCAAGGGTGTGAG 
3’ CCTACCACGAGACATACAGCAA 
60 ºC 1691 bp 
CXCR7 
standard 
5’ GTCTGGGTGGTCAGTCTCGT 
3’ TGCTGTGCTTCTCCTGGTC 
60 ºC 654 bp 
TBP 
standard 
5’ GGGCACCACTCCACTGTATC 
3’ CATCTTCTCACAACACCACCA 
60 ºC 723 bp 
GAPDH 5′ CAAGGCTGAGAACGGGAA 
3′ GGTGGTGAAGACGCCAGT 
55 ºC 115 bp 
SYBRGreen qPCR 
IL-15 5′ AAACCCCTTGCCATAGCCAGCTCT T 
3′ CTTCTGTTTTAGGAAGCCCTGCACT 
55  201bp LSP-IL-15 
320bp SSP-IL-15 
Serpine 1 
qPCR 
5′ GGTTCTGCCCAAGTTCTCC 
3′ CGGTCATTCCCAGGTTCTC 
60 ºC 71 bp 
MMP9 
qPCR 
5’ GGCACCACCACAACATCA 
3’ GCAAAGGCGTCGTCAATC 
60 ºC 79 bp 
PTEN 
qPCR 
5’ AGGCGAGGGAGATGAGAGA 
3’ CGAAGAGGAGGCGAGAAAC 
60 ºC 140 bp 
DENR 
qPCR 
5’ TCGTCCTTGGCATTTTCACT 
3’ TCTCCCGTTTATTTGACTTTGG 
60 ºC 73 bp 
TIMP4 
qPCR 
5’ GCCAACAGCCAGAAGCAG 
3’ GCCACAGTTCAGATGGTAGTGA 
60 ºC 150 bp 
CDH11 
qPCR 
5’ CCTATTTTTCGGTGGAAGCA 
3’ TTGGTTGTCCCTGAGAGTCC 
60 ºC 142 bp 
CXCR4 
qPCR 
5’ TGTTGTCTGAACCCCATCCT 
3’ ATGAATGTCCACCTCGCTTT 
60 ºC 132 bp 
CXCR7 
qPCR 
5’ CCTACCACGAGACATACAGCAA 
3’ GTCTCATTGTTGGACGCAGA 
60 ºC 122 pb 
TBP 
qPCR 
5’ AGGATAAGAGAGCCACGAACC 
3’ GCTGGAAAACCCAACTTCTG 
60 ºC 137 pb 
TaqMan qPCR 
Gene Assay ID 
IL-15 Hs99999039_m1  
PSGL1 Hs00380945_m1 
CXCR3 Hs00171041_m1 
Albumin 5’ TGAAACATACGTTCCCAAAGAGTTT 
3’ CTCTCCTTCTCAGAAAGTGTGCATAT 
Table 2-6 Primer details for PCR, SYBR Green qPCR and TaqMan qPCR.  
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2.8.2 Generation of standards 
The ‘outer’ primers were used to generate PCR products containing the amplicon of 
interest. cDNA from multiple cell lines was tested for expression of the gene of 
interest. Following a standard PCR reaction, the PCR products were electrophoresed 
using 2% agarose gel and visualized using ethidium bromide. The appropriate band 
was excised from the gel using a sharp blade. PCR products were then purified from 
the excised gel fragment using QIAquick Gel-Extraction kit (Qiagen), according to 
manufacturer’s instructions. The standard product was tested for specificity by 
performing a standard PCR reaction using the appropriate inner primers and using the 
purified standard product as template. Successful amplification was confirmed by gel 
electrophoresis. These steps are described below.  
2.8.2.1 PCR to generate standards 
Two microlitre template cDNA and 1 µl diluted primers (1 µM final concentrations) 
were added to a commercially available pre-mixed ReddyMix (Revolab) containing 
buffer, MgCl2, dNTPs and Taq DNA polymerase. PCR reactions were performed on a 
Veriti thermal cycler (Applied Biosystems). The PCR cycling conditions are presented 
in Table 2-7. 
Step Temperature (ºC) Time 
1. 95 3 minutes 
2. 95 15 seconds 
3.  60 20 seconds 
4.  72 40 seconds 
Repeat steps 2-4 for 40 cycles 
5. 72 7 minutes 
6. 4 Indefinitely 
Table 2-7 PCR cycling conditions for generating standards 
 
2.8.2.2 Agarose gel electrophoresis of PCR standards 
PCR products were separated and visualized using agarose gel electrophoresis. 2% 
Agarose gel was prepared in TAE buffer by boiling till the powder completely 
dissolved. Ethidium Bromide was added, and the solution carefully poured into a gel 
cassette with combs inserted. Gel was left to set and then transferred to an 
electrophoresis tank filled with TAE buffer. PCR products were carefully loaded to 
wells along with 100 BP DNA ladder (Biolegend). Electrophoresis was conducted at 
100V for 30 minutes. The gel was transfer the UV gel imager AlphaImager (Alpha 
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Innotech) and visualize under ultraviolet (UV) light. 
2.8.2.3 Gel extraction of PCR standards 
Following gel electrophoresis, gel fragments containing the bands were carefully 
excised using a sterile scalpel and transferred to a new 1.5 ml Eppendorf tube. DNA 
from the gels was extracted using QIAquick gel extraction kit (Qiagen) according to 
manufacturer’s instructions. 
2.8.2.4 Standard verification with PCR 
The PCR product recovered from gel extraction was used as a template for testing the 
inner primers. PCR was performed as described under 2.8.2.1. PCR products were run 
on a gel as described under 2.8.2.2 and visualized for specificity of PCR product. A 
sharp band of expected size with no other bands or primer dimers implied acceptable 
amplification by primers. 
2.8.3 TOPO cloning of vectors 
PCR standards were cloned into TOPO vectors using TOPO TA cloning kit with One 
Shot vector cells (Invitrogen, Paisley, UK). First, the standard PCR products were 
ligated with the TOPO TA vector (1 µl PCR product, 0.25 µl salt solution, 0.25 µl 
TOPO vector) by gentle tapping, and incubating at room temperature for 30 minutes. 
This was followed by transformation of One Shot competent cells. Chemically 
competent E. coli cells were thawed on ice, mixed with ligation product (12 µl cells + 
2µl ligation product) by gentle tapping, and incubated on ice for 5 minutes. The 
mixture was then heat shocked by incubating at 42 ᴼC for 30 seconds and immediately 
transferred onto ice. 250 µl of Super optimal broth (SOC) media was added and the 
tubes were incubated on a shaking incubator for 1 hour at 37 ᴼC. LB agar + amplicillin 
plates were taken and coated with X-gal. 100 µl of transformation product was spread 
on the agar and incubated overnight at 37 ᴼC. For each standard cloned, 4 white 
colonies were then picked using a sterile pipette tip, transferred to 5 ml broth and 
incubated overnight in a shaking incubator at 37 ᴼC. Next morning, cloned vectors 
were purified using QIAprep Spin Miniprep Kit ( Qiagen, Venlo, the Netherlands). 
This purified product was analysed for specificity by determining the sequence of 
product.  
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2.8.4 SYBR Green qPCR 
Following cDNA synthesis, analysis of gene expression was performed by SYBR 
Green qPCR. The assays were performed on Applied Biosystem 7500 HT- or 7900 HT 
real time systems. All assays were performed in triplicates and expression levels were 
normalised to that of the housekeeping gene, TATA box – binding protein (TBP). TBP 
expression was analysed on the same assay plate in triplicates. PerfeCta SYBR green 
supermix (Quanta Biosciences, Gaithersburg, USA) was used for the SYBR green 
qPCR which contains all the enzymes, nucleotide bases, ROX dye and buffers in a 
single tube. Standards were serially diluted and a minimum of 5 dilutions were used to 
form a standard curve. Three no template control (NTC) wells were also analysed to 
test for contamination. 
A Mastermix was created as follows per reaction well: 
Reagent Volume 
2x SYBR green mix  10 µl 
Primer mix  0.3 µl (at a final concentration of 0.8 μM) 
nuclease free water 7.7 µl 
Table 2-8 Calculation for SYBR Green qPCR mastermix 
10% extra was prepared to account for pipetting errors. 18 µl Mastermix was added 
per well in a 96 well plate. 2 µl of sample, standard or nuclease free H2O was added to 
each well and the plate covered with a clear PCR plate sealing film. In case of 386 
well plate, half volumes of the mastermix and samples were used. The plate was then 
centrifuged at 200g for 1 minute to make sure all the contents were placed at the 
bottom.  
The PCR reactions were performed on 7900HT or 7500 Fast Realtime PCR systems. 
The thermal cycling conditions for both the machines are presented in Table 2-9. 
Step Temperature (ºC) Time 
1. 94  3 minutes 
2. 94 5 seconds 
3. 60 15 seconds 
Repeat step 2-3 40 times 
4. Melt/dissociation stage  
Table 2-9 Temperature conditions for SYBRGreen qPCR assay 
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2.8.5 Analysis of SYBR Green qPCR assay 
Following completion of the SYBR qPCR assay, it is crucial to analyse the quality of 
the assay. A number of quality control checks are required to ensure the data from the 
assay are valid. Cycle Threshold (Ct) value is the point at which the fluorescence from 
the sample wells crosses the machine threshold for detection. During a qPCR reaction, 
the SYBR green signal intensity rises exponentially. Therefore, the fewer cycles it 
takes for fluorescence intensity of a given well to cross the threshold, the more target 
cDNA was present in the corresponding sample. 
Correlation coefficient (R2) values represent the quality of the standard curve and 
relates to how accurately the dilution series was prepared. A R2 value of >0.97 was 
considered acceptable. The standard curve slope represents the amplification 
efficiency of the primers and the optimal value of -3.3 means doubling of the DNA 
with each 3.3 thermal cycles. Generally, values <-3.3 imply inefficient primers and 
>3.3 imply presence of PCR inhibitors in the standards. Values between -3.1 and -3.9 
were considered satisfactory. A variation in amplification in the triplicates of >1.5 Ct 
cycles was considered unsatisfactory. There should have been no amplification in the 
NTC wells. However, if an amplification was seen, the Ct values should be >3 Ct 
cycles further away from the sample of interest. Melting curve analysis was performed 
to determine the specificity of amplification. 
2.8.6  Normalization of qPCR data 
In order to allow comparison of gene expression levels between experimental groups, 
it is important to normalize for the variations introduced due to sample processing. A 
number of methods were utilized to control for such potential biases. Wherever 
possible, equal numbers of cells were utilized for extracting RNA. In addition, equal 
concentrations of RNA were used for synthesising cDNA, the same cDNA synthesis 
kit was used in the experimental groups, and subsequently. Following this, equal 
volumes of cDNA were used in qPCR reactions. Housekeeping genes or reference 
genes are required for cell metabolism and are expressed in cells with minimal 
variation in response to the experimental treatment. This implies that the levels of 
housekeeping genes will be unaffected by the experimental condition and any 
observed difference in expression levels of a housekeeping gene will be due to the 
difference in quantity of cDNA. In an initial experiment, a number of housekeeping 
genes were tested with SD1, Sup B15, REH and SEM. In these cell lines, GAPDH and 
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TATA binding protein (TBP) were found to be robust and therefore used for the 
experiments performed in this thesis. 
2.9 Molecular biology: TaqMan qPCR 
2.9.1 TaqMan qPCR for relative gene expression 
TaqMan qPCR system uses a fluorescent probe, specific to the gene of interest, in 
addition to the primers. This adds to the level of specificity of amplification. However, 
these primers and probes are difficult to design and usually purchased as a lyophilized 
mastermix solution. In addition absolute quantification is only possible after 
purchasing the known standards. Generally, TaqMan gene expression assays are 
performed to analyse the relative differences between two groups of cells. TaqMan 
qPCR mastermix solutions containing the primers, probe, enzymes and other reagents 
in a pre-mixed tube were purchased from Life Technologies (Paisley, UK). The 
Mastermix solution was prepared according to the manufacturer’s instructions. 18 µl 
Mastermix solution was aliquoted to each well of a 96 well qPCR plate (Starlab) and 2 
µl cDNA of each sample was added to wells in triplicate. NTC samples were included 
to ensure the quality of the assay. qPCR reaction was performed on Applied 
Biosystems 7900-HT for 40 CT cycles as described (Section 2.8.4). Relative 
quantitation was analysed on RQ manager software (Applied biosystems)  
2.9.2 TaqMan qPCR for Albumin gene 
Quantity of DNA extracted from human CSF samples was measured by qPCR using 
an Albumin gene-specific Taqman assay and a standard curve containing known 
quantities of DNA. Primer design and verification were performed at Glasgow MRD 
laboratory according to the guidelines from European study group (ESG) (van der 
Velden et al., 2007, van der Velden et al., 2003). 
2.9.2.1 Preparation of standard dilution 
DNA was isolated and pooled from mononuclear cells (MNC DNA), purified from the 
blood of 20 healthy individuals. Standards containing known quantities of DNA were 
then prepared as follows. Briefly, stock solution of normal MNC DNA (100 ng/ µl) 
and DNA diluent Salmon sperm DNA (100ng/ µl) was incubated at 37 ºC for 30 
minutes with intermittent vortexing to ensure adequate mixing. First dilution (10:1) 
(10 ng/ µl) was generated by adding 100 µl of MNC DNA to 900 µl of Salmon sperm 
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DNA. The sample was incubated at 37 ºC for 30 minutes with intermittent vortexing. 
Similarly, 5 serial dilutions were prepared and the serial samples stored at -20°C until 
use. 
2.9.2.2 Preparation of qPCR Mastermix for DNA quantification 
qPCR Mastermix was prepared as shown in Table 2-10. 20 µl of mastermix was added 
to each well of a 96 well qPCR plate along with 5 µl of sample or standard DNA 
template. In some cases, due to limited DNA availability, 15 µl of reaction volume 
was used. Nuclease free water was added to the appropriate wells as a negative 
control.  
Reagent Concentration Volume Added (µl) Final Concentration 
Real-time master mix 2x 12.5µl 1x 
Alb Forward primer 10µM 2.25µl 0.9µM 
Alb Reverse primer 10µM 2.25µl 0.9µM 
Alb Probe 5µM 0.5µl 0.1µM 
BSA 2 % (w/v) 0.5µl 0.04% (w/v) 
RNAse free water - 2 - 
Template 50 – 200ng/µl 5µl/PCR reaction - 
Table 2-10 Calculation of TaqMan qPCR mastermix for Albumin gene 
2.9.2.3 TaqMan qPCR assay for Albumin gene 
PCR conditions were as described in Table 2-11. 
Step Temperature (ºC) Time  
1 50 2 minutes 
2 95 15 minutes 
3 95 15 seconds 
4 60 1 minutes 
Repeat 2-4 for 40 cycles 
5 4 Indefinitely 
Table 2-11 Temperature conditions for TaqMan qPCR assay for Albumin gene 
 
2.9.2.4 Analysis of TaqMan qPCR assay 
All quality control checks were performed as described in section 2.8.5. 
2.10 Cytology methods 
2.10.1 Cytospin preparation 
Cells were counted, washed and resuspended at a concentration of 0.5 x 106 cells/ml in 
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PE buffer. Glass slides (VWR Internation, Radnor, USA) were labelled and inserted 
into a metal slide holder, followed by a cytospin filter and a cuvette. 200µl of cell 
suspension was added to the cuvette and placed in the cytospin centrifuge. It was 
centrifuged at 800 rpm for 5 minutes. The slide was carefully removed from the metal 
slide holder and left to air dry. Slides were fixed in 100% methanol for 20 minutes and 
air dried overnight before staining.  
2.10.2 Blood smear preparation 
Blood smears were prepared by placing a 4mm diameter spot of blood about 5 mm 
from the end of a glass slide. Another slide (spreader) was placed at 45 degree and 
backed into the blood spot spreading the blood by capillary action. The spreader slide 
was pushed smoothly towards the other end of the sample slide yielding a smear. The 
slide was air dried, fixed in 100% methanol and air dried overnight before staining.  
2.10.3 Giemsa staining 
Blood smear/ cytospin slides were immersed in diluted Giemsa stain (1:20 in ddH2O) 
for 20 minutes, rinsed in tap water and then air dried for examination.  
2.10.4 Immunofluorescence staining 
Cytospin slides were prepared and fixed as described in section 2.10.1. 
Immunofluorescence (IF) staining was performed to analyse the expression of CXCR4 
and CXCR7. A circle was drawn around the cells using a hydrophobic wax pen. Cells 
were washed in TBS-Tween (5 minutes x 2) and then blocked with 20% horse serum 
in TBS-Tween for 30 minutes at room temperature. Blocking serum was tapped off 
and 2.5-10 µg primary antibodies, or relevant isotype control antibodies, diluted in 
antibody diluent (2.5% normal human serum, 2.5 % horse serum in TBS-Tween) were 
added to the fixed cells. The slides were carefully transferred to a covered humidified 
box and incubated at 4 ᴼC overnight. The slides were then washed in TBS-Tween (5 
minutes x 2) and secondary antibody added at 1/300 dilution in antibody diluent for 30 
minutes at room temperature protected from light. Cells were washed in TBST (5 
minutes x 2). Slides were mounted in 4',6-diamidino-2-phenylindole (DAPI), covered 
with cover slips and sealed with nail varnish. Slides were visualized under fluorescent 
microscope.  
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2.11 Histology methods 
2.11.1 Tissue fixation, embedding and cutting 
Murine tissue (liver, spleen, kidneys, ovaries and testes) was weighed and fixed in 4% 
PFA solution for 24 hours. Organs were then put into tissue processing cassettes and 
processed in automated tissue processor Thermo Shandon Citadel 1000. The sections 
were gradually dehydrated by treating with 70% ethanol (1hour), 90% ethanol (1 
hour), 95% ethanol (1hour), 100% ethanol (5.5 hours) and then treated with Xylene 
(3.5 hours) and liquid paraffin (9 hours). Tissue sections were then embedded in tissue 
cassettes on Shandon Histocentre 3. Five micrometer thick slices of tissue were cut on 
a microtome and transferred on a labelled glass slide. The glass slide was placed on a 
hot plate to evaporate excess water transferred from water bath. 
2.11.2 Haemotoxylin and Eosin staining 
Fixed tissue sections, processed as described above, were rehydrated by serially 
treating with xylene, 96% ethanol, 70% ethanol and water. The tissue was then 
immersed in Haemotoxylin, rinsed with water and treated with 1% acid alcohol and 
then Scott’s tap water substitute (STWS). Slides were then immersed in eosin and 
rinsed again. Sections were then dehydrated by serially treating with 70% ethanol, 
absolute ethanol and xylene. Finally, these were mounted with DPX and covered with 
coverslips.  
2.11.3 Immunohistochemistry 
Formalin fixed paraffin embedded tissues were stained using an anti-human CD45 
antibody (DAKO). The sections were first dewaxed, after treatment with xylene (10 
minutes x 2), and gradually rehydrated by treating the sections with 100% ethanol (5 
minutes x2), 90% ethanol (5minutes x2) and 70% ethanol (5 minutes). The cells were 
then washed with PBS-Tween (5 minutes) and treated with H2O2 for 30 minutes to 
block endogenous peroxidase. Cells were again washed twice in PBS-Tween (5 
minutes). Antigen retrieval was carried out using Citrate buffer. The Citrate buffer was 
boiled in a plastic container in a microwave oven. The slides were submerged 
completely and boiled in the microwave for 6 minutes. The container was left to cool 
at room temperature for 30 minutes before removing the slides. The slides were then 
washed in running water (5 minutes) and PBS-Tween (5 minutes). A wax ring was 
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drawn around the tissue using a wax pen, after carefully drying the glass with a tissue. 
The sections were blocked using serum block (20% normal horse serum in PBS-
Tween) for 30 minutes. The sections were washed briefly in PBS-Tween, and primary 
anti-human anti-CD45 (2.5-10 µg/ml) (Dako) was added to the sections. The slides 
were kept in a humidified contained at 4°C overnight. The slides were then brought to 
room temperature and washed twice in PBS-Tween (5 minutes). A biotinylated 
secondary antibody was added and incubated for 30 minutes at room temperature. This 
was followed by 2 x PBS-Tween washes (5minutes). Sections were then incubated in 
ABC solution (Vector) as per manufacturer’s instructions. Sections were again washed 
twice in PBST (5 minutes). DAB was prepared as per manufacturer’s instructions and 
applied sections for 1 minute. The DAB reaction was stopped by immersing the slides 
in tap water. The sections were counterstained with Haemotoxylin and then gradually 
dehydrated by incubating in 70% ethanol (2 minutes x 2), 90% ethanol (2 minutes x 
2), 100% ethanol (2 minutes x 2), and then xylene (2 minutes x 3). The sections were 
mounted with DPX and covered with coverslip.  
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2.12 Molecular biology: Protein 
2.12.1 Western blotting 
Western blot assays were performed for detection of cellular signalling molecules. A 
list of the antibodies and reagents used is presented in Table 2-12. 
Antibody Cat.no Manufacturer Dilution 
p38 MAPK Antibody 9212S Cell signalling/NEB 1:1000 
Phospho-p38 MAPK (Thr180/Tyr182) (3D7) 
Rabbit mAb 
9215S Cell signalling/NEB 1:1000 
p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb 
#4695  
4056S Cell signalling/NEB 1:1000 
Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (197G2) Rabbit mAb 
4377 Cell signalling/NEB 1:1000 
Phospho-CrkL (Tyr 207)  3181 Cell signalling/NEB 1:1000 
Phospho-Akt (Thr308) (244F9) Rabbit mAb 4056 Cell signalling/NEB 1:1000 
Akt (pan) (11E7) Rabbit mAb 4685 Cell signalling/NEB 1:1000 
Anti-rabbit IgG, HRP-linked Antibody 7074 Cell signalling/NEB 1:10,000 
Reagents and equipment Cat.no Manufacturer 
RIPA buffer (150 nM NaCl, 1 % IGEPAL, 
0.5% sodium deoxycholate, 0.1% SDS, 50nM 
Tris, pH 8.0) 
R0278 Sigma-Aldrich 
NuPAGE® MES SDS Running Buffer 
(20X) 
NP0002 Novex/Life technologies 
NuPAGE® MOPS SDS Running Buffer 
(20X) 
NP0001 Novex/Life technologies 
NuPAGE® LDS Sample Buffer (4X) NP0007 Novex/Life technologies 
NuPAGE® Novex® 4-12% Bis-Tris Gels, 
1.0 mm, 12 well 
NP0322BO
X 
Novex/Life technologies 
iBlot® Gel Transfer Device IB1001UK Invitrogen/life technologies 
Albumin from bovine serum A9418-50G Sigma-Aldrich 
Kodak Carestream Medical X-ray film 814 3059 Kodak 
Novex Sharp protein standard R028-50ml Sigma-Aldrich 
Table 2-12 Antibodies and reagents for western blotting 
 
2.12.1.1 Isolation of protein from cells 
Proteins were extracted from suspension or adherent cells. Cells were counted and 
between 1 x 106 – 1 x 107 cells were used to create lysates. Suspended cells were 
washed twice in PBS and pelleted by centrifugation. Adherent cell cultures were 
washed in the flask twice and then trypsinised, scraped and washed again. 
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Subsequently, cells were pelleted and lysed in 100-200 µl of lysis buffer (RIPA buffer, 
1% Protease and Phosphatase inhibitor cocktail) by through vortexing. Lysate was 
incubated on ice for 10 minutes to complete lysis and vortexed again. Lysates were 
cleared of debris by centrifugation at 8000 g x 10 min 4°C. Supernatant containing 
protein were carefully transferred to a new eppendorf tube, mixed well be pipetting 
and stored at -80°C till further use. 
2.12.1.2 Protein quantification 
Bicinconic acid (BCA) assay is widely used to quantify proteins for western blotting 
to ensure equal loading of proteins for electrophoresis. Proteins were quantified using 
BCA assay. Each sample was analysed in duplicate and PBS and lysis buffer were 
used as negative controls. BSA assay standards were created by preparing a bovine 
serum albumin (BSA) solution at 2 mg/ml in PBS. Serial dilutions (1:3) were created 
from 2 mg/ml down to 25 µg/ml to generate 8 standard dilution points. 200 µl of BCA 
assay working reagent (prepared as per manufacturer’s instructions) was added per 
well to a 96 well plate. 25 µl of each sample were added to the wells in duplicate. Well 
contents were mixed well in a plate shaker and incubated at 37°C, 5% CO2 and 
protected from light for 30 minutes. The plate was cooled to room temperature and the 
absorbance at 570 nm was measured on a plate reader. Raw measurements were 
adjusted by subtracting the blank measurements. A standard curve was created using 
standard measurements and sample values were generated extrapolating values from 
standard curves. Data was analysed using Prism (Version 4.0, GraphPad Software, Inc. 
CA, USA). 
2.12.1.3 SDS gel electrophoresis 
Proteins were separated using SDS gel electrophoresis. Protein samples were thawed 
and incubated with 4x LDS sample loading buffer at 70°C for 10 minutes. 
Commercially available Novex 4-12% SDS gel was loaded in an electrophoresis tank. 
The tank was filled with MES running buffer as per manufacturer’s instructions. 20µl 
of sample was carefully loaded to each well using extra-long gel loading tips. Protein 
size marker was added in one well. Electrophoresis was run at 120 volts for 90 
minutes until the protein bands had run approximately 80% length of the gel. After the 
electrophoresis, the gel was removed from its cassette and transferred to the 
Polyvinylidine fluoride (PVDF) membrane using iBlot (Novex) dry protein transfer 
system according to manufacturer’s instructions.  
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2.12.1.4 Estimation of protein loading 
To ensure equal loading using loading control antibody, the blot was stripped off from 
antibody using Western stripping buffer. Blot was washed in TBS-Tween buffer (5 
minutes) and then incubated with Western stripping buffer (15 minutes), washed again 
in TBS-Tween (5 minutes) and stained with loading control antibody. Two types of 
loading control antibodies were used. For example, for a western blot to determine the 
phosphorylation of p44/42 MAPK in CXCL12 stimulated cells, the signal of interest 
Phospho-p44/42 MAPK was determined by Phosph-p44/42 MAPK and the loading 
was determined by total p44/42 MAPK and Histone-H3.  
2.12.1.5 Antibody binding and visualization 
The blot was blocked in block buffer (5% BSA in TBS-Tween) for 1 hour at room 
temperature on a plate shaker. Primary antibody (diluted 1:1000 in block buffer) was 
added and the blot was incubated at 4°C overnight, with gentle continuous agitation, in 
a sealed container to prevent evaporation. The blot was then washed in TBS-Tween (5 
minutes x 6) and HRP linked secondary antibody was added (diluted 1:4000-10,000 in 
block buffer). The blot was incubated with gentle continuous agitation for one hour. 
The blot was then washed in TBST (5 minutes x 6). Binding of the antibody was 
detected by an HRP mediated chemiluminescent reaction using Supersignal West Pico 
substrate solution (Thermofisher). Depending on the protein and antibody, a more 
sensitive chemiluminescent substrate, Supersignal West Femto substrate 
(Thermofisher) solution was used. After incubating the blot in substrate solution for 5 
minutes, the blot was placed between two clear plastic sheets and fixed on an X-ray 
cassette with sellotape. Excess substrate solution was removed using tissue paper. The 
blot was exposed to X-ray film. Blots were optimized to exposure time of 1 minute 
where possible, however, in some cases, different exposure times between 10 seconds- 
10 minutes were used.  
2.12.2 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a widely utilized technique for 
detecting and quantifying proteins. Test antigen is immobilized to the ELISA plate 
surface and then complexed to an enzyme-conjugated antibody. Subsequently, a 
suitable substrate is added which is cleaved by the conjugated enzyme to produce a 
measureable product.  
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Briefly, 96 well microplates (Ebioscience) were coated with capture antibody diluted 
in coating buffer and incubated at 4 ºC overnight to allow complete binding of the 
antibody to the wells. Subsequently, the plate was washed with wash buffer provided 
and then blocked with 200 µl assay diluent for 1 hour. IL-15 stock solution (1000 
ng/ml) was serially diluted 1:2 to generate 7 serial dilutions. Following the incubation, 
all samples and standards (100µl) were transferred to respective wells. The standards 
and samples were run in duplicate. The samples were applied to the wells in two-fold, 
4-fold and 10-fold dilutions, each in duplicates. The plate was sealed and incubated at 
room temperature on a plate shaker for 1 hour at ̴ 500 rpm. Subsequently, the plate was 
washed 5 times before adding 100µl of biotinylated polyclonal antibody to each well 
(binding time?). 100µl of streptavidin-HRP conjugate was then added to each well and 
the plate was sealed and incubated for 30 minutes at room temperature. The plate was 
washed for 7 times in TBS-Tween buffer. Substrate solution was added at volume of 
100ul/ well and the plate was incubated at room temperature for 15 minutes on a plate 
shaker. 50µl of stop solution then added to each well. The optical density was 
measured by an ELISA micro plate spectrophotometer (Multiskan EX, Thermo 
Electron Corporation) at 430 nm and data collected was compiled using Assent 
Version 2.6 Software.  
2.12.3 Luminex multiplex protein detection assay 
Luminex is a multiplex immunoassay designed for simultaneous detection of multiple 
proteins in one plate. In addition, Luminex assays have a lower sample volume 
requirement and a lower protein detection limit in comparison to ELISA. The assay 
principle is similar to that of an ELISA. Capture antibodies directed against the desired 
protein are conjugated to fluorescence magnetic beads with distinct fluorescence 
wavelengths for each antibody. Coupled beads bind to the biomarker of interest. 
Subsequently, a biotinylated detection antibody is added to the samples followed by 
addition of a reporter streptavidin-PE antibody. The antigen-antibody-reporter 
complex is analysed with a fluorescence reader.. In this thesis, Luminex assays were 
performed to determine a number of chemokine ligands in CSF from ALL patients. 
The assay reagents were purchased from Bio-Rad laboratories (Hercules, CA, US)  
Briefly, standards and reagents were prepared according to manufacturer’s 
instructions. Seven standards dilutions were prepared 1:4 with sample diluent 
supplemented with BSA at a final concentration of 0.5%. The samples were diluted 
1:2 with sample diluent. Magnetic beads were reconstituted according to 
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manufacturer’s instructions and 50 µl reconstituted beads were transferred to each 
well. Subsequently, the plate was washed twice with the buffer provided. Standards, 
samples and blanks (50 µl each) were added to the respective wells. All standards and 
samples were analysed in duplicate. The plate was sealed and incubated on a shaking 
incubator, in the dark, for 1 hour at room temperature. Following the incubation, the 
plate was washed 3 times with the buffer provided and then detection antibody mix 
(25 µl) was added to the wells. The plate was incubated for 30 minutes as described 
above. Following the incubation, the plate was washed 3 times and then 50 µl diluted 
Steptavidin-PE (dilution factor) was added to each well. The plate was incubated for 
10 minutes as before and then washed 3 times. Finally, beads were resuspended in 125 
µl assay buffer and analysed on Bio-Plex 100 multiplex plate reader (Bio-Rad). 
Fluorescence values were adjusted by subtracting values in the negative control wells. 
Fluorescence values in standard wells were used to generate standard curves, and 
concentrations of target proteins were calculated by comparing each value to the 
standard curves. Data were analysed using Bio-Plex Manager software v6.1 (Biorad). 
2.13 Statistical analysis 
All data were analysed using Prism software (Version 4.0, GraphPad Software, Inc. 
CA, USA) unless otherwise specified. Normality of data distribution was determined 
by Kolmonogrov test and by visual inspection of values in case of small number of 
data points. The statistical tests used for each experiment are described in the figure 
legends.  
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3 Investigating frequency and patterns of central 
nervous system infiltration in xenograft models 
of acute lymphoblastic leukaemia 
3.1 Introduction and aims 
Central nervous system (CNS) involvement by leukaemia continues to pose diagnostic and 
therapeutic challenges. CNS disease is commonly asymptomatic and is usually diagnosed 
using microscopic examination of the cerebrospinal fluid (CSF). Patients with overt CNS 
involvement at diagnosis (CNS-3) are considered to be at a high risk for developing CNS 
relapse. However, without CNS directed treatment, 50-70% children with CNS-1 develop 
CNS relapse as well (Evans et al., 1970). Even with CNS directed prophylaxis, the number 
of CNS relapses seen are greater in CNS-1 patients compared to CNS-2 or CNS-3 patients 
(te Loo et al., 2006). T-ALL patients are considered to be at a higher risk for CNS relapse. 
However since BCP-ALL is the commonest type of acute lymphoblastic leukaemia (ALL), 
CNS relapses are more frequently seen in this category (Masurekar et al., 2014). Therefore, 
there is a clear need for improvement in the risk stratification for CNS relapse. 
Understanding biological mechanisms underlying CNS infiltration might help in better risk 
stratification and may lead to development of novel therapies.  
Animal models of human disease are widely used in ALL research. However, CNS disease 
has not been extensively studied. Therefore, there is a need for developing a robust and 
reproducible animal model of CNS disease that allows us to investigate critical aspects of 
CNS infiltration in ALL. This chapter begins with a discussion for the rationale of 
selecting the most suitable mouse strain for xenograft experiments, followed by a brief 
analysis of the characteristics of the xenograft. The research questions are presented at the 
end of this section. 
Human ALL develops in the bone marrow (or thymus) and disseminates into 
extramedullary organs including the immune specialised CNS. Since leukaemia originates 
from the haematopoietic cells, the human immune system does not recognise them as 
foreign. As a consequence these cells proliferate easily within the nurturing 
microenvironments. Therefore, to dissect mechanisms of cellular dissemination into the 
CNS compartment, a model has to be able to: 
- Allow leukaemic cells to proliferate without external selective pressures. 
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- Recapitulate characteristics of human leukaemic cells. 
- Have competent physical barriers between the circulation and the CNS. 
3.1.1  Selecting an appropriate model 
A variety of animal species has been used to model ALL including mice, rats and zebra 
fish. Mouse models are perhaps the most frequently used in vivo model systems since they 
are easy to maintain and their biology is well understood. Selecting an appropriate mouse 
model that allows leukaemic cells to function physiologically is a key factor for 
investigating disease biology. 
3.1.1.1 Syngenic mouse models 
Syngenic models are usually produced to investigate the role of a particular gene or 
molecular pathway in disease pathogenesis. Transgenic models (induction of a genetic 
event at embryonal stage) are produced by introducing a genetic mutation at the embryonal 
stage. Mosaic models (ex vivo manipulation of HSPCs and re-implantation) offer better 
alternatives to transgenic mouse models in that the genetic abnormality is only present in 
the cells of interest and not seen ubiquitously as in transgenic mice. Syngenic mice models 
are frequently utilized in ALL research. For instance, transgenic mice generated with Bcr-
abl1 have been utilized for analysing tyrosine kinase pathways in leukaemia pathogenesis 
(Voncken et al., 1995). Similarly, the role of NOTCH1 activating mutations in ALL 
pathogenesis is comprehensively studied. The majority of T-ALL  harbour NOTCH1 
activating mutations and consequently many groups have developed different notch1 
transgenic mice with various T- cell abnormalities including T- cell leukaemia (Kindler et 
al., 2008, Kong et al., 2013). The advantage of these models is that the interaction between 
the leukaemic cells, the immune system and the microenvironment is within a single 
species. Despite the benefits offered by these models they are limited by multiple 
abnormalities such as carcinogenesis and variable time to leukaemia development. In 
addition, the murine leukaemias may not accurately represent the diversity of human ALL.  
3.1.1.2 Xenograft mouse models 
Xenograft models in ALL rely upon the principle of proliferation of human leukaemic cells 
in murine hosts, replicating human leukaemia, in a controlled environment. Perhaps the 
most crucial element affecting the experiment is the immune system of the hosts. When 
foreign leukaemic cells are transplanted into mice, the cells are rapidly cleared by the 
host’s immune system. Therefore, the success of xenograft models is based on selecting 
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mice with impaired immune function that is unable to reject the foreign leukaemia cells. 
Immunodeficient host mice are engineered to provide a non-hostile environment enabling 
the transplanted leukaemic cells to continue functioning under physiological conditions. 
Over the past several decades, numerous genetically engineered mouse strains have been 
generated with increasing levels of immunodeficiency. Early attempts at establishing xeno-
transplants used immunodeficient mice carrying the prkdcScid mutation (Cesano et al., 
1991). Mice homozygous for this ‘severe combined immunodeficiency’ (scid) mutation at 
the ‘Protein kinase, DNA activated, catalytic polypeptide’ (prkdc) locus were deficient in 
PRKDC enzyme responsible for V(D)J recombination and therefore lacked functional B- 
and T- cells. PrkdcScid (SCID) mice nevertheless retain their innate immune system such as 
NK cells and may spontaneously generate B- and T cells with ageing (called ‘leakiness’). 
Crossing over of the mice with scid mutation with non-obese diabetic (NOD) mice led to 
the development of a highly immunodeficient mouse strain with deficient B- and T-cells 
(Greiner et al., 1995). Several strains of NOD/SCID mice have been generated since and 
have been widely utilized in leukaemia research. These mice show additional defects in 
NK- and macrophage function. NOD/SCID mice lack the age-related ‘Immunoglobulin 
(Ig) leakiness’. However, graft rejection still poses concerns and irradiation is frequently 
required to overcome this. High rate of engraftment failure have been reported in some 
studies (Diamanti et al., 2012). Targeted mutations at ‘recombination activation gene1’ 
(Rag1) and Rag2 loci lead to a phenotype with defective V(D)J recombination and a 
resultant lack of mature B- and T- cells. Back-crossing of Rag-/- mice (Mombaerts et al., 
1992, Shinkai et al., 1992) with NOD mice (NOD/LtSz-Rag1null) generate extremely 
immunodeficient phenotype and lack the ‘leakiness’ seen in NOD/SCID mice but are still 
relatively poor recipients of human grafts (Shultz et al., 2000). 
NOD/scid/IL2Rγ null (NSG) mice offer the advantage of additional defects in innate 
immunity due to the lack of Interleukin-2 Receptor-γ chain which is a component of 
several cytokine receptors and is essential for NK cell development. Several different 
strains of NSG mice exist which are comparable in their immune deficient status. NSG 
mice engraft primary samples with a much higher success and faster speed of engraftment. 
Samples which are rejected in NOD/SCID mouse strains are frequently engrafted in NSG 
mice (Agliano et al., 2008). NSG mice are currently the most widely used model in ALL 
biology with high rates of engraftment of a wide variety of leukaemic cell lines and 
primary samples (Diamanti et al., 2012, Ito et al., 2002, Agliano et al., 2008). Therefore, 
the extremely immunodeficient NSG mice with consistently superior engraftment rates 
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made these as an appropriated model for studies presented in this thesis. 
3.1.2 Selecting leukaemic samples for xenograft experiments 
Leukaemic cell lines are widely used in ALL research and have the benefit of producing 
well characterised pure leukaemic populations to study disease mechanisms. Furthermore, 
leukaemic cell lines are universally available and can be grown in large numbers and 
rapidly manipulated. Cell lines are suited to investigating effects of individual genes on 
leukaemia biology using gene transfection, silencing or inhibition of signalling. Use of cell 
lines is sometime necessary for ethical issues associated with human samples. 
Published research on CNS disease in ALL is limited to the use of cell lines for xenograft 
experiments (Gunther et al., 1995, Holland et al., 2011, Cavallo et al., 1992). However, 
despite the many advantages offered by cell lines, they are not without limitations. For 
instance, aggressive subtypes of ALL may be considered interesting/challenging to 
investigate and may be chosen for establishing ALL cell lines. For example, 8 out of 10 
ALL cell lines in American Type Culture Collection (ATCC) are derived from T 
lymphoblasts (ATCC, 2014). In addition, aggressive clones within a cell line may be more 
capable of surviving in long-term culture and may overgrow and replace the less 
aggressive clones in a Darwinian fashion. Furthermore, long term culture may induce 
technical artefacts. In an study performed by Drexler and colleagues (2003) up to 15% 
stocks of cells lines from original stocks were found to be cross-contaminated or 
mislabelled. Similar frequencies of mycoplasma infection have been found in stocks of 
cells lines (Drexler and Uphoff, 2002). This is a cause for concern since contaminated cell 
lines may be responsible for inconsistent and sometime contradictory results within 
published research. Therefore, care must be taken in clinical interpretation of data 
generated from xenograft models using cell lines.  
In comparison to cell lines, primary leukemic cells better represent the genotypic and 
phenotypic heterogeneity found in leukaemia. Therefore, for the purpose of confirmation 
of results from the former, primary cells are often used to validate findings obtained from 
cell lines. Primary human ALL cells have poor viability after isolating from the body and 
may take longer to engraft. Nevertheless, for the questions addressed in this chapter it was 
necessary to use primary ALL samples. 
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3.1.3 Other factors influencing xenograft models 
The method of transplantation can also play a key role in engraftment success. The 
Intrafemoral (IF) route of administration increases engraftment efficiency compared to 
intravenous (IV) injection of cells (Mazurier et al., 2003). Cells injected via IV route are 
distributed to various organs and only a fraction reaches the bone marrow niche. In 
addition, IF route of administration more closely mimics the natural history of human 
disease with leukaemia first expanding in the bone marrow and subsequently disseminating 
to the extramedullary tissues. A potential disadvantage of the IF route of administration is 
the risk of selecting leukaemic cells more suited to the bone marrow microenvironment. 
Theoretically, the bone marrow microenvironment may not be suited for the cells destined 
for the CNS microenvironment and coupled with the foreign nature of the murine 
microenvironment, such cells may be at a survival disadvantage. However, to date no 
proven literature exists to shed light on this issue.  
Following removal from the patient bone marrow, ALL samples have limited viability and 
cryopreservation of samples may negatively affect engraftment. When engraftment rates in 
freshly isolated samples were compared with cryopreserved samples, mice were found to 
engraft fresh samples at a higher engraftment success rate, shorter time to engraft and with 
a much smaller transplant dose required (Greystoke et al., 2013). Despite the advantages of 
using fresh samples, cryopreserved samples may be the only practical option in many 
instances due to logistic issues.  
Another crucial step in investigating CNS infiltration would be monitoring the progress of 
leukaemia in mice. Ideally, the xenograft experiments should allow leukaemic cells to 
proliferate and follow a course mimicking the natural history of human disease. If the 
experiments are stopped too early, the biological effects may be missed. On the other hand, 
if the leukaemia is allowed to proliferate for too long, the results may not truly represent 
the natural history of the disease course seen in patients. Therefore, a method of 
monitoring the progress of leukaemia has to be adopted. Monitoring of engraftment in real-
time can be analysed with flow cytometry for markers expressed on human cells such as 
CD45 on blood sampled from tail vein (Cox et al., 2007). Direct bone marrow sampling 
can also be used for monitoring engraftment, however this method is technically 
challenging and potentially traumatic to the bone marrow. Alternatively, progress of 
leukaemia can be monitored by a non-invasive technique using transduction of luciferase 
gene in leukaemic cells before the transfer into mice (Fazzina et al., 2012, Bomken et al., 
2013). This additional step prior to the transplant might risk cell death/selection of clones 
114 
 
 
within leukaemic cells. 
In summary, the development of animal models that can closely recapitulate characteristics 
of leukaemia has been an ongoing effort. Research on CNS engraftment capabilities and 
patterns has produced inconclusive results due to differences in animal models and 
leukaemia types. To investigate biological factors that may affect CNS infiltration, a robust 
and reproducible in vivo model that more closely represents human disease is required. 
Therefore, an aim of this chapter was to develop and characterize a xenograft model of 
extramedullary disease using human primary leukaemic samples from patients with and 
without overt CNS disease. With this and additional xenograft materials obtained from 
collaborators, the key questions addressed in this chapter are: 
1. Do leukaemic cells from patients with CNS-1 disease produce CNS infiltration in 
xenograft mice? 
2. Is CNS disease in xenograft models secondary to bone marrow engraftment? 
3. Do xenograft mice engrafted with small numbers of injected cells demonstrate 
CNS leukaemia? 
4. Do xenograft mice engrafted with immunophenotypically sorted leukaemic 
subpopulations demonstrate CNS leukaemia? 
5. Do cells retrieved from the CNS and bone marrow preferentially home to their 
original site when used in serial transplantation? 
In addition to the above aims, a secondary aim of this chapter included in vivo expansion 
and retrieval of cells from the bone marrow and the CNS to address research questions 
described in chapter 4 and 5. 
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3.2 Development of a xenograft model of extramedullary 
disease 
In this section, I have presented the methods and techniques used to establish an 
informative model of extramedullary infiltration of ALL. The general scheme of xenograft 
experiments is presented in Figure 3-1. 
 
Figure 3-1 Scheme of transplantation experiments 
Mice were injected with primary ALL cells using IV or IF routes and were followed for signs leukaemia by 
inspection, measurement of weights and peripheral blood sampling for circulating blasts. Upon signs of 
engraftment, mice were culled and organs processed for identification and isolation of leukaemic cells. 
3.2.1 Primary leukaemic cells 
Following informed consent, diagnostic bone marrow samples from children with BCP-
ALL were purified by mononuclear cell enrichment using density gradient centrifugation 
(Ficoll-Paque; GE Healthcare, Amersham, UK) and cryopreserved in liquid nitrogen until 
use. Diagnostic bone marrow samples from children with ALL were obtained from the 
Leukaemia & Lymphoma Research (LLR) Childhood Leukaemia Cell Bank.  
3.2.2 Mice 
Due to the severe immunodeficiency, NSG mice are at a particular risk for infections. 
Strict infection control measures and close monitoring is necessary to avoid infection and 
death during the experiment. Therefore, the mice were kept in sterile isolators with 
autoclaved bedding, food and water. To ensure reproducibility of results, for each primary 
sample, at least 3 age and sex matched mice per patient sample. However due to low 
numbers of viable cells in one case (#6294) only two mice were used. Female mice are 
better transplant recipient than male mice (Notta et al., 2010). This effect is mediated by 
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the pro-survival effects of female estrogen hormones on transplant stem cells (Nakada et 
al., 2014). It was therefore decided to use female mice in the experiments wherever 
possible. Mice were transplanted at a median age of 10 weeks (range 6-16 weeks) as IF 
transfer of cells could be difficult in younger mice due to the narrow femoral canal. 
3.2.3 Flow cytometry for identification of leukaemic cells 
For xenograft experiments, it is essential to accurately identify human leukaemic blasts 
within the mouse blood and bone marrow. Although, NSG mice lack mature B- and T 
cells, they possess myeloid cells and haematopoietic precursors. Therefore, it may be 
difficult to discriminate these from leukaemic cells on microscopy. Expression of specific 
antigens on the surface of leukaemic cells allows identification for human cells by flow 
cytometry within mouse background. CD45 (leukocyte common antigen or LCA), CD10 
and CD19 are considered lineage markers. High levels of CD45 are present on all human 
leukocytes and leukaemic cells whereas CD10 and CD19 expression levels together can 
easily identify leukaemic cells by their location as a cluster on flow cytometry dot-plot. 
Mouse cells may show some background fluorescence, however a distinct CD45FITC or 
CD10FITC/CD19PE-Cy7 positive cluster allows identification of human cells. Human specific 
anti-CD45FITC, anti-CD10FITC and anti-CD19PE-Cy7 were utilized. In experiments where it 
was intended to monitor engraftment, antibodies against CD10 and CD19 were used. In 
contrast, experiments where expression levels of additional markers were analysed, anti-
CD45FITC antibodies were used. As example of gating strategy for CD10-CD19 based 
identification of leukaemic cells in murine bone marrow is presented in Figure 3-2. 
 
Figure 3-2 Monitoring for engraftment 
Representative pseudocolour plots of cells from a xenograft bone marrow showing a cluster of human 
CD10FITC /CD19PE-Cy7 positive cells. Arrows represent gating strategy. Forward- and side- scatter were used 
to exclude residual cell fragments and doublets. Dead cells were excluded using the dead cell exclusion dye 
‘viaprobe’. Data were analysed using Flowjo (version 4.0). 
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3.2.4 Determining engraftment at early and late time points 
In the initial phase of the project, an estimation of the expected time required for successful 
engraftment could not be made. Therefore, a pilot experiment to determine the time 
required for engraftment was performed. Leukaemic cells from one patient (#4861) were 
injected into four age and sex matched mice. One pair of mice was culled at an early time 
point (12 weeks post injection) and a late time point (24 weeks) each. Mice organs were 
harvested and assessed for engraftment. Cells were isolated from the bone marrow, spleens 
and spinal cords, and RNA extracted and reverse transcribed to cDNA. Murine heads were 
processed for histology. Upon analysis by flow cytometry, no evidence for bone marrow, 
spleen or CNS engraftment was found in the early-time point mice. Leukaemic growth in 
mice may follow a lag phase preceding exponential growth. In order to analyse if the cells 
had failed to survive the new environment or whether submicroscopic levels were indeed 
present in the bone marrow, a more sensitive method such as PCR could be used (Gunther 
et al., 1995). Therefore, a TaqMan qPCR assay for human specific GAPDH primers was 
performed. Analysis by qPCR showed presence of human transcript in bone marrow 
samples from both mice was found whereas qPCR was negative for samples from the 
CNS. In the mice culled at late time point, flow cytometry revealed heavy engraftment of 
the bone marrow however no CNS infiltration was evident. These mice are included in the 
analysis for CNS engraftment presented in later sections. 
Mouse Id Sex Age Route  Cell dose Duration (weeks) BM engraftment CNS engraftment 
4861-1 F 11 IF 8 x 105 12 PCR only  No 
4861-2 F 10 IV 1 x 106 12 PCR only  No 
4861-3 F 10 IF 4 x 105 24 50%  No 
4861-4 F 11 IV 2 x 105 24 82%  No 
Table 3-1 Analysis of engraftment at early and late time point 
 
3.2.5 Monitoring for engraftment 
The results from experiments presented in section 0 implied that engraftment time in 
primary samples could be longer than observed in cell lines. In addition, leukaemic cells 
might grow exponentially following a lag phase. It was essential to monitor the progress of 
engraftment and to end the experiment at a suitable time point where the burden of 
leukaemia in the mice mimicked human disease course. Leukaemic cells in the bone 
marrow expand in the bone marrow and subsequently extravasate into circulation. 
Leukaemic progress was monitored by periodic blood sampling of the transplanted mice 
and analysis for CD10/CD19 positive cells. Blood samples from tail vein were obtained on 
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a maximum of four occasions. Blood cells were labelled with anti-human 
CD10FITC/CD19PE-Cy7 antibodies following red cell lysis. In addition, the mice were 
monitored for the development of leukaemia by daily inspection for clinical signs of 
leukaemia such as weight loss or hind-limb paralysis. The mice were culled for analysis 
when leukaemic cells were present at 10% of peripheral blood cells or higher. A 
representative graph showing percentage of leukaemic cells in blood along with weight 
measurements is presented in Figure 3-3. For pragmatic reasons, in cases with no 
circulating blasts till week 28 the mice were culled and organs analysed for engraftment.  
 
Figure 3-3 Kinetics of engraftment 
Representative plots for the weight measurement and circulating blasts. Weights were measured on a weekly 
basis. Tail vein blood samples were taken at 12, 18 and 24 weeks and analysed for percentage of circulating 
leukaemic blasts. Percentage = CD10FITC/CD19PE-Cy7 cells/total circulating cells x100) Representative plot 
from one mouse (#5449-2) 
In summary, in the initial phase of this project, BCP-ALL samples from CNS-3 and 
CNS-1 patients were obtained. The initial set of experiments revealed that the progress 
of leukaemia required careful monitoring and that it could be achieved with peripheral 
blood sampling and analysis for human specific CD10 and CD19 antibodies.  
3.2.6 Analysis of bone marrow engraftment upon cull 
During the course of the project, cells from 3 sets of 14 BCP- ALL patients (3 CNS-3 and 
11 CNS-1) were used in a total of 43 NSG mice. Leukaemic samples from three 
cytogenetic subtypes, namely t(12;21), 11q23 (MLL-rearranged) and High Hyperdiploid 
were chosen. The cytogenetic subtypes represent high-risk (11q23), and low-risk (t(12;21) 
and high Hyperdiploid) BCP-ALL categories (Table 3-2). 
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Patent 
id. 
CNS 
status 
Sex Age at 
diagnosis 
(years) 
Cytogenetics WCC 
(x109/l) 
Outcome 
#5094 CNS-3 F 2.1 t(12;21) 84.6 *CCR (6.7 years) 
#4630 CNS-1 F 3.0 t(12;21) 103.6 CCR (7.7 years) 
#4736 CNS-1 F 3.5 t(12;21) 113.3 CCR (7.3 years) 
#5449 CNS-1 F 2.5 t(12;21) 62.2 CCR (6.3 years) 
#5705 CNS-1 F 3.4 t(12;21) 221 CCR (5.7 years) 
#6112 CNS-1 F 3.6 t(12;21) 120 CCR (4.7 years) 
#6240 CNS-3 M 16.6 11q23 800 BM relapse at 8 months, 
died at 8 months 
#4861 CNS-1 F 1.1 11q23 9604 CCR (5.7 years) 
#5655 CNS-1 M 1.2 11q23 153 CCR (5.7 years) 
#5980 CNS-1 M 2.7 11q23 70.9 not available 
#5027 CNS-3 F 1.1 H Hyper 23.3 CCR (6.3 years) 
#5969 CNS-1 F 3.0 H Hyper 24.8 CCR (5.2 years) 
#6037 CNS-1 F 2.9 H Hyper 14.6 CCR (3.9 years) 
#6294 CNS-1 F 1.8 H Hyper 24.5 CCR (4.3 years) 
Table 3-2 Clinical and laboratory features of patients  
For each sample from CNS-3 patient, 4-5 CNS-1 control samples matched for age, sex, WCC and 
cytogenetics were used *CCR= continuous complete remission. H. Hyper = High Hyperdiploid. 
Transplanted mice were followed up for a median follow up time of 22 weeks (range 14-29 
weeks). Upon culling, bone marrows were harvested from the femurs and analysed for 
leukaemia. If leukaemic cells were >2% of the bone marrow population, the mouse was 
considered to have successfully engrafted. During the course of experiments, 3 mice died 
of unexplained causes. In such cases, it was not possible to perform flow cytometry 
analysis for engraftment. Engraftment was assessed using histology on fixed bone marrow 
sections. These mice were included in the analysis. 
Analysis for engraftment revealed that primary cells from 78% (11/14) patients had 
successfully engrafted in at least 1 out of 2-4 NSG mice transplanted. Cells from 6/6 
t(12;21) patients, 3/4 11q23 and 2/4 high hyperdiploid ALL patients demonstrated 
successful engraftment in NSG mice. Overall, 2/3 CNS-3 samples and 9/11 CNS-1 
samples successfully engrafted in NSG mice (Table 3-3). A comparison of engrafted vs 
unengrafted samples reveal no differences between the engraftment success and age, sex 
and clinical outcome (Table 3-3). A tendency of higher engraftment was seen in patients 
with a high WCC at presentation (p=0.051). Samples from 4/8 patients with WCC <100 
engrafted in the bone marrow whereas all seven samples with WCC >100 showed 
successful engraftment. In the cytogenetic subtypes, all t(12;21) samples engrafted 
successfully while high hyperdiploid samples, another less aggressive subtype, revealed 
less efficient engraftment (2/4 samples). One 11q23 sample (#5980) also failed to engraft. 
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This could be due to differences in cell viability of individual samples, or the ability of 
these samples to proliferate in murine microenvironment.  
Variable Category Engraftment + Engraftment -  p-value* 
n=11 n=3  
    n  n    
Age <10 year 10 3 0.588 
>10 years 1 0  
Sex Male 2 1  0.571 
Female 9 2  
WCC WCC <100 4 4 0.051 
WCC >100 7 0 
Cytogenetics High Hyperdiploid 2 2 0.165 
t(12;21) 6 0 
11q23 3 1 
CNS status CNS-1 9 2 0.165 
CNS-3 2 1 
Outcome **CCR 9 4 0.588 
  Relapse 1 0 
Table 3-3 Association of successful engraftment with clinical feature 
*chi square test, ** continuous clinical remission 
Overall, 26/43 (60%) mice demonstrated leukaemia engraftment. A high concordance of 
leukaemia engraftment was observed in replicate mice. At least 2 replicate mice per 
primary sample demonstrated successful engraftment except sample #6294 which 
engrafted in one of the two mice transplanted.  
The rate of engraftment was variable between the replicate mice injected with individual 
patient samples. Some samples exhibited marked similarity of speed of engraftment within 
replicate mice while others revealed more variable time to engraftment – as seen with 
variable standard deviations shown in Table 3-4.  
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Trial 
No 
Route of 
injection 
No of cells 
/mouse 
Duration of 
experiment 
(median) 
No of  
engrafted 
mice 
engraftment 
rate(days mean 
+/- SD 
#5094 IV (x2), IF (x2) 1 x106 17.5 weeks 4/4 109.2 +/- 19.8 
#4630 IV (x1), IF (x2) 1-4 x105 29 weeks 2/3 205.29* 
#4736 IV (x1), IF (x2) 6 x105 24 weeks 2/3 169.5 +/- 40.9 
#5449 IV (x1), IF (x2) 2-4 x106 22 weeks 2/3 144.5 +/- 12.7 
#5705 IF(x3) 1 x106 10 weeks 3/3 71.4 +/- 3.8 
#6112 IF(x3) 1 x106  28 weeks 2/3 167.9 +/- 38.8 
#6240 IF(x3) 8 x105 14 weeks 3/3 99.6* 
#4861 IV (x2), IF (x2) 2-4 x105 12/24 weeks 2/4 156.5* 
#5655 IF(x3) 2.3 x105 17 weeks 3/3 111.6 +/- 10.4 
#5980 IF(x3) 1 x106  26 weeks 0/3 - 
#6294 IF(x3) 5 x105 26 weeks 1/2 182* 
#5027 IF(x3) 1 x106  28 weeks 0/3 - 
#6037 IF(x3) 9 x105 27 weeks 0/3 - 
#5969 IF(x3) 6 x105 28 weeks 2/3 197.8* 
Total    26/43  
Table 3-4 Details of individual xenograft experiments 
Samples are grouped by cytogenetic subtype; Engraftment was determined by FCM analysis of the BM 
samples at the end of experiment. *The mice were culled simultaneously 
3.2.6.1 Engraftment with secondary transplants 
As part of the model validation process, a pilot experiment was performed to determine the 
re-engraftment capabilities of primagraft cells harvested from mice. Primagraft cells from 
patient #4736 were subjected to secondary transplant using two NSG mice and followed up 
for engraftment. Leukaemic cells in both the mice successfully engrafted at 20 and 26 
weeks post-transplant respectively. In general, serial transplant robustly reproduce 
engraftment kinetics. However, in a minority of cases may result in a faster rate of 
engraftment (Lock et al., 2002). This may reflect selection of an aggressive subclone with 
serial transplants. 
In summary, the xenograft experiments show that 78% of BCP-ALL samples from CNS-
1 and CNS-3 patients successfully engrafted in the bone marrow. There was some 
association of the success of engraftment with high WCC (>100 x 109/L) Secondary 
transplant demonstrated successful engraftment. 
3.2.7 Analysis of extramedullary infiltration (excluding the CNS) 
At the time of diagnosis, patients with leukaemia often present with hepatosplenomegaly, 
lymphadenopathy and sometimes with gonadal infiltration. Therefore, at the time of 
harvest, leukaemic infiltration in the spleen, liver, kidneys and gonads was analysed. All 
mice were examined for extramedullary involvement irrespective of bone marrow 
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engraftment to ensure no cases of isolated extramedullary disease were missed. Spleens 
were analysed for engraftment by weight measurements and flow cytometry for human 
CD10/CD19 positive cells, whereas the engraftment in liver, kidneys and gonads was 
assessed using histology. In order to identify patterns of leukaemic infiltration, 
immunohistochemistry for anti-human CD45 was performed in an initial batch of organs. 
Subsequently, as an understanding of the patterns of infiltration developed analysis by 
H&E staining was performed by two observers blinded for identifiers.  The patterns of 
leukaemic infiltration in the organs are briefly described below.  
3.2.7.1 Infiltration in the liver 
Infiltration of the liver was seen in the majority of the engrafted mice. The leukaemic 
infiltration involved the perivascular regions and comprised of small clusters to large 
sheets of small round blue cells, mostly around the blood vessels and portal areas. In most 
cases, liver architecture was preserved. However, in some cases, extreme leukaemic 
infiltration resulted in distortion of liver architecture (Figure 3-4). This was paralleled with 
heavy engraftment in other organs such as the bone marrow and the spleen. 
 
Figure 3-4 Pattern of leukaemic infiltration in the liver 
Representative photomicrographs (H&E and CD45) from formaline fixed paraffin embedded liver sections 
from engrafted mice. Left column shows vascular infiltration by dark purple staining leukaemic cells in 
mouse #6240-1. Middle column shows extensive infiltration of leukaemic cells around the blood vessels and 
small clusters scattered in the parenchyma in mouse 5094-4. Right column depicts anti-human anti-CD45 
staining from mouse #5094-4 showing leukaemic infiltrates. Top row (10x), bottom row (20x). 
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3.2.7.2 Infiltration in the spleen 
In most of the cases with successful engraftment of the bone marrow, leukaemic 
infiltration of spleen was observed, manifesting as enlargement in size. In several mice, 
enlargement of the spleen size was not seen despite heavy bone marrow infiltration. For 
instance, in one case (#5969), 85% bone marrow engraftment was seen with only 3% 
engraftment in the spleen. This reflects that the splenic infiltration may be a secondary 
event after the replacement of the murine bone marrow with leukaemic cells. As can be 
seen in Figure 3-5, a higher correlation of bone marrow engraftment with splenic 
infiltration was seen (r2=0.88). Slightly lower correlation of bone marrow engraftment with 
splenic weights was observed (r2=0.75). 
(a) (b) 
 
Figure 3-5 Correlation of BM engraftment with splenic infiltration 
Percentage of splenic involvement compared to bone marrow engraftment. (a) % splenic engraftment 
compared to BM engraftment. (b) splenic weights compared to BM engraftment. Analysed using linear 
regression analysis. r2=coefficient of correlation 
3.2.7.3 Infiltration in the kidneys 
Renal involvement was seen in the majority of the engrafted mice. The extent and pattern 
of infiltration varied with small clusters of leukaemic cells to large patches of leukaemic 
infiltrates. Leukaemic cells appeared to be clustered between the renal tubules and around 
blood vessels. In a few cases (e.g. #5655), peri-hilar and renal capsular infiltration was also 
seen. The renal tubular system was largely preserved with leukaemic infiltrates mainly in 
the interstitium.  
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Figure 3-6 Pattern of leukaemic infiltration in the kidneys 
Representative photomicrographs (H&E and CD45) from formaline fixed paraffin embedded renal tissue 
sections from engrafted mice. Left column shows pericapsular infiltration by dark purple staining leukaemic 
cells in mouse #5655-2. Middle column shows infiltration of leukaemic cells around the blood vessels 
sparing the renal parenchyma in mouse 5904-2. Right column depicts anti-human anti-CD45 staining from 
mouse #5094-2 showing leukaemic infiltrates. Top row (10x), bottom row (20x). 
3.2.7.4 Infiltration in the gonads 
Testes are conventionally considered sanctuary sites for leukaemia, ovaries on the other 
hand are generally not assessed routinely for leukaemia in girls at diagnosis or relapse. 
Given that the ovaries are counterparts to testes, assessment of ovarian leukaemia could 
provide useful insights into the biology of relapse in girls. Ovarian tissue generally 
contains small round blue cells which could make the analysis of leukaemic infiltration 
very difficult. Therefore, anti-CD45 staining was performed in all the gonads. 
Histological examination of testes from 3 mice transplanted with samples from 2 patients 
(#5655, #4736) showed minimal infiltration of the testes. Leukaemic cells were seen 
scattered between seminiferous tubules sparing the parenchymal tissue. In one case, 
infiltrates were seen in the pericapsular fat around the testes. 
Analysis of ovarian tissue revealed variable leukaemic infiltrate. No isolated ovarian 
infiltration was seen in mice which failed to engraft in the bone marrow. Overall, mice 
from 6 samples showed ovarian infiltration. A differential pattern of infiltration was 
observed in murine ovaries. For instance, mice engrafted with cells from patient #6240 
exhibited diffuse infiltration with effacement of ovarian parenchyma, but no infiltration in 
mice engrafted with #6112 was observed. Such examples of specific tropism in the ovaries 
can be used to further investigate the mechanism ovary specific homing (Figure 3-7). 
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Figure 3-7 Histological sections of gonads showing patterns of leukaemic infiltration 
(a) Photomicrographs of testes sections (Top row H&E, bottom row CD45) from mouse with no testicular 
infiltration (#5969, left) and combined bone marrow and testicular infiltration (#5655, right). (b) Ovarian 
tissue (Top row H&E, bottom row CD45) from mouse with no infiltration (#5112, left) and combined bone 
marrow and ovarian infiltration (#6240, right). Images at 20x magnification, scale bar = 200 µm.  
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3.2.7.5 Extramedullary tumours 
Upon dissection of the engrafted mice, the abdominal and thoracic cavities were inspected 
for gross tumour infiltration. One case (#5655) revealed nodular tumour formation in the 
abdominal cavity. Upon histological examination, diffuse infiltration of the skeletal muscle 
and the wall of the uterus was observed (Figure 3-8). This case represents t(11;23) ALL 
which is a high-risk leukaemia. Uterine wall infiltration was observed in one mouse 
transplanted with cells from (#6240) 
 
Figure 3-8 Histological sections of nodules showing patterns of leukaemic infiltration in 
skeletal muscle and uterus 
Photomicrographs of H&E staining of a representative section from a nodule in an engrafted mouse showing 
leukaemic infiltration in skeletal muscle (left) and murine uterus showing infiltration in the smooth muscle 
wall (right) Top panels x10, bottom panels x20 
In summary, at the end of xenograft experiments, murine samples from liver, spleen, 
testes and ovaries were evaluated for leukaemic infiltration. Leukaemic cells were 
present in the perivascular regions of liver and kidney specimen. Leukaemic infiltration 
in the spleen correlated closely with bone marrow engraftment. There was no evidence 
of isolated extramedullary infiltration in these organs. Solitary nodular deposits of 
leukaemic cells were found in two cases where leukaemic infiltration of uterine and 
skeletal muscle was observed. 
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3.3 Analysis of CNS infiltration 
Quantification of CNS leukaemia can be challenging therefore various methods can be 
used all of which have certain advantages and disadvantages. Histology of whole brain 
with intact skull allows analysis of the leukaemic infiltrate within the various important 
landmarks such as brain parenchyma and the CSF compartment, flow cytometric analysis 
for cells isolated from the brain/spinal meninges identifies small numbers of leukaemic 
cells and finally quantification of leukaemic cells by immunohistochemistry using anti-
CD45 antibodies on histological sections is widely used for assessment of organ 
infiltration. However, preliminary work in the laboratory using leukaemic cell lines 
established that quantification with immunohistochemistry was technically difficult. 
Initially, immunohistochemistry was utilized to identify leukaemic cells in the brain 
parenchyma however, due to the technical difficulties experienced this was superseded by 
histology using the H & E staining method. Murine heads with in situ brain were fixed and 
sliced coronally into 6 slices for analysing various regions of the brain. Two independent 
researchers visualized the brain sections with blinded slide identifiers. 
3.3.1 Comparison of IV vs IF route of transplant 
Route of injection may influence leukaemic infiltration of the CNS. In order to determine 
whether CNS infiltration was determined by the initial seeding of cells via IV route, or was 
more likely a secondary event following bone marrow engraftment, analysis of CNS 
infiltration in mice injected via IV and IF routes was carried out. CNS engraftment was 
seen 4/10 mice injected using IF route and 4/8 mice using IV route. No isolated CNS 
involvement was seen in any IF or IV injected mice (Table 3-5).  
  
128 
 
 
mouse ID Route BM engraftment CNS engraftment 
4861-1 IF PCR only No   
4861-2  IV PCR only No   
4861-3 IF 50% FCM No   
4861-4  IV 82% FCM No - 
5094-1 IV Yes (Histology) Yes   
5094-2 IV Yes (Histology) Yes   
5094-3 IF Yes (Histology) Yes   
5094-4 IF 96% FCM Yes 2 IF, 2 IV 
4630-1 IV 0.5% FCM No   
4630-2 IF 73.3% FCM No   
4630-3 IF 8.1% FCM No  
4736-2 IF 61.1% FCM Yes   
4736-3 IV 22.2% FCM Yes 1 IF, 1 IV 
5449-1 IF 89.1% FCM Yes   
5449-2 IF 96.1% FCM Yes  
5449-3 IV 0% FCM No 1 IF, 1 IV 
6294-1 IV 0% FCM No   
6294-2 IF 8.06% FCM No  - 
Total IF(x10) IV(x8)             4/10 IF, 4/8 IV 
Table 3-5 Comparison of IV vs IF route of transplant. 
Leukaemic samples were injected via IV or IF route. Engraftment in the bone marrow was monitored with 
flow cytometry (FCM). In case #5094, histological examination was used. In case 4861, submicroscopic 
levels of leukaemia were determined using qPCR, however these mice were not considered to have 
engrafted.  
In summary, CNS infiltration was seen in NSG mice injected with 2/2 CNS-3 and 6/9 
CNS-1 samples. Leukaemic cells were observed within the CSF compartment and in the 
components of the BCSFB (choroid plexus and meningeal vein).  Comparison of IF and 
IV routes of injection revealed similar rates of CNS infiltration in engrafted mice. 
Notably, no case of isolated CNS disease was noted with IV injections.  
3.3.2 Frequency of infiltration in the CNS 
To investigate the frequency and distribution of the CNS engraftment, brain sections were 
examined from NSG mice. 2/2 samples engrafted with cells from CNS-3 patients 
demonstrated significant involvement of the CNS in at least one of the transplanted mice. 
Notably, CNS involvement was also observed in mice engrafted with cells from 6/9 CNS-1 
patients. Overall, CNS infiltration was seen in 8/11 primary xenografts (Table 3-4). 
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Trial 
number 
CNS 
status 
mouse ID BM 
engraftment 
CNS 
infiltration 
CNS infiltration/ bone 
marrow engraftment/ 
mice transplanted 
#5094 CNS3 
 
5094-1 Yes Yes   
5094-2 Yes Yes   
5094-3 Yes Yes   
5094-4 Yes Yes 4/4/4 
#4630 
 
CNS1 
 
4630-1 No No   
4630-2 Yes No   
4630-3 Yes No 0/2/3 
#4736 
 
CNS1 4736-1 No No   
4736-2 Yes Yes   
4736-3 Yes Yes 2/2/3 
#5449 
 
CNS1 
 
5449-1 Yes Yes   
5449-2 Yes No   
5449-3 No No 1/2/3 
#5705 
 
 
CNS1 5705-1 Yes Yes   
5705-2 Yes Yes   
5705-3 Yes Yes 3/3/3 
#6112 
 
CNS1 6112-1 Yes No   
6112-2 No No   
6112-3 Yes Yes 1/2/3 
#6240 
 
CNS3 
 
6240-1 Yes Yes   
6240-2 Yes Yes   
6240-3 Yes Yes 3/3/3 
#4861 CNS1 
 
4861-2  No No   
4861-3 Yes No   
4861-1 No No   
4861-4  Yes No 0/2/4 
#5655 CNS1 5655-1 Yes No   
  5655-2 Yes Yes   
  5655-3 Yes Yes 2/3/3 
#5980 CNS1 5980-1 No No   
  5980-2 No No   
  5980-3 No No 0/0/3 
#5027 
 
CNS3 5027-1 No No   
5027-2 No No   
5027-3 No No 0/0/3 
#6294 
 
CNS1 6294-1 No No   
6294-2 Yes No 0/1/2 
#6037 
 
CNS1 
 
6037-1 No No   
6037-2 No No   
6037-3 No No 0/0/3 
#5969 CNS1 5969-1 Yes No   
5969-2 Yes No   
5969-3 No No 0/2/3 
Total 3 CNS3, 
11 CNS1 
   16/26/43 mice 
08/11/14 samples 
Table 3-6 Analysis of CNS infiltration in primary xenografts 
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3.3.3 Pattern of leukaemic infiltration in the CNS 
Histological patterns in majority of cases revealed leukaemic cells as continuous plaques 
within the leptomeninges with frequent involvement of the central sulcus. Leukaemic cells 
were frequently observed within the choroid plexus epithelium and the walls of the central 
meningeal vein (Figure 3.9). Leukaemic infiltrates were also observed in the cerebral 
ventricles. Notably, parenchymal involvement was rarely seen. However, when observed, 
parenchymal infiltration was disproportionately low compared to the extent of 
leptomeningeal plaques. In one sample (#5655), destruction of the cranial bone and direct 
communication with the CNS was also noted. In this case, leukaemic infiltrates were seen 
around the optic nerve and the eye ball. 
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Figure 3.9 Patterns of leukaemic infiltration in the CNS.  
(Top) Schematic diagram of a coronal section of brain showing common areas of leukaemic infiltration. 
Representative H&E sections from CNS of engrafted mice showing leukaemic infiltration (dark purple cells) 
in (a) leptomeninges from 1 CNS-3 and 5 CNS-1 cases, (x40, scale bar 50µm) (b) choroid plexus (black 
arrows) and (x20, scale bar 100 µm) (c) central meningeal vein (black arrows) (x20, scale bar 100 µm) 
showing leukaemic cells in the CNS (red star) and calvarial bone marrow (red arrows).  
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3.3.4 Validation using independent cohort of primary xenografts 
The results presented above demonstrate the leukaemic cells from CNS-1 patients 
commonly infiltrate the CNS of xenografted mice. However, these only represent a small 
number of CNS-1 patients and a larger sample size was required for validation. Following 
a call for surplus brain samples from NSG mice xenografted with primary BCP-ALL 
samples within the childhood leukaemia research community, murine heads were obtained 
from 83 mice transplanted with 23 BCP-ALL samples. These samples belonged to various 
high and low risk cytogenetic subtypes. The majority of samples (16/18) belonged to CNS-
1 category whereas 3 samples were from TLP +ve patients. The sample details are 
presented in Table 3-7. Examination of the murine heads revealed that out of the 4 samples 
which had failed to engraft in the bone marrow (1 mouse each), none of these showed 
isolated CNS engraftment. On the other hand, 19 samples had shown engraftment in at 
least one mouse. Out of these, CNS infiltration was observed in 17 samples. Similar 
patterns of leukaemic infiltration were observed in these models (Figure 3-9). 
 
Figure 3-9 Pattern of CNS infiltration in NSG mice in the independent cohort of samples 
Representative H & E (top) and corresponding CD45 staining (bottom) for mouse brain sections showing 
leukaemic infiltrates in the (a) meninges (x40) (b) choroid plexus (x20) & (c) central sulcus of the brain 
involving meningeal vein (x20). Leukaemic cells in H & E indicated with red stars. Scale bar= 50µm. 
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Sample 
ID 
Age 
(yrs) Sex WCC* 
Cytogenetic 
characteristic 
CNS 
status Outcome** 
CNS 
infiltration/bone 
marrow 
engraftment/no. of 
mice examined 
#L779 5.5 M 28.1 High hyperdiploiod CNS-1 CCR (6.9 years) 5/5/5 
#21819 1 M 76.8 t(7;9)dic(9;20)  CNS-1 Died (4 months, TRM), 1/1/1 
#4540 1.99 M 71 t(9;22) TLP +ve CCR (5.1 years) 2/2/2 
#M120 16.9 M 66.2 t(9;22) TLP -ve Isolated CNS relapse at 7 
months, died at 12 months 2/2/2 
#WB51 15.8 M 290.2 t(9;22) CNS-1 BM relapse at 2 months then CCR 6.7 years 
7/7/7 
 
#HV101 3.3 F 64.4 t(9;22), del 9p  TLP +ve CCR 5.7 years 2/2/3 
#737c 4.7 M 263.7 BCR-ABL1 like CNS-1 
Relapsed at 28 months, 
died at 29 months 12/13/15 
#758b 6 M 97.5 BCR-ABL1 like CNS-1 CCR  (8.5 years) 3/5/6 
#L910 1.8 F 35.8 t(1;19) CNS-1 CCR (2.5 years) 1/1/1 
#BH01 9 M 24.4 t(1;19) CNS-1 CCR (3.7 years) 0/3/3 
#20580 18 F 1.8 t(8;14) CNS-1 CCR (4.5 years) 4/5/6 
#L868 10.6 F 36.1 iAMP21 CNS-1 CCR (3.75 years) 7/7/7 
#L904 13.8 F 5 iAMP21 CNS-1 CCR (2.75 years) 0/2/2 
#L707 16 F 39.1 t(17;19) CNS-1 BM relapse at 5 months, died at 7 months 4/4/4 
#11538 8 M 400 CRLF2 deletion CNS-1 
BM relapse the combined 
CNS and BM relapse. 
Died 
4/4/4 
#20755 4 M 5.9 del(14q) CNS-1 Alive 0/0/1 
#10671 13 M 2 IgH translocation CNS-1 Alive 0/0/1 
#20951 6.8 F 6.8 IgH translocation CNS-1 CCR (5.75 years) 3/3/3 
#20951 5 F 6.8 IgH transloacation CNS-1 Alive 0/0/1 
#L897 16.8 M 85.9 No result CNS-1 CNS relapse at 17 months, then CCR (1.75 years) 4/4/4 
#L920 4.4 F 22.2 No result CNS-1 CCR (2.2 years) 1/1/1 
#19794 NA NA NA NA NA NA 0/0/1 
#813Y NA NA NA NA NA NA 2/3/3 
23 Primary samples                                      64/74/83 mice 
                                     17/19/23 samples 
Table 3-7 Clinical characteristics and CNS engraftment 
Leukaemic cells from 23 primary samples were transplanted into NSG mice using IF route (except #BH01 
cells were injected IV into NOG.Cg-Prkdc-scid Il2rg-tm1Sug/JicTac (NOG) mice)* WCC x109/l, ** 
outcome censored at last follow-up. CCR= Continuous complete remission, TRM= treatment related 
mortality. Contributing researchers with affiliations: Klaus Rehe, Simon Bomken, Paul Sinclair, Katie 
Dormon, Dino Masic, Helen Blair, Lisa Russel, Olaf Heidenreich, Julie Irving, Josef Vormoor, (Northern 
Institute for Cancer Research, Newcastle University), Tracey Perry, Victoria Weston, Pamela Kearns (School 
of Cancer Sciences, University of Birmingham). 
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When the results from the two datasets were combined, 67.5% (25/37) samples across 13 
different cytogenetic subtypes are found to have evidence for CNS involvement. In all 
samples, no case of isolated CNS infiltration was observed. When samples with no bone 
marrow engraftment were excluded from analysis, 83.3% (25/30) samples had evidence of 
CNS infiltration. 79.1% (19/24) samples from CNS-1 patients demonstrated CNS 
infiltration. The most consistent pattern of infiltration was presence of leukaemic plaques 
on the meninges, and less frequently in the ventricles, the choroid plexus and meningeal 
veins. Presence of leukaemia in these components suggests CNS disease to be primarily a 
CSF compartment disease. Taken together, these findings suggest that in majority of 
paediatric BCP-ALL cases, the leukaemic cells are capable of infiltrating the CNS, 
irrespective of the initial CNS status documented by CSF microscopy. Moreover 
pathological features in murine brains closely resemble clinical disease. Therefore, this 
appears to be a reproducible xenograft model provides an attractive resource for 
investigation of molecular mechanisms of CNS disease and pre-clinical studies on primary 
human samples.  
In summary, murine head samples were obtained from research groups working with 
NSG mouse models of BCP-ALL. Histological examination of the CNS in BCP-ALL 
samples from CNS-1 patients across 13 different cytogenetic subtypes confirmed 
frequent CNS involvement, validating the earlier findings. 
3.3.5 Analysis of CNS leukaemia in mice engrafted with limiting 
numbers of leukaemic cells 
Limiting dilution experiments are performed in leukaemia research to investigate the 
frequency of leukaemia-initiating cells in xenograft models. For instance, in AML, not 
every cell is capable of repopulating a murine bone marrow and this property resides 
within a small infrequent population of leukaemia-initiating or leukaemic-stem cells. 
Theoretically, it is possible that CNS-infiltrating capability of leukaemic cells also resides 
within a minor subclonal population of leukaemic blasts (Figure 1-6). If so, transplanting a 
very small number of cells in NSG mice will decrease the likelihood of transfer of such a 
rare CNS infiltrating leukaemic population. As a consequence, mice engrafted with the 
limited cell numbers might not show CNS infiltration.  
In order to investigate whether CNS infiltration was seen in mice engrafted with limiting 
cell numbers CNS sections were examined from mice engrafted with 10, 100, 1000, and 
1500 cells from a cohort of 6 patients (#4540, #M120, #WB51, #HV101, #737c, #758b) 
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(Table 3-7). These mice were transplanted via IF route. The detailed methods and results 
on bone marrow engraftment are published (Rehe et al., 2013). Histological analysis of the 
brain sections revealed CNS involvement in majority of cases. Remarkably, mice engrafted 
with as low as 10 cells exhibited significant CNS infiltration in 5/6 cases. No relationship 
between cell numbers used for transplant and frequency of CNS infiltration was observed 
(Figure 3-10).  
 
Figure 3-10 Frequency of CNS infiltrating leukaemic cells using limiting dilution experiments 
(a) Serial dilution of cells prepared and injected into NSG mice (b) CNS involvement in mice engrafted with 
1500, 1000, 100, 10 cells. Black bars represent the number of mice with CNS engraftment (CNS+). White 
bars represent the number of mice without CNS engraftment (CNS -). Brain samples contributed by Dr Klaus 
Rehe. 
3.3.6 Analysis of CNS leukaemia in mice engrafted with 
immunophenotypically sorted cells 
Leukaemic cells are characterized by aberrant expression of various surface molecules or 
CD-markers normally associated with maturing haematopoietic cells. Leukaemic cells 
expressing these markers mimic the various stages of lymphoid cell maturation. Within a 
leukaemic sample, cells with differential expression of markers associated with ‘immature’ 
and ‘more mature’ precursors can be identified. During normal haematopoiesis, maturing 
progeny of HSPCs are characterized by loss of CD34 expression, and acquire the ability to 
egress from the bone marrow to home to secondary lymphoid organs. It was hypothesised 
that an absence of CD markers associated with immature HSPCs (which normally reside in 
the bone marrow) on a leukaemic subpopulation may be associated with a migratory 
behaviour in this specific subset and mice engrafted with such subset may have increased 
frequency of CNS disease. 
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In order to assess CNS infiltrating capabilities of such subpopulations, murine CNS 
sections engrafted with leukaemic cells (CD19+) from patients sorted into CD34high 
(immature) CD34low (more mature), CD10low (immature), CD10high (more mature) and 
CD20low (immature), CD20high (more mature) populations (Rehe et al., 2013) were 
examined. 
Histological analysis of brain sections revealed CNS infiltration in mice engrafted with all 
immunophenotypic subpopulations. 6/7 mice engrafted with CD34high cells showed CNS 
infiltration while 7/7 mice with CD34low cells showed engraftment. Similarly, 3/4 mice 
with CD20low cells and 5/5 mice with CD20high cells engrafted in the CNS. All the mice 
engrafted with CD10high or CD10low subpopulations revealed CNS infiltration.  
 
Figure 3-11 Frequency of CNS infiltrating leukaemic cells in various immunophenotypic 
subpopulations 
(a) A schematic representation of CD markers associated with normal cell maturation stages. Leukaemic cells 
were sorted using FACS into various immunophenotypic subpopulations and subsequently injected into NSG 
mice via IF route. (b) CNS involvement in mice successfully engrafted with sorted subpopulations. Black 
bars represent the number of mice with CNS engraftment (CNS+). White bars represent the number of mice 
without CNS engraftment (CNS -). Brain samples contributed by Dr Klaus Rehe. 
 
In summary, mice engrafted with very small numbers of leukaemic cells, and FACS-
sorted immunophenotypic subpopulations demonstrated CNS infiltration. These results 
suggest that CNS infiltrating capability is a commonly present at least 1/10 leukaemic 
cells and is not limited to an immunophenotypic subpopulation.  
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3.3.7 Analysing CNS-specific tropism with serial transplants 
It is possible that CNS infiltrating cells belong to an uncharacterised subpopulation not 
determined by the immunophenotype. Theoretically, cells isolated from the CNS would 
represent such a CNS-infiltrating phenotype. If these cells are re-transplanted into another 
generation of mice, higher CNS infiltration would be expected. Studies on breast cancer 
have identified bone and lung metastasizing subpopulations within a cell line. When cells 
were isolated from the organ of metastasis and serially transplanted, enriched populations 
with site-specific tropism were established. Notably, these studies have identified genetic 
and transcriptional differences between the parent and subpopulations (Minn et al., 2005, 
Kang et al., 2003). 
It was hypothesised that by serially transplanting ALL cells isolated from the CNS of 
engrafted mice, an enriched population with CNS-specific tropism could be identified. It 
was also acknowledged that isolating cells from the CNS at an earlier time point would 
increase the likelihood of isolating a more pure population of cells. Therefore, it was 
decided to use ‘luciferase’ expressing REH cell line (REHLuc-GFP) with the ‘in vivo imaging 
system (IVIS)’. In a mouse engrafted with luciferase expressing cells, injecting ‘luciferin’ 
into the mice will result in a chemical reaction detected as bioluminescence on the imaging 
system. A potential disadvantage of using this technology to assess CNS engraftment is 
that the luminescence signals from the calvarial bone marrow and the CNS cannot be 
discriminated. 
First, REHLuc-GFP cells were injected IV into NSG mice and monitored for clinical signs of 
engraftment. The mice were culled upon engraftment and cells from their bone marrow 
(REHBM) and the CNS (REHCNS) were isolated. Subsequently, equal numbers of cells were 
injected into separate NSG mice (secondary transplants). Speed of onset of CNS 
infiltration was monitored using weekly bioluminescence imaging (Figure 3-12). 
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Figure 3-12 Experimental scheme for analysing CNS-specific tropism of REHLuc-GFP cells 
 
Weekly measurements of bioluminescence revealed slightly higher (p-value =0.05) 
luminescence signal from the head in REHCNS mice at day 8. This difference was reduced 
at days 15 and day 21. On day 21, the mice were culled. Examination of the end-point bone 
marrow and the CNS revealed similar engraftment in mice from both groups (Figure 3-13). 
The early CNS engraftment in REHCNS mice suggested that specific entry of blasts into the 
CNS compartment could be an early event. It was therefore decided to investigate early 
time points for the tertiary transplant. Bone marrow and CNS isolated cells from secondary 
transplant mouse were injected into tertiary mice (3 in each group). Unfortunately, 
immediately after the injection, the mice in the CNS group suddenly became morbid and 
the two of the mice died in this group. It was presumed that during the process of 
harvesting leukaemic cells from the CNS, neuronal fibrillar material may have 
contaminated the cell suspension. As a consequence, intravenous injection of this cell 
suspension may have resulted in a compromise in pulmonary circulation causing death. 
The method of leukaemic cell isolation required further optimization. Two methods of 
purification can be applied. CD19- magnetic bead sorting method allows isolation of CD19 
positive leukaemic cells. However, it contains the risk of removal of CD19- negative 
leukaemic cells population. Alternatively, Ficoll based density purification system allows 
non-selective isolation of mononuclear cell population. Given the small number of cells 
retrieved from the CNS, initial attempts at this method resulted in loss of the majority of 
purified cells. Further experiments on serial transplantation from CNS retrieved cells could 
not be performed due to constraints of time. 
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(a) 
 
(b) 
 (c) 
 
Figure 3-13 Analysis of CNS tropism of CNS- and BM-isolated cells using in vivo 
bioluminescence 
(a) Representative serial IVIS images from mice demonstrating increasing leukaemic burden after injection 
with cells harvested from the BM (REHBM) and the CNS (REHCNS). (b) Measurement of bioluminescence 
signals from head plotted as percentage of luminescence from the head/whole body at day 8, 15 and 21 using 
the formula (luminescencehead/luminescencetotal body x100) (c) % bone marrow engraftment at the end of 
experiment measured using flow cytometry. Data represent mean ± SEM and were analysed using two tailed 
unpaired Student t test.                                                                                                                                                                                                                                                                            
In summary, in this pilot experiment, serial transplant of REHLuc-GFP cells from the CNS 
showed a trend toward early site-specific tropism. However, the experiment had to be 
terminated due to sudden death of mice upon tertiary transplant.  
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3.4 Discussion 
In order to assess the CNS engraftment potential of leukaemic cells, xenotransplantation of 
paediatric ALL cells from CNS-3 and CNS-1 patients into NSG mice were carried out. 
Murine heads and organs (liver, kidneys, spleen and gonads) of the transplanted mice were 
examined for the presence of leukaemic cells. The majority of mice transplanted with cells 
from CNS-3 and CNS-1 patients successfully engrafted in the bone marrow and the CNS. 
Analysis of the frequency and pattern of CNS infiltration by primary ALL cells identified a 
number of key points, the most important being that the majority of leukaemic samples 
from ALL patients possess the ability to infiltrate murine CNS irrespective of the CNS 
status of the patient. Further analysis of an independent set of primary xenografts showed a 
similar frequency and pattern of CNS infiltration in CNS-1 and CNS-3 cases. Histological 
examination of the brain sections revealed leukaemic cells in the CSF compartment 
predominantly manifesting as leukaemic plaques in the meninges. Cells were also noted in 
the choroid plexus epithelium and meningeal veins. Although previous reports have shown 
successful engraftment of primary leukaemic cells in immunodeficient mice, and have 
described CNS infiltration using cell lines, this study is the first of its nature to analyse 
CNS engraftment potential of primary leukaemic samples based on the CNS status of 
patients. Further studies identified that CNS-leukaemia initiating cells are present in a high 
proportion in ALL samples, irrespective of the immunophenotype of the leukaemic 
populations. Results from these models indicate that cells from CNS-1 patients indeed 
possess the capabilities to infiltrate the CNS. Very few CNS-3 cases were analysed in this 
study to identify the quantitative differences between CNS engraftment with samples from 
these two categories. 
The majority of primary ALL samples successfully engrafted in severely immunodeficient 
NSG mice. The use of less immunodeficient strains has been shown to result in 
significantly poor engraftment rates (Agliano et al., 2008, Uckun et al., 1998). For 
instance, in a large study conducted by the COG, only 15.3% (104/608) of primary pre-B 
ALL samples were able to engraft SCID mice (Uckun et al., 1998). On the other hand, 
90% engraftment of diagnostic bone marrow samples was seen when a more 
immunodeficient strain (NOG) was used (Kato et al., 2011). These cause considerable 
challenges for in vivo assessment of the relatively low-risk leukaemic subtypes. Therefore, 
NSG mice appear to be more suitable for studies in leukaemia research. 
Analysis of the engraftment patterns demonstrated a number of key findings. Samples from 
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CNS-1 patients engrafted with a similar efficiency compared with CNS-3 cases. A high 
WCC was associated with higher engraftment. These observations are generally consistent 
with the published literature on xenografts using paediatric ALL cases from diagnosis and 
relapse. In the CCG study using paediatric high-risk BCP-ALL samples, successful 
engraftment correlated with a higher age, higher WCC, and clinical risk. Furthermore 
successful engraftment in mice were found to have a significant risk of relapse (Uckun et 
al., 1995). CNS status was not shown to be associated with different engraftment success 
rates (Uckun et al., 1998).  
The xenograft model recapitulated several characteristics of human disease. These 
included retention within the bone marrow, replacement of the normal murine 
haematopoiesis, and dissemination into extramedullary organs. Most of the engrafted mice 
exhibited leukaemic infiltration of the liver and the spleen. This is in keeping with the 
clinical features observed in humans. The majority of ALL children show signs of overt 
leukaemic involvement of the liver and spleen evident by hepatosplenomegaly. The 
histological patterns of liver infiltration are in agreement with reports by other authors, 
both in mice (Kato et al., 2011) and humans (Raghavendra and Naveen, 2006, Vagace and 
Gervasini, 2011). On the other hand, overt gonadal involvement was seen in few cases. 
Clinical reports suggest that leukaemia may be present in the ovarian tissue at the time of 
diagnosis at submicroscopic levels (Greve et al., 2012), and can cause leukaemia in mice 
(Dolmans et al., 2010). While cryopreservation of ovarian tissue for subsequent post-
treatment re-implantation is may be potentially useful for the preservation of gestation, it 
may bear the risk of leukaemic relapse. This study lends support for the cautious use of this 
strategy.  
The analysis of CNS histology has shown that CNS engraftment is detectable 
microscopically in 83% of a variety of diagnostic primary pre-B ALL subtypes. 
Histological analysis provided crucial insights into the patterns of CNS infiltration by 
leukaemia and suggested key mechanisms by which leukaemic cells may gain access to 
this immune-specialized compartment. In all the murine samples with CNS disease, 
leukaemic cells were seen as cohesive plaques on the surface of meninges. This indicates 
that CNS disease is primarily present in the cerebrospinal compartment rather than the 
brain parenchyma itself. Involvement of the choroid plexus suggests that leukaemic cells 
transit across the BCSFB. Involvement of the meningeal vein, located in the CSF 
compartment, was also frequently noted. Leukaemic cells were observed within the wall of 
the vein. However, it is difficult to comment whether meningeal vein involvement was a 
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secondary event with CNS leukaemic cells infiltrating the vein to access the circulation or 
was the other way round. Presence of leukaemic cells within the walls of meningeal 
vessels points to the possibility of direct extension of leukaemic cells across the vessel 
wall. Furthermore, direct extension of leukaemic cells from the calvarial bone marrow 
cannot be excluded. Clinical studies suggest this as a possible gateway for leukaemic cells 
into the CNS (Gunther et al., 1995, Thomas, 1965, Cavallo et al., 1992).  
In an earlier report on a mouse model of CNS disease, using T-ALL cell lines with 
immunodeficient nude mice, CNS infiltration of leukaemic cells was seen as a direct 
extension from the calvarial bone marrow. The authors argue that expansion of leukaemia 
in the bone marrow causes erosion of the cortical bone and a communication with the CSF 
space (Cavallo et al., 1992). In another model using BCP-ALL cell line Nalm6 in SCID 
mice, the authors showed similar findings suggesting direct extension from spinal and 
calvarial marrow with the CNS. However, in these experiments, clinical signs of CNS 
infiltration (e.g. hind-limb paralysis) were used (Gunther et al., 1995). In these studies, 
differences in the immune status of the mice, and the type of leukaemic cells used and 
clinical assessment of progress of CNS disease may have resulted in an aggressive and 
late-stage disease pattern. More recently Holland et al. (2011) documented that BCP-ALL 
cell line SD1 produced invasive disease with infiltration of the CNS parenchyma and optic 
nerve in SCID/beige mice. In the studies presented in this chapter, in mice engrafted with 
sample #5655, not only infiltration of the optic nerve and bulb was seen, also infiltration of 
the skeletal muscle was noted. This might represent a particularly invasive subtype of 
leukaemia. This highlights the fact that ALL is a heterogenous disease and observations 
from cell lines may not be applied to the spectrum of characteristics seen in primary 
samples.   
There was some indication that leukaemic blasts isolated from the CNS preferentially 
home to the CNS when re-transplanted in the mice. This represents a pilot experiment 
using a BCP-ALL cell line and needs further investigation using primary cells and a larger 
sample size. If this line of investigation demonstrates any differences between the CNS 
engraftment potential of bone marrow and CNS engrafting cells, molecular mechanisms 
guiding these differences should be investigated. 
An aim of this chapter was to analyse if CNS engraftment was an intrinsic property of all 
the leukaemic cell population or a property of a subclonal population within the bulk of 
disease. The studies performed indicate that CNS infiltration capability was present in 
mice engrafted with as low as 10 cells. In addition, mice engrafted with sorted cells at 
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various maturation stages also demonstrate CNS infiltration. The fact that leukaemic 
infiltration was identified in a wide variety of leukaemic subsets, clinical phenotypes, and 
low inoculation dose, indicate that CNS engraftment capability is common and not 
restricted to a rare subclone.  
Previous research on CNS disease using xenograft models has been largely limited to ALL 
cell lines and has produced conflicting results. The differences in CNS infiltration 
capability and patterns of CNS infiltration may be due to the residual immune status of the 
mice and the nature of the samples used. The xenograft models presented in this chapter 
indicate that CNS disease using primary BCP-ALL samples mimics human CNS disease. 
However, modelling human disease across species require careful interpretation of results. 
NSG mice lack a competent immune system and therefore do not represent leukaemia in an 
immunocompetent human. The possibility that leukaemic infiltration of the CNS in mice 
may be due to lack of leukaemia-immune system and leukaemia-CNS microenvironment 
interactions cannot be ruled out. In addition, direct monitoring of the progress of leukaemia 
in the CNS could not be performed. Furthermore, analysis of the CNS infiltration is a non-
quantitative method and cannot measure the extent of CNS leukaemia. Nevertheless, the 
consistent observation of CNS leukaemia in the majority of samples engrafted with a 
variety of primary BCP-ALL samples provides evidence that BCP-ALL cells from CNS-1 
patients possess the capability to infiltrate the CNS.  
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4 Investigating leukocyte trafficking molecules in 
association with central nervous system disease 
in acute lymphoblastic leukaemia 
4.1 Introduction and aims 
Leukocyte entry into an extravascular compartment requires a coordinated expression of 
chemokine receptors, selectins and integrins which provide the molecular ‘address code’ 
for tissue specific entry of leukocytes. Chemokine receptors provide tissue selectivity in 
this process. For instance, circulating haematopoietic precursors require CXCR4 to home 
to the bone marrow (Nagasawa et al., 1996) and CCR7 to enter the thymus (Kwan and 
Killeen, 2004, Zlotoff et al., 2010). In similar ways, it is suggested that leukaemic cells 
might disseminate to extramedullary organs by utilisation of such normal physiological 
trafficking mechanisms. Indeed, evidence of a single chemokine receptor-ligand 
interaction being important for site-specific dissemination has been shown in murine 
models of cancer metastasis in melanoma (Murakami et al., 2002) and breast cancer 
(Muller et al., 2001). Furthermore CXCR4 expression in ALL has been linked to 
dissemination to liver (Kato et al., 2011) and spleen (Crazzolara et al., 2001). T-ALL cells 
expressing CCR7 efficiently infiltrate the CNS in comparison with CCR7 negative cell 
lines, suggesting a role for CCR7 in T-lymphoblast entry into the CNS (Buonamici et al., 
2009). However, no such associations have been identified in BCP-ALL. 
It is hypothesised that leukaemic cell entry to the central nervous system (CNS) 
compartment is the result of interactions of a distinct set of leukocyte trafficking molecules 
on leukaemic cells and the CNS vascular components. Such CNS-leukaemia initiating cells 
may represent a minor subclone within the bulk disease. Despite the observation that mice 
engrafted with FACS sorted immunophenotypic subpopulations show CNS leukaemia, a 
peculiar leukaemic phenotype with the ‘CNS address code’ may exists. Identifying these 
mechanisms may be useful as biomarkers for CNS infiltrating capability of leukaemic 
cells.  These can then potentially be used as therapeutic targets.  Identification of such a 
sub-population may provide important clues on the biology of CNS disease. 
 Figure 4.1 illustrates these hypotheses. 
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Figure 4-1: The potential utility for identifying mechanism of CNS entry of leukaemic cells.  
(i) The ability to enter the CNS compartment may reside in the bulk population (left) or a minor sub-clone 
(right) of cells. Leukaemic cells with the specific address code for CNS entry (red) in the BM. (ii) Leukaemic 
cells enter the circulation and come in contact with vessels at the blood-CSF barrier. (iii) Using the leukocyte 
trafficking molecules, cells transit across the blood-CSF barrier to enter the CSF space. The molecules can be 
used as biomarkers for CNS disease potential. (iv) Inhibiting the molecule required for CNS entry. (v) The 
molecules required for CNS entry are inhibited, preventing the cells to enter the CSF space. 
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To examine the role of leukocyte trafficking molecules in determining CNS disease in 
BCP-ALL, leukaemic cells were transplanted into NSG mice. Samples with rapid 
infiltration of the CNS in mice were analysed for expression of candidate leukocyte 
trafficking molecules. In addition, cells retrieved from primary xenografts (primagrafts) 
(chapter 3) were utilized for addressing the research questions presented in this chapter. 
The primary questions addressed in this chapter are: 
- Is there an association between expression of candidate leukocyte trafficking 
molecules and CNS disease in xenograft models of BCP-ALL? 
- Can a CNS-infiltrating phenotype be identified based on expression levels of 
leukocyte trafficking molecules? 
During the course of experiments performed to address the primary aims, an interesting 
phenomenon was observed. BCP-ALL leukaemic cell line SD1 exhibited minimal 
CXCL12 mediated migration despite the presence of surface CXCR4. Given that similar 
phenomenon is seen in maturing lymphoid cells enabling them to enter the circulation, it 
was decided to investigate the nature of migration defect in SD1 cells.  
- Therefore, a secondary aim of this chapter was to investigate the dysfunctional 
CXCR4-CXCL12 axis in SD1 cells. These results are presented in detail under 
section 4.4.  
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4.2 Differential CNS homing and chemokine receptor 
expression in BCP-ALL cell lines 
Paediatric BCP-ALL cell lines SD1, Sup B15 and REH differ in their ability to infiltrate 
the CNS when engrafted in immunodeficient mice. SD1 cells are known to produce CNS 
disease whereas Sup B15 and REH do not show evidence of CNS infiltration in 
SCID/beige mice (Holland et al., 2011). SD1 and Sup B15 carry the BCR-ABL1 
translocation – a cytogenetic risk factor for CNS disease. Given the different CNS 
engraftment potential of these cell lines, they could be a suitable case-control model for 
investigation of CNS disease and were therefore chosen for our studies. In addition, the 
cell line SEM with unknown CNS engrafting potential was utilized. Characteristics of 
leukaemic patients these cell lines were generated from are presented in Table 4-1. 
Cell line Patient 
age Sex 
Presentation 
/relapse Cytogenetics 
Immuno- 
phenotype* References 
SD1 NA F Presentation t(9;22) m-bcr**  CD34+, CD10-, CD19+, Cy79a+ 
Dhut et al. 
(1991) 
Sup B15 9 years M Second 
relapse t(9;22) m-bcr  CD10+, sIg - 
Naumovski et 
al. (1988) 
REH 15 years F Relapse t(12;21) CD34+, CD10
-
, 
CD19+, Cy79a+ 
Alkatib et al. 
(1985) 
SEM 5 years  F Relapse t(4,11) CD34-, CD19+ Greil et al. (1994) 
Table 4-1: Clinical and cytogenetic features of BCP-ALL cell lines 
*Williams et al.(2014) **minor-breakpoint cluster region 
NSG mice were injected with the cell lines via tail vein injections and monitored for the 
signs of CNS infiltration (hind limb paralysis, or other neurological symptoms) or overt 
leukaemia (weight loss, ill health) – upon which the mice were culled. Examination of the 
xenografted mice revealed bone marrow engraftment and distinct patterns of 
extramedullary involvement. Mice injected with Sup B15 cells showed gross ovarian 
infiltration, REH-engrafted mice demonstrated enlargement of the spleen and the liver 
while SD1-engrafted mice revealed enlarged kidneys and relatively smaller spleens in 
comparison with other xenografts. This implies that the organ infiltration is not merely a 
reflection of non-specific invasive behaviour, but is reflective of a more directed migration 
to distinct extramedullary organs. Mice injected with SD1 cells rapidly developed signs of 
CNS infiltration (23.1±1.5 days) and heavy CNS infiltration on histological examination. 
Remarkably, mice engrafted with other cell lines also exhibited signs of CNS leukaemia, 
although the time to hind limb paralysis was significantly delayed. SEM engrafted mice 
developed hind-limb paralysis at a median of 30.5±2.0 days while REH and Sup B15 
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produced CNS disease at 35.5 ± 2.9 and 46.8 ± 5.1 days respectively (Figure 4-2a). CNS 
disease in these mice was confirmed by histological examination of the brains. These 
observations were in contrast to the study reported by Holland et al. (2011). This could 
perhaps be due to differences in animal models. SCID/beige mice used by the researchers 
are relatively poor recipients of human cells (Lepus et al., 2009). The residual immune 
system in the SCID/beige mice might have adversely affected engraftment of REH and 
Sup B15 cells, evident by reduced overall leukaemic burden in Sup B15 injected mice 
(Holland et al., 2011).  
In order to test if the repertoire of candidate leukocyte trafficking genes expressed by the 
cell lines could provide clues to the phenotypic ‘address code’ required for cells to enter 
the CNS, a screening approach using TaqMan low density array (TLDA) technology was 
undertaken. Using TLDA plates, gene expression of 30 selected chemokine receptors, 
selectins and integrins was investigated. As shown in Figure 4-2b, analysis of relative gene 
expression revealed notable differences in the cell lines. SD1 cells demonstrated more than 
50-fold upregulation of CCR3, CCR6, interleukin-15 (IL-15), Integrin-αL (ITGAL) and 
PSGL1. On the other hand CXCR4, CCR4 and Integrin-β1 (ITGB1) transcripts expression 
was significantly down-regulated in SD1 in comparison Sup B15.  
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(a) (b) 
 
  
 
 
Figure 4-2: Time to hind-limb paralysis and expression of leukocyte trafficking molecules. 
(a) SD1, REH, SEM and Sup B15 were injected in NSG mice and monitored for signs of CNS infiltration. 
The mice were culled when symptomatic. Data represent 4-8 mice/cell line and presented as mean ± SEM. 
Data were analysed by two-tailed unpaired student t tests comparing each of the cell line to the other. 
***<0.001, **<0.01, *<0.05. (b) Heat map created from TLDA analysis of mRNA expression of 30 
chemokine receptors, selectins and integrins in SD1, REH, SEM and Sup B15. Three independent cultures 
were analysed per cell line, and all results are expressed relative to the levels in Sup B15 cells, arbitrarily set 
to 1.0.  Contributed by (a) Dr Mark Williams (b) Dr Christina Halsey. 
 
In summary, BCP-ALL cell lines produced CNS infiltration when injected into NSG 
mice. SD1 demonstrate the most rapid onset of CNS disease amongst the cell lines tested 
while Sup B15 exhibited slowest CNS engraftment. Gene expression profiling of 
leukocyte trafficking genes reveal differential expression patterns of the tested genes. 
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4.2.1 Validation of surface expression using flow cytometry 
In order to test if leukocyte trafficking molecules could be detected on the surface of 
leukaemic cells, flow cytometry using directly conjugated antibodies was performed.  
Taking a more focussed approach, a panel of candidate genes that could potentially be 
implicated in cellular transit across the blood-CSF barrier was selected for further 
investigation. This panel included CXCR3 (Sporici and Issekutz, 2010, Fife et al., 2001, 
Balashov et al., 1999), CXCR4 (Crazzolara et al., 2001, Burger and Burkle, 2007, Sipkins 
et al., 2005, McCandless et al., 2006, Juarez et al., 2007, Shen et al., 2001), CCR6 (Serafini 
et al., 2000, Reboldi et al., 2009), CCR7 (Buonamici et al., 2009), CX3CR1 (Marchesi et 
al., 2010) and PSGL1 (Carrithers et al., 2002, Bahbouhi et al., 2009, Kivisakk et al., 2003). 
In order to determine the expression the selected trafficking molecules, cultured cell lines 
were labelled with directly conjugated antibodies and analysed on a flow cytometer. As 
shown in Figure 4-3, flow cytometric analysis revealed differential expression patterns in 
the cell lines. CXCR3 was highly expressed in all cell lines, while CXCR4 expression 
varied. SD1 cells exhibited intermediate CXCR4 expression while Sup B15 and REH 
showed strong expression of CXCR4. A small proportion of CCR6+ SD1 cells were 
observed whereas the other cell lines were negative for surface CCR6. Similarly, low-
intermediate CCR7 levels of expression could only be documented in SD1 with all of the 
other cell lines showing no surface CCR7. Expression of CX3CR1 could not be 
documented in these cell lines by flow cytometry despite detectible mRNA levels by 
qPCR. PSGL1 was highly expressed in SD1 but minimally in other cell lines. Overall, 
CXCR3 and CXCR4 were consistently expressed at high levels on the surface of all the 
cell lines while CCR6, CCR7 and PSGL1 could only be detected on SD1. 
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Figure 4-3: Chemokine receptor and PSGL1 expression in BCP-ALL cell lines 
Flow cytometric analysis of selected chemokine receptors (CXCR3, CXCR4, CCR6, CCR7 and CX3CR1) 
and selectin ligand (PSGL1) in BCP-ALL cell lines SD1, Sup B15, REH and SEM. Isotype control – shaded 
histogram, specific antibody – open histogram. Peripheral blood mononuclear cells (PBMCs) were isolated 
using Ficoll density gradient separation; Monocytes were isolated using anti-CD14 magnetic bead separation 
method. 
In summary, using flow cytometry, surface CXCR3 and CXCR4 were observed in all the 
cell lines, whereas high levels of PSGL1 and low levels of CCR6 and CCR7 expression 
was documented in SD1 only.  
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4.2.2 Functional analysis using chemotaxis assays 
Chemokine receptor-ligand binding results in activation of a number of cellular processes 
resulting in directional migration or chemotaxis. Transwell® chemotaxis assays are used to 
quantify the migratory response of cells towards increasing concentrations of a chemokine. 
Migration index is calculated by normalizing the number of cells migrating to the 
chemokine with the number of cells migrating towards medium alone. Plotting the 
migration indices against chemokine concentrations typically reveals a bell shaped curve, 
with the highest number of cells migrating towards the most physiologically optimum 
concentration of the chemokine. Fewer cells migrate at lower concentrations as the 
chemotactic signals are not strong enough, whereas at higher concentrations the cells lose 
polarity and thus fail to migrate towards the chemokine (Reichman-Fried et al., 2004). 
The potential interactions between chemokine receptors expressed by the cell lines and 
their cognate ligands shown to be expressed on the blood-CSF barrier and/or CNS 
microenvironment were analysed. CXCR3 binds to CXCL9-11, CCR7 binds to CCL19 and 
CCL21 whereas CCR6 binds to CCL20. Studies performed in the laboratory showed no 
significant migration of the cell lines towards CXCR3 ligand CXCL10, CCR7 ligand 
CCL19 or CCR6 ligand CCL20. CXCL12, a potent chemokine, which binds to the 
chemokine receptors CXCR4 and CXCR7 was investigated next. 
4.2.2.1 Determining CXCL12 mediated chemotaxis 
Analysis of CXCL12-mediated chemotaxis demonstrated a differential pattern of 
chemotaxis in the cell lines. As can be seen in Figure 4-4, Sup B15, REH and SEM cells 
exhibited avid chemotaxis with a classic bell-shaped distribution with maximum 
chemotaxis at a concentration of 100 ng/ml. On the contrary, SD1 showed minimal 
chemotaxis to a range of concentrations (1-1000 ng/ml). The migration indices at a 
concentration of 100 ng/ml for SD1, Sup B15, REH and SEM were 1.58±1.37, 46.9±5.05, 
46.8±27.21, & 46.7±24.97 respectively. These results show that BCP-ALL cell lines Sup 
B15, REH and SEM expressing surface CXCR4 can migrate in response to CXCL12. 
However, the significantly poor response by SD1, despite surface expression of CXCR4 
was startling, and required further investigation. These experiments are described in 
section 4.4.  
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Figure 4-4: CXCL12-mediated chemotaxis in BCP-ALL cell lines 
Chemotaxis of (a) SD1, (b) Sup B15, (c) REH and (d) SEM towards increasing concentrations of CXCL12 
(1, 10, 100, 300 and 1000 ng/ml) in a Transwell® transmigration assay. Migration indices were calculated 
using the equation: Number of cells migrating towards CXCL12 (x ng/ml) / Number of cells migrating 
towards media control. x= specific CXCL12 concentration. Data represent mean ± SEM and are 
representative of 1 of 3 independent experiments each performed in triplicate. (e) Bar chart showing 
migration indices of the cell lines at a CXCL12 concentration of 100ng/ml. Data represent mean ± SEM and 
are pooled from 3 independent experiments each performed in triplicate. Data were analysed using two tailed 
unpaired student t tests and present comparison of SD1 with each of the other cell lines. ***p<0.001, 
**p<0.01, *p<0.05 
In summary, Sup B15, REH and SEM demonstrated avid chemotaxis towards the 
CXCR4 ligand CXCL12 whereas SD1 showed minimal chemotaxis despite moderate 
levels of surface CXCR4. 
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4.2.3 CXCL12 mediated chemotaxis in primagraft cells 
Given the interesting association between CXCR4 dysfunction and rapid onset of CNS 
disease in SD1 cells, it was aimed to test whether leukaemic samples which had produced 
CNS disease in mice exhibit a similar CXCR4 dysfunction. Accordingly, single cell 
suspensions were prepared from murine bone marrow/spleens harvested from primary 
xenograft mice from two CNS-3 and six CNS-1 cases. Subsequently, the samples were 
analysed for CXCL12 mediated chemotaxis using the Transwell® assays. Migrating cells 
were quantified by flow cytometry using anti-human CD45 antibodies.  
As shown in Figure 4-5, the majority of samples exhibited profound chemotaxis towards as 
low as 10 ng/ml CXCL12. The majority of the samples exhibited a typical chemotaxis 
pattern with peak chemotaxis at a concentration of 10-100 ng/ml. There was no correlation 
between CNS disease status of the patient and CXCL12 mediated chemotaxis. Variable 
CXCL12 mediated chemotaxis was seen in samples from patients with CNS-3 disease: 
Sample #5094 demonstrated efficient chemotaxis (41.6%) whereas sample #6112 showed 
relatively poor chemotaxis (11%) Similarly, samples from CNS-1 patients demonstrated 
considerable variation. For instance efficient chemotaxis was seen in #6112 and #4630 
(39.9% and 37.8% respectively) but cells from #5449, #5655, #4736 showed less avid 
chemotaxis (6.1%, 8.1% & 8.6% respectively). Similar trend was seen when analysed 
against the murine CNS-engraftment capability of these samples. Chemotaxis in samples 
with a 100% rate of CNS engraftment in mice (#5094, #5705, #6240)  were 41.6%, 19%, 
and 11% respectively, whereas the only sample that failed to infiltrate the CNS in 
xenograft mice showed efficient chemotaxis (i.e. 37.8%). These results lead to the 
conclusion that CNS-engraftment is not associated with the degree of chemotaxis towards 
CXCL12 in leukaemic cells harvested from the bone marrow. 
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(a) 
 
(b) 
 
(C) Patient CNS status 
CNS disease in  
Engrafted mice 
MI % transmigration 
#5094 CNS-3 4/4 526.7 41.6 
#5705 CNS-1 3/3 213.3 19 
#6112 CNS-1 1/2 84.7 39.9 
#4630 CNS-1 0/2 26.7 37.8 
#4736 CNS-1 2/2 265.9 8.6 
#5449 CNS-1 1/2 6.2 6.2 
#6240 CNS-3 3/3 36 11 
#5655 CNS-1 2/3 266.6 8.1 
 
Figure 4-5 CXCL12 mediated chemotaxis in primagraft cells 
(a) Gating strategy to identify human CD10/CD19 positive cells in xenograft BM/spleen cell suspension. 
Main cell population was gated on the forward- and side-scatters, followed by doublet exclusion. 
Subsequently, live cells were identified by Draq-7 viability dye and human leukaemic cells were identified 
by anti-human CD45 staining.  (b) Chemotaxis of primagraft cells towards increasing concentrations of 
CXCL12 (1, 10, 100, 300 and 1000 ng/ml) in transwell transmigration assay. Percentages of migrating cells 
(% transmigration) were calculated using the equation: Number of CD45+ cells migrating towards CXCL12 
(x ng/ml) / Total number of input CD45+ cells on top of transwell inserts x100 where x= specific CXCL12 
concentration. Data are presented as mean ± SEM of triplicate values. (c) Summary of patient characteristics 
and chemotaxis. CNS status refers to the CNS status of patients at diagnosis. CNS1 (CSF white cell 
count<5/µl, no blasts), CNS-3 (CSF white cell count>5/µl) 
In summary, analysis of CXCL12 mediated chemotaxis in primagraft cells reveal 
differential chemotaxis patterns of cells. There appears to be no correlation with CNS 
engraftment capability and CXCL12 mediated chemotaxis in these samples. 
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4.3 Analysing expression levels of selected leukocyte 
trafficking molecules in cells from the CNS and the 
bone marrow 
CNS disease could result from a subset of the leukaemic population – a minor sub-clone. 
Such a subset may escape identification when the whole population from the bone marrow 
is examined. To test whether cells expressing high/low levels of any particular leukocyte 
trafficking molecule were being positively selected in the CNS compartment, cells from 
the bone marrow and CNS were retrieved from mice engrafted with primary samples. 
Subsequently, these paired cell suspensions were assessed for expression levels of selected 
leukocyte trafficking molecules. Bone marrow cells from one primary sample with no CNS 
engraftment were also used for analysis. Cells from the CNS compartment were retrieved 
as described below.  
4.3.1 Retrieval of cells from the CNS compartment 
Following mouse cull, the vertebral columns were transacted at upper cervical and lower 
thoracic regions and removed from the cadaver. Next, using a wide-bored needle fitted to a 
PBS-filled syringe, the spinal cord sections were expelled out of the spinal canal by 
flushing with PBS. The spinal canal was rinsed with PBS to increase the cell yield. Cells 
on the spinal meninges were gently separated by vortexing in PBS at low speed.  
Isolating cells from neural tissue typically results in contamination of cells with myelin 
debris that could interfere with antibody staining. Therefore, attempts were made to 
remove the debris from cell suspension prior to use in flow cytometry. Ficoll density 
gradient separation method and CD19-magnetic bead sorting method were tested. While 
both the methods yielded a purer cell suspension, they resulted in significant decrease in 
cell counts. CD19-magnetic bead sorting method carried an additional risk of losing CD19-
low sub-population of leukaemic cells which could affect the analysis. Therefore, a more 
conservative approach was followed comprising of following steps: gentle vortex of spinal 
cords to minimize debris, passage through a cell strainer to remove larger particles, 
repeated washes of the cell suspension, addition of  Fc- receptor blocking agent to 
minimize non-specific binding of the antibodies, and gating-out of the neuronal debris on 
forward- and side-scatter on the flow cytometer.  
Following retrieval, cells were evaluated for counts and viability using haemocytometer 
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and trypan blue dead cell exclusion. 1 x 106 cells were used/sample where possible, in 
cases with lower yield, the entire cell suspension were used for staining. Cells from the 
bone marrow and the CNS compartment were incubated with directly conjugated CD45, 
CXCR3, CXCR4, CCR6, CCR7, PSGL1 and CX3CR1 antibodies. Appropriate isotype 
control antibodies were used for each bone marrow- and CNS- cell samples to normalize 
for non-specific staining. While analysing on the flow cytometer, acquisition conditions for 
the bone marrow and the CNS samples were kept unchanged.  
4.3.2 Expression of selected leukocyte trafficking molecules on 
primagraft samples retrieved from the bone marrow 
Analysis of leukaemic cells from the bone marrow samples revealed a pattern similar to the 
cell lines. Intermediate-high levels of surface CXCR3 were seen in 7/8 samples, whereas 
moderate-low levels of CXCR4 were observed in all samples. Low levels of CCR6, CCR7 
expression could be detected in 3/8 and 6/8 samples respectively. Differential levels of 
PSGL1 were observed in 6/8 samples. As seen with the cell lines, CX3CR1 surface 
expression could not be detected in primagraft samples (Table 4-2) 
Sample no. CXCR3 CXCR4 CCR6 CCR7 PSGL1 CX3CR1 
#5094 CNS-3 180 225 5 2.3 119 6.7 
#4736 CNS-1 ND 29 ND 52 80 ND 
#5449 CNS-1 264 34.6 9 13.9 ND 4.1 
#5705 CNS-1 197.7 12 44.7 ND ND ND 
#6112 CNS-1 53.1 102.8 16.8 26 11.2 ND 
#5655 CNS-1 1684 90 42 43 137 10 
#6240 CNS-3 941 70 ND 142 15 ND 
#4630 CNS-1 684 319 ND 59 3 ND 
Table 4-2 FCM analysis of primagraft cells for selected trafficking molecules 
Primagraft samples corrected MFI values for the indicated molecules. ND= Not detected. MFI values for 
specific antibody staining not greater than isotype control antibody. 
4.3.3 Comparing bone marrow- and CNS- retrieved leukaemic 
cells for expression of selected leukocyte trafficking 
molecules 
In order to investigate sub-clonal selection for a particular CNS-engrafting phenotype, 7 
paired bone marrow and CNS samples were compared for surface expression of selected 
leukocyte trafficking molecules. Analysis by flow cytometry revealed no evidence of a 
positive selection of any of these trafficking molecules in cells isolated from the CNS 
compartment (Figure 4-6). Although small differences expression levels of CXCR3 and 
CCR7 were noted in individual pairs, it is clear that the CNS infiltrating subset of cells was 
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not enriched for expression of particular molecules. It is also clear that CNS isolated cells 
did not have lower expression levels of CXCR4. Together, these data strongly suggest that 
a CNS homing signature cannot be identified based on expression levels of the selected 
chemokine receptors and PSGL1.  
 
Figure 4-6 Comparison of expression of chemokine receptors and PSGL1 in primagraft cells 
retrieved from the BM and the CNS compartments. 
Cells were retrieved from murine BM and CNS compartments upon engraftment with primary BCP-ALL 
samples. Live human leukaemic cells (Draq7-/CD45+) were analysed for expression of indicated leukocyte 
trafficking molecules using directly conjugated antibodies. Data represent corrected mean fluorescence 
intensity (cMFI) (MFIspecific - MFIisotype) of the leukaemic cells. Differences between CNS and BM expression 
were analysed using two-tailed paired student t tests. Values above horizontal bars represent p values. 
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In summary, these results demonstrate that the cells from the CNS compartment do not 
appear to be significantly different from cell from the bone marrow compartment in the 
expression levels of the selected chemokine receptors and PSGL1. Therefore the CNS 
infiltrating population of cells do not appear to be enriched for phenotype identifiable by 
selected leukocyte trafficking molecule expression. 
Together, these results show that selected chemokine receptors and selectin ligand PSGL1 
are expressed in leukaemic cells in the bone marrow and the CNS compartment. Although 
these trafficking molecules may be required by leukaemic cells for transit across the blood-
CSF barrier, they do not appear to play an instructive role in determining the site-specific 
homing of these BCP-ALL cells in either of these compartments. 
In order to investigate whether any of the leukocyte trafficking molecules are necessary for 
transit across the blood-CSF barrier, it was aimed to perform further experiments by 
inhibiting the surface expression/function and analysing the effect on CNS engraftment. 
CXCR3 and CXCR4 were the most consistently and highly expressed surface receptors 
amongst the analysed trafficking molecules. Given the implicated role of CXCR4-
CXCL12 axis in leukaemic dissemination to the liver and spleen, it could also have a 
similar role in leukaemic dissemination to the CNS compartment. In order to determine 
whether CXCR4-CXCL12 interaction was required by leukaemic cells for CNS 
engraftment, in vivo studies were carried out in the laboratory. NSG mice were injected 
with REHluc-GFP cells and subsequently treated with CXCR4 inhibitor AMD3100 or vehicle 
control. Engraftment was monitored using bioluminescence imaging system.  
At the end of the experiment, bone marrow and extramedullary leukaemic infiltration was 
evaluated. As expected, the analysis of the murine tissue revealed significant reduction of 
leukaemic burden in the bone marrow and other extramedullary tissues in AMD3100 
treated mice compared to the controls. Strikingly, no reduction in the extent of CNS 
leukaemic burden was observed. Heavy CNS engraftment was seen in both AMD3100-
treated and control treated mice, implying that CXCR4 inhibition does not affect CNS 
engraftment. Overall, these data strongly indicate that unlike the bone marrow, liver and 
spleen, CNS engraftment is independent of CXCR4-CXCL12 axis (manuscript submitted). 
Further investigation would be required to determine whether CXCR3, CCR6, CCR7 and 
PSGL1 play a similar non-essential role. 
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(a) 
 
(b) 
  
(c) PBS control            AMD3100 
 
  
(d) 
 
Figure 4-7 Effect of AMD3100 on REH engraftment in NSG mice. 
(a) Bone marrow engraftment in AMD3100 vs PBS control treated mice as measured by numbers of REHGFP-
luc
 cells on flow cytometry. Data show mean ± SEM in n=7 and n=6 mice for PBS and AMD3100 groups 
respectively. (b) Liver engraftment as measured by numbers of human CD45 positive cells in 8 random fields 
of view per section. Data show mean ± SEM in n=4 and n=5 mice for PBS and AMD3100 groups 
respectively. (c) Histological analysis of murine brain sections from xenografts (n=5 mice in each group). 
Representative H&E stained sections showing dark purple leukaemic cells infiltrating the meninges (black 
star). Each brain was divided into 5 segments and sections were cut from each segment, the maximal depth of 
meningeal infiltrates was recorded for each section using Axiovision Rel 4.3 software (Carl Zeiss) and 
presented as mean ± SEM. (d) Peripheral blood smaears taken at the end of the experiment (n-4 mice each 
group) were stained with H&E and the number of blasts per 50 high-powered fields was recorded. Data were 
analysed using two-tailed unpaired Student t tests. *p<0.05, **p<0.01, ***p<0.001. (a-c contributed by Dr 
Mark Williams). 
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4.4 Investigating the dysfunctional CXCR4-CXCL12 axis 
in SD1 cells 
With the observed dysfunctional CXCR4-CXCL12 axis in SD1 cells, it was aimed to 
dissect out the underlying molecular mechanisms responsible. Chemokine ligand-induced 
migration involves a number of critical steps including: ligand binding to the receptor, 
receptor internalization and recycling, induction of downstream signalling and activation 
of cytoskeletal machinery for locomotion. Any abnormality in one of these steps could 
potentially result in abnormal chemotaxis. In addition, other plausible mechanisms in SD1 
could be counter-regulation by other cellular mechanisms such as CXCR4-CXCR7 axis 
and/or BCR-ABL1 tyrosine kinase signalling. Therefore, a reductionist approach was 
utilized to identify the potential causative factor. For some of the experiments the Sup B15 
cell line was used as a comparator as it possesses the same leukaemic translocation but 
shows avid chemotaxis towards CXCR4. The key questions addressed in this section are 
enlisted below: 
- Do SD1 cells have a normal functioning CXCR4 receptor? 
- Is CXCL12-unresponsiveness due to CXCR7 mediated CXCL12 scavenging? 
- Does the presence of the P190BCR/ABL1 affect CXCR4 expression or function? 
- Is the lack of CXCL12 responsiveness due to loss of key chemotaxis-associated 
signalling pathways? 
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4.4.1 Functional assays of CXCR4 
In order to determine if the surface expressed CXCR4 had normal receptor-ligand 
interactions, CXCR4 structure and function was analysed in a step-by-step manner. 
Initially, sequence analysis of CXCR4 exons was performed by Dr Chris Halsey and 
revealed a normal wild-type CXCR4 gene in SD1 cells.  
4.4.1.1 Blocking CXCR4 results in inhibition of chemotaxis 
To evaluate the specificity of CXCR4 in CXCL12 mediated chemotaxis, the CXCR4 small 
molecule inhibitor AMD3100 was utilised. Cells were treated with AMD3100 (10µM) or 
control and chemotaxis towards CXCL12 assessed. Treatment with AMD3100 
significantly reduced CXCL12-mediated transmigration in SD1 and Sup B15 – confirming 
the specificity of CXCR4-CXCL12-mediated migratory response (Figure 4-8). 
 
(a)            SD1 (b)         Sup B15 
 
Figure 4-8: Effect of CXCR4 blockade on CXCL12 mediated chemotaxis 
CXCL12 mediated chemotaxis in (a) SD1 and (b) Sup B15 subsequent to treatment with CXCR4 small 
molecule inhibitor AMD3100 (100 µM) or media control for 1 hour at 37ºC. Migration indices were 
calculated using the equation: Number of cells migrating towards CXCL12 (100 ng/ml) / Number of cells 
migrating towards media control. Data show mean ± SEM and are representative of 1 of 3 independent 
experiments each performed in triplicate. Data analysed using unpaired two-tailed Student t test. ***p<0.001. 
Note the different scale in the two graphs. 
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4.4.1.2 SD1 cells bind alexa-fluor labelled CXCL12 
In order to determine whether CXCR4 had a functional CXCL12 binding domain, the 
binding efficiency of fluorescently labelled CXCL12 (CXCL12AF647) was tested. SD1 and 
Sup B15 cells were incubated with increasing concentration of alexa-fluor (AF647) 
labelled CXCL12 and fluorescence of cell-bound CXCL12 AF647 measured by flow 
cytometry. As can be seen in Figure 4-9, both SD1 and Sup B15 cells bind to CXCL12 
AF647 in a dose dependent manner. Approximately 92% SD1 cells adequately bind to 
CXCL12 at a concentration of 100 ng/ml. In comparison, Sup B15 had a higher CXCL12 
AF647
 binding efficiency and nearly 100% binding was seen at 100 ng/ml.  
 
(a) 
 
(b) 
 
Figure 4-9: Dose-dependent binding of CXCL12AF647 in SD1 and Sup B15 
(a) Representative pseudocolour density plots of live SD1 and Sup B15 cells showing fluorescence in cells 
treated and CXCL12AF647 (1, 10, 100, 200 and 300 ng/ml) (b) Bar charts representing percentage of CXCL12 
AF647 positive cells calculated by gating on control treated cells. Data presented as mean ± SEM and represent 
one experiment performed in triplicates. 
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4.4.1.3 Determining CXCL12 mediated CXCR4 internalization 
Upon ligand binding, chemokine receptors are rapidly internalized (Neel et al., 2005). 
Generally, stimulation of CXCR4 by CXCL12 results in activation of internalisation within 
a few minutes which plateaus within 30 minutes (Venkatesan et al., 2003). The ability of 
ligands to internalise chemokine receptors is used as an indicator for ligand-induced 
receptor activation. In order to test if binding of CXCL12 stimulated equal internalisation 
of the CXCR4 in SD1 and Sup B15 cells, flow cytometric analysis of receptor 
internalisation was performed. SD1 and Sup B15 cells were incubated with CXCL12 for 
30 minutes at 37 ºC to allow maximal ligand binding and internalisation and subsequently 
analysed for surface expressed CXCR4. As shown in Figure 4-10, CXCR4 stimulation 
with 100 ng/ml CXCL12 resulted in efficient internalisation of CXCR4 in Sup B15 (72.5% 
± 6.1) but less so in SD1 (21% ± 13).  
 
(a) 
 
(b) 
 
Figure 4-10 CXCR4 internalisation in response to CXCL12 stimulation: 
(a) FCM analysis of surface CXCR4 in SD1 and Sup B15 following incubation in CXCL12 (100ng/ml) for 
30 minutes at 37 ºC to measure CXCR4 internalisation. Representative histograms showing surface CXCR4 
expression levels in CXCL12-treated (red histogram), control-treated (blue histogram) and isotype control 
staining (black histogram). (b) Bar graph showing CXCL12-mediated CXCR4 internalisation in SD1 and 
Sup B15. CXCR4 MFI values for control-treated cells were adjusted to a 100% and percent receptor 
internalisation calculated as reduction in surface CXCR4 expression. Data shown are pooled from 4 
independent experiments and presented as mean ± SEM. Data were analysed using two-tailed unpaired 
Student t test. *p<0.05 
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4.4.1.4 SD1 cells are capable of restoring surface CXCR4 following 
internalization 
Following ligand-induced internalisation, the pool of surface chemokine receptors are 
rapidly replenished by intracellular machinery by either recycling of the internalised 
receptor, or by transport of stored receptors to the surface. To determine the kinetics of re-
appearance of surface CXCR4 following CXCL12 mediated internalisation, SD1 cells 
were treated with CXCL12 for 30 minutes at 37 ºC and then incubated in fresh culture 
media for 30, 60, 90 and 120 minutes at 37ᴼC. As shown in Figure 4-11, both SD1 and Sup 
B15 exhibited partial restoration of surface CXCR4. Remarkably, CXCR4 on SD1 cells 
had a more efficient (79.3% ± 13.9) restoration compared to Sup B15 (51.9% ± 9.6). This 
shows that despite lower surface expression and internalisation, SD1 cells are capable of 
restoring CXCR4 expression after CXCL12 mediated internalisation. 
 
Figure 4-11: Time-dependent restoration of surface CXCR4 following CXCL12-mediated 
internalization 
Graph showing CXCL12-stimulated internalisation and subsequent restoration of surface CXCR4 after 
removal of CXCL12 from the media. MFI values for untreated cells were taken as 100% and changes in 
surface CXCR4 expression calculated as % receptor expression. Data shown are pooled from 4 independent 
experiments and represent mean ± SEM. Horizontal bar represents treatment with CXCL12 (100ng/ml) 
 
In summary, these experiments show that CXCL12 mediated chemotaxis is CXCR4 
specific in SD1 and Sup B15. SD1 cells are capable of binding CXCL12; however only a 
minor proportion of surface CXCR4 is internalised. Following internalisation, SD1 cells 
are capable of rapidly restoring the pool of surface CXCR4. Together, these data imply 
that along with lower CXCR4 levels compared to Sup B15, a smaller proportion of the 
total CXCR4 on SD1 cells maintain the critical chemokine ligand-receptor interactions. 
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4.4.2 Analysing the effect of CXCR7 on CXCL12 mediated 
chemotaxis 
The initial TLDA analysis revealed higher expression of CXCR7 in SD1. CXCR7 is an 
alternative receptor for CXCL12 with high affinity binding and can alter the CXCR4-
CXCL12 axis in a number of ways (section 1.6.4.1)  One alternative explanation for the 
lack of CXCL12-mediated migration in SD1 is that CXCR7 might be scavenging 
CXCL12, thus limiting the availability of CXCL12 to bind with and stimulate CXCR4. In 
order to test this hypothesis, first, CXCR7 mRNA expression was confirmed using qPCR. 
Next, protein expression was confirmed using immunofluorescence staining and 
chemokine competition assays. Finally, the effect of blockade of CXCR7 on CXCL12-
mediated chemotaxis was evaluated. 
4.4.2.1 Determining CXCR7 mRNA levels in SD1 cells 
In order to validate the TLDA results, SYBR green qPCR was utilised to compare the 
CXCR7 mRNA expression in SD1 and Sup B15. Analysis of the qPCR results revealed 
significantly higher expression of CXCR7 in SD1 compared to Sup B15 (p<0.001) (Figure 
4-12).  
 
Figure 4-12: Comparison between CXCR7 mRNA in SD1 and Sup B15 
SYBR Green qPCR analysis of CXCR7 transcript in SD1 and Sup B15 normalised to TBP as housekeeping 
gene. Data are pooled from 3 independently grown cultures analysed in triplicate and presented as mean ± 
SEM. Data were analysed using two-tailed unpaired Student t test. **p<0.01 
4.4.2.2 Determining CXCR7 protein expression on SD1 cells 
In order to confirm the higher expression levels of CXCR7 on SD1, it was decided to 
examine CXCR7 expression using immunofluorescence staining. This method allows 
qualitative assessment of both surface and intracellular proteins. Cytospin preparations of 
SD1 and Sup B15 cells were labelled with mouse anti-human CXCR7 antibody (11G8). A 
fluorescently-conjugated secondary antibody (goat anti-mouse IgG conjugated to TRITC) 
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was used to visualize CXCR7. (Figure 4-13) Fluorescent microscopic examination 
revealed scattered expression in a small proportion of SD1 cells. Sup B15 only showed 
minimal staining.  
(a) 
 
  
(b) 
 
Figure 4-13: CXCR7 protein expression in SD1 & Sup B15 
CXCR7 staining in fixed and permeabilised (a) SD1 and (b) Sup B15 cytospin slides. Mouse anti-human 
CXCR7 antibody and Mouse anti-human IgG1 isotype control antibodies (Inset) were used at 10 µg/ml and 
visualized using TRITC labelled goat anti-mouse IgG1. Nuclei were visualised using DAPI. Scale bar = 
20µm. Images are representative of 2 independently performed staining experiments. 
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4.4.2.3 Determining CXCR4 & CXCR7 co-expression on SD1 cells 
CXCR4/CXCR7 co-staining with CXCR4 confirmed higher levels of surface CXCR4 in 
Sup B15 whereas intermediate levels were also noted in SD1 (Figure 4-14 a & b). CXCR7 
was frequently observed in CXCR4 expressing SD1 cells. Rarely, co-localization of 
CXCR4 and CXCR7 was observed. (Figure 4-14c) 
(a) 
 
(b) 
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(c) 
 
Figure 4-14: CXCR7/CXCR4 co-expression in SD1 and Sup B15 
CXCR4/CXCR7 co-staining in fixed and permeabilised cytospin slides in (a & b) SD1 and (c) Sup B15. 
Mouse anti-human CXCR7 antibody and Mouse anti-human IgG1 isotype control were used at 10 µg/ml and 
visualised using TRITC labelled goat anti-mouse IgG1. Mouse anti-human CXCR4 antibody and isotype 
control were used at 2.5 µg/ml and visualised using FITC-labelled mouse anti-human IgG2b. Nuclei were 
visualized using DAPI. Top panel represent individual channel colours and bottom panels show merged 
images. Scale bar = 20µm. Images represent staining at 3 different occasions using independently grown 
cultures. 
4.4.2.4 CXCR7 competitively inhibits CXCL12 binding to CXCR4 
In order to determine the degree of CXCL12 binding to CXCR7, competitive binding 
assays were performed. CXCR7 binds to chemokine ligands CXCL12 and CXCL11. When 
CXCL12 AF647 is added to cells co-expressing CXCR4 and CXCR7, both the receptors bind 
CXCL12 AF647. Subsequently, unlabelled CXCL11 is added in high concentration which 
displaces the CXCR7-bound CXCL12AF647. This displacement is quantified by measuring 
reduction in fluorescence. SD1 and Sup B15 cells were loaded with CXCL12AF647 (100 
nM) with or without an excess of unlabelled CXCL11 (1 µM) at 4ºC and subsequently 
analysed for fluorescence by flow cytometry. As can be seen in Figure 4-15, adding excess 
unlabelled CXCL11 resulted in significant reduction in cell-bound CXCL12 AF647 in SD1 
(33.3% ± 10.2) but not in Sup B15 (3.7% ± 3.1) (p<0.05). These results indicate that SD1 
cells also bind CXCL12 via CXCR7 whereas Sup B15 cells almost exclusively bind 
CXCL12 via CXCR4. 
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(a) 
                 SD1                     Sup B15 
 
 
(b)
 
Figure 4-15: CXCL12-CXCL11 competition assay 
(a) Representative histograms showing CXCL11-mediated reduction in binding of CXCL12AF647 in SD1 and 
Sup B15. The blue histograms show CXCL12AF647 (100 ng/ml) fluorescence, the red histograms show 
CXCL12AF647 fluorescence in presence of excess CXCL11 (1µg/ml), the black histograms (isotype control) 
show the background fluorescence. (b) Corrected MFI values for CXCL12AF647 staining ± CXCL11 (1 µg/ml) 
in SD1 and Sup B15. Data are pooled from 4 independent experiments and presented as mean ± SEM. Data 
were analysed using two-tailed unpaired Student t test. *p<0.05 
4.4.3 Analysing the effect of CXCR7 blockade on CXCL12 
mediated chemotaxis 
In order to examine whether CXCL12 binding to CXCR7 could affect CXCL12 mediated 
chemotaxis, CXCR7- small molecule inhibitors (CCX771 & CCX 754) (Chemocentryx) 
were utilized to block CXCR7 binding domains. SD1 cells were incubated with increasing 
concentrations of CCX771/CCX754 or isotype control antibody and subsequently tested 
for CXCL12-mediated chemotaxis. As can be seen in (Figure 4-16), inhibition of CXCR7 
did not improve CXCL12-mediated migration in SD1. In fact, a reduction in migration 
index was seen with increasing concentrations of the blockers.  
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(a) 
 
(b) 
 
Figure 4-16: Effect of CXCR7 blockade on CXCL12-mediated chemotaxis in SD1. 
(a) CXCL12-mediated migration of SD1 cells following treatment with CCX771 (0.1 µM, 1 µM or 10 µM) 
or isotype control (CCX704 1 µM) for 1 hour at 37ºC. Data are pooled from 3 independent experiments each 
performed in duplicate wells and represent mean ± SEM. (b) CXCL12-mediated migration of SD1 cells 
following treatment with CCX754 (0.1 µM, 1 µM or 10 µM)  or isotype control (CCX704 1 µM). Data from 
one experiment performed and represent mean ± SEM of individual wells.   
In summary, these results show that CXCR7 mRNA is highly expressed on SD1 cells. 
CXCL12 binds CXCR7 on SD1 surface, however, no restoration of CXCL12-mediated 
migration is noted when CXCR7 inhibitors are used; making this unlikely to be the 
reason for the decreased CXCL12 mediated chemotaxis in SD1 cells. 
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4.4.4 Does inhibiting BCR/ABL tyrosine kinase restore CXCL12 
mediated chemotaxis? 
As detailed in section 1.6.8, P210BCR-ABL1 tyrosine kinase is associated with down-
regulation of CXCR4 mRNA, surface expression and downstream signalling. SD1 and Sup 
B15 cell lines both express the P190BCR-ABL1 protein. It was hypothesised that P190BCR-ABL1 
fusion protein could interfere with CXCR4 expression and/or CXCL12-mediated 
chemotaxis in SD1 cells. Given that both the cell lines carry BCR-ABL1 translocation but 
migration defect is only seen in SD1, it was decided to compare the BCR-ABL1 levels and 
activity in these cell lines. If BCR-ABL1 levels were found to be similar in SD1 and Sup 
B15, counter-regulation of BCR-ABL1 with CXCR4-CXCL12 axis would be less likely. 
To test this hypothesis, first, BCR-ABL1 expression was determined in SD1 and Sup B15 
cells. Next, the effect of BCR-ABL1 inhibition on CXCR4 levels and CXCL12-mediated 
chemotaxis was determined. 
4.4.4.1 Determination of relative expression of BCR-ABL1 mRNA and protein 
in SD1 and Sup B15 
To quantify the BCR/ABL1 transcript levels, TaqMan qPCR with primers specific for 
p190BCR/ABL1 fusion gene were utilised. RNA from SD1 and Sup B15 cells was isolated and 
reverse-transcribed to cDNA and subsequently analysed for BCR/ABL1 levels using 
qPCR. ABL1 was used as a housekeeping gene (Foroni et al., 2011). Analysis of p190 
BCR-ABL1 revealed significantly higher expression in SD1 compared to Sup B15 (Figure 
4-17a). To confirm this at the protein level, western blot analysis for phospho-Crkl (p-
CrkL) was performed. CrkL is a substrate of the BCR-ABL1 fusion protein and is 
constitutively phosphorylated in BCR-ABL1-positive leukaemias, and is therefore used as 
a surrogate marker for BCR-ABL1 tyrosine kinase activity. Western blotting confirmed the 
higher activity of BCR-ABL1 in SD1 compared to Sup B15 (Figure 4-17 b & c). 
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(a) 
 
(b) 
 
(c) 
 
Figure 4-17: BCR-ABL1 expression in SD1 and Sup B15 
(a) TaqMan qPCR quantification of BCR-ABL1 transcript in SD1 and Sup B15 normalized to ABL1 as 
housekeeping gene. Data are pooled from 3 independently grown cultures analysed in triplicate and presented 
as mean ± SEM. Data are analysed using two-tailed unpaired Student t test. ***p<0.001 (b) Western blot 
analysis of Crkl phosphorylation (39 KDa) as a surrogate marker for BCR/ABL1 tyrosine kinase activity in 
SD1 and Sup B15. Histone H3 used as a housekeeping protein to ensure equal protein loading. (c) Western 
blot band density analysed using imageJ software (National Institute of Health) and adjusted density 
calculated by dividing relative density for p-Crkl by the relative density for Histone-H3. 
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4.4.4.2 Effects of inhibition of BCR-ABL1 tyrosine kinase in SD1 
To test whether BCR-ABL1 tryrosine kinase was interfering with CXCR4-CXCL12 axis in 
SD1, the effect of inhibition of BCR-ABL1 tyrosine kinase on SD1 chemotaxis was 
investigated. First, a dose-response experiment was performed to measure the adequate 
concentration of BCR-ABL1 tyrosine kinase inhibitor Imatinib (STI-571). SD1 and Sup 
B15 cells were treated with increasing concentrations of Imatinib for 3, 6, 12, 24 and 48 
hours. To rule out any effect of Imantinib on cell viability, cells were monitored for counts 
and viability using haemocytometer and trypan blue dead cell exclusion method. Western 
blot analysis on the cells revealed effective inhibition of p-CrkL at a concentration of 
10uM at all the time points. However, due to the cytotoxic effects on viability, it was 
decided to use shorter treatment time (3 hours) for experiments. (Figure 4-18a & b) 
Next, in order to determine the effect of BCR-ABL1 tyrosine kinase inhibitors on CXCR4 
mRNA and surface receptor expression, SD1 cells were treated with Imatinib and then 
analysed for CXCR4 mRNA using SYBR Green qPCR and CXCR4 surface expression 
using flow cytometry. No effect on CXCR4 mRNA or surface expression was observed in 
Imatinib treated cells (Figure 4-18c & d). Therefore, p190BCR-ABL1 tyrosine kinase does not 
seem to regulate CXCR4 transcription or surface expression in SD1. 
Finally, in order to determine whether BCR-ABL1 tyrosine kinase perturbs CXCR4 
signalling and hence CXCL12 mediated chemotaxis, SD1 cells were treated with Imatinib 
and CXCL12-mediated chemotaxis was assessed using transwell assays. The results reveal 
that BCR-ABL1 tyrosine kinase inhibition did not result in an increase in CXCL12 
mediated chemotaxis in SD1 cells (Figure 4-18e). Imatinib, besides inhibiting BCR-ABL1 
tyrosine kinases, is known to non-selectively target other key cellular pathways (Hantschel 
et al., 2008). In order to determine whether the reason for failed restoration of chemotaxis 
could be the non-specific inhibition of chemotaxis pathways, BCR/ABL1 negative cell line 
REH was treated with Imatinib and analysed for CXCL12-mediated chemotaxis. No effect 
on CXCL12 mediated chemotaxis was observed with Imatinib treatment (Figure 4-18f). 
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(a)                                     Imatinib   
 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
(f) 
 
Figure 4-18 Effect of BCR-ABL inhibition on CXCR4 expression and function.  
(a) Dose-dependent inhibition of p-Crkl activity in SD1. SD1 cells were treated with increasing 
concentrations of Imatinib (500 nM, 1 µM, 2.5 µM, 5 µM and 10 µM) for 6 hours followed by western blot 
analysis for p-Crkl and Histone-H3. (b) SYBR Green qPCR analysis for CXCR4 mRNA were analysed 
following treatment with Imatinib (10 µM) or media control for 6 hours. Relative quantities were calculated 
using TBP as housekeeping gene. (c) FCM analysis for CXCR4 surface expression following treatment with 
Imatinib (1 µM) or control for 6 hours. Corrected MFI (cMFI) represents MFICXCR4 – MFIisotype control. Data 
were pooled from 3 independent experiments performed and represents mean ± SEM and were analysed 
using Student t test. (d) CXCL12-mediated chemotaxis in SD1 cells were analysed following treatment with 
Imatinib (10 µM) or media control for 6 hours. Migration indices were calculated using the equation: 
Number of cells migrating towards CXCL12 (100 ng/ml) / Number of cells migrating towards media control. 
Data were pooled from 5 independent experiments performed in triplicates and presented as mean ± SEM. 
Data were analysed using Student t test. (e) CXCL12 mediated chemotaxis in Imatinib treated REH cells.  
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In summary, these data suggest that CXCR4 mRNA or protein expression is not up-
regulated by inhibition of BCR-ABL1 tyrosine kinase. Furthermore, the deficient 
migration does not appear to be a result of cross-talk of tyrosine kinase signalling and 
CXCR4 signalling, as inhibition by Imatinib failed to enhance CXCL12-mediated 
migration in SD1. 
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4.4.5 Investigating key CXCL12-activated signalling pathways 
CXCL12 binding to CXCR4 has been shown to activate a number of downstream 
signalling pathways. In ALL cells, chemotaxis has been shown to be mediated by p38 
MAPK and to a lesser extent by ERK and PI3K/Akt pathways (Bendall et al., 2005). To 
assess if deficient migration in SD1 was a result of a dysfunctional downstream signalling 
pathways, SD1 and Sup B15 cells were stimulated with CXCL12 at various time points 
and analysed for phosphorylation of p38 MAPK, pERK1/2 and pAkt. As shown in Figure 
4-19 and summarised in Table 4-3, western blot analysis revealed profound differences in 
SD1 and Sup B15. Rapid activation of phosphorylated p38 MAPK and pERK1/2 proteins 
was observed within 5 min of CXCL12 stimulation in SD1, with levels returning to 
baseline within 15-20 minutes after stimulation. In contrast, no activation of these 
pathways was noted in Sup B15. p38 MAPK demonstrated modest levels of 
autophosphorylation in SD1 and Sup B15 whilst minimal constitutive activity of p-ERK1/2 
was noted in SD1 but not in Sup B15. No phosphorylation of Akt was observed in the two 
cell lines. No conclusion could be drawn based on the lack of activation of these pathways 
in Sup B15. Therefore, REH and SEM cell lines were also investigated for CXCL12- 
mediated activation of these signalling pathways. Western blot analysis in CXCL12-
stimulated REH revealed rapid phosphorylation of p38 MAPK and ERK1/2 as early as 5 
minutes with levels returning to baseline in approximately 30 minutes. Analysis of 
CXCL12 stimulated SEM cells showed constitutive phosphorylation of p38 MAPK with 
minimal increase in signal over the course of the experiment. Again, Akt phosphorylation 
was not noted in any of these cell lines. Levels of total p38 MAPK, ERK1/2, Akt and the 
housekeeping protein (Histone H3) remained largely unchanged over the period of 
stimulation (Figure 4-19).  
These results fail to identify a common intracellular pathway in the 4 BCP-ALL cell lines 
that might be vital for chemotaxis, and dysfunction of which could explain the lack of 
chemotaxis in SD1 cells. In contrast to the previously reported association of non-
chemotaxing ALL cells with dysfunctional p38 MAPK (Bendall et al., 2005), no such 
correlation was found in these cell lines (Table 4-3). The simplest explanation is that there 
are alternative signalling pathways in leukaemia subsets. Further investigation would be 
required to identify the intracellular signalling pathways involved in SD1 or Sup B15 
chemotaxis. 
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SD1 Sup B15 REH SEM Positive control  
 
 0   5  10   15  30  60  90     0   5  10   15  30  60  90 0  5   10  15   30  60  90 0   5    10   15  30 60 90  
Time post stimulation (minutes)  
Figure 4-19: Downstream signalling pathways activated by CXCL12 in cell lines 
Cells were treated with CXCL12 (100 ng/ml) for 5, 10, 15, 30, 60 or 90 minutes or with media control. Cell lysates were analysed by western blot using antibodies against the indicated 
signalling pathway molecules. Representative positive controls: IL-15 treated SD1 cells for phospho-p38 MAPK, LPS treated Raw264.7 cells for phospho-ERK1/2, Calyculin-A treated 
Jurkat cells for phospho-Akt. Representative blots for Histone H3 used to ensure equal loading. 
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Cell line Chemotaxis p38-MAPK p-ERK1/2 p-Akt 
SD1 - + ++ - 
Sup B15 +++ - - - 
REH ++ ++ +++ - 
SEM ++ + ++ - 
Table 4-3: Correlation of chemotaxis with signalling molecules 
Tabular presentation of findings from western blots as shown in Figure 4-16. 
In summary, the results show that SD1, Sup B15, REH and SEM, upon stimulation with 
CXCL12, initiate different signal transduction pathways associated with chemotaxis.  
  
180 
 
 
4.5 Discussion 
In this chapter, a combination of approaches was utilised to determine whether specific 
leukocyte trafficking molecules associated with leukaemic cell entry in the CNS 
compartment in BCP-ALL could be identified. Our initial screening using gene expression 
analysis identified a range of chemokine receptors, selectins and integrins expressed in cell 
lines with variable potential to infiltrate the CNS in xenograft mice. Validation by flow 
cytometry identified down-regulated CXCR4 as a potential candidate for CNS infiltration. 
Analysis of chemotaxis revealed disproportionately reduced chemotaxis to CXCR4 ligand 
CXCL12 in SD1 cells. Subsequent analysis of primagraft samples failed to show any 
correlation between CXCL12 mediated chemotaxis and CNS disease. Leukaemic cells 
isolated from the CNS of xenograft mice did not differ from cells from the bone marrow 
compartment in expression of selected leukocyte trafficking molecules. Further in-depth 
analysis of CXCR4 function in SD1 cells failed to reveal a single mechanism responsible 
for this dysfunctional chemotaxis. 
BCP-ALL cells lines SD1, Sup B15 and REH are reported to differ in their ability to 
infiltrate the CNS (Holland et al., 2011). However, when injected into NSG mice, all the 
cell lines were found to cause CNS disease; although the kinetics of CNS infiltration 
differed significantly. As reported previously, when mice injected with leukaemic cells are 
monitored for long observation times, almost all mice show signs of engraftment. 
However, samples with short time-to-leukaemia predict early patient relapse and a distinct 
gene expression signature (Meyer et al., 2011), suggesting that using engraftment kinetics 
as a surrogate marker has a rational scientific basis. Therefore, time-to-CNS-leukaemia 
was used as a marker for CNS engraftment capability in our studies. Out of the 4 cell lines 
tested, SD1 cells were associated with the most rapid onset of CNS disease followed by 
SEM, REH and Sup B15 respectively.  
Among a wide panel of leukocyte trafficking molecules analysed using TLDA, CXCR3, 
CXCR4, CCR6, CCR7, PSGL1 and CX3CR1 were chosen for further analysis. Analysis 
by flow cytometry indicated that SD1 cells had comparatively lower levels of CXCR4, 
higher expression levels of PSGL1 and a minor proportion of CCR6 and CCR7 expressing 
cells. In addition, SD1 cells demonstrated minimal CXCL12 mediated chemotaxis. This 
suggested that dysfunctional CXCR4-CXCL12 axis response correlated with rapid onset of 
CNS disease. Maturing haematopoietic precursors down-regulate response to CXCL12 to 
egress from the bone marrow and enter the circulation (Fedyk et al., 1999, Bleul et al., 
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1998, Honczarenko et al., 1999). Inhibiting CXCR4 results in egress of cells from the bone 
marrow and extramedullary organs such as the liver into the circulation (Welschinger et 
al., 2013, Juarez et al., 2007). Interestingly, a high peripheral blood white cell count in 
ALL is associated with increased incidence of CNS disease at diagnosis and increased risk 
of CNS relapse (Pui et al., 2008). However, when an independent cohort of primagraft 
samples was analysed, no significant association of CNS disease with a particular 
chemokine receptor could be identified. Further investigation of CXCR4-CXCL12 
interaction showed no association of CNS disease with CXCL12 mediated chemotaxis. In 
addition, use of CXCR4 anihibitor in xenografted mice resulted in similar extent of CNS 
disease despite a reduction in overall leukaemic burden. Using AMD3100 with Imatinib in 
a mouse model of chronic myeloid leukaemia (CML) showed similar results with reduction 
in overall leukaemia but an increase in CNS infiltration (Agarwal et al., 2012). Overall, 
these observations indicate that CNS engraftment is independent of CXCR4-CXCL12 axis. 
Leukaemic cells in a patient are composed of phenotypically diverse subsets which could 
differ in their ability to enter the CNS compartment.  The CNS compartment did not show 
enrichment of a particular leukaemic sub-population with higher/lower levels of the 
selected trafficking molecules. It is clear from our results that BCP-ALL cell entry into the 
CNS compartment cannot be attributed to a particular subset of cells expressing a CNS 
‘address code’. It is also clear that a single chemokine-receptor ligand pair is unlikely to be 
essential or sufficient for leukaemic cell entry into the CNS compartment. These findings 
are in contrast to studies reported by Buonamici et al. (2009) showing CCR7 expression to 
be critical for CNS entry of T-lymphoblasts. These differences may be explained by a 
number of reasons. Firstly, a different experimental model was used by Buonamici et al. 
Secondly, it is possible that CNS infiltration seen in CCR7+/+ T-lymphoblasts may be a 
mere representation of non-specific lymphoblast dissemination. Mice transplanted with 
CCR7 expressing lymphoblasts showed a higher overall leukaemic burden and a 
significantly shortened survival of the transplanted mice. Thirdly, B- and T- cells are 
intrinsically different in cellular behaviour. CCR7+ memory T-cells are the most abundant 
leukocytes in the CSF and it may not be surprising if T-lymphoblasts conserved the CCR7-
CCL19 axis to enter the CNS. Interestingly, pilot data presented on cells carrying 
BCR/ABL or MLL fusions failed to show any reduction in CNS infiltration in mice 
lacking the CCR7 ligand CCL19 (Buonamici et al., 2009).  
One secondary aim of this chapter was to investigate the dysfunctional chemotaxis of SD1 
by characterising the functional expression of CXCR4. The majority of SD1 cells exhibit 
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ligand-binding at 100ng/ml CXCL12 demonstrating slightly lower, but comparable, 
binding efficiency. The incomplete receptor internalization in SD1 is rather paradoxical. 
Typically, more rapid CXCL12-mediated CXCR4 internalization is associated with a 
dysfunctional migratory response (Shen et al., 2001), whereas leukocytes carrying mutated 
CXCR4 in WHIM syndrome show sluggish internalization and an exaggerated chemotaxis. 
(Gulino et al., 2004) However, in SD1, one may argue that a fraction of ligand-bound 
receptor might be non-functional.  
Analysis of CXCR7 expression in SD1 showed elevated levels of CXCR7 transcripts. 
Staining of SD1 cytospins allowed visualization of CXCR7 in SD1 cells. CXCR7 was 
shown to be present in a subset of SD1 cells – rarely co-localised with CXCR4. It was also 
shown that CXCR7 out-competed CXCR4 in binding CXCL12. Blocking CXCR7 binding 
to CXCL12 showed no improvement in the chemotaxis of SD1 cells. This implies that 
CXCR7 scavenging of CXCL12 would not be enough to critically reduce the amount of 
CXCL12 present in the chemotaxis chamber. This inference is also supported by the fact 
that SD1 chemotaxis to CXCL12 remains minimal even at high CXCL12 concentrations 
(1µg/ml). However, the role of CXCR7-scavenging in tissue micro-environment, where 
chemokines are not in a free suspension state, small differences in chemokine 
concentration can potentially be important.  
SD1 and Sup B15 cells both harbour the BCR-ABL1 translocation – a chromosomal 
translocation resulting in a constitutively phosphorylated tyrosine kinase. In CML, the 
BCR-ABL1 tyrosine kinase has been shown to interfere with CXCR4 expression and 
signalling (Ptasznik et al., 2002, Salgia et al., 1999, Lichty et al., 1998, Geay et al., 2005). 
Inhibiting BCR-ABL1 tyrosine kinase activity by Imatinib did not increase CXCR4 
mRNA or surface levels, or chemotaxis to CXCL12. It appears that p190BCR/ABL1 tyrosine 
kinase does not counter-regulate CXCR4 signalling in the same way as seen in p210 
BCR/ABL1
. This is also supported by the fact the Sup B15 cells carrying the same 
translocation, albeit at a much lower level, exhibit efficient CXCL12-mediated chemotaxis. 
This raises the question whether this phenomenon is limited to p210 BCR/ABL1. If so, this 
could be due to the different lineage and maturation status of cells carrying the BCR-ABL1 
translocation variants (i.e myeloid vs lymphoid). On the other hand, this could also be 
explained by the intrinsic differences in these variant oncoproteins - p190 BCR/ABL exhibits a 
higher tyrosine kinase activity and leukaemic transformation potential (Quackenbush et al., 
2000, Li et al., 1999). However, this hypothesis requires further validation. These results 
could be replicated by inhibiting p190 BCR/ABL1 tyrosine kinase with novel tyrosine kinase 
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inhibitors or by inhibiting transcription of p190 BCR/ABL1. 
CXCL12 stimulation resulted in modest but rapid increase in phorphorylated p38-MAPK 
and ERK1/2 on some background phosphorylation of these pathways in SD1. A common 
pathway could not be identified in CXCL12-responsive cell lines. These results contradict 
studies carried out by Bendall et al. (2005) where primary ALL samples are shown to 
require p38-MAPK signalling for chemotaxis. The authors further showed that in primary 
samples lacking CXCL12-mediated chemotaxis (despite presence of surface CXCR4), 
p38-MAPK induction was not seen – hinting towards an uncoupled of CXCR4-p38-MAPK 
pathway. Contrary to this observation, CXCL12 stimulation of SD1 activates p38-MAPK 
phosphorylation. This raises the question whether the lack of CXCL12-mediated 
chemotaxis in SD1 may be a result of a dysfunction further down the MAPK pathway or 
perhaps in the cytoskeletal machinery of the cell. To support the second, studies on Nalm6 
(CXCL12-responsive) and Fc4M (CXCL12-unresponsive) cell lines have shown a critical 
role for activation of RhoGTPases Rac1 and Cdc42 – crucial for actin polymerization 
(Palmesino et al., 2006). Taken together, the observations made from investigating the 
signalling pathways activated following CXCL12 stimulation suggest that the intracellular 
downstream pathways may be cell- and context- specific. It can be suggested that CXCR4 
dysfunction at multiple levels (i.e moderate levels of CXCR4, only a minor proportion of 
signalling receptor evident by inefficient internalisation, and constitutive p38-MAPK and 
ERK1/2 pathways) collectively result in an inefficient chemotactic response in SD1 cells. 
Overall, two main conclusion can be drawn from data presented in this chapter: (i) that 
BCP-ALL cells do not require a specific combination of leukocyte trafficking molecules to 
enter the CNS, & (ii) that CNS infiltration appears to be CXCR4 independent. However, 
the studies performed are not without limitations. The observations presented in this 
chapter are drawn from a limited samples size and based mainly on xenograft models. 
Moreover, all the cell lines and majority of primary cells showed CNS engraftment, 
making adequate comparison between CNS-infiltrating and non-infiltrating samples 
difficult. Furthermore, time-to-hind-limb paralysis represents CNS-related symptoms 
which may appear late in the course of CNS disease and/or may reflect cord compression 
due to expansion of vertebral column bone marrow. The initial screening for leukocyte 
trafficking molecules identified several chemokine receptors, selectins and integrins, 
however, a candidate approach was carried out subsequently. The role of integrins was 
unexplored in this study. Furthermore, chemotaxis assays were utilised to test chemokine 
receptor-ligand function. These assays lack the essential leukaemic cell-endothelium 
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interaction necessary for extravasation into extramedullary compartment. More complex 
models of blood-CSF barrier could be utilised instead of transmigration assays. Finally, 
pharmaceutical inhibitors (Imatinib, AMD3100, CCX771 & CCX754) were used in these 
studies. As with any pharmacological agent these potentially carry the risk of incomplete 
inhibition of the target receptor, or non-specific effects on other pathways. These studies 
could be supplemented by inhibition of chemokine receptors at the transcriptional level. 
These data could be strengthened by using a larger cohort of patients with and without 
CNS disease. Cells taken directly from the CNS compartment could be tested for the 
expression patterns of leukocyte trafficking molecules and analysed for factors associated 
with disease dissemination such as chemotaxis, transendothelial migration and invasion. 
However, due to the relatively low incidence of CNS disease in patients and the ethical 
issues in taking large volumes of CSF to isolate sufficient cells from the CNS 
compartment, this can prove challenging. From a translational aspect, attempts at blocking 
the CNS entry of leukaemic cells do not appear to be feasible, since the cells are likely to 
have entered this compartment by the time the patient presents to the hospital. 
Alternatively, identifying factors that enable long-term survival of leukaemic cells may be 
a better therapeutic target. The role of bone marrow microenvironment in the survival, 
proliferation and evasion of therapy is well known. Preliminary data also suggests a similar 
role of the components of the CNS microenvironment in survival and chemotherapy 
evasion of ALL (Akers et al., 2011). 
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5 Investigating interleukin-15 mediated 
proliferative advantage in B- cell precursor 
acute lymphoblastic leukaemia cells 
5.1 Introduction and aims 
As discussed in chapter 4, the established xenograft model which utilized NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice and B-cell precursor (BCP) acute lymphoblastic 
leukaemia (ALL) cell lines demonstrated variable rate of central nervous system (CNS) 
engraftment by the cell lines. It was further shown that CNS entry of leukaemic cells is not 
governed by the leukocyte trafficking molecules investigated. Importantly, it was shown 
that CNS infiltration is not determined by selective entry of leukaemic cells with a high or 
low expression of a particular combination of chemokine receptors and P-selectin 
glycoprotein ligand -1 (PSGL1). Consequently, in order to understand the molecular 
mechanisms underlying CNS disease, other possibilities such as the retention and 
proliferation of leukaemic cells once they have entered the CNS compartment may be 
considered.   
Interleukin-15 (IL-15), a member of the cytokine family, is one such candidate. Previous 
studies have identified single nucleotide polymorphisms (SNPs) in IL-15 gene to be 
associated with leukaemia development (Lin et al., 2010), minimal residual disease (MRD) 
at the end of induction therapy (Yang et al., 2009) and poor event free survival (EFS) (Lu 
et al., 2014). Furthermore, gene expression analysis has linked high IL-15 mRNA 
expression with aggressive disease features in ALL such as T-ALL and mediastinal 
leukaemia (Wu et al., 2010) and the risk for CNS relapse (Cario et al., 2007). However, 
these studies merely demonstrate association between the IL-15 gene and disease factors. 
A number of possible mechanisms could explain this association: Firstly, IL-15 could be 
directly influencing leukaemic cells in the CNS environment, via its well documented 
proliferative/anti-apoptotic actions. Secondly, IL-15 could be promoting retention of 
leukaemic cells in the CNS compartment by affecting cellular localization. Thirdly, IL-15 
could indirectly affect leukaemia by modulating effectors of the host immune surveillance 
effectors, such as NK- and T- cells. And finally, IL-15 production by the host 
microenvironment may affect leukaemic behaviour irrespective of IL-15 expression by the 
leukaemic cells. 
This chapter aims to investigate the direct biological effects of IL-15 on leukaemic cell 
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survival and behaviour. BCP-ALL cell lines and primary cells were utilized to investigate 
the association of high IL-15 expression levels and CNS disease. Additionally, this chapter 
aims to ascertain the effects of IL-15 on leukaemic cells proliferation and gene expression. 
The key questions addressed in this chapter are: 
1. Do BCP-ALL cell lines and primary cells express IL-15 and IL-15 receptor 
subunits? 
2. Can secreted IL-15 be readily detected in human cerebrospinal fluid (CSF)? 
3. Can BCP-ALL cell lines respond directly to IL-15? 
4. Via inhibition of IL-15 stimulated signalling pathways, can the effect of IL-15 be 
blocked? 
Data presented in this chapter are part of an ongoing project in the laboratory. 
Contributions by other members of the laboratory are presented in brief and acknowledged 
in text. More detailed description of the work is presented in Appendix 1.  
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5.2 Expression patterns of IL-15 and IL-15 receptors in 
BCP-ALL 
Prior to investigating IL-15 function, it was necessary to determine whether IL-15 and IL-
15 receptor subunits were expressed by BCP-ALL. Therefore, 4 BCP-ALL cell lines (SD1, 
Sup B15, REH and SEM), 13 primary ALL samples and 6 primagraft samples were 
utilized for analysis. The clinical details of the cell lines and primary samples are presented 
in Table 4-1 and Table 5-1 respectively. Cells were homogenized in Trizol® and total RNA 
was isolated following DNAse digestion of the lysates. RNA samples were quantified by 
spectrophotometric method using Nanodrop. 200 ng total RNA was utilized for cDNA 
synthesis. However, in some primary samples, due to limited RNA yield, the entire 
extracted RNA was used for cDNA synthesis and the relative transcript for the 
housekeeping gene (GAPDH) was used for comparison following qPCR. 
Patient 
ID 
Sex  Age  
(Years)  
WCC  
(x109/l)  
Cytogenetics  CNS 
status  
Outcome  
#G01  M  2  23  11q23  1  CCR (19 months)  
#G02  F  5  29  t(12;21)  1  CCR (19 months)  
#G06  M  4  52  t(12;21)  1  CCR (13 months)  
#ED7  M  10  3  Normal  1  CCR (13 months)  
#G08  F  11  35  dic(7;9)  1  CCR (13 months)  
#G09  F  6  23  Hyperdiploid  1  CCR (13 months)  
#G11  M  10  14  High Hyperdiploid  TLP+ve  CCR (11 months)  
#G16  M  2  90  High Hyperdiploid  1  CCR (10 months)  
#G17  F  3  50  t(12;21)  1  CCR (9 months)  
#E2 F  3  34.4  Hyperdiploid  1  CCR (21 months)  
#E3  F  6  9.6  t(12;21)  1  CCR (21 months)  
#E4  M  3  16.8  Hyperdiploid  1  CCR (20 months)  
#E5  F  2  4.3  t(12;21)  1  Died during induction* 
(week 3)  
#5449  F  2.5  62.2  t(12;21)  1  CCR (5.3 years)  
#4630  F  2.9  103.6  t(12;21)  1  CCR (7.0 years)  
#5094  F  2.1  84.6  t(12;21)  3  CCR (6.6 years)  
#4736  F  3.5  113.3  t(12;21)  1  CCR (6.1 years)  
#5705  F  3.4  221  t(12;21)  1  CCR (4.7 years)  
#R3276 M 5.5 98 NA 1 CNS relapse (4.2 years) 
#6539 M 1.3 NA NA NA CNS relapse 
#4336 F 7 NA NA NA CNS relapse 
       
Table 5-1: Clinical features of patients 
CCR = continuous clinical remission, CNS = central nervous system NA = not available, TLP = traumatic 
lumbar puncture. 
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5.2.1 ALL cells express differential levels of IL-15 mRNA 
First, the expression pattern of the two IL-15 isoforms, IL15-long signal peptide (IL-15-
LSP) and IL-15-short signal peptide (IL-15-SSP), and three IL-15 receptor subunits (IL-15 
Rα, β and γ) was analysed. To allow identification of the two IL-15 isoforms differing in 
their sizes due to insertion of 119 bp sequence to IL-15 SSP, standard RT PCR followed by 
agarose gel electrophoresis was utilized. All samples expressed IL-15-LSP whereas only 
6/18 primary/primagraft samples and 3/4 cell lines expressed the cytoplasmic IL-15-SSP. 
Representative gel images from 3 samples (SD1, #ED-7 and #5449) are shown in Figure 
5-1, whereas results from individual samples are presented in Table 5-2.  
Next, in order to assess the relative expression of IL-15 gene in the leukaemic samples, 
SYBR Green qPCR was utilized. Using GAPDH as the housekeeping gene and setting 
SD1 IL-15 expression to a value of 1, relative expression was calculated. Figure 5-1b and 
Table 5-2 shows that IL-15 is differentially expressed in primary ALL samples. Due to 
limited availability of primary ALL samples, validation of IL-15 or the IL-15 receptor 
subunits expression by flow cytometry could not be possible. 
These results not only confirm differential IL-15 expression in BCP-ALL cells as 
previously shown by Cario et al. (2007), but also extend to show that the cell-
surface/secreted IL-15-LSP is the predominant isoform expressed in ALL, while the 
cytoplasmic IL-15-SSP is expressed in a minority of samples. It can be implied that BCP-
ALL cells can potentially express and secrete IL-15. 
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Figure 5-1: IL-15 mRNA expression in BCP-ALL cells  
(a) RT PCR analysis of IL-15 isoforms in ALL samples. Nucleotide sizes shown in brackets: IL-15 LSP (201 
bp), IL-15 SSP (320 bp). Sizes measured with reference to 100 bp DNA ladder (black arrows). 
Representative samples from BCP-ALL cell lines, primary samples and primagraft samples are shown. (b) 
SYBR Green relative quantification of IL-15 mRNA in primary samples using GAPDH as housekeeping 
gene and IL-15 mRNA expression in SD1 set to the arbitrary unit 1. Calculated using ABI RQ manager 
software. 
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5.2.2 ALL cells differentially express IL-15 receptor sub-units 
The IL-15 receptor complex, is comprised of a specific high affinity IL-15Rα subunit, and 
shared β- and γc- receptor subunits. In order to assess if leukaemic cells could potentially 
respond to IL-15, analysis of IL-15 receptor subunits was performed using RT-PCR. 
Analysis by gel electrophoresis revealed that the majority of ALL samples express IL-15 
receptor subunits.  IL-15 Rα and γc subunits were expressed in all the samples whereas IL-
15 Rβ was detected in 4/4 cell lines and 14/17 primary/primagraft samples. Representative 
gel images from 3 samples (SD1, #ED-7 and #5449) are presented in Figure 5-2 and the 
results from individual samples are presented in Table 5-2. IL-15 receptor expression could 
not be evaluated in two primagraft samples due to lack of amplification of GAPDH 
implying inadequate cDNA. These results imply that BCP-ALL samples can potentially 
respond to IL-15. 
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Figure 5-2 IL-15 receptor subunit mRNA expression in BCP-ALL cells  
RT PCR analysis of IL-15 Rα, IL-2/IL-15 Rβ and IL15-Rγc in ALL samples. Nucleotide sizes shown in 
brackets: IL-15 Rα (402 bp), IL-2/IL-15 Rβ (403 bp) and IL15-Rγc (447). Sizes measured with reference to 
100 bp DNA ladder (black arrows). Representative samples from BCP-ALL cell lines, primary samples and 
primagraft samples are shown. 
 
Sample ID. IL-15 RQ IL-15 LSP IL-15 SSP IL15 Rα IL15 Rβ IL15 Rγ 
SD1 1 Y Y Y Y Y 
Sup B15 0.082 Y Y Y Y Y 
REH 0.384 Y Y Y Y Y 
SEM 0.337 Y N Y Y Y 
#G01 2.09 Y Y Y Y Y 
#G02 0.44 Y N Y Y Y 
#G06 0.44 Y Y Y Y Y 
#ED7 1.93 Y Y Y Y Y 
#G08 0.80 Y N Y Y Y 
#G09 0.21 Y Y Y Y Y 
#G11 0.48 Y N Y Y Y 
#G16 0.10 Y N Y Y Y 
#G17 1.34 Y Y Y Y Y 
#E2 0.56 Y N Y Y Y 
#E3 2.56 Y N Y Y Y 
#E4 1.86 Y N Y Y Y 
#E5 0.56 Y N Y Y Y 
#5449 0.37 Y N Y N Y 
#4630 0.20 Y N Y N Y 
#5094 n.d Y N Y N Y 
#4736 n.d Y Y Y Y Y 
#5705 n.d Y N n.d n.d n.d 
Total: 22  22/22 9/22 21/21 18/21 21/21 
Table 5-2: Individual results of IL-15 and IL-15 receptor expression data in 4 cell lines, 13 
primary samples and 5 primagraft samples.  
RQ= relative quantitation. ID = identity. Y= yes, N= No, n.d= not determined due to unavailability of 
material. 
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5.2.3 Association of IL-15/IL-15 receptor expression with CNS 
disease in xenograft models 
In the previous chapter, it was documented that BCP-ALL cell lines vary in their time to 
develop overt CNS disease once engrafted into NSG mice. As shown in table 5.2, SD1 
with the shortest time to CNS disease demonstrated elevated expression of IL-15, in 
contrast to Sup B15 with the slowest onset of CNS disease. RT PCR analysis also 
confirmed expression of IL-15 receptor subunits in these cell lines. However, to accurately 
understand IL-15/IL-15 receptor interactions, it was necessary to quantify IL-15 receptor 
expression. Therefore the relative expression of IL-15 receptor subunits in SD1, Sup B15, 
REH and SEM was determined. TaqMan qPCR analysis for IL-15 Rα, IL-15 Rβ and IL-
15γc revealed remarkable differences in the expression of IL-15 receptor subunits. SD1 
exhibited highest expression levels of all the three IL-15 receptor subunits whereas Sup 
B15 demonstrated lowest levels among these 4 cell lines (Figure 5-3). These data show 
that SD1 cells can not only express both soluble and cytoplasmic isoforms of IL-15, but 
they also possess the potential to respond to IL-15. 
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(a) 
 
(b) 
 
(c) 
 
 
Figure 5-3: Relative expression levels of IL-15 receptor subunits in BCP-ALL cell lines. 
cDNA from SD1, REH, SEM and Sup B15 was analysed for expression of (a) IL-15 Rα, (b) IL-2/IL-15 Rβ 
and (c) IL-15 Rγc. Relative expression was calculated using ABI RQ manager software. GAPDH was used as 
a housekeeping gene and gene expression in Sup B15 was set to arbitrary unit of 1 as a calibrator. Three 
independently grown cultures were analysed in triplicate. Data are presented as Mean ± SEM and analysed 
by Two-tailed unpaired Student t tests comparing SD1 to each of the other cell lines. ***p<0.001, **p<0.01, 
*p<0.05. RQ, relative quantification. (Contributed by Dr Chris Halsey) 
Overall, these results demonstrate that BCP-ALL samples consistently express IL-15 and 
IL-15 receptor subunits at the mRNA level, the majority of samples express the cell-
surface/secreted IL-15-LSP isoform, and all IL-15 receptor subunits suggesting that 
ALL cells can express and potentially respond to IL-15. RQ PCR analysis of IL-15/IL-15 
receptor subunits in cell lines suggests a correlation with onset of CNS engraftment 
kinetics in mice.  
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5.2.4 Detecting IL-15 in CSF samples from BCP-ALL patients 
IL-15 secretion is known to be tightly controlled and difficult to detect in culture 
supernatants in cells shown to express IL-15 (Tinhofer et al., 2000). Nevertheless, 
detection of secreted IL-15 in fluid compartments might potentially be very informative. 
Secreted IL-15 could influence the behaviour of not only the leukaemic cells, but also cells 
of the immune system. Furthermore, detection of IL-15 could be a useful biomarker of 
disease. Therefore, it was decided to assess whether readily detectable levels of IL-15 were 
present in CSF samples from patients with CNS-3 disease. A pilot experiment was 
performed using sandwich ELISA assay (catalogue no. 88-7158-22, eBioscience) to 
quantify IL-15 levels in 6 CSF samples from 3 patients with CNS-3 disease (#R3276, 
#6539 and #4336). Three standard dilutions (1:2, 1:4 and 1:10) of each CSF sample were 
assayed to ensure accurate quantitation. Analysis of CSF IL-15 levels by ELISA failed to 
show detectable levels of IL-15 in any of the samples (Figure 5-4). Consistent with 
previous studies (Tinhofer et al., 2000, Bergamaschi et al., 2012, Tagaya et al., 1996), 
these results are suggestive of a more controlled secretion of IL-15. It can be implied that 
the routine ELISA screening methods with a relatively high limit of detection (>15 pg/ml) 
may not be suitable for measurement of IL-15 levels in CSF supernatants. 
 
Figure 5-4: ELISA detection of IL-15 levels in CSF supernatants from patients with CNS 
disease.  
CSF supernatants from 3 BCP-ALL patients were analysed for IL-15 levels by ELISA. Absorbance (430 nm) 
from standard and sample wells was measured on a microplate reader. CSF IL-15 levels (red) were 
interpolated from standard curve generated from standard concentrations of IL-15 (black dots). Data were 
analysed using GraphPad prism software and represents means of duplicate values.  
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5.3 Investigating mechanisms of the association of IL-15 
with the CNS disease 
Given the well documented role of IL-15 in proliferation of malignant cells in T-ALL 
(Barata et al., 2004), CLL (Trentin et al., 1996), multiple myeloma (Tinhofer et al., 2000) 
and T-cell lymphomas (Dobbeling et al., 1998), it was decided to investigate whether IL-
15 plays a direct role in growth and survival of BCP-ALL. Furthermore, it is not known 
how IL-15 affects cell proliferation under hostile conditions such, as the CSF compartment 
which contains lower levels of proteins (Huhmer et al., 2006) and glucose (Nigrovic et al., 
2012) compared to serum. This section describes experiments performed to assess the 
effects of IL-15 stimulation on the growth of BCP-ALL cells under normal and serum 
depleted conditions, followed by analysis of genes associated with leukocyte trafficking or 
metastasis in IL-15 treated cells. 
5.3.1 Analysing effect of exogenous IL-15 on growth of BCP-ALL 
cells 
SD1, Sup B15, REH and SEM were chosen for analysis. In order to determine effects of 
IL-15 on cell growth, cells grown in normal culture media (10% FCS in RPMI) were 
exposed to exogenous IL-15 and growth assessed by measuring viable cell counts are 24, 
48, 72 and 96 hours. First, a dose-response experiment was performed on SD1 and Sup 
B15 using three different IL-15 concentrations (1, 5 and 25 ng/ml). SD1 exhibited a dose-
dependent increase in cell numbers in response to IL-15. Significant increase in cell counts 
was observed at 72 and 96 hours with 25ng/ml IL-15. Sup B15 on the other hand appeared 
to be non-responsive to IL-15 induced growth advantage at these concentrations. Similarly, 
minimal effect was observed in REH and SEM cells at concentrations of 25 ng/ml. 
The growth promoting effect of exogenous IL-15 was only seen in 1 out of 4 cell lines 
tested. However, IL-15 unresponsive cell lines Sup B15, REH and SEM carry IL-15 
receptor subunits and therefore can potentially respond to IL15. Furthermore, these results 
were subsequently validated in primary BCP-ALL samples. Using a primary cell 
suspension culture model, addition of exogenous IL-15 resulted in a consistent increase in 
cell counts and significantly enhanced growth rates. (Williams et al., 2014) 
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(a) SD1 (b) Sup B15 
  
 
(c) REH (d) SEM 
  
 
Figure 5-5 Effect of exogenous IL-15 on growth of BCP-ALL cell lines 
Growth of (a) SD1 and (b) Sup B15 cells in response to increasing concentrations of exogenous IL-15 (media 
control, 1, 5, 25 ng/ml) at 24, 48, 72 and 96 hours. Growth of (c) REH and (d) SEM in response to media 
control or 25 ng/ml IL-15. Data are representative of 3 independent experiments, each performed in triplicate. 
Data are presented as mean ± SEM and analysed using an unpaired Student t test. *p<0.05.  (a &b 
contributed by Dr Mark Williams). 
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5.3.2 Determining the role of endogenous IL-15 on growth by IL-
15Rα blockade 
In order to determine whether endogenous IL-15 also affects growth, cells were treated 
with IL-15Rα neutralizing antibody (catalogue no. AF247, R&D systems) to inhibit IL-15 
mediated receptor stimulation in the absence of exogenous IL-15. Cell counts were 
monitored at 24, 48, 72 and 96 hours. IL-15Rα blockade resulted in significantly reduced 
cell numbers in SD1 at 72 and 96 hours (p<0.05). As seen previously, the other cell lines 
did not show any differences in growth in control treated and IL-15 Rα neutralized groups 
(Figure 5-6). These results show that endogenous IL-15 production plays a significant role 
in the growth of SD1 cells. 
(a) SD1 (b) Sup B15 
 
 
 
 
(c) REH (d) SEM 
 
 
 
 
Figure 5-6: Growth of BCP-ALL cell lines following blockade of IL-15 Rα. 
Growth of (a) SD1, (b) Sup B15, (c) REH and (d) SEM cells exposed to media control, IL-15 Rα 
neutralization antibody ( 6µg/ml) or isotype control antibody (6 µg/ml). Data represents mean ± SEM. Data 
were analysed using Student t test and are representative of 3 independent experiments per cell lines, each 
performed in triplicates. *p<0.05 (a & b contribute by Dr Mark Williams) 
In summary, these results show that IL-15 promotes dose-dependent growth in SD1 cells 
expressing the IL-15 receptors. Stimulation of IL-15 receptor by endogenous IL-15 is an 
important mechanism of cell proliferation evident by significant reduction in cell growth 
subsequent to blockade of IL-15Rα. 
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5.3.3 Determining IL-15 mediated growth advantage under serum 
depletion 
In order to analyse the effect of IL-15 stimulation on leukaemic growth under serum 
depleted conditions, cells were cultured in various low serum conditions (0% FCS, 1% 
FCS, 5% FCS and 10% FCS) with exogenous IL-15 or with IL-15 neutralizing antibody 
(HuMax-IL-15, Amgen) for 96 hours. Analysis of the cell counts revealed a significant 
increase in cell counts under conditions of 0% serum, 1% serum and 5% serum in IL-15 
treated cells compared to media control (Figure 5-7a). Maximum % increase in cell counts 
in response to exogenous IL-15 was seen under serum free conditions although this failed 
to reach statistical significance (Figure 5-7b). A consistent reduction in cell counts was 
seen in cell treated with HuMax-IL-15 although this difference was small and failed to 
reach statistical significance, suggesting that there is a greater role for exogenous IL-15 
stimulation compared to endogenous stimulation (Figure 5-7c). 
(a) 
 
(b) 
 
(c) 
 
Figure 5-7: Growth of IL-15 treated SD1 cells under low serum conditions:  
SD1 cells were cultured in RPMI supplemented with 0%, 1%, 5% and 10% FCS with or without IL-15 (25 
ng/ml) for 96 hours. (a) Total numbers of viable cells in each group after 96 hours. (b) Precentage increase in 
cell counts of IL-15 treated SD1 cells. (c) Cell counts in HuMax-IL-15 treated cells vs isotype control. Data 
are pooled from 3 independent experiments performed in triplicates and presented as mean ± SEM. Data 
were analysed using two-tailed unpaired Student’s t tests. **p<0.01, *p<0.05 
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5.3.4 IL-15 mediated growth is a result of increased proliferation 
The increase in SD1 cell numbers in response to IL-15 stimulation could be a consequence 
of reduced apoptosis or increased cellular proliferation. A number of methods can be used 
to measure apoptosis along with other members of the laboratory. One of these is the flow 
cytometry based detection using Annexin V staining. This method allows identification of 
cells in early apoptosis by measuring Annexin V fluorescence coupled with dead cell 
discriminator 7-AAD. SD1 cells were cultured in various serum conditions with/without 
IL-15 for 96 hours and then labelled with Annexin V and 7-AAD. Analysis using flow 
cytometry revealed no significant differences in the percentage of cells undergoing early 
apoptosis (Figure 5-8a). Other measures of apoptosis such as Caspase-3 cleavage, 
poly(ADP ribose) polymerase (PARP) cleavage or the levels of anti-apoptotic proteins 
BCL-xL and BCL-2, were tested by the members of the laboratory, with no differences 
evident in IL-15 treated vs control treated SD1 cells (Appendix 1, Williams et al. 2014). 
These results clearly demonstrate that the IL-15 mediated growth advantage is unlikely to 
be due to an effect on apoptosis.  
Next, to demonstrate whether the IL-15 mediated growth advantage was due to increased 
proliferation, cell division analysis was performed using a non-toxic cytoplasmic 
fluorescent dye CellTrace Violet (CTV). The cells are labelled with the fluorescent dye, 
and each time the labelled cell divides, the fluorescence intensity is reduced in its progeny. 
In some cell types, this manifests as a halving of fluorescence intensity with each cell 
division leading to peaks on histogram plots (Quah and Parish, 2012). In other cases, 
reduction in intensity is more variable and mean fluorescence intensity (MFI) can be used 
as a surrogate marker (Sisirak et al., 2011). In the case of SD1 cells considerable variation 
in cell size leads to smearing of peaks. Therefore, the MFI values were used instead. SD1 
cells were labelled with CTV and cultured under various serum conditions with or with IL-
15. Upon analysis by flow cytometry, consistently lower MFIs were observed in cells 
treated with IL-15 compared to controls, confirming higher cell proliferation in IL-15 
treated SD1 cells (Figure 5-8b). 
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(a) 
 
(b) 
 
Figure 5-8: Effect of IL-15 treatment on apoptosis and cell proliferation: 
(a) SD1 cells were cultured in RPMI supplemented with 0%, 1%, 5% and 10% FCS with or without IL-15. 
The percentage of live cells positive for Annexin-V in each group at 96 hours is shown. (b) SD1 cells were 
labelled with CTV and subsequently grown in RPMI supplemented with 0%, 1%, 5% and 10% FCS with or 
without IL-15. Cells were analysed for CTV fluorescence using flow cytometry. Fluorescence in control 
treated SD1 cells was calibrated as 100% and percent decrease in MFIs of IL-15 treated SD1 cells calculated. 
Data are pooled from 3 independent experiments performed in duplicates and presented as mean ± SEM. 
Data were analysed using two-tailed unpaired Student t test. **p<0.01, *p<0.05 
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5.3.5 Investigating the effects of IL-15 - induced signalling on the 
growth of SD1 cells 
IL-15 stimulation results in the activation of a number of downstream signalling pathways 
in normal lymphocytes. These include JAK/STAT, ERK1/2, PI3K/Akt and NFκb/IκBα 
pathways. IL-15 stimulation of SD1 cells results in the rapid phosphorylation of ERK1/2 
and STAT5 accompanied by minimal phosphorylation of Akt and NFκb. With other 
members of the laboratory, using specific inhibitors of ERK1/2 and STAT5, it was shown 
that IL-15 elicited growth advantage is dependent on the Ras/Raf/MEK/ERK pathway. 
Using specific MEK inhibitor to block ERK1/2, it was shown that IL-15 mediated growth 
advantage was completely abolished with affecting the overall growth of SD1 cells. 
STAT5 inhibition, on the other hand reduced overall growth but the IL-15 mediated 
growth advantage remained (Appendix 1, Williams et al. 2014). To analyse whether 
PI3K/Akt and NFκb/IκBα pathways are also implicated in IL-15 mediated proliferation in 
SD1, inhibitors of PI3K (LY 294002, Calbiochem) and NFκb (IKK-2 inhibitor IV, 
Calbiochem) were used along with exogenous IL-15. Treatment with either of the 
inhibitors resulted in profound inhibition of growth of cells along with elimination of any 
growth advantage due to exogenous IL-15. Given that both PI3K and NFκb are 
constitutively phosphorylated in SD1, and that the inhibition of these pathways results in 
complete arrest of proliferation, it appears that these pathways are vital to cellular 
proliferation. The slight increase in phosphorylation in response to IL-15 may be directly 
or indirectly involved in proliferation in response to IL-15. However, it is difficult to draw 
conclusions based on these results. Further investigation into the role of these pathways 
will be required. 
 
Figure 5-9: Effect of inhibition of downstream signalling pathways on IL-15 mediated 
growth. 
SD1 cells were treated with 5 µM NFκb inhibitor (IKK2 inhibitor IV) or 20 µM PI3K inhibitor (LY 294002) 
or vehicle control (0.1% DMSO) ± IL-15. The total number of viable cells in each group after 72 hours. Data 
are pooled from 3 independent experiments performed in triplicates and presented as mean ± SEM. Data 
were analysed using two-tailed unpaired Student t test. *p<0.05, n.s. = Not significant 
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5.3.6 Regulation of genes associated with leukaemic 
dissemination following exposure to IL-15 
In addition to the growth advantage under serum depletion, other possible mechanisms 
could account for the association of IL-15 with the CNS disease. For instance, IL-15 could 
indirectly regulate chemotaxis and homing of leukaemic cells into the CNS. In order to 
assess whether IL-15 could be involved in regulation of genes associated with leukaemic 
dissemination, two separate realtime qPCR gene expression arrays on IL-15 treated SD1 
cells were performed. First, RT2 human tumour metastasis profiler array (catalogue no. 
PAHS-028Z-2, SABiosciences) comprising of 96 genes associated with cancer metastasis 
was used. Next, custom designed TLDA (Applied Biosystems) plates comprising 30 
selected chemokine receptors, selectins and integrin genes were utilized. Overall, out of 
126 genes associated with leukocyte trafficking and cancer metastasis, 9 genes were 
identified to be up-regulated or down-regulated with IL-15 treatment (Appendix 1, 
Williams et al. 2014) . Although these arrays are marketed as gene validation arrays, this 
technology is not without limitations (Gaj et al., 2008). Therefore, to confirm these results, 
qPCR assays for individual genes identified in array analysis were performed.  
First, SYBR Green qPCR primers were designed against 7 genes (CDH11, MMP9, PTEN, 
SERPINE1, DENR, MMP3 and TIMP4) identified by RT2 profiler arrays. SD1 cells had 
shown maximum growth advantage to IL-15 treatment at 72 and 96 hours. However, it 
could be possible that regulation of gene expression occurs at earlier time points. 
Therefore, both early (4, 6 and 24 hours) and late (72 hours) time points were chosen.  
Analysis by qPCR showed only SERPINE1 mRNA levels to be significantly up-regulated 
in IL-15 treated SD1 cells at 72 hour time points (Figure 5-10). None of the genes showed 
any difference between control- and IL-15 treated SD1 cells at the earlier time points (data 
not shown). MMP3 validation could not be performed due to lack of a suitable positive 
control. Therefore, MMP3 was excluded from the analysis. 
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(a) 
 
(b) 
 
(c) 
 
(c) 
 
(d) 
 
(e) 
 
Figure 5-10: qPCR analysis of metastasis-associated genes identified by RT2 profiler array 
SD1 cells were grown in complete culture media ± IL-15 (25 ng/ml) for 72 hours. SYBR Green qPCR 
analysis of (a) SERPINE1 (b) TIMP4, (c) DENR, (d) CDH11, (e) PTEN and (f) MMP9 using tata-binding 
protein (TBP) as housekeeping gene. Data are pooled from 3 independently grown cultures analysed in 
triplicates. Data were analysed using two-tailed unpaired Student’s t test and presented as mean ± SEM. 
*p<0.05. n.s= non-significant. 
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Next, in order to confirm targets (PSGL-1 and CXCR3) identified by TLDA analysis, 
TaqMan qPCR analysis was performed on SD1 cells treated with IL-15. Relative 
quantitation confirmed significant up-regulation of PSGL-1 and CXCR3 (Figure 5.9 a & 
b). To establish whether these genes were also up-regulated at surface protein level, flow 
cytometric analysis was performed. Comparison of surface protein expression levels 
confirmed significant up-regulation of PSGL-1 in IL-15 treated SD1 cells. (Figure 5-11 c 
& d) 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
Figure 5-11: qPCR and FCM analysis of IL-15 treated SD1 cells. 
SD1 cells were grown in complete culture media ± IL-15 (25 ng/ml) for 72 hours. TaqMan qPCR analysis of 
(a) CXCR3 and (b) PSGL-1 using GAPDH as housekeeping gene. Data are pooled from 3 independently 
grown cultures analysed in triplicates. Surface expression of (c) CXCR3 and (d) PSGL1 were analysed using 
flow cytometry. Corrected MFIs (cMFI) represents MFIspecific antibody – MFIisotype control. Data are pooled from 3 
independent experiments and presented as mean ± SEM. Data were analysed using two-tailed unpaired 
Student’s t test. *p<0.05, **p<0.01. n.s= not-significant. 
In summary, these data support the hypothesis that in addition to providing proliferative 
advantage, IL-15 stimulation may result in increased interaction of leukaemic cells with 
CNS barriers by up-regulating molecules involved in leukocyte trafficking 
(CXCR3/PSGL-1) or invasion (SERPINE1). 
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5.4 Discussion 
In this chapter, mechanisms underlying the association of IL-15 expression with CNS 
disease in ALL were examined. Using BCP-ALL cell lines, the effect of IL-15 stimulation 
at multiple time points on the growth of leukaemic cells under normal and serum depleted 
conditions was analysed. SD1, which exhibited the highest IL-15 and IL-15 receptor 
expression among the cell lines, showed significantly elevated cell numbers under normal 
and serum depleted conditions in the presence of exogenous IL-15. Moreover, growth was 
significantly reduced with IL-15-Rα blockade in the absence of exogenous IL-15, 
suggesting IL-15 production by leukaemic cells may play an important role in their growth. 
The IL-15 mediated growth advantage was demonstrated to be a result of an increased cell 
division and with no apparent effect on markers of apoptosis. Secreted IL-15 could not be 
detected in CSF samples of patients with CNS disease. Gene targets identified by high 
throughput arrays were analysed by qPCR. CXCR3, PSGL-1 and SERPINE1 were found 
to be significantly up-regulated by qPCR. IL-15 stimulation results in modest activation of 
PI3K and NFκb pathways. Using specific pathway inhibitors to determine their specific 
role in IL-15 mediated growth showed inconclusive results due to profound inhibition of 
overall growth. Briefly, this chapter focusses on determining mechanistic explanation of a 
clinical phenomenon, namely, the association of high IL-15 expression and CNS disease in 
ALL. 
Several studies have identified IL-15 as a candidate gene for leukaemia development (Lin 
et al., 2010),  treatment response (Yang et al., 2009), survival (Lu et al., 2014), and CNS 
disease (Cario et al., 2007). However, these studies do not provide a mechanistic link 
between IL-15 and such high-risk factors. In the cohort of patients tested for IL-15 
expression, all samples were shown to express IL-15 – highlighting the relevance of IL-15 
in the context of ALL. Increased cell growth in response to exogenous IL-15, and growth 
reduction in response to IL-15 receptor blockade and IL-15 neutralization demonstrate that 
both exogenous and endogenously produced IL-15 may be simultaneously involved. 
The role of IL-15 receptor levels in ALL is not known. Analysis of IL-15 receptor 
expression in primary ALL samples and cell lines showed heterogeneous expression of IL-
15 receptor subunits. In the cohort of patients assessed, the majority of samples expressed 
IL-15 receptor subunits. Whether expression levels of IL-15 receptor subunits influence 
outcome, remains to be elucidated. Larger sample size and longer follow-up would be 
required to draw associations between IL-15 receptor expression and patient outcome.  
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High IL-15 mRNA expression is predictive of CNS relapse (Cario et al., 2007). In chapter 
3, we have shown that CNS leukaemia is predominantly limited to the CSF compartment – 
a site presumably less conducive to cellular growth compared to the bone marrow 
microenvironment. IL-15 has a more potent proliferative effect under conditions 
mimicking the CSF.  Consistent with our findings, IL-15 is also involved in NK cell 
survival under serum free conditions (Carson et al., 1997). IL-15/IL-15 receptor mediated 
growth advantage may be more important in the CNS compared to the bone marrow.   
Several reports have shown suppression of apoptosis as the main mechanism of IL-15 
mediated survival in neutrophils (Bouchard et al., 2004), Large granular lymphocytes 
(Hodge et al., 2009), NK cells (Carson et al., 1997), and malignant plasma cells (Tinhofer 
et al., 2000). On the contrary, IL-15 stimulation resulted in increased proliferation evident 
from dye-dilution in IL-15 treated cells whereas measures of apoptosis such as Annexin V 
expression remained unchanged. Although intriguing, these data are limited to SD1 and 
require further investigation. ALL is a heterogeneous disease with complex acquired 
mutations. Study of a larger cohort of primary samples would be needed to confirm this 
mechanism.  
In addition to proliferation, exogenous IL-15 was also shown to up-regulate CXCR3, 
PSGL1 and SERPINE1 transcripts. These observations provide an alternative explanation 
to the association of IL-15 with CNS disease. The IL-15 receptor is shown to regulate 
lymphoid homeostasis and IL-15 knockout mice have shown reduced numbers of 
circulating T- and B cells and fewer leukocytes in lymph nodes (Lodolce et al., 1998). The 
up-regulation of leukocyte trafficking molecules provides a link between IL-15 and 
leukaemic cell trafficking. As shown in chapter 3 and 4, PSGL1 and CXCR3 are unlikely 
to be essential for entry into the CNS compartment. However, an assistive role for these 
receptors in CNS infiltration cannot be excluded. Human CD4+ T cells are shown to transit 
across the BCSFB via P-selectin/PSGL1 interactions (Kivisakk et al., 2003). In addition, 
CXCR3 expressing T cells are found in CSF in multiple sclerosis (MS) patients (Balashov 
et al., 1999). Upregulation of SERPINE1 following IL-15 stimulation can explain the 
aggressive disease characteristics associated with IL-15 expression. SERPINE1 is a serine 
protease inhibitor, which has been implicated in metastasis and invasion (Bajou et al., 
1998). Interestingly, SERPINE1 expression in melanoma cells is linked to site-specific 
metastasis to the skin. (Klein et al., 2012) Whether SERPINE1 up-regulation in response to 
IL-15 represents merely an aggressive behaviour of disease or is associated with CNS-
specific tropism of leukaemic cells, requires further clarification. 
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IL-15 treatment stimulates several downstream signalling pathways such as ERK1/2, 
STAT5, PI3K and NFκB. Inhibition of the MEK/ERK pathway abrogated IL-15 mediated 
growth advantage without affecting overall cell growth. However, the role of other 
pathways, such as PI3K and NFκB resulted in an overall reduction in cell proliferation. It 
remains to be investigated whether IL-15 mediated activation of these pathways indirectly 
affect leukaemic cells behaviour by IL-15 regulated genes (CXCR3, PSGL1 and 
SERPINE1).  
The GWAS data provides a list of SNPs in the IL-15 gene statistically associated with 
various ALL disease factors (Yang et al., 2009, Lin et al., 2010). However, these do not 
provide any direct evidence on how these genetic changes can affect the disease 
phenotype. For instance, it is not known whether IL-15 SNPs lead to an increase or 
decrease in IL-15 production. Also, no distinction can be made between IL-15 production 
by leukaemic blasts themselves or the tumour microenvironment. However, such statistical 
associations together with functional analysis of the candidate gene help us generate 
hypotheses about the mechanism of the underlying clinical phenotype. Our studies 
demonstrate that exogenous IL-15 production provides a greater growth advantage 
compared to endogenous IL-15 production by leukaemic cells, suggesting that IL-15 
production by host microenvironment may be more important than IL-15 production by 
leukaemic cells. The growth advantage is maximal under serum depleted condition. 
Additionally IL-15 up-regulates genes associated with leukocyte migration and invasion. 
We hypothesise that IL-15 may facilitate engraftment and long-term survival in the hostile 
CNS microenvironment. In the bone marrow – where serum starvation is unlikely to be a 
selective pressure – IL-15 may play a less important role in leukaemic cell growth. 
Alternately, high IL-15 in the bone marrow may activate anticancer immune response 
which may be more efficient in the bone marrow compared to the CNS due to efficient 
barriers between the circulation and the CNS. Further investigation into the role of host 
micro-environment/immune system in leukaemia is required. Our studies are based on 
observations from xenograft NSG mice which lack mature B- and T- cells and are IL-2Rγc 
deficient, and therefore are not suitable for investigating IL15/IL-15 receptor interactions 
between leukaemia and the host microenvironment/immune system. In order to 
discriminate between IL-15 production by leukaemic cells vs the microenvironment, and 
autocrine vs paracrine signalling, other models such as transgenic or knock-down models 
would be required. 
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6 Investigating novel biomarkers to improve 
diagnostic accuracy of central nervous system 
disease in childhood acute lymphoblastic 
leukaemia 
6.1 Introduction and aims 
The involvement of central nervous system (CNS) by acute lymphoblastic leukaemia 
(ALL) cells is routinely determined by microscopic examination of a small amount of 
cerebrospinal fluid (CSF) obtained by lumbar puncture. With this method approximately 
4% children are considered to have CNS leukaemia at diagnosis (Marwaha et al., 2010). 
However, the following lines of clinical and experimental investigation suggest that the 
frequency of CNS involvement at diagnosis may be higher:  
1. The majority of children with ALL, if left untreated, rapidly develop signs of overt 
CNS disease (Evans and Craig, 1964). 
2. Historic autopsy data prior to CNS prophylaxis) reveals involvement of the meninges 
in up to 70% cases (Azzarelli and Roessmann, 1977, Price and Johnson, 1973, Thomas, 
1965). 
3. CNS relapses are seen in patients with no evidence of CNS disease at diagnosis. 
4. In some, studies using more sensitive techniques such as flow cytometry and 
polymerase chain reaction (PCR), up to 50% patients test positive for the presence of 
leukaemia in their CSF samples (Scrideli et al., 2004, Martinez-Laperche et al., 2013). 
Notably, data from murine models (chapter 3) reveal a distinct histological pattern of CNS 
involvement by ALL. Leukaemic cells are seen to adhere to the meningeal surfaces rather 
than in a free-floating state. It can be argued that sampling a small volume of the CSF 
(from the lumbar spine) carries the risk of underestimating the true incidence of CNS 
disease. Therefore, it is necessary to test alternative methods to diagnose CNS disease. 
Various Studies have tested soluble biomarkers for the detection of CNS disease (Section 
1.3.7.4) However, many CNS-1 patients may potentially have submicroscopic CNS 
involvement (these could be considered to be false-negative cases). Consequently, any 
comparison between CNS-1 and CNS-3 patients will lack sensitivity.  Therefore, it is 
hypothesised that using a more sensitive technique such as quantitative PCR (qPCR) will 
more accurately define the group of patients with CNS disease and therefore be more likely 
to identify soluble biomarkers of CNS disease with good predictive value.  
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The long term aims of using such accurate diagnostic methods would be diagnosis, 
monitoring and prediction of overt CNS relapse. The envisaged potential of this is 
presented in Figure 6.1. 
This chapter present preliminary data that could lay the foundations for a larger multicentre 
clinical trial to address the aforementioned aims. The key questions addressed in this 
chapter are: 
1. Can qPCR using patient specific minimal residual disease (MRD) reagents be used to 
detect and monitor sub-microscopic levels of CNS disease? 
2. Can the levels of selected chemokines in the CSF correlate with sub-microscopic levels 
of CNS disease? 
In order to address these questions, CSF samples from children with ALL were collected 
and an ethically approved CSF Biobank was established to efficiently store and catalogue 
samples and clinical information. As DNA extraction from the low number of cells 
normally found in CSF could prove challenging, various DNA extraction and storage 
methods were compared. In order to test the frequency of sub-microscopic CNS disease, 
qPCR assays using patient specific TaqMan qPCR primers were utilized. Finally, levels of 
a panel of chemokines were analysed in CSF supernatants from CSF qPCR+ve vs. CSF 
qPCR-ve patients to assess whether these could be used as disease biomarkers. 
 
 
Figure 6-1: Envisaged potential for using more sensitive methods for the diagnosis of CNS 
disease in ALL. 
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6.2 Study design 
6.2.1 Ethics  
The study was conducted in accordance the ethical standards of the Helsinki declaration 
and was approval by West of Scotland research ethics committee (WoSREC reference: 
09/SO703/77).  
6.2.2 Study population 
From the period between July 2011 and July 2014, all patients diagnosed with ALL at the 
Royal Hospital for Sick Children (Yorkhill henceforth) were assessed for recruitment on 
the inclusion criteria. 
6.2.3 Inclusion criteria 
- All patients under the age of 18 years at the time of diagnosis with a first diagnosis 
of ALL diagnosed using standard criteria.  
- Willing to participate in the study. 
6.2.4 Exclusion criteria 
- Infants less than 1 year of age at diagnosis. 
- Patients diagnosed with mature B-ALL (Burkitt-like) or Lymphoblastic lymphoma. 
- Patients who have received prior ALL therapy except clinical urgency for no more 
than 1 week prior to their first lumbar puncture. 
6.2.5 Patient selection and enrolment 
Potentially eligible patients were identified at Yorkhill. All persons taking informed 
consents had received training in Good Clinical Practice (GCP). Parents were approached 
and the study aims and objectives were explained verbally and by written parent 
information leaflets. In case of children >6 years of age, and >10 years of age, separate 
patient information leaflets were also provided. It was explained to the parents that they 
were under no obligation to enter the study and they could withdraw at any time during the 
study. Following their interest, written informed consents were obtained from parents of 
patients. In cases where patients were enrolled in UK MRC trials and had given blanket 
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consent allowing the researchers to use leftover samples, additional consents were not 
obtained. Patients enrolled in UK MRC trials who had refused to give permission for the 
use of leftover samples, were not contacted for enrolment in the study. If patients chose to 
withdraw from the study, no further sample collection or analysis was performed. 
6.2.6 Treatment protocols 
Patients were treated under UKALL2003 (Vora et al., 2013), UKALL2011 or EsPhALL 
(Biondi et al., 2012) protocols. Patients with BCP-ALL received NCI risk assessed 
induction where NCI- low risk patients received 3 drug induction and NCI- high risk 
patients received 4 drug induction therapy. Patients with BCR-ABL1 positive ALL 
received additional Imatinib along with National Cancer Institute (NCI)- high risk 
induction therapy. All patients with T-ALL received NCI- high risk induction therapy. 
Subsequently, post induction therapy was stratified based on day 29 MRD results. Details 
of the UKALL2011 trial can be found online at: 
http://www.haematologyclinicaltrials.co.uk/trials/123. 
6.2.7 Data collection 
Following patient recruitment, patient clinical and demographic details were recorded from 
patient treatment files on a study proforma and stored in the study site file, located at 
Yorkhill. Data, managed electronically, were stored in a secure and encrypted computer at 
the Glasgow Biomedical Research Centre (GBRC).  
6.2.8 Initial sample processing 
Patients underwent lumbar puncture for sampling of the CSF. This procedure is performed 
under general/local anaesthesia. The procedure was performed by appropriately qualified 
and registered staff at Yorkhill. Approximately 1 ml fluid was withdrawn and transferred 
to the haematology laboratory for cytospin preparation and automated cell counting. 
Presence of leukaemic cells/normal leukocytes was recorded and CSF cell count was 
measured on an automated cell counter. After the appropriate diagnostic tests were 
performed, and verified by trained haematologists, leftover samples were transferred to the 
GBRC. Patient identifiers were replaced with the unique patient number (UPN) allocated 
at the time of recruitment. CSF cell pellets, supernatants and matched peripheral blood 
samples were stored at the CSF Biobank at -80 ºC till further use. A study flow chart is 
presented in the Figure 6-2 
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Figure 6-2 Scheme for patient recruitment and sample analysis 
Procedures indicated with: red font  were performed by the research nurses Alison Spence and Wendy 
Taylor, green colour were performed by team led by Sandra Chudleigh, and blue by clinical registrars and 
specialists. Procedures indicated with black font were my responsibility. 
6.2.9 Detection of leukaemic DNA  
During development, B- and T cell precursors undergo immunoglobulin (Ig) and T-cell 
receptor (TCR) gene rearrangement resulting in V(D)J sequences unique to the cell and its 
progeny. The clonal concept implies that leukaemic cells in a patient would carry identical 
Ig/TCR rearrangements. This principle is utilized for monitoring MRD by qPCR. The 
Glasgow MRD laboratory is part of the larger UKMRD laboratory network specialized for 
the analysis of MRD with a sensitivity of up to 1 leukaemic cell in 1 x 105 cells. This 
Flow chart for the study
Study site file 
maintained at 
Yorkhill
Clinical records and CSF 
samples catalogue 
electronically  
maintained at the GBRC
CSF Biobank 
maintained at the 
GBRC
Patient recruitment 
Bone marrow aspirated
Patient specific primers designed at
Glasgow MRD laboratory
CSF obtained
CSF cell count and cytology performed at 
Yorkhill
CSF supernatant 
stored in the biobank
DNA extracted from cell 
pellet 
Leftover CSF samples anonymized and 
transferred to the GBRC
DNA quantity assessed by
qPCR for Albumin gene 
PCR performed using 
patient specific primers 
CSF tested for 
soluble biomarkers 
New ALL
Consent obtained and patient enrolled in 
study. Unique patient no. allocated and 
Clinical information recorded in site file
Sample processing
213 
 
 
process involves identification of MRD targets by a screening method, designing and 
testing patient specific junctional primers (allele specific oligonucleotides or ASO 
primers), and testing for sensitivity and specificity of the targets. Standard curves 
constructed by serial dilution of diagnostic DNA are used to test the sensitivity of the assay 
and control (mononuclear cell (MNC)) DNA is used to test the specificity of the assay.  
6.3 Method optimization 
The CSF is a pauci-cellular fluid. The mean CSF cell count in neonates is approximately 9 
cells/µl (Kestenbaum et al., 2010), and sharply declines with age to approximately 2 
cells/µl in young children (Portnoy and Olson, 1985). Given the small volume of CSF 
available for analysis (300-500 µl), it was anticipated that the amount of amplifiable DNA 
extracted from the cell pellet might be extremely low. Therefore it was vital to test if 
conventional methods could achieve adequate DNA yield required for qPCR analysis. In 
addition, methods for DNA quantification were optimized. 
6.3.1 Optimization of DNA quantification 
In order to discriminate between samples truly negative for leukaemic cells and false 
negatives, it was essential to accurately quantify the extracted DNA. Spectrophotometric 
methods are widely used for DNA quantification. NanoDrop (Thermofisher) offers DNA 
measurement using UV- absorbance and requires a small volume for measurement (1 µl). 
However, this method was found to be unsuitable for our studies. NanoDrop lacked 
accuracy for two reasons: firstly the absorbance measurements were found to be affected 
by residual trace amounts of RNA and phenol, secondly, this method was not precise at 
low DNA quantities (data not shown). Therefore, it was decided to use qPCR based 
method to accurately assess DNA quantity and quality.  
qPCR is routinely used by the UK MRD labs to assess the quantity of DNA and provides 
accurate quantification of amplifiable DNA. TaqMan primers are designed to amplify a 
sequence in the albumin gene and a fluorescent probe is utilized to quantify the 
amplification of DNA. A drawback of this method is the requirement of up to 15 µl sample 
volume for the assay. CSF samples were analysed against known quantities of control 
DNA. This control DNA was extracted using peripheral blood mononuclear cells pooled 
from 20 healthy individuals (mononuclear cell DNA or MNC DNA). First, two different 
commercial TaqMan master mix solutions, QuantiTect Probe PCR Master Mix (Qiagen), 
and Gene expression Master Mix (Applied Biosystems), were tested to assess qPCR 
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efficiency. Both the solutions demonstrated equally efficient amplification when tested 
with control DNA serial dilutions (Figure 6-3a). Given that the QuantiTect probe PCR 
master mix is routinely used by the UK MRD labs, it was decided to use the QuantiTect 
probe PCR master mix henceforth.  
Next, DNA from primary CSF samples quantified using qPCR. Figure 6-3b demonstrates 
qPCR amplification in standard dilution of MNC DNA and DNA from a CSF sample. 
Unfortunately, the majority of CSF DNA samples were found to be below the quantifiable 
range. Therefore, it was necessary to use an arbitrary cut-off value to define adequate DNA 
amplification. DNA was considered as low quantity/poor quality and was excluded from 
the analysis if: (i) DNA amplification not seen until a Ct value of 38, (ii) there was greater 
than 1.5 Ct cycles difference between the triplicate wells, (iii) there was non-specific 
amplification in the NTC or MNC wells less than 3 Ct- from the samples, or (iv) there was 
no amplification in any of the triplicate wells.  
(a) 
 
(b) 
 
Figure 6-3: Optimization of DNA quantification 
Pooled DNA extracted from healthy controls (MNC DNA) was serially diluted. TaqMan primers against 
control gene (albumin) were used to amplify DNA. (a) Comparison between QantiTect Probe PCR master 
mix and Applied Biosystems Gene Expression master mix, (b) amplification of CSF DNA sample. 
In summary, two qPCR master mix solutions tested achieved comparable amplification 
efficiency. Due to the small quantities of DNA extracted from the CSF samples, 
qualitative measures for DNA amplification in qPCR were used. 
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6.3.2 Optimization of DNA extraction 
A number of methods exist for DNA extraction from primary samples. These include 
phenol/chloroform based methods such as Trizol®, bead based methods or silica-membrane 
column based commercial kits. Trizol® based DNA extraction is widely used for isolating 
DNA from primary human samples, and offers the additional benefit of simultaneous 
extraction of RNA and proteins. However, this method has not been widely tested for DNA 
extraction from low cell numbers. To increase the DNA yield using Trizol®, DNA co-
precipitants such as Glycogen or carrier RNA (cRNA) are frequently used. The co-
precipitants reduce non-specific adsorption of DNA and reduce the chances of loss of the 
DNA pellet during extraction due to improved visibility of the pellet. It was decided to 
initially test these methods on leukaemic cell lines grown in culture before testing on 
clinical samples. 
An initial set of experiments was performed to compare extraction efficiency of Trizol® 
with/without co-precipitants. SD1 cells (1 x 103- 105) grown in culture were lysed in 
Trizol® with or without co-precipitants (Glycogen, cRNA, and PelletPaint). DNA was 
extracted and subsequently assessed for amplification using qPCR primers specific for a 
sequence in albumin/CXCR7 gene. The results as shown in Figure 6-4a, demonstrate that 
the amplifiable DNA yield from 1000 leukaemic cells is extremely low even with co-
precipitants (Glycogen & cRNA). Although, the co-precipitant PelletPaint® significantly 
increased the DNA yield from cultured cells and CSF samples (Figure 6-4b & c). To test 
whether low amplification of DNA was due to PCR inhibitors in the eluted DNA, it was 
decided to test DNA-cleanup methods. Four DNA cleanup methods were tested including 
three commercial kits: Zymo Qick-gDNA® Micro prep (Zymo), Zymo DNA clean and 
concentrator kit (Zymo), and QiAMP DNA micro kit (Qiagen) and a manual clean-up 
method developed in our laboratory. None of these improved qPCR amplification of the 
extracted DNA (Data not shown).  
Next, column based commercial kits were tested for DNA extraction. Of these (Qiagen 
DNEasy mini kit, Gentra puregene blood kit, High pure PCR cleanup micro Kit, QiAMP 
DNA micro kit) only QIAmp DNA Micro kit achieved adequate yield of DNA from small 
samples. As can be seen in Figure 6-4d, whilst Trizol® based method had a better DNA 
extraction efficiency at higher cell numbers, more amplifiable DNA was recovered with 
the QiAMP DNA micro kit at low (1 x 103-104) cell numbers. 
 
216 
 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
Figure 6-4: Optimization of DNA extraction methods  
DNA was extracted from cultured SD1 cells/ patients CSF samples, and relatively quantified using real time 
qPCR. Primers were specific for Albumin/CXCR7 gene. (a) DNA from 1000 cells using Trizol®, Trizol plus 
Glycogen as carrier, and Trizol® plus cRNA (n=3), (b) DNA from 1000 cells with Trizol® alone & Trizol® 
plus PelletPaint® (n=3 & 6 respectively). (c) DNA extracted from randomly selected CSF samples from ALL 
patients using Trizol® and Trizol® plus PelletPaint® (n=7,13 respectively). (D) DNA from serial dilutions 
(106-1000 SD1) using Trizol or QIAmp DNA micro kit (n=3). PCR Cycle threshold was subtracted from 40 
(40-Ct) and plotted with bars representing mean ± SEM. Data were analysed using Mann-Whitney U test. 
*p<0.05, **p<0.01, ***p<0.005 
 
In summary, a number of methods for DNA extraction were compared. Use of the co-
precipitant PelletPaint improved yield from samples lysed in Trizol. QiAmp DNA micro 
kit significantly improves DNA yield from 1000-10000 cells in comparison with any of 
the other methods tested. 
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6.3.3 Effect of storage and shipment on DNA yield 
Leukaemic cells have a limited viability in the CSF following removal by lumbar puncture. 
One aim of this study was to determine if qPCR based analysis could be conducted in a 
multi-centre setting with a core facility performing the qPCR assays. This would permit 
standardization and increase patient numbers. For this purpose, it was necessary to assess 
the effect of storage and shipment conditions on the quality of DNA. In order to test 
whether amplifiable DNA could be recovered from samples sent from national centres, 
CSF samples were exposed to postal conditions and then assessed for DNA yield.  
The CSF sample was then centrifuged and the acellular supernatant was divided in 18 
tubes (1ml/tube), and spiked with 1 x 106 SD1 cells. Subsequently, the cell suspension was 
diluted with equal volumes of RPMI or DNAGuard® Blood (Biometrica), or left untreated. 
RPMI has been shown to be a preservative for CSF DNA (Pine et al., 2005), whereas 
DNAGuard® blood is marketed as a DNA preservative. These samples were subjected to 
storage at ambient temperature for various time points up to 7 days. One set of samples 
was subjected to postage through the Royal Mail postal services. DNA was extracted after 
each time point and was assessed for amplifiability using qPCR. Figure 6-5 shows DNA 
ampifiability after (a) 7 days storage at room temperature, and (b) 7 days with shipping at 
ambient temperature. The results show that amplifiable DNA could be achieved without 
any additives or with addition of RPMI after incubation at these time points and shipping 
conditions. DNAGuard blood showed inferior DNA preservation.  
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(a) 
 
(b) 
 
Figure 6-5: Effect of storage and shipping on CSF DNA yield 
CSF supernatant from one ALL patient was spiked with in vitro cultured SD1 cells and subsequently diluted 
with RPMI or DNAguard® blood. Samples were incubated at ambient temperature for (a) 7 days or (b) posted 
to a residential address in Glasgow and posted back to the GBRC. DNA extracted and amplified using PCR 
with primers specific for a sequence in CXCR7 gene.. Bar graphs of Ct values subtracted from 40 (Ct-40) are 
presented. Each experimental condition was carried out in triplicates and each replicate analysed in triplicate 
wells on qPCR. Data were analysed using two-tailed unpaired Student t tests. Bars represent mean ± SEM. 
*p<0.05, **p<0.01 
In summary, amplifiable DNA can be extracted from CSF samples left at room 
temperature for up to 1 week with or without shipping. Use of DNA stabilizer 
DNAGuard® blood or RPMI does not improve DNA yield in comparison with samples 
without any preservative. 
 
6.3.4 Optimization of patient specific (ASO) primers and probes 
The qPCR method for MRD detection requires a relatively large amount of DNA (50-100 
ng/ul). Furthermore, a potential drawback of this method was the risk of false negative 
results due to clonal evolution or secondary rearrangements in the V(d)J regions in the CSF 
compartment. For the purpose of bone marrow MRD, at least two different sets of primers 
are used. However, due to the small quantities of DNA isolated from CSF, this was not 
always possible. Bone marrow MRD method detects leukaemic cells on a background of 
normal cells. Furthermore, accurate quantification of residual leukaemia in the bone 
marrow is of vital importance to clinical decision-making. However, it was anticipated that 
leukaemic cells in the CSF would not be a minor component of the CSF cell population. 
Also, the aim was to detect the presence of leukaemic cells and quantification was not 
necessary. Allele specific oligonucleotides (ASO primers) were designed and qPCR run 
conditions were optimized at the Glasgow MRD laboratory according to the Biomed-II 
guidelines. It was aimed to utilize two sets of ASO primers/patient wherever possible. 
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An arbitrary cut-off value for the CSF qPCR positivity was set. For a CSF sample to be 
considered positive, the following criteria must be met: 
- PCR amplification must be seen before Ct value of 40. 
- At least 2/3 wells must show amplification in the qPCR reaction. 
- Amplification in the wells should not be more than 1.5 Ct cycles apart. 
- MNC or NTC wells should not amplify within 5 Ct cycles of CSF DNA samples. 
6.4 Detection of CNS disease by PCR 
During the period from July 2011 – July 2014, 66 patients were diagnosed with ALL at 
Yorkhill. Out of these, 62 were assessed for eligibility. Following assessment on inclusion 
criteria, 57 patients were enrolled in the study. A study flow chart is present in Figure 6-6. 
 
Figure 6-6: Flow chart for patient recruitment and analysis 
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¨ Declined to participate (n= 5 )
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6.4.1 Clinical and demographic features of recruited patients 
The median age of children was 4.7 years (±4.3) with approximately 77% children <10 
years of age. The ratio of boys to girls was 2:1. The majority of patients had BCP-ALL 
(88.9%) and the most common cytogenetic abnormality was High Hyperdiploid (37%) 
followed by t(12;21) (18.5%). Upon microscopic examination of the CSF cytospins, 50 
patients (87%) had CNS-1 disease while traumatic lumbar puncture (TLP) was seen in 7 
patients (12.3%). These findings are presented in table 6.1. Clinical features of ALL 
patients from two large cohorts (SJCRH and BFM) is presented for comparison. 
Characteristic   no.  (%)  SJCRH* BFM** 
Age (years) <10 44  77.1%  74.1% 82.1% 
 
>10 13  22.9%  25.7% 17.9% 
Sex Male 38  66.7%  56% 57.9% 
 
Female 19  33.3%  44% 42.1% 
Immunophenotype BCP-ALL 51 89.4%  82.6% 86.5% 
 
T-ALL 6  10.6%  15.4% 13.5% 
Cytogenetics t(9;22) 1  1.9%  2.4% 2.2% 
 
MLL-rearranged 3  5.6%  3.0% 2.9% 
 
t(12;21) 10  18.5%  18.9% 
 
  High Hyperdiploid 21  36.8%      
WCC <10 28  49.1%  46.2% 45.9% 
(x 109/L) 10-50 22  38.5%  29.3% 31.8% 
 
>50 7  13%  24.5% 22.3% 
CNS disease CNS1 50 87.7%  
  
 
TLP- 3  5.2%  
  
 
TLP+ 4  7.0%  
  
 
CNS-3 0 0%  2.7% 2.5% 
Anaemia Hb<8g/dl 30 52.6%  51.8% 53.7% 
 
Hb>8g/dl 27 47.4%  48.2% 46.3% 
Table 6-1 Demographic and clinical features of recruited patients in comparison with SJCRH 
and BFM trial cohorts 
*SJCRH, St. Judes children Research Hospital (1979-2002), **BFM, Berlin-Frankfurt-Munster 90 (1990-
95). Adopted from (Liang and Pui, 2005) 
6.4.2 Frequency of CSF qPCR positivity at diagnosis 
Of 57 patients enrolled in the study, 4 patients had no leftover CSF for analysis and 7 
patients samples had poor quality DNA (albumin amplification >38 Ct cycles). In addition, 
5 patients were excluded due to lack of suitable primers, 3 qPCR assays had to be excluded 
for other technical reason. Therefore, diagnostic samples from 38 patients were available 
for qPCR analysis. A single primer set was utilized in 18 patients and two primer sets each 
were used for the remaining 20 patients.  
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Out of the 38 patients analysed for CNS disease by qPCR (CSF qPCR henceforth), 15 
(39.5%) tested positive for leukaemic DNA whereas 23 (60.5%) were negative for CSF 
qPCR. Comparison of clinical and cytogenetic features of CSF qPCR +ve patients with 
CSF qPCR –ve patients revealed an association with a higher WCC (mean 26.6 x 109/l vs 
19.4 x109/l) and high risk cytogenetics (p=0.04). Interestingly, 2/5 (40%) patients with 
WCC>50 x 109/l tested positive in comparison with 9/14 (64%) patients with WCC 10-50 
x 109/l. A trend towards male sex was also noted (50% vs 21%), although this was not 
significant (p= 0.1). 
 
 
Variable Category QPCR+ve QPCR-ve 
 
 
 
n % n % 
    15 39.5% 23 60.5% p-value*  
Age <10 year 12 39% 19 61% 0.839  
  >10 years 3 43% 4 57%    
Sex Male 12 50% 12 50% 0.101  
  Female 3 21% 11 79%    
Immunophenotype BCP-ALL 12 35% 22 65% 0.280  
  T-ALL 3 75% 1 25%    
WCC <10 4 21% 15 79% 0.043  
 (x109/L) 10-50 9 64.3% 5 35.7%    
 >50 2 40% 3 60%   
CNS status CNS-1 11 35% 20 65% 0.084  
  TLP+ 4 80% 1 20%    
  TLP- 0 0% 2 100%    
Cytogenetic risk Low risk 7 28% 18 72% 0.04  
  High risk 3 100% 0 0%    
  Others 5 50% 5 50%    
Day 29 MRD High risk/ MRD risk 8 50% 8 50% 0.258 
 
  
Low 
risk/standard 
risk 
7 35% 15 65%   
 
Table 6-2 Comparison between CSF qPCR+ve and qPCR –ve patients 
*calculated using Chi square test 
cytogenetic risk: 
Low risk  t(12;21), High hyperdiploid 
High risk t(9;22), MLL-rearranged 
Others t(7;9), del 12p, t(9;18), complex cytogenetics of uncertain origin 
 
 
6.4.2.1 Concordance between cytology and qPCR 
In 5 patients with TLP+ve status (traumatic lumbar puncture with blasts) 4 tested positive 
when assessed using CSF qPCR. One patient (#5) with TLP+ve status tested negative. This 
patient had a CSF WCC of <0.001/l and on CSF cytospin analysis, the majority of white 
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cells were normal with occasional blasts. As mentioned above, no CNS-3 cases were 
available for analysis. 
6.4.2.2 Concordance between qPCR targets within individual patients 
Two qPCR targets each were used for the 7 patients who tested positive for CNS disease 
using CSF qPCR. Of these, 4 patients had both targets amplified while target amplification 
in 1/2 targets was seen in 3 patients. In cases where both targets amplified, similar 
amplification efficiencies of both the targets were seen. Representative qPCR amplification 
plots are presented in Figure 6-7. 
(a) 
 
(b) 
 
(c) 
 
  
Figure 6-7 CSF qPCR detection by PCR 
Real time PCR reactions were performed for 50 thermal cycles using Applied Biosystems 7500 Real Time 
thermal cycler. Data were analysed using 7500 SDS software v2.0.6. Representative amplification plots of 
patients with CSF qPCR positivity by (a) 2/2 qPCR ASO targets and (b) 1/2 qPCR ASO targets. (c) CSF 
qPCR negative case. 
In summary, diagnostic CSF DNA samples from 38 patients were analysed for presence 
of leukaemic DNA. Fifteen (39.5%) tested positive while 23 (60.5%) were negative. High 
risk cytogenetics and a WCC between 10-50 x 109/L were seen in association with qPCR 
positivity.  
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6.4.3 Frequency of qPCR positivity during treatment 
Following the diagnosis, patients are treated with an intensive induction regimen in the 
first month. At day 29 of treatment, bone marrow MRD is measured for response to 
treatment. During this period, patients receive intrathecal therapy along with CSF 
examination for leukaemic blasts in the CSF. In order to test whether treatment during the 
induction phase could eliminate submicroscopic levels of disease from the CNS in CSF 
qPCR positive patients, samples from patients during the induction phase of treatment 
were analysed. To test this, follow up samples from 10 qPCR negative and 9 qPCR 
positive patients were tested. All the day 29 samples tested negative for leukaemic DNA. 
Day 8 and day 15 samples from patient #37 tested positive. Patient #37 had a traumatic 
lumbar puncture at diagnosis. Notably, the diagnostic sample from this patient was 
negative by qPCR. In retrospect, this patient was included in the analysis as CSF qPCR 
positive. Samples from all other (CSF qPCR +ve and –ve) patients tested negative for day 
8and day 29 of induction phase. Representative data are presented in Figure 6.2. Overall, 
these results show that qPCR positive disease is cleared from the CSF during the induction 
phase of treatment.  
 
Figure 6-8 CSF qPCR positivity during induction chemotherapy 
CSF DNA samples from diagnosis and during the induction period were tested by qPCR. Representative data 
from 6 patients with and without CSF qPCR positive disease. 
In summary, qPCR analysis of diagnostic CSF DNA from 15/38 patients demonstrated 
amplification of at least one qPCR target. Amplification of two targets was seen in 4/7 
patients. Patients with qPCR positive disease at diagnosis became CSF qPCR negative at 
the end of induction phase. 
1 8 21 29
#26
#10
#31
#2
#1
#37
CSF PCR +ve
Low DNA yield
CSF PCR-ve
Time points (days)
UP
N
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6.4.4 Analysing chemokines as novel biomarkers for CNS disease 
Having established a cohort of patients with CSF qPCR positive disease, it was aimed to 
test the levels of candidate biomarkers of CNS disease. Although CSF qPCR appears to be 
a more sensitive tool in detecting and monitoring CNS disease, this method is technically 
challenging and expensive. Having established that ALL cells possess a repertoire of 
chemokine receptors on their cell surface it was hypothesised that measurement of their 
cognate ligands in the CSF may identify patients with leukaemia cells residing in this 
compartment. Luminex technology allows simultaneous detection of multiple soluble 
proteins in a small volume of samples. A panel of candidate chemokines (CXCL9, 
CXCL10, CXCL11, CXCL12, CCL19, CCL21, CCL2, CXCL13 and IL10) was selected to 
analyse the differences in the levels in CSF qPCR positive and negative patients. 
Diagnostic CSF supernatant samples from 15 CSF qPCR+ve and 23 CSF qPCR negative 
patients were utilized. In addition, CSF supernatant samples from 10 patients with benign 
intracranial hypertension (BIH) were used as controls. Details of individual patients and 
controls is presented in Table 6.3. 
  
225 
 
 
ID Age  Sex Diagnosis Cytogenetics CNS 
status 
WCC  
(x109/L) Day 29 MRD 
CSF 
qPCR 
status 
Outcome Follow 
up (yr) 
#1 7.9 F BCP-ALL High hyperdiploid 1 1 High risk No CCR 2.4 
#2 17.1 M BCP-ALL t(9;22) 1 98.49 High risk yes CCR** 2.0 
#3 11.1 F BCP-ALL dic(7;9)  Unbalanced transloccation p7 and p9  1 23.8 High risk No 
Refractory 
disease 2.3 
#4 2.8 F BCP-ALL High hyperdiploid 1 9.1 Risk No CCR 0.4 
#5 6.4 M BCP-ALL DER (1,16), DER 3,+9, DEL12p TLP +ve 3.6 Low risk No CCR 3.2 
#6 15.0 F BCP-ALL t(9;18) TLP -ve 167.5 High risk No CCR 2.8 
#7 2.7 M BCP-ALL High hyperdiploid 1 82 Risk No CCR 2.0 
#8 6.2 F BCP-ALL High hyperdiploid 1 11.7 Risk No CCR 0.6 
#9 3.9 M BCP-ALL High hyperdiploid 1 33.2 Risk yes CCR 1.1 
#10 14.2 M T-ALL Normal Karyotype 1 6.4 High risk No CCR 3.3 
#11 1.1 M BCP-ALL MLL rearrangement  1 3.2 Low risk Yes CCR 0.7 
#12 2.4 M BCP-ALL Normal karyotype 1 11.1 Low risk Yes CCR 3.0 
#13 10.3 M BCP-ALL Normal Karyotype 1 1.8 High risk No CCR 2.3 
#14 2.5 M BCP-ALL High hyperdiploid 1 2 Low risk No CCR 1.5 
#15 3.8 M BCP-ALL t(12;21) 1 10.6 Low risk No CCR 3.2 
#16 6.1 M BCP-ALL High hyperdiploid 1 2 Low risk Yes CCR 1.3 
#17 4.9 M BCP-ALL t(12;21) 1 52 Low risk No CCR 2.3 
#18 9.1 M T-ALL Normal Karyotype 1 36.4 High risk Yes CCR 2.2 
#19 1.1 M BCP-ALL High hyperdiploid 1 17.6 Risk No CCR 1.9 
#20 4.9 M BCP-ALL High hyperdiploid 1 6.9 Risk No CCR 1.6 
#21 1.7 F BCP-ALL High hyperdiploid 1 2.7 Risk Yes CCR 1.3 
#22 2.7 M BCP-ALL High hyperdiploid TLP+ve 10.8 Low risk Yes CCR 2.8 
#23 3.5 M BCP-ALL t(12;21) TLP+ve 46 Low risk Yes CCR 2.8 
#24 2.3 F BCP-ALL High hyperdiploid 1 3.2 Risk No CCR 0.4 
#25 5.5 F BCP-ALL High hyperdiploid 1 4.2 MRD Risk No CCR 2.1 
#26 5.4 F BCP-ALL Normal Karyotype 1 28 Low risk Yes CCR 2.8 
#27 6.0 F BCP-ALL High hyperdiploid 1 1.1 Low risk No CCR 2.1 
#38 2.5 F BCP-ALL t(12;21) 1 19.1 MRD risk No CCR 2.0 
#29 3.7 M BCP-ALL t(12;21) 1 4.9 MRD Risk No CCR 0.5 
#30 2.6 F BCP-ALL High hyperdiploid 1 6.2 Low risk Yes CCR 1.8 
#31 5.4 M BCP-ALL t(12;21) 1 5.3 Low risk No CCR 3.1 
#32 2.1 M T-ALL Normal Karyotype 1 56.5 Low Risk Yes CCR 1.8 
#33 3.3 M BCP-ALL High hyperdiploid 1 1.7 MRD Risk No CCR 1.9 
#34 13.9 M T-ALL NA 1 28 Risk Yes CCR 1.3 
#35 3.2 F BCP-ALL High hyperdiploid TLP-ve 3.1 Low risk No CCR 0.5 
#36 10.8 M BCP-ALL High hyperdiploid TLP +ve 13.6 High risk Yes CCR 2.2 
#37 2.3 M BCP-ALL 11q23 TLP+ve 23.4 High risk Yes CCR 2.9 
#38 3.5 F BCP-ALL NA 1 8.1 Low Risk No CCR 1.6 
Controls  
#39 25.9 F BIH     
 
        
#40 27.3 F BIH     
 
        
#41 65.5 F BIH     
 
        
#42 39.2 F BIH     
 
        
#43 25.6 F BIH     
 
        
#44 30.9 F BIH     
 
        
#45 45.9 F BIH     
 
        
#46 27.7 F BIH     
 
        
#47 35.7 F BIH     
 
        
#48 27.0 F BIH     
 
        
Table 6-3 Raw data of individual patients  
CCR= continuous clinical remission, NA= not available, BIH= benign intracranial hypertension 
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Analysis of CXCR3 ligands (CXCL9, CXCL10 and CXCL11) revealed that there was 
overall low levels of both CXCL9 (15.8 ± 5.4 pg/ml) and CXCL10 (105.1 ± 24.1 pg/ml) in 
CSF supernatants. Levels of CXCL11 were negligible (1.04 ± 0.39 pg/ml). Remarkably, 
levels of CXCL9 and CXCL10 were modestly lower in CSF qPCR+ve group (7.96±2.3 & 
88.74±59.36 respectively) compared to CSF qPCR-ve (25.9±10.8 & 94.0 ±30.6 
respectively) and control groups (5.1±0.8 & 155.1 ± 28 respectively) (Figure 6-9). 
Similarly, levels of CXCR4 ligand CXCL12 were lower in the CSF qPCR+ve (18.1±10.9) 
group in comparison with CSF qPCR-ve (23.1 ± 7.5) and controls (105.8 ±17.8). Analysis 
of CCR7 ligands CCL19 and CCL21 showed similar trends. Levels of CCL21 were higher 
than CCL19 (808.3±87.5 vs 4.1± 0.69). Notably, CCL21 levels in the CSF qPCR+ve group 
(473.5±123.5) were significantly lower than CSF qPCR-ve (690±91.7) and control groups 
(1582±141.8).  
CCL2 (monocyte chemotactic protein 1 or MCP1) is a ligand for CCR2 and CCR4. Levels 
of CCL2 were found to be significantly lower in CSF qPCR+ve group (60.4±10.1) 
compared to CSF qPCR-ve group (86.8±7.6). Finally, CXCL13 and IL-10 levels have been 
shown to be candidate biomarkers of primary CNS lymphoma (Rubenstein et al., 2013). 
However, in our cohort, the levels of CXCL13 were beyond the quantitative range of the 
assay whereas IL-10 levels were undetected in any of the CSF samples analysed. 
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
(f) 
 
(g) 
 
(h) 
 
Figure 6-9 Levels of chemokines in CSF qPCR +ve and CSF qPCR –ve patients 
CSF supernatants from CSF qPCR +ve (n=15), CSF qPCR –ve (n=23) and the control (n=10) groups were 
tested for the levels of selected chemokines using Luminex assay. Individual values are presented along with 
mean ± SEM. Data were analysed on log transformed values using Two-tailed independent samples t- tests. 
*p<0.05, **p<0.01, ***<0.001. Levels for CXCL13 were not analysed statistically as the majority of values 
were lower than the quantifiable range. 
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Due to the small differences in the levels of the selected chemokines between the groups, it 
was clear that the diagnostic utility of these as biomarkers of CNS disease would be low. 
To confirm this, receiver operating curve (ROC) analysis was performed. Levels of 
chemokines in CSF qPCR positive and negative cases were plotted to measure the area 
under curve (AUC) to evaluate the diagnostic accuracy of measuring chemokines to predict 
CNS disease. This would identify an optimum cut-off point where the levels of a 
chemokine can predict CSF qPCR positivity with an optimum sensitivity and specificity. 
As expected, analysis by ROC revealed poor predictive ability of chemokine levels for 
CSF qPCR positivity. As can be seen in Figure 6-10a, the plotted values for the 
chemokines (indicated with colours) illustrate a narrow area above the diagonal line, 
indicating low sensitivity and specificity. A cut-off point where chemokine levels could 
predict CSF qPCR positivity with a high sensitivity and specificity could not be identified 
(Figure 6-10b). 
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(a) 
 
(b) 
 Chemokine Cut-off   
levels (pg/ml) 
Sensitivity Specificity 95% CI 
 CXCL9 <2.5 82.6% 7% 42.4-79.1 
 CXCL10 <10.1 87% 60% 56.3-92.7 
 CXCL11 <1.2  21.7% 87.3% 48.7-86.4 
 CCL21 <215.0  87% 47% 48.9-86.8 
 CCL19 <1.4 82.6% 40% 42.9-80.3 
 CCL2 <50.4 87.3% 46.7% 59.4-92.5 
 CXCL12 <1.4 42.6% 40% 44.6-81.4 
Figure 6-10 ROC analysis for diagnostic accuracy of chemokine levels to predict CSF qPCR 
positivity 
(a) ROC analysis to measure area under curve (AUC) for diagnostic accuracy of the levels of selected 
chemokines.  (b) Selected cut-off values of chemokines to discriminate between CSF qPCR positive and 
negative cases. Values calculated using chemokine levels from diagnostic samples from 15 CSF qPCR 
positive and 23 CSF qPCR negative patients. Data were analysed using SPSS (v21) (IBM) software.  
 
In summary, the results from Luminex assay show that the levels of CXCL9, CXCL10, 
CCL21 and CCL2 in CSF qPCR +ve patients were generally lower than the CSF qPCR -
ve patients. However, these levels do not appear to be of any diagnostic utility. 
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6.5 Discussion 
The main aim of this study was to identify the incidence of sub-microscopic levels of 
leukaemia in the CNS in children with ALL using qPCR and Luminex assays. Preliminary 
work included: initiating patient recruitment allowing large numbers of data points 
required for the study, setting up a human tissue biobank to collect and store CSF, blood 
and bone marrow samples from patients, and optimization of methods required for the 
aforementioned aims. A cohort of 38 patients was analysed for qPCR detection of 
leukaemia and 15 patients tested positive for presence of sub-microscopic levels of disease 
in the CNS by qPCR. Subsequently, to try and identify proteins which could be used as a 
biomarkers of CNS disease in ALL patients, the concentrations of a panel of candidate 
chemokines and IL-10 were compared in CSF of CSF qPCR+ve and CSF qPCR-ve 
patients and that of a control group. 
It was shown that amplifiable DNA could be extracted from CSF samples for up to one 
week without adding any preservative. Pine et al. (2005) reported a similar series of 
experiments with primary samples and have demonstrated that use of RPMI as an additive 
considerably improve the otherwise poor DNA yield from primary CSF samples. Results 
presented in this chapter do not show superiority of RPMI as an additive for DNA stability. 
This contrast could be due to the use of CSF supernatant spiked with a relatively large 
number (1 x 106/ml) SD1 cells. Immortalized cell lines in comparison to primary cells may 
be more resistant to degradation in the CSF. An alternate approach to obtaining patient 
samples could be that the DNA extraction could be performed at the local centres and 
purified DNA, which is stable at room temperature, transferred to the core facility.  
Real-time qPCR has previously been utilized to detect leukaemic DNA in the CSF (Pine et 
al., 2005, Scrideli et al., 2004, Biojone et al., 2012). However, consensus primers used in 
these studies require additional analysis of the qPCR products for specificity of 
amplification. The leukaemia specific ASO primers for the detection of leukaemic DNA in 
the CSF offers the advantage of very high specificity for leukaemic DNA. In addition, 
these primers are routinely designed and optimized for all the patients in the UK. 
Therefore, CSF analysis for leukaemia can potentially be performed within an already 
established setup for the bone marrow MRD.  
qPCR on CSF DNA identified 39.5% patients as having submicroscopic levels of 
leukaemia. This percentage of qPCR positivity is consistent with the previously reported 
46.8 % (Biojone et al., 2012) and 45.9% (Scrideli et al., 2004) of PCR positivity. However, 
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Pine et al. (2005) reported only 3/23 samples from CNS-1 patients amplified by qPCR. It is 
possible that technical issues with sample processing such as the in-house method for DNA 
extraction might have underestimated the frequency of occult CNS disease. In some cases, 
only one of the two tested qPCR targets showed amplification. Differences in qPCR 
amplification efficiency of these primers could account for such discordance. Alternately, 
evolution of leukaemic clones in the CNS may be responsible. Interestingly, in the study 
by Scrideli et al. (2004), two patients had clonal rearrangements that differed from bone 
marrow sequences. If leukaemic cells in the CNS are evolved clones, then using ASO 
primers may underestimate the true frequency of CNS disease.   
The demographic and clinical features of the patients recruited were similar to the global 
ALL population, suggesting that there was very little sampling bias. CSF qPCR positivity 
at diagnosis was associated with a high WCC and high risk cytogenetics – a risk factor for 
CNS relapse. Most patients with TLP tested positive at diagnosis or during the induction 
period. The question arises whether these patients should have been included in the 
analysis. TLP status at diagnosis has disputed significance. Patients with a traumatic 
lumbar traditionally have a worse outcome (Gajjar et al., 2000). However, a link of TLP 
with increased CNS risk is not well established (te Loo et al., 2006, Burger et al., 2003). 
TLP may introduce leukaemic blasts in the CNS which might adversely affect outcome. 
Alternately, TLP at diagnosis may reflect an overall aggressive nature of the disease. For 
instance coagulopathy or a high WCC increase the risk of TLP (te Loo et al., 2006). 
Further analysis of larger numbers of patients would be required to establish whether TLP 
is an independent risk factor for CNS relapse.  
Follow up CSF qPCR measurements at day 29 were negative for all the patients analysed, 
suggesting efficient clearance of CNS disease. In the relatively short duration of follow up 
(2.0 ±0.9 years median ±SD) no CNS or bone marrow relapses were observed.  This raises 
questions regarding the significance of low level CNS disease at diagnosis. If the majority 
of the CSF qPCR positive patients achieve clearance of the CNS disease with conventional 
treatment, will monitoring of low level disease provide useful assessment of risk? The 
significance of low number of CSF blasts (CNS-2) is debated. Some authors have reported 
the poor prognostic value of small number of blasts in the CSF at diagnosis. (Mahmoud et 
al., 1993) However, others have disputed this observation. (Gilchrist et al., 1994, Burger et 
al., 2003, te Loo et al., 2006) Similar controversy exists about the presence of 
submicroscopic disease at diagnosis. Earlier studies reported an association between 
submicroscopic CNS disease the risk of relapse (Scrideli et al., 2004), however more 
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recent studies have shown no association with the outcome (Martinez-Laperche et al., 
2013, Biojone et al., 2012). This improved outcome in the more recent studies appears to 
be associated with the higher intensity of the more recent treatment regimen. For instance, 
Biojone et al. (2012) have shown that CSF qPCR positive patients had a significantly 
higher relapse rate and poor outcome in patients treated with low-intensity treatment 
protocol. However, when an independent cohort with CSF qPCR positivity was treated 
with high intensity treatment regimen, no differences in the EFS were observed. Therefore, 
more intensive protocols eliminate the adverse significance of subclinical CNS disease. 
However, it may also indicate that high intensity protocols may considerably over treat 
patients. 
The majority of patients in our cohort belonged to MRD low-risk group, with 60% patients 
in this group testing negative for CNS disease by CSF qPCR. This is an attractive group 
for dose reduction strategies. Recently, reduction in post-induction maintenance therapy in 
MRD-low risk patients was carried out successfully without any increase in adverse events 
(Vora et al., 2013). Similar principles can be applied to this group at a low potential risk of 
CNS relapse. Although a number of factors may still be considered. For instance, the fact 
that leukaemic cells primarily reside within the CSF compartment and may not always be 
detected in the CSF – even with the most sensitive diagnostic methods. In addition, if 
leukaemic cells in the CNS are clonally evolved then the qPCR primers may show false 
negative results. 
One aim of this chapter was to test soluble biomarkers of CNS disease which could help 
better risk-stratify patients with CNS disease and inform on biology of CNS disease. 
Generally, levels of selected chemokines were found to be marginally lower in the CSF 
qPCR positive patients compared to CSF qPCR negative patients. Such a phenomenon has 
previously been reported in the bone marrow – a CXCR4 dependent site – where levels of 
CXCL12 were significantly lower in ALL patients compared to normal controls and rose 
significantly with treatment (van den Berk et al., 2014). Another case report has shown 
lower levels of CCL2 in association with CNS disease (Eisenkraft et al., 2006). An 
intriguing hypothesis is that the leukaemic blasts in the CSF compartment may utilize the 
chemokines secreted by the CNS micro-environment thus lowering the levels in the CSF. 
Primary CNS lymphoma cells have been shown to secrete high levels of CXCL13 and IL-
10. CSF levels of these biomarkers are not only associated with poor outcome, but also are 
highly specific for the diagnosis of primary CNS lymphoma (Rubenstein et al., 2013).  In 
my cohort, CSF levels of these candidate biomarkers were found to be very low (CXCL13) 
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or absent (IL-10) in the CSF. It is not known whether ALL cells express/secrete IL-10 or 
CXCL13 – these results suggest they do not. Due to unavailability of age matched healthy 
controls, samples from a considerably older group with benign intracranial hypertension 
were used.  
The results from this chapter present data that may be of relevance to clinical decision-
making and may improve our understanding of the biology of CNS disease. However, 
several limitations must be acknowledged. The data are generated from a relatively small 
group of patients, and do not include infant ALL – a group at risk of CNS relapse. 
Furthermore, samples from 7 patients had to be excluded from the analysis due to low 
DNA yield. Whether this low yield represent lack of leukaemic cells in the CNS 
compartment, or is merely due to poor sample quality cannot be ascertained. In addition, it 
is theoretically possible that leukaemic blasts localized to the meningeal surface may not 
be sampled in the CSF, thus reducing the sensitivity of the CSF qPCR technique. Data 
presented in chapter 3 lends some support to this hypothesis. A longer follow-up of such 
CSF qPCR –ve patients will help to analyse this. Diagnostic imaging techniques such as 
magnetic resonance imaging (MRI) allow identification of localized deposits, however, 
these are currently not sensitive and only identify advanced disease. Advanced high 
resolution imaging with 7-t MRI has shown promise in detecting lesions in MS. This can 
potentially be very useful in detecting CNS lesions in ALL as well (Gaitan et al., 2014). 
In summary, it is shown that submicroscopic levels of leukaemia are commonly present in 
patients without cytological evidence of CNS disease. Follow up of such patients show 
rapid clearance of disease from the CSF compartment. Using qPCR for the detection of 
leukaemia appears to be feasible for the diagnosis and monitoring of CNS disease, 
although the effect of CSF qPCR positivity on the long term outcome remains to be seen. 
In this chapter, methods for DNA extraction and analysis have been optimized. It is 
proposed that CSF qPCR monitoring can be incorporated into the routine bone marrow 
qPCR monitoring. Alternatively, more sensitive and informative genomic strategies using 
next-generation sequencing (NGS) technology can be utilized to detect CNS disease. 
Detection of bone marrow MRD by Immunoglobulin gene rearrangement analysis using 
NGS has shown comparable efficacy with the added advantage of analysis of clonal 
heterogeneity (Faham et al., 2012). Analysis of paired bone marrow and CNS samples can 
be more informative than ASO qPCR method. Not only would such an analysis measure 
precisely the frequency of CNS disease but also will inform on biological questions such as 
clonal relationship between the bone marrow and CNS blasts. 
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7 General discussion and conclusions 
7.1 Summary of findings 
This thesis sets out with the broad aims to investigate the mechanisms underlying central 
nervous system (CNS) disease in childhood acute lymphoblastic leukaemia and focusses 
on the frequency, pattern and molecular and cellular determinants that could be associated 
with CNS disease. The major findings from the previous chapters are summarized below: 
1. CNS infiltration is commonly seen in B-cell precursor (BCP)-acute lymphoblastic 
leukaemia (ALL) cells engrafted in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. 
Contrary to the clinical presentation of patients, the majority of mice engrafted with BCP-
ALL cells from patients with CNS-1 disease demonstrated heavy CNS infiltration. 
Histological examination of mice brains clearly showed that the leukaemic cells reside 
within the cerebrospinal fluid (CSF) compartment, mostly seen as plaques of disease in the 
leptomeninges. This implies that cells transit across the blood-CSF barrier (BCSFB). CNS 
parenchyma was sparingly devoid of leukaemia.  
2. CNS infiltrating leukaemic cells are common and present in all tested 
immunophenotypic sub-populations of BCP-ALL and at least 1/10 leukaemic cells possess 
the ability to infiltrate the CNS.  
3. BCP-ALL cells differentially express a variety of leukocyte trafficking molecules at 
mRNA and surface protein level. The majority of leukaemic samples demonstrate surface 
expression levels of CXCR3 and CXCR4. However, a molecular ‘address code’ for CNS 
entry, based on surface expression of selected leukocyte trafficking molecules, is unlikely. 
No subclonal population based on expression levels of selected leukocyte trafficking 
molecules could be identified.  
4. Dysfunctional expression of CXCR4 in SD1 cells was associated with rapid onset of 
CNS disease. However, in primary samples, no such association was found. A detailed 
investigation into the lack of CXCL12 mediated chemotaxis in SD1 cells failed to identify 
a single mechanism underlying this dysfunction. There was evidence that reduced CXCR4 
expression, reduced internalization and constitutively phosphorylated downstream 
signalling pathways may act synergistically to result in the observed lack of CXCL12 
mediated chemotaxis. 
5. The majority of primary BCP-ALL samples and cell lines were shown to express 
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interleukain-15 (IL-15) and IL-15 receptor subunits at mRNA level. Stimulation of SD1 
cells with exogenous IL-15 promoted cell growth and upregulated genes associated with 
trafficking and invasion. The growth promoting effects of IL-15 were more profound in 
low serum conditions. Unlike IL-15 action on other leukocytes, the increase in cell growth 
in ALL cells is likely to be accounted by an increased cell proliferation rather than reduced 
apoptosis. Secreted IL-15 was undetectable in the CSF supernatant samples of patients 
with overt CNS disease. 
6. Methods for DNA extraction from clinical CSF samples were optimized. Using allele 
specific oligonucleotide (ASO) primers on CSF DNA, 15/38 patients demonstrated 
positivity for CNS disease. Investigation of selected soluble factors did not reveal a 
sensitive biomarker of CNS disease. However, levels of CXCL9, CXCL10, CCL2 and 
CCL21 were found to be lower in patients with CNS disease.  
The potential significance of these findings and how they fit into the current body of 
knowledge on CNS disease in ALL is presented below. How this work can be further  
investigated, is discussed subsequently. 
7.2 How do these finding extend current knowledge on 
CNS involvement in leukaemia? 
These studies aimed to shed light on two main areas: Firstly, the mechanism of CNS 
disease in ALL and secondly methods to improve diagnosis and CNS-risk stratification of 
children with ALL. Several aspects of the results identified in this thesis add to knowledge 
of the biological mechanisms underlying the CNS disease in ALL and may ultimately 
translate to the clinical aspects of CNS disease diagnosis and risk stratification. A number 
of clinical and cytogenetic factors are associated with an increased risk of CNS disease. 
However, to date, very little is known about the biological processes that enable leukaemic 
cells to enter and proliferate in the CNS. The evidence for CCR7 expressing T-ALL cells 
in entering the CNS is limited and has not been replicated in primary samples. The studies 
performed in this project provide evidence for a number of biological and clinical 
questions in ALL. 
7.2.1.1 Xenograft model of CNS disease recapitulates human CNS disease 
Engraftment of primary BCP-ALL cells into immunodeficient NSG mice illustrated a 
pattern of extramedullary disease resembling human leukaemia. Not only did samples from 
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the majority of low-risk ALL patients engraft but CNS engraftment was also noted in most 
of these. This model answers a number of questions concerning the pathogenesis of CNS 
disease in ALL. For instance, it shows that the CSF compartment, rather than the brain 
parenchyma, is involved in the CNS disease. Parenchymal involvement is only seen late in 
the disease course following extensive infiltration of the CSF compartment. Furthermore, 
leukaemic cells are present in the CNS as plaques in the leptomeninges, rather than in a 
free-floating state, supporting the hypothesis that leukaemic cells may be present in the 
CNS in patients with CNS-1 disease but missed in the CSF examination. The patterns of 
infiltration closely resemble the earlier description of human CNS disease presented by 
Price and Johnson (1973) on a large series of autopsies performed on children with 
leukaemia. The authors argued that leukaemic cells most commonly enter the CNS via the 
meningeal veins. From the xenograft model, leukaemic cells were seen in the walls of the 
meningeal vessels as well as the choroid plexus – both communicate with the CSF 
compartment. It is difficult to say with confidence whether one route is preferred over the 
other. What can certainly be said is that the leukaemic cells do not appear to cross the 
BBB. This has important implications for research. For instance, while investigating CNS 
disease in vitro, BCSFB models are likely to be more representative of trafficking routes 
than BBB models. This argument goes against findings presented by Holland et al. (2011) 
who argue that leukaemic cells infiltrate the blood-brain barrier (BBB) in an invasive 
manner. A number of factors could account for this discrepancy. The observation that SD1 
cells but not Sup B15 or REH produce CNS disease in SCID/beige mice (Holland et al., 
2011), was not reproducible in NSG mice in our laboratory (Williams et al., 2014). The 
residual immune system of the SCID/beige mice might have caused selective expansion of 
invasive sub-clones in SD1 cells only. In addition, there results were based on the 
observation of leukaemic infiltration of the optic nerve and no direct evidence of invasion 
across the BBB was presented.  Alternately, at the time of cull the disease may have 
approached to the advanced stage where the expansion of CNS leukaemia may have 
resulted in physical disruption of the BBB.  
Due to the lack of B-, T- and NK cell mediated immunity, NSG mice are the most 
immunodeficient strain currently available, and therefore represent a more suitable model 
for investigation of CNS leukaemia in primary ALL samples. However, as with any 
disease model, is not devoid of drawbacks. A lack of competent immune system in the 
xenograft mice does not simply equate with leukaemia in an immune-competent patient. 
As a consequence, human ALL cells may proliferate unchecked in the murine model. 
Another disadvantage of the xenograft models in the lack of leukaemia-host interactions. 
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Despite the many known conserved growth factors and cytokines, cross-species differences 
exist and may affect the cellular behaviour (e.g. receptor/ligand interactions) of the blasts. 
In addition, the murine microenvironment may be more suited to a particular 
leukaemia/cell type due to factors not related to leukaemic aggressiveness – the failure of a 
high-risk leukaemic subtype (11q23) to engraft may be an example of such factors. Despite 
these various disadvantages, this represents an attractive tool for the study of human 
disease in mice. This model can be used to investigate biological questions or test novel 
therapies. The recent report on reduction in CNS disease burden in xenograft mice with the 
use of MEK inhibitors, provide the proof-of-principle for this argument (Irving et al., 
2013). 
7.2.1.2 CNS-leukaemia initiating cells are frequent and not related to a 
distinct phenotype 
At diagnosis, only a minority (3-5%) patients present with overt leukaemia; however 
without CNS prophylaxis, the majority of patients rapidly develop CNS relapse. This 
forms the basis of risk-stratified CNS prophylaxis. I have provided a scientific basis forthis 
clinical practice by showing that the majority of samples from patients who are negative 
for CNS disease at diagnosis, possess the capability to infiltrate the CNS. Currently, all 
patients without evidence of CNS disease receive some CNS-directed prophylaxis. From 
clinical studies, it is clear that while patients with CNS-3 disease at diagnosis are at a 
higher risk for CNS relapse, CNS-1 patients also relapse in the CNS. The fact that samples 
from CNS-3 patients show a higher proportion of CNS infiltration in mice in comparison 
with CNS-1 samples supports the current clinical practice.  
The question whether all the cells in an individual leukaemia possess the ability to infiltrate 
the CNS or if it is a property of a subclone that allows leukaemic cells entry into the CNS, 
is of great scientific interest. If only a subset of leukaemic cells possess the ability to 
infiltrate the CNS, then comparison of CNS-infiltrating population with that of the bone 
marrow homing population will lead to identification of novel biomarkers of CNS disease. 
Data presented in this thesis do not support this hypothesis. Evidence from histological 
examination of xenograft mice demonstrated that different immunophenotypically sorted 
ALL subpopulations are able to infiltrate the CNS in mice. Moreover, CNS engraftment 
was seen in mice transplanted with as low as 10 cells suggesting that CNS engraftment 
ability is present at a high frequency in ALL. Furthermore, leukaemic populations from the 
CNS compartment did not appear to be distinct from the bone marrow homing cells in the 
expression of selected leukocyte trafficking molecules. Still, it cannot be completely 
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excluded that CNS infiltrating cells are indeed a distinct subpopulation within the bulk of 
leukaemic cells. CNS infiltrating cells may differ from the cells elsewhere in factors not 
yet known or investigated in these studies and an unbiased transcriptomic approach may 
help answer this.  
Primary xenografts developed in this thesis represent a snap-shot in the natural history of 
evolution of CNS-leukaemia. Engraftment kinetics may be a critical factor in identifying 
the mechanisms underlying the CNS infiltration. In the serial transplant experiments, 
REHGFP-Luc cells were retrieved from the CNS and the bone marrow of engrafted mice, and 
then re-transplanted into a second set of mice. A trend towards early CNS involvement in 
mice injected with CNS-retrieved cells was observed. It is possible that cells with distinct 
‘address code’ for the CNS gain access and subsequently expand to form a diverse 
phenotypic population within the CNS compartment. Isolation of cells from the CNS at 
this point would not allow identification of such a CNS-specific phenotype. When 
immunophenotypically sorted populations are transplanted in mice, the leukaemic cells 
reconstitute the diverse phenotypes found in the original patients (le Viseur et al., 2008). In 
addition, leukaemic cells might have downregulated chemokine receptors required for 
entry into the CNS once they have entered the CSF compartment.  
7.2.1.3 Leukocyte trafficking molecules do not drive CNS entry in BCP-ALL 
Although leukaemic cells may require chemokine receptors, selectins and integrins for 
access to the CNS compartment, they do not appear to play an instructive role in CNS 
entry of leukaemic cells. Although leukaemic blasts express chemokine receptors at the 
mRNA and surface level and their ligands are present in the CSF samples of ALL patients, 
there was no association between chemokine receptor expression and the ability to 
infiltrate the CNS. Comprehensive analysis of CXCR4-CXCL12 interactions suggested 
that is not essential for driving CNS entry of leukaemic cells (Williams et al., 2014). 
Contrary to the argument presented by Crazzolara et al. (2001) that CXCR4 expression can 
be a biomarker for predicting extramedullary dissemination, the CNS appears to be an 
exception. In support of this hypothesis, in a murine model of CML, use of CXCR4 
inhibitor AMD3100 showed an increase in CNS disease in the mice, suggesting that CNS 
is a CXCR4-independent niche (Agarwal et al., 2012). The role for CXCR3-CXCL9-11 
interaction requires further investigation. Not only do leukaemic cells consistently express 
high levels of CXCR3, but also the levels of its ligands are lower in patients with CNS-
disease. This suggests are CXCR3 expressing leukocytes may utilize CXCL9-11 for 
homing and retention in the CNS. Whether this plays an essential role in leukaemic entry 
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or survival remains to be investigated.  
7.2.1.4 The CXCR4 surface expression level is insufficient to determine the 
efficiency of CXCL12 mediated chemotaxis 
The characteristic feature of chemokine receptor-ligand interactions is their ability to 
initiate directional motility of cells. CXCR4-CXCL12 interactions produce potent 
chemotactic responses. With the CXCR4 receptor implicated in a number of malignant and 
non-malignant disorders, there a need to focus on the chemokine receptor expression – 
function relationship. SD1 cells, despite surface expression levels of CXCR4, fail to 
migrate towards the ligand CXCL12. This observation mirrors several reports of a similar 
phenomenon seen in normal haematopoiesis (Fedyk et al., 1999, Bleul et al., 1998, 
Honczarenko et al., 1999) and leukaemia (Bendall et al., 2005). This carries important 
implications for the use of CXCR4 expression and function as a biomarker of disease. Do 
CXCR4 surface levels or CXCL12 mediated chemotaxis most adequately represent 
CXCR4 function? Leukaemic cells expressing surface CXCR4 but lacking CXCL12 
mediated migration are still able to home and engraft in the bone marrow (Bendall et al., 
2005). It appears that CXCR4 expression, CXCL12 mediated chemotaxis, and in vivo 
migration do not correlate well. Therefore, a combination of in vitro and in vivo 
approaches should be utilized when investigating the role of CXCR4 in disease. Analysis 
of CXCL12- mediated downstream signalling pathways can provide additional clues to 
disease biology.  
7.2.1.5 Blockade of p190BCR-ABL1 tyrosine kinase with Imatinib does not 
restore CXCL12-mediated migration 
In CML, blast crisis is associated with a down-regulation of CXCR4 expression and 
CXCL12 mediated chemotaxis. In ALL cell lines SD1 and Sup B15, despite a correlation 
of BCR-ABL1 expression with dysfunctional migration, inhibition of p190BCR-ABL1 
tyrosine kinase fails to restore CXCL12 mediated chemotaxis in SD1 cells.  This 
phenomenon has not been previously reported in ALL. Although intriguing, this 
observation is only limited to BCR-ABL1 positive cell lines. Further work is required to 
investigate this phenomenon using primary samples.  
7.2.1.6 Interleukin-15 promotes proliferation of ALL cells under serum free 
conditions 
IL-15 is a cytokine associated with growth and promotion of various cell types. A role for 
IL-15 in ALL has been suggested (Lin et al., 2010, Cario et al., 2007, Yang et al., 2009) 
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but the underlying mechanisms are incompletely understood. Whereas IL-15 is also 
thought to improve anti-tumour immune response by stimulating T- and NK- cells. IL-15 is 
currently being used as an adjuvant in AML treatment to enhance anti-leukaemic effect of 
donor lymphocytes (ClinicalTrials.gov, 2011). The data presented in this thesis provides 
evidence that such a therapy in ALL may actually enhance tumour growth. IL-15 disease 
biology is complicated by the fact that both endogenous and exogenous IL-15 production 
may have pro-survival effects on leukaemic cells. Hypothetically, IL-15 may act in a 
number of ways: (i) IL-15 complex may stimulate cells in an autocrine manner, (ii) IL-15 
secreted by one leukaemic cell may stimulate another leukaemic cell in a paracrine or 
endocrine manner, (iii) IL-15 production by the tumour microenvironment may result in 
stimulation of leukaemic blasts, (iv) IL-15 secretion by the tumour microenvironment may 
stimulate anti-tumour response, or (v) IL-15 secretion by the leukaemic cells may result in 
stimulation of the anti-tumour response. IL-15 providing a greater growth advantage under 
serum free conditions may allow leukaemic cells with high IL-15 and IL-15 receptor to 
survive better in the CNS. In the bone marrow, serum starvation is unlikely to be a 
selective pressure and other factors such as cytokines, chemokines and growth factors may 
play a greater role. In addition, IL-15 secretion by leukaemic cells in the bone marrow may 
stimulate anti-leukaemia immune response which may antagonise IL-15 mediated tumour 
growth in the bone marrow but not in the CNS where entry of immune cells is more 
restricted. Preliminary data presented recently at an international conference supports the 
greater role for IL-15 mediated NK- cell response restricting leukaemic growth in the bone 
marrow but not in the CNS (Shemesh et al., 2013). IL-15 mediated upregulation of genes 
associated with dissemination may assist in CNS homing, where together with an increased 
growth advantage and reduced anti-leukaemia immune surveillance, IL-15 expressing cells 
may be fit to survive better than the bone marrow microenvironment. This hypothesis is 
presented in Figure 7.1 
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Figure 7-1 IL-15 stimulation may provide survival advantage to leukaemic cells in the CNS 
but less so in the bone marrow 
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7.2.2 Clinical implications of the findings 
7.2.2.1 CNS disease at diagnosis is significantly more common than 
currently diagnosed 
The observation that patient specific minimal residual disease (MRD) method can be 
applied and detects leukaemia in approximately 40% diagnostic samples reiterates the need 
for a more sensitive diagnostic method for the determination of CNS disease. Several 
authors have used a number of techniques to identify submicroscopic levels of CNS 
disease in patients. These range from immunohistochemistry to multiparameter flow 
cytometry and PCR using consensus primers. I utilized the novel patient specific ASO 
primers and consensus probes to detect CNS disease in patients. MRD determination 
requires the use of at least two MRD targets. The fact that in some cases only one of the 
two targets was amplified in the CSF DNA raises important questions. Whether this is due 
to the differences in sensitivity of the qPCR primers or this phenomenon is due to clonal 
evolution in the CNS compartment remains to be determined. What is evident is that there 
may be false negative cases where only one target was analysed. This in theory would 
underestimate the percentage of qPCR positive cases in the cohort of tested patients. It 
would be essential to analyse two or more targets for added sensitivity. Alternatively, an 
unbiased approach using novel techniques such as next generation sequencing (NGS) on 
DNA isolated from CSF cells may be used. This would eliminate the need for designing 
and optimizing patient specific reagents. Such an approach is in experimental stage and 
may be utilized for bone marrow MRD monitoring in future. 
The presence of submicroscopic levels of leukaemia in the CNS also raises some important 
questions. The ultimate aim of determining CNS disease at diagnosis is to determine the 
true risk for CNS relapse and modification in treatment according to the risk. Whether the 
patients identified to be negative for CNS disease by qPCR represent truly negative cases? 
Furthermore, whether patients with CSF qPCR positive disease are at an increased risk for 
CNS relapse? The improved treatment has enabled excellent prognosis of patients. 
However, this has made testing new diagnostic and therapeutic measures increasingly 
difficulty – even more so when relatively rare events such as CNS relapse in low-risk 
groups are to be investigated. The low incidence of relapse mean that large numbers of 
patients would be required to follow for long period of times to provide adequate statistical 
power to draw accurate conclusions. In the set of patients analysed, all but one patient were 
in CCR during the median follow up of two years. To test whether CSF qPCR predicts 
CNS relapse, a group of 200 patients would be required to follow up for a period of 3 years 
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(Michele Robertson and Suzanne Lloyd, The Robertson Centre for Biostatistics, Glasgow 
– personal communication). Alternatively, the use of post-induction MRD levels is an 
attractive tool for use as a surrogate marker for predicting outcome. Although a higher 
percentage of patients with MRD risk were positive for CNS disease by qPCR, this 
difference was not significant. Bone marrow MRD levels despite being an excellent 
measure of overall prognosis and the risk of bone marrow relapse, do not predict 
extramedullary relapse well (Bowman et al., 2011). 
Furthermore, are there patients who would not develop CNS relapse? Data from the 
xenograft model and the qPCR study suggests that in some cases even with heavy bone 
marrow infiltration, the CNS appears to be free of leukaemia. Nevertheless, bone marrow 
and CNS relapse are competing events – bone marrow relapse may mask an impending 
CNS relapse and vice versa. It is very much plausible that all patients may eventually 
developed CNS disease if they present later in the course of disease.  
Another question concerning the origin of CNS relapse is, ‘when do the leukaemic cells 
enter the CNS?’ At the time of diagnosis, the cells might already be in the CNS. 
Inadequate clearing of the CNS disease may leave residual leukaemic cells in the CNS 
which during the post-treatment period will eventually grow to cause overt CNS relapse. 
Alternately, CNS relapse may be a result of secondary seeding from minimal residual 
leukaemic cells in the periphery. The fact that adequate systemic treatment without 
adequate CNS prophylaxis would eventually lead to CNS relapse (Evans et al., 1970) and 
marked improvement in CNS relapse rates with CNS prophylaxis in CNS-1 patients lead to 
the general consensus that CNS relapse is indeed a result of CNS-residual leukaemic cells. 
The data presented in this thesis support this hypothesis. Evidence from the xenograft 
models show that CNS disease in largely in a non-fluid state and a negative CSF cytospin 
may not exclude CNS disease. CSF qPCR positivity provides further evidence in support. 
This may have significance for future research. If this hypothesis were true, the identifying 
the therapeutically targetable molecules that allow entry to the CNS compartment would be 
clinically less relevant. 
7.2.2.2 Selected soluble molecules are not sensitive biomarkers of 
submicroscopic CNS disease 
Improving the methods of diagnosis of CNS disease is an ongoing effort. An ideal 
biomarker of CNS disease would be: specific to the disease, secreted in the CSF and 
specific to the CNS compartment. The successful soluble biomarkers in cancer such as 
prostate specific antigen (PSA) achieve high accuracy due the high levels secreted in 
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prostate cancer. Others such as gonadal tumours are characterized by aberrant secretion of 
α-fetoprotein. Leukaemia, despite possessing aberrant functions, is not known to secrete 
aberrant soluble molecules. Leukaemic cells in the meninges may secrete molecules which 
could be detected by analysing the CSF. Alternately, factors secreted by the 
microenvironment in response to presence of leukaemic cells could also be used as 
biomarkers. Previous studies have tested several candidate biomarkers without much 
success. Chemokine levels have not been tested previously in the CSF compartment. A 
possible reason could be that many of the CNS-disease free patients might have 
submicroscopic levels of leukaemia. Stratifying patients according to the CSF qPCR 
presented an opportunity to address this issue. Due to technical limitations in selecting the 
biomarkers of interest meant that only limited number of molecules could be analysed. As 
discussed below, the results of the Luminex assay provide promising clues to the biology 
of CNS disease, the differences in the levels of these do not appear to be useful in 
identifying CSF qPCR positive patients. 
7.3 Future directions 
7.3.1 Leukaemia-host microenvironment factors may play a 
dominant role in determining the risk of CNS relapse 
disease 
Leukaemic entry in the CNS compartment is unlikely to be the selective event determining 
CNS relapse – instead it may be determined by the ability to survive long term in the CNS 
micro-environment, or evasion of chemotherapy or immune-surveillance at this site. Once 
leukaemic cells have entered the meninges they need to adapt to this new 
microenvoronment. Although B cells not normally present in this compartment in large 
numbers, there is evidence from MS that B cells can survive for extended periods and 
clonally expand in the CNS (Owens et al., 2003). In addition evidence for lymphoid 
neogenesis in the meninges in MS illustrates the role of meninges in lymphoid cell 
proliferation (Serafini et al., 2004).  
Akers et al (2011) have shown that ALL cells can proliferate in vitro in contact with 
meningeal cells and co-culture of meningeal cells with ALL confers protection against 
chemotherapy. The lower levels of certain chemokines such as CXCL9, CXCL10, CCL21 
and CCL2 in CSF qPCR positive patients raise the intriguing question as to whether these 
molecules are being utilized by leukaemic cells for retention in the CNS. Leukaemic cells 
are shown to manipulate the levels of chemokines in the bone marrow niche (van den Berk 
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et al., 2014). If leukaemic cells indeed utilize chemokine receptors such as CXCR3-
CXCL9/10 and CCR7-CCL19/21 for retention in the CNS microenvironment, then 
blocking this interaction is may result in release of cells from leptomeninges and increase 
the drug penetration by reducing the protective effects of the CNS niche.  
In addition to chemotherapy penetration, drug delivery to the meninges might equally 
affect the susceptibility of cells to therapy. Use of prednisolone is associated with a higher 
risk of CNS relapse in comparison with Dexamethasone. Rapid clearance of prednisolone 
from the CSF may limit the duration of leukaemic cell exposure to cytotoxic 
concentrations of the drug (Balis et al., 1987). Therefore, current trials use Dexamethasone 
despite the toxicities associated with its use. Strategies to increase the CNS penetration 
could improve CNS relapse risk without increasing toxicities. It has been suggested that 
the increased risk of CNS relapse with TLP might be attributed to CSF leakage and the 
resultant reduction in drug distribution. The incidence of TLP can be reduced by better 
care such as monitoring of platelet counts and improving skills of the lumbar puncture 
procedure.  
The role of anti-leukaemia immune surveillance in the CNS remains to be investigated. 
There is some suggestion that graft-versus-leukaemia effect following HSCT is more 
pronounced in the bone marrow in comparison with the CNS (Ganem et al., 1989, 
Thompson et al., 1986, Oshima et al., 2008). This implies that the donor lymphocytes do 
not cross the CNS barriers well. Attempts at improving immune surveillance in the CNS 
can prove useful in eradicating the disease. As mentioned earlier, cytokine therapy to 
potentiate the immune surveillance may be counterproductive and benefit leukaemic cells.  
7.3.2 Investigating the biomarkers for CNS disease 
Improving the methods of diagnosis of CNS disease is an ongoing effort. An ideal 
biomarker of CNS disease would be: specific to the disease, secreted in the CSF and 
specific to the CNS compartment. The successful soluble biomarkers in cancer such as 
prostate specific antigen (PSA) achieve high accuracy due the high levels secreted in 
prostate cancer. Others such as gonadal tumours are characterized by aberrant secretion of 
α-fetoprotein. Leukaemia, despite possessing aberrant functions, is not known to secrete 
aberrant soluble molecules. The search for a soluble biomarker in the CNS may require 
unbiased screening approaches such as proteomic analysis of the CSF. Nevertheless, 
certain candidate biomarkers require further investigation. sL-selectin, sCD19 and sCD27 
are such molecules of interest. From the CSF Biobank established during the course of this 
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project, CSF supernatant samples from patients with CSF qPCR positive and negative 
disease can be utilized to carry out these investigations. 
7.3.3 Clonal origins of CNS infiltrating cells 
In understanding the origins of CNS disease at diagnosis and relapse, an investigation into 
the clonal differences between leukaemic cells from the CNS and the bone marrow is 
likely to provide crucial insights. CSF qPCR detection of CNS disease can be technically 
challenging and the fact that in a number of samples, only 1 out of 2 targets assessed was 
identified by qPCR hints towards presence of an evolved clone in the CNS. If this is the 
case, CSF qPCR is unlikely to be a diagnostically useful or biologically informative. In the 
recent years, next generation sequencing analysis has emerged as a powerful tool for 
detection of MRD as well as for the investigation of the clonal hierarchy in leukaemia. 
Utilizing this technique on the paired bone marrow and CNS samples can simultaneously 
provide insights into both the avenues. Again, the CSF Biobank will be crucial in 
providing patient resource material for these studies. In addition, collaboration with 
national and international centres will ensure sharing of techniques and resources.  
7.4 Overall conclusions 
Using a range of in vivo, in vitro and clinical methods, the data presented in this thesis 
strongly indicate that: CNS disease is present at diagnosis in a higher frequency than 
clinically diagnosed, CNS entry is frequent and not restricted to a particular CNS risk 
category and immunophenotypic subtype, and is not determined by a particular set of 
leukocyte trafficking molecules. In addition, it is suggested that the direct effects of IL-15 
on cellular proliferation and gene expression might facilitate leukaemic survival in the 
CNS. Therefore, attempts at blocking CNS entry of leukaemic cells are unlikely to prevent 
CNS relapse. The focus of future research should be at exploring the mechanisms that 
allow long-term survival of leukaemic cells in the CNS is essential preventing CNS 
relapse. 
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Appendix: Interleukin-15 enhances cellular proliferation and 
upregulates CNS homing molecules in pre-B acute 
lymphoblastic leukaemia 
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